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PREFACE 
 
The studies described in this thesis were conducted at Royal Prince Alfred Hospital, Sydney, 
Australia, between 2004 and 2010.  Prior to the commencement of data collection, ethical approval 
was obtained from the Human Research Ethics Committee of Sydney South West Area Health Service 
and The University of Sydney for each study, and written informed consent was obtained from every 
participant.  This thesis consists of six chapters, written so that each chapter can be read 
independently.  A single reference list is located at the end of thesis.  Chapter 1 provides an 
introduction to the thesis and review of the literature.  Original studies are described in Chapters 2, 3 
and 5.  A systematic review and meta-analysis is presented in Chapter 4.  Chapter 6 provides a general 
overview of the thesis, a summary of the main findings and clinical implications, and suggestions for 
further research.  Appendices located at the end of the thesis contain supplementary material for 
Chapter 4 (Appendix A) and copies of published papers that arose from the work contained in this 
thesis (Appendix B).   
 
Protocols for the studies presented in Chapters 2 and 5 were developed by the candidate and Dr 
Elizabeth Ellis.  Data was collected by the candidate with the assistance of Mr Daniel Flunt.  The 
protocol for the study described in Chapter 3 was devised by the candidate and Associate Professor 
Jennifer Alison.  The data acquisition software program used to record ventilation data was designed 
by Mr John Eisenhuth, The University of Sydney.  Assistance with the experimental set up for the 
measurement of ventilation during exercise was provided by Mr Gunnar Unger, The Woolcock 
Institute of Medical Research.  Statistical advice was given by Dr Keith Wong, Department of 
Respiratory and Sleep Medicine, Royal Prince Alfred Hospital.  Data collection was performed by the 
candidate with the assistance of Dr Elizabeth Ellis and Ms Carly Hollier.  The protocol for the 
systematic review presented in Chapter 4 was developed by the candidate and Dr Amanda Piper.  The 
Cochrane Airways Group Trials Search Coordinators, Ms Elizabeth Arnold and Ms Susan Hansen, 
assisted the candidate to search for trials on The  Cochrane Central Register of Controlled Trials 
(CENTRAL) and the Latin American and Caribbean Health Sciences Literature database (LILACS).  
The selection of studies for inclusion in the review, data extraction, and the assessment of 
methodological quality of included trials were performed by the candidate and Dr Amanda Piper.  The 
remaining work contained in this thesis, including statistical analysis and interpretation, preparation 
of figures, tables and photographs are claimed as the original contribution of the candidate. 
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ABSTRACT 
 
Exercise training is an important component of management for people with chronic obstructive 
pulmonary disease (COPD) and may also be beneficial in people with kyphoscoliosis, with the 
potential to significantly reduce dyspnoea, increase functional exercise capacity and improve health 
related quality of life (HRQL).   However, individuals with severe disease and limited ventilatory 
reserve may have difficulty performing exercise training at a sufficient intensity, or for an adequate 
duration due to severe exertional dyspnoea.  Therefore, identification of adjuncts that can reduce 
dyspnoea and increase ventilatory capacity may be important in order to optimise the benefits 
associated with exercise training.  While short term improvements in dyspnoea and endurance 
exercise capacity have been observed with a single application of non-invasive ventilation (NIV) 
during lower limb exercise in people with moderate to severe COPD, it is unclear whether NIV could 
also be of benefit during functional exercise or during exercise training.  In addition, the optimal NIV 
settings for use during exercise are unknown.  The work contained in this thesis aimed to address 
some of these questions, in particular, the role of NIV as an adjunct during exercise in individuals 
with chronic hypercapnic respiratory failure (HRF) secondary to very severe COPD or severe 
kyphoscoliosis. 
 
The literature review presented in Chapter 1 provides a background of the pathophysiology associated 
with COPD and kyphoscoliosis, and the impact of these conditions on exercise capacity and 
functional status with a focus on individuals with severe disease and HRF.  Common management 
strategies are described, in particular the use of exercise training and NIV.  In addition, the role of 
NIV as an adjunct during exercise in people with COPD and individuals with kyphoscoliosis is 
discussed. 
 
The randomised crossover study presented in Chapter 2 aimed to determine the immediate effects of 
NIV during unsupported arm exercise (UAE) and ground walking on exercise capacity in people with 
chronic HRF secondary to very severe COPD or severe kyphoscoliosis who were already established 
on domiciliary NIV.  Seventeen participants with chronic HRF performed a series of UAE tests, and 
15 participants performed a series of endurance shuttle walk tests, with and without NIV in random 
order.  Non-invasive ventilation during UAE increased endurance time by a mean of 91 seconds (95% 
confidence interval (CI) 10 to 172, p = 0.031) and reduced dyspnoea by a mean of 2.3 points on the 
Borg scale (95% CI 1.0 to 3.7, p = 0.002) compared to exercise without NIV.  There was a trend for 
greater walking endurance time with NIV during exercise (119 seconds, 95% CI -17 to 254, p = 
0.081), however isotime dyspnoea was unchanged compared to walking without NIV (-1.0 points on 
the Borg scale, 95% CI -3.0 to 1.0, p=0.29).  Non-invasive ventilation during UAE reduced dyspnoea 
and allowed people with chronic HRF to exercise for longer compared to exercise without NIV in 
 xxxi 
patients with chronic HRF.  Investigation of the role of NIV as an adjunct to UAE training is 
warranted.  In contrast, NIV during ground walking did not improve exercise capacity.  However, the 
level of pressure support (PS) provided may have been insufficient as dyspnoea was not reduced. 
 
The level of PS provided during exercise may be particularly important in people with severe 
kyphoscoliosis as they often have marked chest wall stiffness, and consequently may require high 
inflationary pressures to support ventilation during exercise.  Low level PS of approximately 10 
cmH2O during exercise has been shown to improve exercise capacity in people with severe COPD and 
a limited ventilatory capacity.  However, low level PS during exercise decreased distance walked in 
individuals with severe kyphoscoliosis.  In order to determine whether the level of PS delivered 
during exercise influences the efficacy of NIV during exercise in people with severe kyphoscoliosis 
and chronic HRF, a double blind randomised crossover study was performed in Chapter 3.  Thirteen 
participants with severe kyphoscoliosis performed four endurance treadmill tests in random order: 
unassisted; with sham PS; low level PS of 10 cmH2O (PS 10) and high level PS of 20 cmH2O (PS 20).  
Participants and assessors were blinded to the level of PS delivered during exercise.  Endurance time 
was greater with PS 20 (median 217 seconds, interquartile range (IQR) 168-424) compared with 
unassisted exercise (median 139 seconds, IQR 111-189), sham PS (median 103 seconds, IQR 88-155) 
and PS 10 (median 159 seconds, IQR 131-206).  In addition, isotime respiratory rate was decreased by 
8 breaths/minute (95% CI -11 to -5) and isotime oxygen saturation (SpO2) increased by 4% (95% CI 1 
to 7) with PS 20 compared with unassisted exercise.  A moderately strong inverse correlation was also 
found between the change in endurance time and the change in isotime dyspnoea with high level PS 
relative to unassisted exercise (rS = -0.651, p = 0.016).  Therefore, not only was the level of PS 
provided during walking important in order to increase exercise endurance time, the effect that high 
level PS had on isotime dyspnoea also influenced exercise performance.  The findings of this study 
indicate that the level of PS delivered during exercise does affect the efficacy of NIV during exercise, 
and that people with severe kyphoscoliosis require high level PS during walking to improve exercise 
performance.   
 
While the immediate effects of NIV during exercise appear to be beneficial in people with COPD, 
reports of NIV during exercise training have yielded conflicting results.  In addition, participant 
numbers are generally small in several randomised controlled trials (RCT) that have assessed the 
effect of NIV during exercise training in people with COPD, and may have reduced the ability to 
detect important differences between groups.  In order to improve statistical power and determine 
whether NIV during exercise training can improve exercise capacity, HRQL or physical activity in 
people with COPD above that of exercise training alone or exercise training with sham NIV, a 
systematic review and meta-analysis was performed in Chapter 4.  Electronic databases (MEDLINE, 
EMBASE, PUBMED, CENTRAL, PEDro, LILACS, CINAHL, PsycINFO, AMED), conference 
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proceedings, reference lists of included RCTs and relevant review articles were searched up to 
December 2009 for RCTs of NIV during exercise training in COPD.  Two investigators independently 
selected RCTs and determined the risk of bias of each included study and assessed methodological 
quality using the PEDro scale.  A random effects model was used.  Of 7479 reports, 6 RCTs 
comprising 126 individuals were included in the analysis.  The mean ± standard deviation PEDro 
score was 5.2/10 ± 1.7.  Non-invasive ventilation during exercise training increased peak and 
endurance exercise capacity (mean difference 17%, 95% CI 7 to 27; and mean difference 59%, 95% 
CI 3 to 114 respectively).  No change was found in HRQL although only two RCTs reported this 
outcome.  Physical activity was not measured.  Training intensity was higher with NIV (mean 
difference 17%, 95% CI 3 to 32) and post training isoload lactate was reduced (mean difference -0.96 
mmol/L, 95% CI -1.60 to -0.33).  This review provides evidence that NIV during exercise training 
allows people with COPD to exercise at a higher training intensity and to achieve a greater 
physiological training effect compared with exercise training alone or exercise training with sham 
NIV.  While there was also evidence that training with NIV improved peak and endurance exercise 
capacity above that of exercise training alone, significant treatment effects were only found when 
baseline inter-individual differences were taken into account by analysing percentage change data 
rather than post intervention data.  Interpretation of the clinical significance of these results is 
difficult, as the minimal clinically important difference for the percentage change in peak or 
endurance exercise capacity is unknown.  Further studies are required to assess the impact of NIV 
during exercise training on HRQL and physical activity. 
 
Exercise rehabilitation may be delayed in people recovering from acute on chronic HRF due to severe 
exertional dyspnoea.  While NIV has been shown to reduce dyspnoea and improve exercise 
performance in individuals with stable chronic HRF, the effect of NIV during exercise in people 
recovering from acute on chronic HRF is unknown.  To determine the immediate effects of non-
invasive ventilation plus oxygen (NIV+O2) during functional exercise compared to exercise with 
oxygen (O2) alone, a randomised crossover study with repeated measures was performed and is 
presented in Chapter 5.  Eighteen participants performed a series of six minute walk tests (6MWT) 
and 16 participants performed a series of UAE tests with NIV+O2 and with O2 alone in random order.  
Total distance walked increased by a mean of 43.4 metres (95% CI 14.1 to 72.8, p = 0.006) with 
NIV+O2 compared to exercise with O2 alone.  Isotime SpO2 also increased by a mean of 5% (95% CI 
2 to 7, p = 0.001) and isotime dyspnoea was reduced (median 2 points on the Borg scale (IQR 1 - 4) 
versus median 4 points (IQR 3 - 5), p = 0.028) with NIV+O2.  In addition, a significant inverse 
correlation was found between the change in total distance walked and the change in isotime 
dyspnoea with NIV+O2 compared to walking with O2 alone (r = -0.52, p = 0.026).  A statistically 
significant increase in UAE endurance time (median 201 seconds (IQR 93-414) versus 157 seconds 
(90-342), p = 0.033), and a reduction in isotime perceived exertion (arm muscle fatigue) by a mean of 
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1.0 points on the Borg scale (95% CI -1.9 to -0.1, p = 0.037) was also observed with NIV+O2 
compared with O2 alone.  Non-invasive ventilation plus O2 during walking resulted in an immediate 
improvement in distance walked and oxygen saturation, and a reduction in dyspnoea compared to 
exercise with O2 alone in people recovering from acute on chronic HRF.  The reduction of dyspnoea 
during walking and arm muscle fatigue during UAE observed with NIV+O2 may allow patients to 
better tolerate exercise early in the recovery period.  The relationship between the reduction in 
dyspnoea with NIV+O2 and distance walked suggests that selection of ventilator settings that 
adequately unload the respiratory muscles and reduce dyspnoea is important in order for NIV to be of 
benefit during ground walking. 
 
A summary of the findings is presented in Chapter 6, along with a discussion of the clinical 
implications of the findings and suggestions for further research. 
 
  
 
 
CHAPTER 1 
 
 
 
 
 
 
 
 
Literature review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
INTRODUCTION 
In healthy individuals, ventilatory reserve is large at rest and can easily accommodate the increase in 
ventilatory demand associated with daily activities (Lahaije et al, 2010).  Even during maximal 
exercise, ventilatory reserve is ample at approximately 20% of maximum voluntary ventilation (MVV) 
(Freedman, 1970).  Maximal exercise performance is usually limited by the cardiovascular system 
although the ability of working muscles to utilise oxygen (O2) may also play a role (Pardy et al, 1984).  
In contrast, people with very severe chronic obstructive pulmonary disease (COPD) or severe 
kyphoscoliosis have a reduced ventilatory reserve at rest and commonly have a ventilatory limitation 
to exercise (Highcock et al, 2002; Montes de Oca et al, 1996).  While the aetiologies of very severe 
COPD and severe kyphoscoliosis are markedly different, both conditions often lead to the 
development of hypercapnic respiratory failure (HRF) and are usually associated with disabling 
dyspnoea, impaired functional status and reduced health related quality of life (HRQL) (Carone et al, 
1997). 
 
Very severe COPD and severe kyphoscoliosis are both progressive and largely irreversible.  
Therefore, management aims to minimise disease progression, treat symptoms, and optimise 
functional capacity and HRQL.  Exercise training is an important component of management in 
COPD, and may also be beneficial in kyphoscoliosis, with the potential to significantly reduce 
dyspnoea, and improve functional capacity and HRQL (Cejudo et al, 2009; Ries et al, 2007; 
Shneerson, 1998).  However, individuals with severe disease and limited ventilatory reserve may have 
difficulty performing exercise training at a sufficient intensity or for an adequate duration due to 
severe exertional dyspnoea.  Therefore, identification of adjuncts that reduce dyspnoea and increase 
ventilatory capacity may be important in order to optimise the benefits associated with exercise 
training.  Non-invasive ventilation (NIV) during exercise has been proposed as one potential strategy 
to improve exercise performance in people with COPD and people with kyphoscoliosis.  This 
literature review will describe the pathophysiology associated with COPD and kyphoscoliosis, and the 
impact of these conditions on exercise capacity and functional status, with a focus on individuals with 
severe disease and HRF.  In addition common management strategies will be addressed, in particular 
the use of exercise training and NIV.  Finally, the role of NIV as an adjunct during exercise in people 
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with COPD and individuals with kyphoscoliosis will be discussed and the aims of the thesis will be 
outlined. 
 
VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
Definition 
Chronic obstructive pulmonary disease is characterised by airflow limitation that is not fully 
reversible.  Airflow limitation is usually progressive and is associated with an abnormal inflammatory 
response of the lungs to noxious gases or particles.  In addition to local pulmonary effects, COPD is 
also associated with significant systemic effects.  While COPD is preventable and treatable, it is not a 
curable disease (Celli & MacNee, 2004; Rabe et al, 2007; Viegi et al, 2007).  Based on the degree of 
airflow limitation, disease severity is defined as mild or stage I (forced expiratory volume in one 
second (FEV1)/forced vital capacity (FVC) <0.70, FEV1 ≥80% predicted), moderate or stage II 
(FEV1/FVC <0.70, 50%≤ FEV1 <80% predicted), severe or stage III (FEV1/FVC <0.70, 30%≤ FEV1 
<50% predicted) and very severe or stage IV (FEV1/FVC <0.70, FEV1 < 30% predicted or FEV1 
<50% predicted and chronic respiratory failure) (Rabe et al, 2007).  However, FEV1 alone is not a 
strong predictor of functional capacity or mortality, and is relatively unresponsive to a number of 
treatments offered to people with COPD (Maclay et al, 2009). 
 
Chronic obstructive pulmonary disease is a leading cause of morbidity and mortality in the developed 
world and imposes a significant social and economic burden on the global community (Pauwels & 
Rabe, 2004).  The 2008 World Health Organisation World Health Report (World Health Organisation, 
2008) listed COPD as the fourth leading cause of death worldwide, and projected that COPD would 
rise to the third leading cause of death by 2030.  A wide range of estimates of the prevalence of COPD 
have been published.  However the true prevalence of COPD is likely to be underestimated due to 
factors such as the timing of diagnosis, different methods of diagnosis and variations in definitions of 
airflow obstruction (Halbert et al, 2003).  Chronic obstructive pulmonary disease is more prevalent in 
smokers and ex-smokers compared to non-smokers, as well as in people aged more than 40 years and 
in men compared to women (Rabe et al, 2007).  Based on post bronchodilator spirometry in people 
aged greater than 40 years from twelve different sites around the world, the BOLD study reported a 
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prevalence of COPD at GOLD stage II or higher (Rabe et al, 2007) as 10.1% (Buist et al, 2007).  The 
economic and social costs of COPD are substantial (Pauwels & Rabe, 2004).  Within the last decade, 
estimates of the annual economic costs ranged between €151-541 million in a number of individual 
European countries (Chapman et al, 2006), and in the United States direct economic costs were 
estimated at $14.5 billion (Wilson et al, 2000).  Acute exacerbations of COPD (AECOPD) that require 
admission to hospital are one of the biggest contributors to direct health care costs and increase in 
proportion to worsening disease severity (Viegi et al, 2007).   
 
Pathophysiology 
In addition to pulmonary disease and dysfunction, COPD is often associated with a number of 
systemic manifestations and comorbidities including systemic inflammation, skeletal muscle 
dysfunction, cachexia, cardiovascular disease, lung cancer, osteoporosis, anaemia, diabetes, 
depression, metabolic syndrome and obstructive sleep apnoea (Agusti et al, 2003; Barnes & Celli, 
2009).  This section will primarily focus on the respiratory, skeletal muscle and cardiovascular 
pathophysiology associated with COPD. 
 
Respiratory System  
Chronic obstructive pulmonary disease is associated with pathological and structural changes in the 
central airways, peripheral airways, lung parenchyma and pulmonary vasculature secondary to chronic 
inflammation that occurs in response to repeated exposure to inhaled noxious particles and gases such 
as cigarette smoke (Hogg, 2004).  Oxidative stress, and an imbalance of proteinases and 
antiproteinases in the lungs also contribute to the development of COPD (Repine et al, 1997).  Mucous 
hypersecretion (Celli, 2010) and increased cough (Hogg, 2004) frequently occur as a direct result of 
the inhalation of toxic particles and gases.  Expiratory flow limitation is the hallmark sign of COPD 
(Celli, 2010; O'Donnell & Parker, 2006) and is caused by a combination of increased resistance of the 
small airways and permanent damage to the lung parenchyma (emphysema) (Hogg, 2004; O'Donnell 
& Laveneziana, 2006).  Increased airways resistance may be caused by inflammation, bronchospasm, 
sputum or compression of the airways by overdistended surrounding tissue (Roussos & Koutsoukou, 
2003; Wrigge & Putensen, 2000).  Emphysematous changes lead to a reduction in lung elastic recoil 
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pressure, increased lung compliance and a higher relaxation volume of the respiratory system 
(O'Donnell & Laveneziana, 2006).  Expiratory flow limitation is demonstrated by a reduction in both 
FEV1 and FEV1/FVC (Hogg et al, 1968; Mead et al, 1967; Pride et al, 1967).  In addition, both small 
airways obstruction and the loss of elastic recoil predispose airways to collapse at higher lung 
volumes, resulting in gas trapping or ‘static’ pulmonary hyperinflation (O'Donnell & Laveneziana, 
2006).  The degree of pulmonary hyperinflation is reflected by an increase in residual volume (RV), 
functional residual capacity (FRC) and total lung capacity (TLC), while vital capacity (VC) and FVC 
tend to decrease over time secondary to a disproportionate rise in RV relative to TLC (Field, 1973; 
Macklem, 2010).   
 
Respiratory muscle function is also commonly impaired in people with COPD.  Pulmonary 
hyperinflation alters the length-tension relationship of the inspiratory muscles.  In particular, the 
diaphragm is placed at a mechanical disadvantage, which leads to a reduction in force generating 
capacity (Macklem et al, 1983; Roussos & Koutsoukou, 2003).  Diaphragmatic remodelling occurs in 
response to chronic pulmonary hyperinflation, with improved oxidative capacity (Ribera et al, 2003), 
an increased in the number of Type I fatigue resistant fibres (Levine et al, 2003) and reduced 
sarcomere length (Orozco-Levi et al, 1999).  However, compared with healthy individuals 
diaphragmatic strength is reduced in people with severe COPD, and decreases further with acute on 
chronic (dynamic) pulmonary hyperinflation (Polkey et al, 1996a).  Pulmonary hyperinflation is also 
associated with the development of intrinsic positive end expiratory pressure (PEEPi) which imposes 
an inspiratory threshold load on the inspiratory muscles and leads to an increased work of breathing 
(Chen & Yan, 1999; Loring et al, 2009).  As a result of the high mechanical loads placed upon the 
inspiratory muscles secondary to PEEPi, increased airways resistance and reduced dynamic lung 
compliance (Stubbing et al, 1980), the inspiratory muscles are required to generate greater changes in 
pressure (ie. higher force generation) for a given level of ventilation (De Troyer, 1997; Rochester & 
Arora, 1983).  Consequently, individuals with severe or very severe COPD often use accessory 
inspiratory muscles to assist the diaphragm, even at rest (De Troyer et al, 1997; Field, 1973; Gandevia 
et al, 1996).  As a result, both work of breathing and the O2 cost of breathing are elevated in people 
with COPD compared with healthy individuals (Field et al, 1982; Levison & Cherniack, 1968; Loring 
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et al, 2009).    
 
The efficiency of gas exchange is also often reduced in people with severe or very severe COPD 
(O'Donnell et al, 2001a) and may increase work of breathing further by raising ventilatory demand at 
rest (Loring et al, 2009).  Hypoxaemia may arise from a reduction in the surface area available for gas 
exchange due to the destruction of alveolar walls, or from ventilation-perfusion mismatch (Field, 
1973).  In addition, a rapid shallow breathing pattern is commonly adopted in people with severe 
COPD and is associated with the development of hypercapnia and hypoxaemia (Loveridge et al, 1984; 
Parot et al, 1982; Rochester, 1991).   
 
Skeletal Muscle Dysfunction 
Skeletal muscle dysfunction is common in people with COPD and is typically characterised by a 
reduction in muscle strength, muscle endurance, the proportion of Type I (aerobic) fibres (Swallow et 
al, 2009), capillarity and oxidative capacity (Casaburi & ZuWallack, 2009; Maltais et al, 2000).  
Increased apoptosis (Agusti et al, 2002) and the presence of inflammatory cells (Swallow et al, 2009) 
have also been reported in peripheral muscles.  Almost one third of people with COPD have 
quadriceps weakness, with a maximum voluntary contraction of the quadriceps approximately 73% of 
predicted (Seymour et al, 2010a).  The prevalence of quadriceps weakness is higher in people with 
very severe COPD (38%) or individuals with an MRC dyspnoea score of ≥4 (43%) compared with 
mild to moderate COPD (26-28%).  Quadriceps fatigability is also greater in severe COPD compared 
with age and sex matched healthy controls (Mador et al, 2003).  Furthermore, peripheral muscle 
weakness is amplified both during, and several months after, an AECOPD (Spruit et al, 2003).  The 
extent of skeletal muscle dysfunction appears to vary depending on location and function of the 
muscle.  For example, upper limb strength (hand grip) (Gosselink et al, 1996) and oxidative capacity 
(deltoid muscle) (Gea et al, 2001) are relatively preserved compared to the quadriceps muscle.  In 
addition, oxidative capacity and mitochondrial function are enhanced in the inspiratory muscles of 
individuals with severe COPD (Ribera et al, 2003) and a strong inverse correlation between FEV1 and 
the proportion of Type I fibres in the diaphragm has been observed (r = -0.85) (Levine et al, 2003).   
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Skeletal muscle abnormalities in people with COPD are most likely to be a result of deconditioning 
secondary to reduced levels of physical activity (Schonhofer et al, 1997; Wagner, 2006; Watz et al, 
2009).  Other factors may also play a role including high dose oral corticosteroids (Decramer et al, 
1994), systemic inflammation (Puente-Maestu et al, 2009; Spruit et al, 2003) and oxidative stress 
(Couillard et al, 2003), particularly during an AECOPD.  Body mass was also found to be 
independently related to skeletal muscle oxidative capacity and may account for some of the 
variability in exercise capacity observed between individuals with a similar degree of ventilatory 
limitation during exercise (Palange et al, 1998).  Quadriceps weakness is a strong independent 
prognostic indicator in COPD, and has been shown to directly relate to health care resource utilisation 
(eg. days in hospital, r = 0.35) (Decramer et al, 1997) and mortality (hazard ratio 0.91, 95% CI 0.83 to 
0.99) (Swallow et al, 2007).     
 
Cardiovascular System 
Cardiovascular disease, such as pulmonary hypertension, can occur as a direct result of primary lung 
disease in individuals with COPD.  Secondary pulmonary hypertension is common in severe and very 
COPD and has been shown to have a negative impact on survival and health care costs (Barbera et al, 
2003; Cuttica et al, 2010).  Over time, sustained pulmonary hypertension can also lead to the 
development of cor pulmonale (Chemla et al, 2002).  The pathogenesis of pulmonary hypertension 
appears to involve a number of factors.  The most commonly cited cause is chronic hypoxaemia, 
which leads hypoxic vasoconstriction of the pulmonary vessels and remodelling of the pulmonary 
vasculature (Naeije & Barbera, 2001).  It has also been suggested that recurrent intermittent 
hypoxaemia (eg. during sleep or exercise), may contribute to this process (Weitzenblum, 1994).  
Furthermore, exposure to cigarette smoke has been shown to cause endothelial damage (Giaid & 
Saleh, 1995), and low-grade systemic inflammation may also promote vascular remodelling (Barbera 
et al, 2003; Joppa et al, 2006).  Pulmonary hypertension is common in people with severe COPD, with 
an estimated prevalence of 23-30% (Cuttica et al, 2010; Sims et al, 2009).  The prevalence of other 
types of cardiovascular disease, such as coronary artery disease, is also elevated in people with COPD 
compared with the general population (Mannino et al, 2008; Sin et al, 2005).  This finding is perhaps 
not surprising given the similarity in risk factors for both diseases such as cigarette smoking, a 
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sedentary lifestyle and increased age.  The presence of low-grade systemic inflammation may also 
provide a link between the two conditions (Barnes & Celli, 2009).   
 
Exercise 
Exercise Capacity 
Exercise intolerance is a common complaint in people with COPD and is reflected by impaired 
performance during cardiopulmonary exercise tests, functional walk tests and during tests of upper 
limb exercise capacity.  Individuals with severe or very severe COPD have been shown to exhibit 
significantly reduced peak O2 consumption (VO2) (54 ± 18% predicted), peak work rate (45 ± 18% 
predicted) (van 't Hul et al, 2004) and six minute walk distance (6MWD) (median 280 metres, 
interquartile range (IQR) 204 to 350 metres; median 59% predicted, IQR 41 to 71% predicted) 
(Budweiser et al, 2008) compared to healthy individuals.  Peak VO2 is also lower during supported 
and unsupported upper limb exercise in people with severe COPD compared with healthy controls 
(McKeough et al, 2003).  In addition, further clinically significant reductions in exercise capacity (eg. 
mean decrease in 6MWD 59 ± 80 metres) (Carr et al, 2007) and peripheral muscle strength (Spruit et 
al, 2003) have been reported in individuals with an AECOPD, often without complete recovery to pre-
morbid levels. 
 
While people with very severe COPD tend to walk shorter distances compared to people with 
moderate COPD, considerable variability in 6MWD is observed in individuals with a similar degree of 
airflow limitation (Spruit et al, 2010).  This observation is not surprising and most likely reflects inter-
individual variability in cardiovascular and peripheral muscle function, and the perception of 
symptoms.  Exercise capacity is one of the most important prognostic indicators in people with COPD 
(Celli, 2010).  Indices of exercise capacity such as peak VO2 (relative risk 0.994) (Oga et al, 2003) and 
6MWD (hazard ratio 3.75, 95% CI 2.06 to 5.85) (Budweiser et al, 2008) are strong predictors of 
mortality, independent of pulmonary function.  A 6MWD of <350 metres is common in severe or very 
severe COPD (Dreher et al, 2007; Pinto-Plata et al, 2004) and is associated with increased mortality 
(Cote et al, 2008).  Moreover, poor exercise capacity (incremental shuttle walk distance <270 metres) 
is an independent predictor of hospital admissions 
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with moderate to severe COPD (Emtner et al, 2007).  Exercise capacity is also inversely associated 
with health care costs in people with COPD (Weiss et al, 2004). 
 
Mechanisms of Exercise Limitation 
A number of mechanisms may contribute to exercise limitation in people with COPD, including 
respiratory, cardiovascular, peripheral muscle, nutritional and psychological factors (Belman, 1993).  
Both exercise capacity and the primary reason for exercise limitation vary between individuals with 
COPD, even after controlling for the severity of airflow limitation (Foglio et al, 2000; Spruit et al, 
2010).  Exertional dyspnoea is a hallmark feature of COPD (Viegi et al, 2007) and is more likely to be 
reported as the symptom limiting exercise in individuals with severe COPD compared to those with 
milder disease (Killian et al, 1992; O'Donnell & Webb, 1993), and during walking compared to 
cycling exercise (Man et al, 2003).  People with severe COPD commonly have a very limited 
ventilatory reserve (ratio of minute ventilation to maximum voluntary ventilation (VE/MVV) >0.80) at 
peak exercise, suggestive of a ventilatory limitation to exercise (Borghi-Silva et al, 2008; McKeough 
et al, 2003; van 't Hul et al, 2004).  Detrimental changes to ventilatory mechanics play an important 
role in exercise limitation in people with severe or very severe COPD (Montes de Oca et al, 1996).  As 
expiratory flow is commonly limited during tidal breathing (Grimby & Stiksa, 1970; Stubbing et al, 
1980), the majority of people with severe or very severe COPD dynamically hyperinflate during 
exercise in order to increase expiratory flow rates and minute ventilation (VE) (Macklem, 1984; 
O'Donnell et al, 2001a).  However, dynamic hyperinflation is associated with the development of 
PEEPi which imposes an inspiratory threshold load on the inspiratory muscles (Chen & Yan, 1999), 
and significantly increases work of breathing and dyspnoea (O'Donnell & Webb, 1993).  Dynamic 
increases in PEEPi have been shown to account for a large proportion (38 ± 17%) of total 
diaphragmatic work in people with very severe stable COPD and chronic HRF (Vitacca et al, 2004).  
The additional diaphragmatic loading associated with dynamic hyperinflation is particularly 
problematic during unsupported arm exercise (UAE) as a portion of ventilatory work is distributed 
away from the accessory inspiratory (ribcage) muscles to the diaphragm and expiratory muscles to 
enable some of the accessory inspiratory muscles to assist with the performance of upper limb 
activities (Celli et al, 1988; Criner & Celli, 1988; Martinez et al, 1991).  Dynamic hyperinflation also 
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simultaneously reduces the capacity of the inspiratory muscles by increasing the operational lung 
volume, placing muscles in a shortened position, which represents a mechanical disadvantage 
(Macklem, 1984) and reduces force output (Sinderby et al, 2001).  Breathing on the flattened portion 
of the compliance curve (where end expiratory lung volume approaches TLC) also dramatically 
increases the elastic work of breathing (Casaburi & ZuWallack, 2009; Dodd et al, 1984) and places a 
mechanical ‘restriction’ on the ability to increase tidal volume (VT) (O'Donnell & Laveneziana, 2006).  
Consequently, a higher VE is achieved solely through increasing respiratory rate (RR), and the 
combination of reduced expiratory time and expiratory flow limitation leads to further dynamic 
hyperinflation (Calverley & Koulouris, 2005; O'Donnell et al, 2001a).  The rapid shallow breathing 
pattern increases dead space ventilation, leading to carbon dioxide (CO2) retention (Roussos & 
Koutsoukou, 2003) and the development of a respiratory acidosis, which has been associated with 
diaphragm fatigue in healthy individuals (Jonville et al, 2002; Juan et al, 1984).  Impaired gas 
exchange may also contribute to exercise limitation in people with COPD (O'Donnell et al, 2002) as 
hypoxaemia reduces O2 delivery to working muscles, and predisposes muscles to early fatigue 
(Thompson et al, 1993).   
 
Although ventilatory capacity is often limited in people with severe COPD, other factors such as 
peripheral muscle dysfunction may contribute importantly to exercise limitation (American Thoracic 
Society/European Respiratory Society, 1999).  Leg muscle fatigue was identified as the primary 
symptom limiting cycling exercise in approximately one third of patients with severe COPD, despite 
evidence of a limited ventilatory reserve (mean VE/MVV 0.75) at peak exercise (Killian et al, 1992).  
In addition, quadriceps weakness is associated with reduced exercise capacity (Casaburi, 2003; 
Seymour et al, 2010a).  For example, a significant correlation between 6MWD and quadriceps force 
has been observed (r = 0.63) (Gosselink et al, 1996).  The ability of peripheral muscle dysfunction to 
limit exercise performance is further supported by the study performed by Saey and colleagues (2003), 
where a bronchodilator was used to improve ventilatory capacity in people with severe COPD and a 
limited ventilatory reserve at peak exercise (VE/MVV >1.0).  While post-bronchodilator exercise 
endurance time significantly increased in some individuals, exercise endurance time did not improve 
post-bronchodilator in a subgroup of participants (n = 9/18) who demonstrated quadriceps fatigue after 
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the cycle test with placebo nebulisation, despite an improvement in FEV1 of 11 ± 18%.  This suggests 
that peripheral muscle fatigue, rather than ventilatory capacity, was the primary factor determining 
exercise limitation in these individuals.  Furthermore, peripheral muscle dysfunction may increase the 
burden placed on inspiratory muscles during exercise.  Reduced skeletal muscle oxidative capacity is 
associated with early onset lactic acidosis during exercise (Maltais et al, 1996a), which in turn 
increases ventilatory demand for any given workload (Casaburi et al, 1991).  High inspiratory muscle 
workloads are associated with a high O2 cost of breathing (Field et al, 1982; Levison & Cherniack, 
1968), and may result in cardiac output being diverted from the locomotor muscles to the inspiratory 
muscles, as has been shown in elite cyclists (Harms et al, 1998).  However, during high intensity 
exercise in people with moderate COPD, intercostal muscle blood flow was shown to be restricted, 
while quadriceps muscle perfusion was preserved despite a reduction in cardiac output (Vogiatzis et 
al, 2010).  This finding challenges the notion that blood flow is prioritised in favour of the respiratory 
muscles at the expense of the locomotor muscles when the circulatory system is unable to meet the 
demands of both muscle groups.  Whether a similar pattern occurs in people with severe or very severe 
COPD is unknown. 
 
Cardiovascular system dysfunction may also contribute to exercise limitation in people with severe or 
very severe COPD.  Resting pulmonary hypertension is common in severe COPD and has been shown 
to be an independent predictor of a reduced 6MWD (Cuttica et al, 2010; Sims et al, 2009).  Pulmonary 
hypertension transiently worsens during exercise in people with COPD (Fujimoto et al, 2002), and is 
associated with increased right ventricular afterload, impaired contractility of the right ventricle, and 
limits the increase in stroke volume compared to that observed in healthy individuals (Holverda et al, 
2009).  Increased right ventricular afterload may also shift the septum towards the left ventricle, 
impairing left ventricular filling (Matthay et al, 1980).  Approximately 40% of people with moderate 
to severe COPD exhibit reduced cardiac output during exercise (Stewart & Lewis, 1986), and cardiac 
output has been shown to correlate strongly with peak VO2 (r = 0.77) (Morrison et al, 1987).  In 
addition, dynamic hyperinflation and PEEPi may impede venous return and reduce right ventricular 
preload (Pepe & Marini, 1982), or increase pulmonary vascular resistance further if breathing occurs 
close to TLC (Matthay et al, 1980). 
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In summary, the mechanisms leading to exercise limitation in COPD are complex and multifactorial 
(Nici, 2000).  However, the contribution of abnormal ventilatory mechanics, respiratory muscle 
dysfunction and impaired gas exchange appear to be significant in people with severe or very severe 
COPD.  Understanding the mechanisms that lead to exercise limitation is important, and may assist 
with the selection of appropriate management strategies and adjuncts in order to optimise exercise 
capacity in this population. 
 
Hypercapnic respiratory failure 
Chronic Hypercapnic Respiratory Failure 
Respiratory failure is defined as the inability to maintain adequate gas exchange and is reflected by 
abnormalities in arterial blood gases (British Thoracic Society Standards of Care Committee, 2002).  
Chronic HRF is characterised by elevated arterial partial pressure of carbon dioxide (PaCO2) (>45 
mmHg) with a normal pH, indicating complete metabolic compensation of the respiratory acidosis 
(bicarbonate >26 mmol/L) (British Thoracic Society Standards of Care Committee, 2002; Roussos & 
Koutsoukou, 2003).  It is estimated that 0.8-6.7% of people with COPD have severe or very severe 
disease (Buist et al, 2007), and of those with very severe disease, the prevalence of chronic HRF is 
likely to be high.  For example, one study reported a prevalence of chronic HRF of 63% in people with 
COPD who required long term oxygen therapy (Aida et al, 1998).  The likelihood of developing 
chronic HRF is greater in individuals with a high inspiratory workload and reduced inspiratory muscle 
strength, and is thought to occur due to a reduction in VE and alveolar ventilation in an attempt to 
avoid respiratory muscle fatigue (Roussos & Koutsoukou, 2003).  In COPD, the severity of 
hypercapnia has been shown to significantly correlate with lung resistance (r = 0.53) and dead space 
ventilation (r = 0.48), and is inversely related to FEV1 (r = -0.53) (Begin & Grassino, 1991) and 
inspiratory muscle strength when the maximum inspiratory occlusion mouth pressure (PImax) is <50% 
predicted (Rochester & Braun, 1985).  Compared to normocapnic people with COPD, individuals with 
elevated PaCO2 also tend to have increased RV and PEEPi (Begin & Grassino, 1991).  Signs and 
symptoms associated with chronic HRF commonly include early morning headaches, excessive 
daytime sleepiness, sleep fragmentation, confusion, severe exertional dyspnoea, poor exercise 
tolerance, cyanosis, pulmonary hypertension and cor pulmonale (Cormick et al, 1986; Simonds, 2003).   
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The impact of sleep on breathing appears to play a role in the development of chronic HRF in people 
with COPD.  Sleep imposes several physiological changes on the respiratory system such as a 10-15% 
reduction in VE (Douglas et al, 1982; Krieger et al, 1983) achieved primarily through a decrease in VT 
(Becker et al, 1999), reductions in ventilatory drive (Douglas et al, 1982), a decline in the ventilatory 
response to hypercapnia and hypoxia (Gonzalez et al, 2002), and a substantial increase in upper airway 
resistance (Lopes et al, 1983; Tangel et al, 1991).  During rapid eye movement (REM) sleep, the 
decline in VE and ventilatory drive are greater compared with non-REM sleep (Douglas et al, 1982), 
and the diaphragm is left to take over work of breathing secondary to REM related inhibition of 
intercostals and accessory respiratory muscles (Duron, 1973; Sawicka & Branthwaite, 1987).  While 
these changes are of little consequence in healthy individuals, physiological and clinical complications 
can manifest in people with COPD.  The most commonly observed sleep related breathing 
abnormality in COPD is hypoventilation (Cormick et al, 1986).  Hypoventilation is primarily caused 
by a reduction in VT and is more pronounced during REM sleep (Becker et al, 1999).  The severity of 
sleep hypoventilation in people with COPD is related to baseline PaCO2, body mass index and the 
percentage of REM sleep (O'Donoghue et al, 2003).  Sleep hypoventilation is thought to be involved 
in the pathogenesis of diurnal HRF, as the acute rise in PaCO2 associated with sleep promotes a 
gradual retention of bicarbonate, and leads to blunted central chemoreceptor response to hypercapnia 
(O'Donoghue et al, 2003).  Sleep related hypoxaemia is also common in COPD and is most severe 
during REM sleep, particularly in individuals with chronic HRF (Cormick et al, 1986; Fleetham et al, 
1982).  In addition, sleep quality is often reduced in COPD, with a reduction in total sleep time, and 
increase in sleep stage changes and arousals (Cormick et al, 1986; Fleetham et al, 1982; McEvoy et al, 
2009).  The progression of sleep hypoventilation to daytime chronic HRF in individuals with COPD is 
associated with a poor prognosis (Burrows & Earle, 1969; Vandenbergh et al, 1973) and an increased 
risk of hospitalisation secondary to an AECOPD (Kessler et al, 1999).   
 
Acute Hypercapnic Respiratory Failure 
Acute HRF is characterised by elevated PaCO2 (>45 mmHg), low pH (<7.35) and normal bicarbonate 
levels (22-26 mmol/L).  Similarly, in acute on chronic HRF, PaCO2 is high and pH is low, however 
bicarbonate is elevated due to pre-existing chronic HRF (British Thoracic Society Standards of Care 
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Committee, 2002).  Severe AECOPD may lead to the development of acute (or acute on chronic) 
HRF, particularly in individuals with severe or very severe COPD and limited ventilatory reserve 
(Calverley, 2003).  Viral and bacterial infections are the most common causes of an AECOPD, and are 
associated with a greater decline in pulmonary function and increased length of stay compared with 
non-infective exacerbations (Papi et al, 2006).  Acute exacerbations of COPD account for a significant 
proportion of admissions to hospital, for example an estimated 10% of all medical admissions in the 
United Kingdom (Currie & Wedzicha, 2006), and subsequently impose a significant financial burden 
on health care systems around the world (Hurst & Wedzicha, 2004; Viegi et al, 2007).  The prevalence 
of acute HRF in patients admitted to hospital with an AECOPD is high at approximately 20% (Plant et 
al, 2000).  Acute HRF in people with COPD is associated with a high risk of mortality both in-hospital 
(6-11%) and at 12 months following discharge (35-49%) (Chu et al, 2004; Connors et al, 1996; 
Groenewegen et al, 2003).  The risk of readmission to hospital after an AECOPD is also high.  In a 
large multi-centre study that included data from 234 hospitals and 7529 patients admitted to hospital 
with an AECOPD, the hospital readmission rate at three months following discharge was 31% (Price 
et al, 2006).  In 110 patients admitted with an AECOPD and acute HRF, the hospital readmission rate 
at 12 months following discharge was markedly high at almost 80% (Chu et al, 2004).  Both the 
frequency and severity of exacerbations increase with disease severity in people with COPD 
(Donaldson et al, 2003).  In turn, as the frequency of exacerbations increase, lung function (Donaldson 
et al, 2002) and HRQL (Seemungal et al, 1998) decline at a faster rate, and perpetuate a cycle of 
exacerbations and accelerated disease progression. 
 
Severe AECOPD with acute HRF are characterised by derangements in ventilatory mechanics, 
respiratory muscle function and gas exchange.  Critical expiratory flow limitation and severe dynamic 
hyperinflation are integral to the development of acute HRF in people with COPD (Fleury et al, 1985; 
O'Donnell & Parker, 2006; Purro et al, 2009).  Expiratory flow limitation is worsened during an 
AECOPD due to a marked increase in airways resistance secondary to bronchospasm, airway 
inflammation or sputum (Barbera et al, 1997).  A rapid shallow breathing pattern is subsequently 
adopted (Purro et al, 2009), and as a result of increased expiratory flow limitation and reduced time 
available for expiration secondary to tachypnoea, severe dynamic hyperinflation often ensues and 
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leads to high levels of PEEPi (O'Donnell & Parker, 2006; Rossi et al, 1985).  Dynamic hyperinflation 
causes a shift towards breathing on the flattened portion of the compliance curve and a substantial 
increase in elastic loading (O'Donnell & Parker, 2006).  The combination of increased elastic and 
resistive loading, and the inspiratory threshold load imposed by PEEPi significantly increases work of 
breathing relative to the severity of the mechanical impairment (Fleury et al, 1985; Purro et al, 2009).  
However, respiratory muscle strength decreases during an AECOPD (Purro et al, 2009), particularly in 
the presence of dynamic hyperinflation (O'Donnell & Parker, 2006).  Consequently the load placed on 
the respiratory system may outweigh the capacity of the respiratory muscles, leading to a reduction in 
alveolar ventilation and the development of acute HRF (Roussos & Koutsoukou, 2003).  Increased 
ventilation-perfusion mismatch, with perfusion of poorly ventilated alveoli (Barbera et al, 1997), and 
increased dead space ventilation secondary to a rapid shallow breathing pattern (Purro et al, 2009) also 
contribute to the development of hypoxaemia and hypercapnia.  Common signs and symptoms include 
increased dyspnoea, reduced exercise tolerance, cyanosis, increased sputum, cough, wheeze, oedema, 
confusion and fatigue (Hurst & Wedzicha, 2004).   
  
Functional status and health related quality of life 
In addition to a significant reduction in exercise capacity (Budweiser et al, 2008; McKeough et al, 
2003; van 't Hul et al, 2004), people with COPD also exhibit decreased levels of physical activity 
compared with healthy individuals (Watz et al, 2009).  Physical activity is particularly reduced in 
people with very severe COPD, where daily step count and the level of moderate intensity activity 
have been reported to be as little as 29 ± 20% and 22 ± 34% respectively, of that observed in healthy 
controls (Troosters et al, 2010a).  During admission to hospital for an AECOPD, physical activity 
levels are reduced further (Pitta et al, 2006).  These findings are concerning, as low levels of physical 
activity are strongly associated with an increased risk of readmission to hospital (Garcia-Aymerich et 
al, 2003) and mortality (Garcia-Aymerich et al, 2006).  In addition, people with COPD have difficulty 
performing daily activities such as vacuuming, carrying heavy objects, showering and dressing.  
Compared with healthy individuals, people with COPD spend less time performing daily activities, 
experience significant dyspnoea and have a marked ventilatory constraint during the performance 
daily activities, particularly in individuals with severe disease (Lahaije et al, 2010).  Furthermore, 
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HRQL is significantly reduced in people with severe or very severe COPD compared to healthy 
individuals, as demonstrated using both disease specific (Peruzza et al, 2003; Weatherall et al, 2009) 
and generic questionnaires (Windisch et al, 2003).  Exacerbations of COPD have been shown to have 
a negative impact on HRQL, both during the acute exacerbation (Menn et al, 2010) and after frequent 
AECOPD (Seemungal et al, 1998) that required admission to hospital (Esteban et al, 2009).   
Management strategies that aim to increase functional exercise capacity and physical activity are 
likely to be important in people with very severe COPD and may affect important outcomes such as 
mortality, hospital admission rates and HRQL.  Physical activity in people with COPD is strongly 
related to functional exercise capacity (r = 0.76) (Pitta et al, 2005) and inversely correlated with 
dynamic hyperinflation (r = -0.73) (Garcia-Rio et al, 2009).  Therefore interventions that aim to 
improve functional exercise capacity and reduce pulmonary hyperinflation may also impact upon 
physical activity and HRQL.  
 
SEVERE KYPHOSCOLIOSIS  
Definition 
The term kyphoscoliosis is used to describe the spectrum of chest wall disorders characterised by the 
combination of posterior angulation (kyphosis), and lateral angulation and rotation (scoliosis) of the 
spine (Bergofsky et al, 1959).  The angle between the upper and lower sections of the spinal curve 
(Cobb angle) is commonly used to describe the severity of the lateral curvature (Cobb, 1948) and 
correlates reasonably well with the clinical severity of scoliosis (Bergofsky et al, 1959; Koumbourlis, 
2006).  Involvement of the thoracic spine is common and Cobb angles greater than 100° are usually 
associated with significant respiratory impairment and may lead to the development of HRF 
(Bergofsky et al, 1959).  While mild forms of scoliosis are found in approximately 15% of the general 
population (Donath & Miller, 2009), severe kyphoscoliosis is uncommon, affecting approximately one 
in 10,000 individuals (Bergofsky, 1979).  Kyphoscoliosis usually begins in childhood, although is 
more noticeable during adolescence due to periods of rapid growth (Grassi & Tantucci, 1993).  The 
degree of spinal curvature usually progresses over time until skeletal maturity is achieved, and in 
severe cases may continue to worsen with increasing age (Koumbourlis, 2006).  In approximately 80% 
of cases, the cause of kyphoscoliosis is unknown (idiopathic) (Grassi & Tantucci, 1993).  
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Kyphoscoliosis may also occur as a result of congenital abnormalities, neuromuscular disease 
(paralytic), trauma or connective tissue disorders (Koumbourlis, 2006).  The work contained in this 
thesis will focus on the non-paralytic (eg. idiopathic and congenital) forms of severe kyphoscoliosis. 
 
Pathophysiology 
Respiratory System 
The most serious consequence of chest wall deformity is respiratory impairment, which in some cases 
may lead to cardiorespiratory failure.  Severe kyphoscoliosis is characterised by a marked restrictive 
ventilatory defect.  Notably, static lung volumes are decreased with reductions in TLC, FRC and VC 
observed in proportion to the degree of spinal deformity (Bergofsky et al, 1959; Caro & Dubois, 1961; 
Godfrey, 1970).  Residual volume is normal or only slightly reduced, resulting in a disproportionate 
reduction in VC relative to TLC (Bergofsky, 1979; Godfrey, 1970).  In addition to an increased Cobb 
angle, the reduction in VC (% predicted based on arm span (Hepper et al, 1965)), is correlated with the 
number of vertebrae involved, cephalad location of the curvature, and the loss of normal thoracic 
kyphosis (Kearon et al, 1993a).  A restrictive pattern is also observed in spirometry with a reduction in 
FEV1 proportional to FVC such that FEV1/FVC is normal or slightly elevated (Lisboa et al, 1985).  In 
addition, ventilatory capacity is reduced with a decrease in MVV in proportion to the degree of spinal 
curvature (Belaise et al, 1988; Godfrey, 1970; Ting & Lyons, 1964). 
 
While impaired lung development can directly impede pulmonary function when kyphoscoliosis 
begins in infancy (Godfrey, 1970), low lung volumes in severe kyphoscoliosis are primarily caused by 
a marked reduction in chest wall compliance.  Reduced chest wall compliance increases the elastic 
resistance of the thoracic cage such that a substantial change in pressure is required for a given change 
in lung volume, leading to a higher work of breathing and higher O2 cost of breathing (Bergofsky et al, 
1959).  Total respiratory system compliance is also reduced, although this is mainly attributable to the 
change in chest wall compliance as pulmonary compliance is often only mildly decreased (Bergofsky 
et al, 1959; Ting & Lyons, 1964).  Despite the presence of chest wall deformity and reduced lung 
volumes, chest wall compliance is relatively preserved during childhood and early adulthood.  
However, with increasing age it does appear to decrease over time, leading to a greater respiratory 
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impairment (Caro & Dubois, 1961).  While airways resistance was found to be higher than normal in 
people with kyphoscoliosis (Belaise et al, 1988), the difference was less impressive when low lung 
volumes were taken into account (Godfrey, 1970).  In addition, diffusion capacity is reported to be 
reduced in individuals with severe kyphoscoliosis and cor pulmonale (Bergofsky et al, 1959), but 
normal in people with less severe kyphoscoliosis after correction for low lung volumes (Olgiati et al, 
1982).  Mild ventilation-perfusion inequalities may also contribute to the respiratory impairment 
associated with severe kyphoscoliosis as a result of small airways closure above FRC (Grassi & 
Tantucci, 1993). 
 
Due to the altered shape of the chest wall, the respiratory muscles are often placed at a mechanical 
disadvantage and not surprisingly, respiratory muscle impairment is a common feature of severe 
kyphoscoliosis.  A significant reduction in diaphragmatic strength (Pdimax) and global inspiratory 
muscle strength (PImax) has been demonstrated compared with healthy controls, while the proportion of 
Pdimax used during quiet breathing was significantly higher (Estenne et al, 1998; Lisboa et al, 1985).  
Increased activity in both the accessory inspiratory muscles (scalenes) and expiratory muscles occurs 
during quiet breathing in individuals with severe kyphoscoliosis and is similar to that observed in 
people with severe COPD (Estenne et al, 1998).  In the absence of expiratory flow limitation, the 
performance of active expiration allows the increased work of breathing to be shared between the 
inspiratory and expiratory muscles.  However, despite assistance from the accessory muscles, a rapid 
shallow breathing pattern is usually adopted (Estenne et al, 1998).  Expiratory muscle strength (PEmax) 
may also be reduced (Jones et al, 1981), and together with a reduction in expiratory flow rates (Caro & 
Dubois, 1961; Sinha & Bergofsky, 1972) may reduce cough effectiveness. 
 
Skeletal Muscle Dysfunction 
In addition to impairment of the respiratory system, there is growing evidence to suggest that 
kyphoscoliosis may also have systemic effects such as skeletal muscle dysfunction.  Quadriceps 
weakness has previously been identified in people with severe kyphoscoliosis (Schonhofer et al, 2003; 
Swallow et al, 2009).  However rather than being a local process, it appears that skeletal muscle 
weakness may be generalised.  In 60 individuals with idiopathic kyphoscoliosis and a mild ventilatory 
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impairment, a significant reduction in respiratory muscle strength, quadriceps strength and handgrip 
strength were found compared with healthy controls (Martinez-Llorens et al, 2010).  The decrease in 
strength was proportional across the different muscle groups and correlated with the reduction in fat 
free mass that was also observed.  While the loss of muscle mass could explain in part the reduction in 
peripheral muscle strength, it was postulated that factors such as systemic inflammation could also 
play a role (Martinez-Llorens et al, 2010).  In people with severe kyphoscoliosis, quadriceps muscle 
biopsy data revealed evidence of oxidative stress and a change in muscle fibre type, reflected by a 
reduction in Type I myosin, compared with healthy controls (Swallow et al, 2009).  Interestingly, the 
degree of quadriceps weakness, oxidative stress and change in muscle fibre type in participants with 
severe kyphoscoliosis was not different to that found in subjects with severe COPD, suggesting that a 
common aetiological mechanism may exist between the two conditions.  
  
Cardiovascular System 
Pulmonary arterial hypertension is a relatively common complication associated with chest wall 
restrictive disorders, affecting approximately 30% of individuals with kyphoscoliosis (Shneerson, 
1978a; Shneerson et al, 1977).  In severe cases, pulmonary hypertension can lead to the development 
of cor pulmonale (Bergofsky et al, 1959).  Rather than relating to the degree of spinal curvature, 
resting pulmonary arterial pressure was found to be inversely correlated to the arterial partial pressure 
of O2 (PaO2) in individuals with kyphoscoliosis and unexplained dyspnoea or suspected pulmonary 
hypertension (mean Cobb angle 75°, range 10 - 140°) (Shneerson et al, 1977).  The prevalence of 
resting pulmonary hypertension is also greater with increasing age (Belaise et al, 1988).  In addition, 
abnormalities in pulmonary arterial pressure have also been detected during exercise in a large 
proportion of people with kyphoscoliosis.  Compared with healthy controls, the rate of rise, and peak 
pulmonary arterial pressure achieved during exercise were higher in individuals with thoracic 
kyphoscoliosis, particularly when VC was <1.5L, and were shown to be inversely proportional to 
TLC, VC and FRC (Shneerson, 1978a).   
 
The reasons for the development of pulmonary hypertension in this setting involve both anatomical 
and functional factors.  Firstly, pulmonary vascular resistance is increased due to a reduction in the 
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pulmonary vascular bed secondary to reduced lung volumes (Belaise et al, 1988; Naeye, 1961).   
Small pulmonary blood vessels are also reduced in number and have thicker walls compared with 
normal vessels (Bergofsky et al, 1959; Godfrey, 1970).  Secondly, both hypoxaemia and hypercapnia 
cause vasoconstriction of the pulmonary vasculature, which in turn increases pulmonary vascular 
resistance (Naeye, 1961; Viitanen et al, 1990).  Interestingly, the addition of 100% O2 during exercise 
had little effect on the development of pulmonary hypertension in subjects with kyphoscoliosis and no 
correlation was found between PaO2 and pulmonary artery pressure (Shneerson, 1978a).  Therefore it 
appeared that during exercise, the impact of hypoxic vasoconstriction was far less important than the 
reduction in the size of the vascular bed on the development of increased pulmonary vascular 
resistance and pulmonary hypertension. 
 
In addition, displacement of the intra-thoracic organs may occur as a direct consequence of chest wall 
deformity.  For example, restriction of the heart may result in an inability to increase stroke volume, 
particularly during times of increased demand such as exercise.  The incidence of mitral valve 
prolapse is also approximately 25% higher in individuals with idiopathic kyphoscoliosis compared 
with healthy individuals (Koumbourlis, 2006).   
 
Exercise 
Exercise Capacity  
Individuals with kyphoscoliosis have a reduced exercise capacity compared to healthy age matched 
controls, even if chest wall restriction is mild (Barrios et al, 2005; Swallow et al, 2009).  The reduction 
in exercise capacity has been consistently demonstrated during formal cardiopulmonary exercise tests 
and during a number of field walking tests across people with a range of severity in spinal curvatures.  
For example, peak VO2 was found to be reduced in people with moderate kyphoscoliosis (mean Cobb 
angle 47°) (Kesten et al, 1991) and in those with more severe spinal curvatures (mean Cobb angle 72°) 
where the reduction in peak VO2 was proportional to FEV1 and peak VE (Shneerson, 1978b).  
Likewise, in individuals with severe kyphoscoliosis and chronic HRF a reduction in peak work rate 
during cycling and distance walked during the shuttle walk test have been demonstrated (median 
13.5% predicted and median 210 metres respectively) (Lopez-Campos et al, 2008).  In this cohort, a 
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significant inverse correlation was found between PaCO2 and distance walked (r = -0.48), indicating 
that increased levels of hypercapnia were associated with poorer exercise capacity.  In 112 people with 
chronic HRF secondary to a variety of restrictive diseases including chest wall disorders, 6MWD was 
also markedly reduced at 61% of predicted (IQR 45 to 79) and was found to be an independent 
predictor of mortality (hazard ratio 3.31, 95% CI 1.73 to 14.10) when distance walked was less than 
205 metres (Budweiser et al, 2008).  Reports on the effect of the severity of spinal curvature or 
pulmonary function on exercise capacity are conflicting.  Several studies have reported no significant 
relationship between the Cobb angle or indices of pulmonary function on exercise capacity (Barrios et 
al, 2005; Kearon et al, 1993b; Martinez-Llorens et al, 2010), whereas one study demonstrated a 
significant decline in exercise endurance time with every 20° increase in the spinal curvature (Chong 
et al, 1981).  This discrepancy may simply reflect that the respiratory system is only one part of the 
complex interaction of body systems that occurs during exercise, and impairment of the cardiovascular 
system or peripheral muscle dysfunction may also have a negative effect on exercise capacity.  While 
the impact of kyphoscoliosis on lower limb exercise capacity is clear, upper limb exercise capacity has 
not been reported.   
 
Mechanisms of Exercise Limitation 
The primary mechanisms of exercise limitation in people with kyphoscoliosis appear to differ 
depending on the severity of chest wall deformity.  In people with mild to moderate kyphoscoliosis, 
cardiovascular and peripheral deconditioning secondary to reduced activity levels are thought to be the 
main causes of exercise limitation (Barrios et al, 2005; Kesten et al, 1991).  In contrast, individuals 
with severe kyphoscoliosis have been shown to have a very limited ventilatory reserve at peak 
exercise (VE/MVV close to 100%), suggestive of a ventilatory limitation to exercise (Highcock et al, 
2002).  The respiratory impairment associated with severe kyphoscoliosis such as decreased chest wall 
compliance, low lung volumes, respiratory muscle weakness and increased work of breathing 
(Bergofsky et al, 1959; Lisboa et al, 1985) serve to reduce ventilatory capacity (Ting & Lyons, 1964) 
and have a negative impact exercise performance.  Firstly, the pattern of breathing adopted during 
exercise by people with kyphoscoliosis is different from that of healthy individuals as reduced 
respiratory system compliance limits the ability to increase ventilation.  Tidal volumes are lower for a 
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given level of VE while the RR is higher (Kearon et al, 1993b; Shneerson, 1978b), leading to increased 
dead space ventilation (Bergofsky et al, 1959).  Although, when peak exercise VT was expressed as a 
percentage of VC, the ratio has been found to be within normal limits (Kesten et al, 1991; Shneerson, 
1978b).  In addition, for a given level of VO2, VE was approximately 20% higher than expected, while 
peak VE was significantly lower compared with healthy individuals (Shneerson, 1978b).  This relative 
hyperventilation places a substantial load on already overburdened respiratory muscles, and severe 
exertional dyspnoea often ensues (Bergofsky et al, 1959; Borel et al, 2008).  Furthermore, the 
development of a combined respiratory and metabolic acidosis has been observed during exercise in 
people with severe kyphoscoliosis (Vila et al, 2007), and may independently impair respiratory muscle 
function (Jonville et al, 2002; Juan et al, 1984). 
 
Pulmonary hypertension could also play a role in exercise limitation in people with severe 
kyphoscoliosis.  In people with COPD, pulmonary hypertension was shown to limit stroke volume 
during exercise (Holverda et al, 2009) and have a detrimental effect on exercise performance (Sims et 
al, 2009).  While a larger than normal rise in pulmonary arterial pressure has been reported during 
exercise in people with kyphoscoliosis (Shneerson, 1978a), the resultant effect on stroke volume has 
not been examined.  However, a significant reduction in stroke volume (16-20%) and cardiac output 
(16-20%) during exercise has been demonstrated in healthy subjects with simulated external thoracic 
restriction, despite a compensatory increase in heart rate (Miller et al, 2002).  This suggests that 
pulmonary hypertension could contribute to exercise limitation in individuals with severe 
kyphoscoliosis, although further investigation of this potential mechanism is required.    
 
Recently, the role of peripheral muscle dysfunction as a potential mechanism of exercise limitation has 
been investigated in people with kyphoscoliosis.  In individuals with moderate kyphoscoliosis (mean 
Cobb angle 56°), a multivariate analysis revealed that peripheral muscle strength was the primary 
factor that contributed to exercise capacity (r2 = 0.62), whereas no correlation was observed between 
exercise capacity and the severity of spinal deformity (Martinez-Llorens et al, 2010).  Similarly, lean 
body mass and lean leg volume were shown to account for approximately 60% of the variance in peak 
work capacity after controlling for age, sex and arm span in people with mild to moderate 
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kyphoscoliosis (Kearon et al, 1993b).  Both of these studies were comprised of participants with a 
relatively mild ventilatory impairment and consequently, the extent to which peripheral muscle 
dysfunction limits exercise performance in people with severe kyphoscoliosis and significant 
ventilatory impairment may differ.  Marked quadriceps weakness has been identified in individuals 
with severe kyphoscoliosis and chronic HRF, and was associated with a reduction in functional 
exercise capacity (Swallow et al, 2009).  In addition, a reduction in Type I slow twitch fibres was 
detected in the quadriceps muscle, which may predispose these individuals to leg discomfort and low 
frequency fatigue during exercise (Swallow et al, 2009).  Furthermore, significant O2 desaturation 
often occurs during exercise in severe kyphoscoliosis (Meecham Jones et al, 1995a), and may also 
have a detrimental effect on peripheral muscle function by limiting O2 supply to the working muscle 
(Thompson et al, 1993). 
 
While the primary mechanism limiting exercise in people with severe kyphoscoliosis appears to be 
ventilatory in nature, other factors relating to the cardiovascular system, peripheral muscle dysfunction 
or deconditioning may also play a role.  Identification of the mechanisms underlying exercise 
limitation in this population is integral in the selection of appropriate management strategies and 
adjuncts in order to improve exercise capacity in people with severe kyphoscoliosis.  
 
Hypercapnic respiratory failure 
Chronic Hypercapnic Respiratory Failure 
Chronic HRF is a common complication of severe kyphoscoliosis (Bergofsky et al, 1959) and left 
untreated, can result in early death (Fowles et al, 1978; Grassi & Tantucci, 1993).  While a relatively 
rare occurrence in individuals aged less than 20 years, the prevalence of chronic HRF increases with 
age, particularly in the fourth or fifth decade of life (Godfrey, 1970).  The risk of developing chronic 
HRF is related to the severity of the spinal curvature.  Generally, if the Cobb angle is less than 100° 
and the angle of the kyphosis is mild (less than 20°), the risk of developing chronic HRF is low 
(Bergofsky et al, 1959).  However, considerable variation in respiratory impairment and clinical status 
have been observed between individuals with a similar degree of spinal curvature, indicating that other 
factors may also be important in the development of HRF (Bergofsky et al, 1959).  For example, a 
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strong inverse correlation between inspiratory muscle strength (PImax and Pdimax) and PaCO2 has been 
demonstrated (r = -0.76), and suggests that inspiratory muscle weakness also plays an important role 
in the development of chronic HRF (Lisboa et al, 1985).  In the setting of chronic HRF, signs and 
symptoms commonly include early morning headaches, excessive daytime sleepiness, sleep 
fragmentation, severe exertional dyspnoea, poor exercise tolerance, cyanosis, pulmonary hypertension 
and peripheral oedema (Bergofsky et al, 1959; Shneerson & Simonds, 2002). 
 
Sleep plays an integral role in the development of chronic HRF in people with severe kyphoscoliosis.  
While the impact of normal sleep related changes in ventilation are negligible in healthy people with 
ample respiratory reserve, significant physiological abnormalities can occur during sleep in severe 
kyphoscoliosis, particularly in individuals who require assistance from the accessory respiratory 
muscles to maintain adequate alveolar ventilation during wakefulness (Estenne et al, 1998).  
Hypoventilation is the most significant breathing abnormality detected during sleep in severe 
kyphoscoliosis (Sawicka & Branthwaite, 1987), and not surprisingly, the greatest physiological 
disturbances are observed during REM sleep (Guilleminault et al, 1981; Mezon et al, 1980).  Initially 
hypoventilation is confined to REM sleep.  However, with secondary blunting of ventilatory responses 
to hypercapnia and hypoxia, greater derangements in blood gases are tolerated, hypoventilation 
progresses into non-REM sleep, and eventually diurnal HRF ensues (Belaise et al, 1988; Bergofsky et 
al, 1959; Mezon et al, 1980).  The extension of hypoxaemia and hypercapnia into wakefulness further 
impairs respiratory and peripheral muscle function (Juan et al, 1984; Thompson et al, 1993), 
exacerbating daytime symptoms such as dyspnoea and exercise intolerance, and often leads to the 
development of cor pulmonale (Bergofsky et al, 1959).  
 
Acute Hypercapnic Respiratory Failure 
Acute HRF can develop in people with severe kyphoscoliosis for a number of reasons, the most 
common precipitants being pneumonia, cardiac failure, a viral respiratory tract infection or 
progression of untreated chronic HRF to the point of respiratory decompensation (Libby et al, 1982).  
Pneumonia is not uncommon in kyphoscoliosis, and the combination of expiratory muscle weakness 
(Jones et al, 1981) and reduced expiratory flow (Caro & Dubois, 1961; Sinha & Bergofsky, 1972) that 
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are often observed, may impair secretion clearance and increase the risk of repeated infections.  In 
addition, signs of cor pulmonale are common in people with acute HRF and kyphoscoliosis, affecting 
approximately 60% of individuals (Libby et al, 1982).   
 
The mechanisms involved in the development of acute HRF in individuals with severe kyphoscoliosis 
differ from those observed in people with COPD with respect to respiratory system mechanics.  Unlike 
people with severe COPD, increases in PEEPi and airways resistance are mild and play only a minor 
role in acute respiratory decompensation in severe kyphoscoliosis.  In contrast, a dramatic reduction in 
respiratory system compliance and marked increase in respiratory resistance play an important role 
(Conti et al, 1997).  In the early stages of acute respiratory decompensation in seven patients with 
severe kyphoscoliosis, Conti and colleagues (1997) found that respiratory resistance was 50% higher 
than expected, and was primarily due to increases in tissue resistance rather than changes in airway 
calibre.  Tissue resistance was approximately six times greater than that observed in control subjects, 
and was explained by the reduction in both chest wall compliance (due to kyphoscoliosis) and lung 
compliance (due to atelectasis, oedema and sputum) (Conti et al, 1997).  In light of the strong 
relationship between PaCO2 and inspiratory muscle strength (Lisboa et al, 1985), the findings from the 
study by Conti et al (1997) suggest that the additional load placed on the respiratory system by the 
presence of infection, fluid overload or atelectasis can outweigh the capacity of the respiratory 
muscles and contribute to the rapid clinical deterioration often observed during the development of 
acute HRF.  While an episode of acute HRF can be a life threatening event, once treated, mortality 
rates are substantially lower compared to individuals with COPD post acute HRF (Libby et al, 1982). 
 
Functional status and health related quality of life 
A clear reduction in exercise capacity has been demonstrated during both formal cardiopulmonary 
tests (Lopez-Campos et al, 2008; Shneerson, 1978b) and functional walk tests (Budweiser et al, 2008; 
Fuschillo et al, 2003) in individuals with severe kyphoscoliosis.  Not surprisingly, physical activity 
levels are also substantially reduced in people with severe kyphoscoliosis and untreated chronic HRF 
compared with age and sex-matched healthy individuals (1,413 ± 1,870 movements/day and 8,590 ± 
4,060 movements/day respectively) (Schonhofer et al, 1997).  In addition, compared with healthy 
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individuals, people with kyphoscoliosis report great difficulty in the performance of daily activities 
that involve carrying and lifting such as vacuuming, sweeping, shopping and making beds, irrespective 
of whether spinal surgery has been performed (Dickson et al, 1995). 
 
A significant reduction in HRQL has also been demonstrated in people with severe kyphoscoliosis 
using either generic (Nauffal et al, 2002; Windisch et al, 2003) or condition specific (Cejudo et al, 
2009; Windisch, 2008) questionnaires across a range of domains.  Interestingly, exercise capacity, 
peripheral muscle strength and dyspnoea were found to be important factors in determining HRQL in 
people with severe kyphoscoliosis (Cejudo et al, 2009).  For example, significant correlations between 
the domain fatigue of the Chronic Respiratory Disease Questionnaire (CRDQ) and peak VO2 (rS = 
0.451), and distance walked during the shuttle walk test (rS = 0.599) were observed.  This finding 
suggests that impaired exercise capacity may result in a deterioration of HRQL.  A significant 
correlation was also detected between PaCO2 and the domain mastery of the CRDQ (r = 0.518), 
indicating that the severity of chronic HRF does impact upon an individual’s sense of control over the 
disease process.  Therefore, management strategies that aim to improve exercise capacity and 
peripheral muscle strength, and reduce dyspnoea and PaCO2 could have the potential to improve 
HRQL in people with severe kyphoscoliosis and chronic HRF. 
 
Summary  
While the aetiology and hallmark features of COPD and kyphoscoliosis are markedly different, for 
example, COPD is characterised by expiratory flow limitation and pulmonary hyperinflation, and 
kyphoscoliosis by a restrictive ventilatory impairment secondary to reduced chest wall compliance, a 
number of similarities exist between the two conditions.  Very severe COPD and severe 
kyphoscoliosis both significantly alter respiratory system mechanics and place the respiratory muscles 
at a mechanical disadvantage, leading to increased work of breathing and dyspnoea, particularly 
during exercise.  In addition, the ability to increase VT is hampered by mechanical constraints in both 
COPD and kyphoscoliosis, albeit at a higher operational lung volume in COPD (O'Donnell et al, 
2001a), and plays a fundamental role in the genesis of dyspnoea (Scano et al, 2010).  Both conditions 
are often associated with a ventilatory limitation to exercise (Highcock et al, 2002; McKeough et al, 
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2003; Montes de Oca et al, 1996) and in addition to significantly decreased exercise capacity, 
individuals commonly exhibit a reduced level of physical activity and have difficulty performing daily 
activities.  A significantly reduced 6MWD has also been shown to predict mortality in people with 
COPD and in people with kyphoscoliosis (Budweiser et al, 2008).  Furthermore, severe COPD and 
severe kyphoscoliosis often lead to the development of HRF (Carone et al, 1997), which is associated 
with increased mortality and morbidity (Burrows & Earle, 1969; Fowles et al, 1978; Vandenbergh et 
al, 1973), and impaired HRQL (Cejudo et al, 2009; Weatherall et al, 2009; Windisch et al, 2003).  
Therefore management strategies that aim to improve exercise capacity and treat HRF may have a 
positive impact on mortality, morbidity, HRQL and functional status in people with very severe COPD 
and individuals with severe kyphoscoliosis.  Management strategies for COPD and kyphoscoliosis will 
be discussed in turn, with a particular focus on exercise training and NIV. 
.  
MANAGEMENT OF VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
General management 
Comprehensive management of COPD includes assessment and monitoring, strategies to reduce the 
risk of developing COPD or disease progression, management of stable COPD, and management of 
AECOPD (Rabe et al, 2007).  The most important and effective strategy to reduce the risk of 
developing COPD or to attenuate the decline in pulmonary function that occurs over time is smoking 
cessation (Fletcher & Peto, 1977; Rabe et al, 2007; Scanlon et al, 2000).  In the management of very 
severe stable COPD, inhaled long-acting bronchodilators and inhaled glucocorticosteroids are 
recommended, along with influenza vaccines and in individuals >65 years of age, pneumococcal 
polysaccharide vaccines (Rabe et al, 2007).  Comprehensive pulmonary rehabilitation that includes 
exercise training is also an integral component of management (Nici et al, 2006).  While these 
interventions are not curative, they are effective in improving symptoms, exercise capacity and HRQL, 
and in reducing the frequency of exacerbations.  In people with severe COPD and resting daytime 
hypoxaemia (PaO2 <55 mmHg), long term O2 therapy (>15 hours/day) is indicated and has been 
shown to reduce mortality (Medical Research Council, 1981).  A subgroup of individuals with very 
severe COPD and chronic HRF may also benefit from domiciliary NIV (Meecham Jones et al, 1995b; 
Simonds, 2003).  Surgical procedures including bullectomy, lung volume reduction surgery and lung 
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transplantation play a limited role in the management of people with severe stable COPD, although 
may be beneficial in select individuals (Alifano et al, 2010). 
 
During an AECOPD, pharmacological management comprises of short-acting bronchodilators, oral or 
intravenous glucocorticosteroids, and antibiotics if clinical signs of a bacterial infection are present 
(Hurst & Wedzicha, 2004).  Supplemental O2 is commonly used to maintain oxygen saturation (SpO2) 
>90% or in the case of acute HRF or in known CO2 retainers, judicious use of supplemental O2 to 
maintain SpO2 88-92% is recommended (Roberts et al, 2008).  If an exacerbation is severe and acute 
HRF develops, NIV is considered a first line treatment in conjunction with maximal medical 
management (Ram et al, 2004), although some individuals may require invasive ventilation.  Despite 
the omission of early exercise rehabilitation as a management strategy from published reviews and 
consensus guidelines (Gold, 2009; Rabe et al, 2007; Rodriguez-Roisin, 2006), there is growing 
evidence to support exercise rehabilitation early in the recovery from an AECOPD (Nava, 1998; 
Troosters et al, 2010b).  The role of exercise training and the role of NIV as management strategies for 
people with severe or very severe stable COPD and also during AECOPD will be discussed in further 
detail, with a focus on individuals with HRF. 
 
Exercise training 
Stable Chronic Obstructive Pulmonary Disease  
Exercise training as part of a multidisciplinary pulmonary rehabilitation program is supported by a 
high level of evidence as one of the few effective interventions in the management of COPD (Nici et 
al, 2006; Rabe et al, 2007; Ries et al, 2007).  Pulmonary rehabilitation has been shown to produce 
clinically significant improvements in HRQL and exercise capacity in people with COPD (Lacasse et 
al, 2006).  For example, in a meta-analysis performed by Lacasse and colleagues (2006), data was 
combined from 16 randomised controlled trails (RCT) (total of 669 participants) comparing exercise 
training to usual care, and showed a mean difference in 6MWD of 48 metres (95% CI 32 to 65) in 
favour of exercise training, with the lower limit of the CI surpassing the minimal clinically important 
difference (MCID) of 25 metres (95% CI 20 to 61) (Holland et al, 2010).  A reduction in dyspnoea 
(O'Donnell et al, 1995) and decreased health care resource utilisation (Griffiths et al, 2001; Ries et al, 
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2007) have also been reported.  While there is no direct evidence that pulmonary rehabilitation 
improves survival in people with stable COPD, strong associations have been described between 
physical activity levels and the risk of an exacerbation, risk of readmission to hospital after an acute 
exacerbation, and mortality (Garcia-Aymerich et al, 2003; Garcia-Aymerich et al, 2006).  A strong 
correlate of physical activity is 6MWD (Pitta et al, 2005), which has been shown to increase after 
exercise training in people with COPD (Garrod et al, 2006).  Although it is important to note that 
improvements in exercise capacity do not necessarily translate into higher levels of physical activity in 
people with COPD (Pitta et al, 2008).   
 
The benefits associated with exercise training in people with COPD are not achieved through direct 
improvements in pulmonary function or gas exchange (Zuwallack, 2007).  Instead, the aim of exercise 
training is to change the reversible systemic consequences of COPD including peripheral muscle 
dysfunction, physical deconditioning, body composition abnormalities and possibly to reduce 
sensitivity to dyspnoea (Troosters et al, 2010c).  Both lower limb and unsupported upper limb 
endurance training are important components of a comprehensive exercise training program in people 
with COPD (Costi et al, 2009; Ries et al, 2007).  Lower limb endurance training has been shown to 
improve skeletal muscle oxidative capacity (Maltais et al, 1996b) and reduce VE for a given workload 
in proportion to the decrease in blood lactate levels in people with moderate to severe COPD 
(Casaburi et al, 1991).  In addition to enhanced peripheral muscle efficiency, improvements in pattern 
of breathing may occur with a mild increase in VT and a reduction in RR for a given workload 
(Casaburi et al, 1997), which in turn prolongs expiratory time and decreases dynamic hyperinflation 
(Porszasz et al, 2005).  Improvements in mechanical efficiency and muscle strength are also likely to 
contribute to the improvements observed in exercise capacity (Troosters et al, 2000). 
 
High intensity exercise training has been shown to produce greater physiological improvements 
compared to lower intensity exercise training in people with COPD (Casaburi et al, 1991).  While 
people with very severe COPD and chronic HRF can benefit from pulmonary rehabilitation (Carone et 
al, 2007), individuals with severe exertional dyspnoea or a marked reduction in ventilatory capacity 
may not be able to perform whole body endurance exercise at a high intensity (Maltais et al, 1997) for 
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an adequate duration to provide a sufficient training stimulus and therefore may not achieve the same 
improvements with exercise training as those without a significant ventilatory limitation, particularly 
if peripheral muscle strength is relatively preserved (Garrod et al, 2006; Plankeel et al, 2005; Troosters 
et al, 2001).  Consequently, a range of adjuncts that aim to reduce ventilatory load or increase 
ventilatory capacity during exercise have been trialled in people with severe COPD, with a view to 
permitting exercise training at higher intensities.  Long acting bronchodilators were observed to 
acutely reduce respiratory muscle loading and dynamic hyperinflation (Man et al, 2004), and to 
augment the effects of pulmonary rehabilitation compared to placebo in people with severe COPD 
(Casaburi et al, 2005).  Using a rollator frame during walking has also been shown to increase walking 
distance and ventilatory capacity compared to walking unaided (Probst et al, 2004), particularly in 
individuals with severe COPD who walked <300 metres or who needed to rest during the six minute 
walk test (6MWT) (Solway et al, 2002).  Although supplemental O2 was reported to be beneficial 
during a single bout of exercise in people with severe COPD and mild chronic HRF (O'Donnell et al, 
2001b), the use of supplemental O2 during exercise training in non-hypoxaemic individuals is 
currently not supported by strong evidence (Nonoyama et al, 2007).  Similarly, heliox was shown to 
be advantageous in the short term (Laude et al, 2006), but not during exercise training in severe COPD 
(Johnson et al, 2002).  Interestingly, the combination of helium and hyperoxia (fraction of inspired O2 
28%) during exercise training permitted participants to exercise at a higher training intensity and 
achieve greater improvements in exercise capacity and HRQL compared to placebo (Eves et al, 2009).  
Although immediate improvements in ventilatory load, ventilatory capacity or exercise performance 
were identified with the aforementioned adjuncts, benefits were not consistently observed when these 
adjuncts were used during exercise training.  Clearly, exercise training as a part of a comprehensive 
pulmonary rehabilitation program is an essential component of management for people with COPD.  
Identification of additional adjuncts, or novel combinations of adjuncts, is important and may allow 
individuals with a limited ventilatory reserve or severe exertional dyspnoea to tolerate high intensity 
endurance exercise training and to optimise the benefits associated with pulmonary rehabilitation.          
 
After an Acute Exacerbation of Chronic Obstructive Pulmonary Disease  
Exercise training as a component of pulmonary rehabilitation is also important in the management of 
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individuals recovering from an AECOPD.  In a systematic review, Puhan and associates (2009) 
combined data from six RCTs (total of 219 participants) and found that in addition to achieving 
clinically worthwhile improvements in HRQL and exercise capacity, pulmonary rehabilitation 
performed as early as four to seven days after admission to hospital with an AECOPD significantly 
reduced the rate of future hospital admissions (odds ratio 0.13, 95% CI 0.04 to 0.35) and mortality 
(odds ratio 0.29, 95% CI 0.10 to 0.84) at 12-24 months post discharge from hospital compared with 
usual care.  In addition, pulmonary rehabilitation performed after an AECOPD significantly decreased 
the number of unscheduled visits to hospital (either admission or review and discharge from the 
emergency department) compared with usual care (attendance 27% vs 57%) in the three months 
following discharge from hospital in patients with moderate to severe COPD (Seymour et al, 2010b).  
As hospital admissions constitute a significant proportion of the economic cost associated with COPD 
(Viegi et al, 2007), pulmonary rehabilitation has the potential to substantially reduce healthcare costs 
in people recovering from an AECOPD (Seymour et al, 2010b).   
 
Studies included in the meta-analyses performed by Puhan and coworkers (2009) that showed a 
reduction in hospital admissions and mortality with early pulmonary rehabilitation after an AECOPD 
largely included participants without acute HRF.  However, survivors of severe AECOPD with acute 
HRF have a very high risk of being re-admitted to hospital or dying within 12 months after discharge 
from hospital (Chu et al, 2004) and therefore may also benefit from early exercise rehabilitation.  The 
optimum time to commence early exercise rehabilitation in patients recovering from acute HRF 
secondary to an AECOPD is unknown.  Theoretically, exercise rehabilitation should occur as early as 
possible in order to minimise or avoid deconditioning and the negative consequences associated with 
bed rest (Clini & Ambrosino, 2005; Gosselink et al, 2008) provided that it is safe and well tolerated.  
In critically ill patients with acute respiratory failure secondary to a variety of aetiologies (including 
COPD), exercise rehabilitation commenced as early as 48 hours after initiation of invasive mechanical 
ventilation has been shown to be safe, feasible (Bailey et al, 2007; Morris et al, 2008), and result in 
significant improvements in functional exercise capacity, peripheral muscle strength and aspects of 
HRQL at discharge from hospital compared with standard care (Burtin et al, 2009; Schweickert et al, 
2009).  Similarly, in patients recovering from acute HRF secondary to an AECOPD, a stepwise 
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progressive pulmonary rehabilitation program commenced three to five days after transfer to a 
respiratory intensive care unit was also shown to increase functional exercise capacity and inspiratory 
muscle strength, and was associated with a greater reduction in dyspnoea at discharge compared to 
usual medical care (Nava, 1998).  Despite being safe in patients recovering from acute HRF secondary 
to an AECOPD, commencing exercise rehabilitation early may be challenging for patients as the 
reduction in ventilatory capacity and increase in respiratory load that is observed during the early 
stages of an acute exacerbation (Purro et al, 2009) often leads to severe dyspnoea even with mild 
activity (Nava, 1998).  Consequently, identification of adjuncts that can unload the respiratory muscles 
and reduce dyspnoea may be required to enable patients to tolerate exercise rehabilitation early in the 
recovery period.  The delivery of invasive mechanical ventilation during mobilisation in people with 
HRF is one potential adjunct that has previously been described in the literature (Chiang et al, 2006; 
Martin et al, 2005; Nava, 1998).  However, this technique appears to have been reserved for 
individuals who were relatively ventilator dependent.  Currently, NIV is considered the ventilatory 
mode of choice in the management of acute HRF secondary to an AECOPD (Liesching et al, 2003), 
and as NIV can be applied intermittently, it may be more feasible as an adjunct during exercise than 
invasive ventilation and could be used in combination with other adjuncts such as supplemental O2 and 
forearm support frames (Yohannes & Connolly, 2003).  Overall, the effects of early exercise 
rehabilitation performed at various stages in the recovery from an AECOPD are promising.  However, 
further research is required to determine the optimal timing of early exercise rehabilitation, to identify 
the important components of the training program (mode, intensity, frequency, duration), and to 
identify and evaluate potential adjuncts in order to maximise the benefits of early exercise 
rehabilitation in people recovering from an AECOPD. 
 
Non-invasive ventilation 
Non-invasive ventilation is the treatment of choice for many individuals with HRF due to a range of 
aetiologies.  The term NIV almost exclusively refers to positive pressure ventilatory support delivered 
via the patient’s upper airway using a mask or mouthpiece (British Thoracic Society Standards of Care 
Committee, 2002).  While positive pressure ventilation can be delivered effectively using either 
pressure preset or volume preset modes of ventilation (Windisch et al, 2005), pressure preset 
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ventilation is generally better tolerated (Girault et al, 1997) and more commonly used in the treatment 
of HRF (Lloyd-Owen et al, 2005), and therefore will be the focus in this review.   
 
Chronic Hypercapnic Respiratory Failure  
In the short term, NIV has been shown to improve a range of physiological and clinical variables in 
people with very severe stable COPD and chronic HRF.  During wakefulness, the application of NIV 
for as little as ten minutes was associated with improvements in arterial blood gases, alterations in the 
pattern of breathing with increases in VE and VT in proportion to the level of inspiratory pressure 
support (PS), a reduction in RR, prolonged duration of the respiratory cycle and respiratory muscle 
unloading (Ambrosino et al, 1992; Nava et al, 1993; Vanpee et al, 2002; Vitacca et al, 2000).  The 
addition of external positive end expiratory pressure (PEEPe) to inspiratory PS was shown to augment 
respiratory muscle unloading through reducing PEEPi and the inspiratory threshold load, provided that 
PEEPe did not exceed PEEPi (Nava et al, 1993; Vanpee et al, 2002; Vitacca et al, 2004).  However, the 
application of even low levels of PEEPe (eg. 5 cmH2O) may have negative haemodynamic 
consequences, such as a reduction in cardiac output, in some individuals with severe stable COPD 
(Ambrosino et al, 1993).   
 
The long term effects of NIV in very severe stable COPD are less clear.  Although individuals with 
lung and airway diseases comprise more than one third of the population on home mechanical 
ventilation in Europe (Lloyd-Owen et al, 2005), the use of NIV in people with stable COPD remains 
controversial due to a lack of strong evidence regarding the efficacy of NIV.  To date, two systematic 
reviews have evaluated the effects of NIV in people with stable COPD.  Wijkstra and colleagues 
(2002) combined data from two RCTs and two randomised crossover trials (total of 86 participants) 
that investigated the effects of three or more months of nocturnal NIV in people with severe COPD 
compared with usual medical management (with or without long term O2 therapy).  No significant 
effect on pulmonary function, gas exchange, expiratory muscle strength or sleep efficiency was 
observed between NIV and usual medical care.  While PImax increased by a mean 6.2 cmH2O (95% CI 
0.2 to 12.2) in favour of NIV, the magnitude of the change is unlikely to be clinically significant.  
Kolodziej and coworkers (2007) also performed a systematic review and included data from six 
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parallel RCTs and nine randomised crossover trials (total of 466 participants) that examined the short 
term and long term effects of nocturnal or daytime NIV in people with severe COPD.  No significant 
effect on pulmonary function, exercise tolerance or survival was found with NIV.  Similarly, no 
significant improvement in gas exchange or respiratory muscle strength was observed with NIV when 
data was pooled from RCTs.  However, when data was combined from randomised crossover trials 
significant improvements in gas exchange (PaO2: mean 4.5 mmHg, 95% CI 1.4 to 7.6; PaCO2: mean -
3.5 mmHg, 95% CI -5.9 to -1.1) and respiratory muscle strength (PImax: mean 4.8 cmH2O, 95% CI 0.3 
to 9.4; PEmax: mean 4.8 cmH2O, 95% CI 0.6 to 9.1) were found in favour of NIV.  While routine use of 
NIV in very severe stable COPD with chronic HRF is not supported by either systematic review, 
sample sizes of included studies were often small, study populations were heterogeneous (eg. degree 
of hypercapnia, presence of concomitant obstructive sleep apnoea), and the way in which NIV was 
delivered differed between studies (eg. mode of ventilation, level of PS, usage) and invariably 
contributed to the inconsistent results observed across studies.  Consequently, definitive conclusions 
regarding the efficacy of NIV in the management of very severe COPD and chronic HRF cannot be 
made based on these findings. 
  
More recently, the effects of NIV and long term O2 therapy compared with long term O2 therapy alone 
were investigated in 144 people with COPD and daytime HRF (PaCO2 >46 mmHg) in a multicentre 
RCT with a mean follow-up of 2.21 years (McEvoy et al, 2009).  A survival benefit was found in 
favour of NIV and long term O2 therapy (hazard ratio 0.63, 95% CI 0.40 to 0.99), although this was at 
the expense of reduced HRQL.  No difference was detected in hospitalisation rates, pulmonary 
function or arterial blood gases.  One possible explanation for the lack of improvement in daytime 
arterial blood gases with NIV was that the level of inspiratory PS provided (mean 8 cmH2O) was too 
low to sufficiently decrease nocturnal CO2 (mean overnight rise with NIV was 12.6 mmHg), and 
therefore would have prevented a reduction in daytime CO2 (Elliott, 2009; Meecham Jones et al, 
1995b).  An alternative approach to delivering NIV to people with very severe stable COPD and 
chronic HRF has been proposed whereby ‘high-intensity’ NIV (eg. mean PS 23 cmH2O, mean back up 
rate 21 breaths per minute) is used to achieve a maximal decrease in PaCO2 (Windisch et al, 2009).  In 
a retrospective study, Windisch and colleagues (2009) reported that ‘high-intensity’ NIV achieved 
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significant improvements in arterial blood gases and pulmonary function, and reduced hospitalisation 
rates.  In addition, two and five year survival rates were 82% and 58% respectively, which are higher 
than those previously published in the literature (Budweiser et al, 2007; Leger et al, 1994; Simonds & 
Elliott, 1995) where lower levels of ventilatory support were used.  Base excess has been shown to be 
an independent predictor of mortality in people with very severe COPD and chronic HRF (Budweiser 
et al, 2007), thus highlighting the importance of adequate nocturnal ventilation and correction of 
daytime blood gases in this population.  In a randomised crossover trial, six weeks of ‘high-intensity’ 
NIV was found to be more effective than six weeks of conventional ‘low-intensity’ NIV (PS 
approximately 10 cmH2O, back up rate 8 breaths per minute) in reducing nocturnal PaCO2 (mean -9.2 
mmHg, 95% CI -13.7 to -4.6) and increasing expiratory volumes (mean 96 mL, 95% CI 23 to 169) in 
people with very severe COPD and chronic HRF (Dreher et al, 2010).  It has also been suggested that 
subgroups of people with very severe stable COPD and greater levels of hypercapnia (Meecham Jones 
et al, 1995b), concomitant obstructive sleep apnoea or recurrent episodes of acute or acute on chronic 
HRF requiring treatment with NIV may have a more favourable response to domiciliary NIV 
(Simonds, 2003; Tuggey et al, 2003).  Investigation of the effects of ‘high-intensity’ NIV on survival, 
HRQL, utilisation of health care resources, gas exchange, sleep quality and functional capacity with 
long term follow-up in carefully selected individuals with very severe COPD and chronic HRF is 
warranted and may help to clarify the role of NIV in this population. 
 
The mechanisms behind the improvement in daytime arterial blood gases after treatment with NIV 
appear to relate to improved chemosensitivity to CO2 and a decrease in respiratory workload 
secondary to a reduction in pulmonary hyperinflation, rather than relief of respiratory muscle fatigue 
in people with COPD (Elliott et al, 1991).  Elliott and coworkers (1991) found a significant inverse 
correlation between daytime PaCO2 and the hypercapnic ventilatory response (rS = -0.76), and positive 
correlations between PaCO2 and gas trapping (rS = 0.85) and RV (rS =  0.78).  In contrast, no 
relationship was observed between PaCO2 and respiratory muscle strength.  A strong relationship 
between PaCO2 and PEEPi (r = 0.72) was also identified by Diaz and colleagues (2002) after three 
weeks of daytime NIV (3 hours/day, 5 days/week).  The reduction of pulmonary hyperinflation is 
likely to be important as hyperinflation was shown to be an independent predictor of mortality in 
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people with very severe COPD and chronic HRF (Budweiser et al, 2007).  In individuals with severe 
stable COPD and severe pulmonary hyperinflation (RV/TLC >75%), the reduction in PaCO2 
correlated with the level of inspiratory PS provided (r = 0.56) (Budweiser et al, 2005), suggesting that 
the level of PS delivered during NIV is important in determining the efficacy of treatment.  
 
Acute Hypercapnic Respiratory Failure  
The immediate physiological effects of NIV in people with COPD and acute HRF are similar to those 
observed in patients with severe stable COPD.  Non-invasive ventilation has been shown to unload the 
diaphragm and accessory inspiratory muscles, and alter the pattern of breathing by increasing VT and 
often VE, and decreasing RR (Appendini et al, 1994; Diaz et al, 1997; Girault et al, 1997).  The 
application of PEEPe enhances inspiratory muscle unloading by offsetting PEEPi, particularly when 
PEEPe is set to approximately 80-90% of PEEPi (Appendini et al, 1994; Appendini et al, 1993).  An 
improvement in arterial blood gases is also commonly observed (Appendini et al, 1994; Girault et al, 
1997) secondary to a reduction in dead space ventilation and increased alveolar ventilation, rather than 
improved ventilation-perfusion matching (Diaz et al, 1997).  Similar to individuals with severe stable 
COPD, the application of NIV with expiratory positive airway pressure (EPAP) may cause a 
significant reduction in cardiac output (>15%) in a small proportion of patients (Confalonieri et al, 
1998). 
 
In contrast to the use of NIV in people with severe stable COPD, NIV is considered a standard of care 
in the treatment of acute HRF secondary to an AECOPD.  Numerous prospective RCTs, and 
systematic reviews and meta-analyses have demonstrated a significant reduction in morbidity, 
mortality and health care costs with NIV and usual medical care compared with usual medical care 
alone.  Moreover, individuals with acute HRF due to an AECOPD constitute the largest single 
diagnostic category among recipients of NIV (Mehta & Hill, 2001), and stand to derive the greatest 
benefit from NIV compared with other diagnostic groups (Nava & Hill, 2009).  Ram and colleagues 
(2004) conducted a systematic review and included data from 14 parallel RCTs (total 758 participants) 
that investigated the effects of NIV in conjunction with standard medical care compared with standard 
medical care alone in people with acute HRF secondary to an exacerbation of COPD.  The addition of 
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NIV to standard medical care significantly reduced the risk of treatment failure (relative risk 0.48, 
95% CI 0.37 to 0.63), mortality (relative risk 0.48, 95% CI 0.35 to 0.76), the need for endotracheal 
intubation (relative risk 0.41, 95% CI 0.33 to 0.53), length of stay (mean difference -3.24 days, 95% 
CI -4.42 to -2.06), and complications associated with treatment (relative risk 0.38, 95% CI 0.24 to 
0.60) compared with standard medical care alone.  Non-invasive ventilation was also associated with 
an improvement in pH (mean difference 0.03, 95% CI 0.02 to 0.04), PaCO2 (mean difference 3.0 
mmHg, 95% CI -5.9 to -0.2) and RR (mean difference -3 breaths/minute, 95% CI -4 to -2) within one 
hour of commencing treatment.  In addition, NIV has been shown to reduce dyspnoea (Bott et al, 
1993) and substantially reduce health care costs in both the intensive care unit and ward settings 
(Keenan et al, 2000; Plant et al, 2003).  Individuals presenting with a Glascow coma scale <11, acute 
physiology and chronic health evaluation (APACHE) II ≥29, RR >30 breaths/minute and pH <7.25 at 
admission have an increased risk of treatment failure (>70%) with NIV (Confalonieri et al, 2005).  
Late failure of NIV, defined as recurrent respiratory acidosis more than 48 hours after an initial 
positive response to NIV, occurs in approximately 20% of patients with COPD and acute HRF 
(Moretti et al, 2000).  Along with a low pH and an increased number of comorbidities at the time of 
admission to hospital, a reduced ability to perform activities of daily living is a strong predictor of 
NIV failure in people with COPD (Moretti et al, 2000).  It is feasible that improving functional 
capacity in people with very severe or severe COPD could reduce the risk of late treatment failure in 
the setting of acute HRF, although this remains to be demonstrated. 
 
Effect of non-invasive ventilation on exercise capacity 
Nocturnal Non-Invasive Ventilation 
Without exercise training  
Nocturnal NIV appears to have a variable effect on exercise capacity in people with COPD.  In a 
meta-analysis that included data from two RCTs (total of 23 participants), three months of nocturnal 
NIV (inspiratory positive airway pressure (IPAP) 10-18 cmH2O, EPAP 2 cmH2O) was not associated 
with a significant increase in 6MWD (mean difference 27.5, 95% CI  -28.1 to 81.1 metres) in people 
with very severe COPD and chronic HRF (Wijkstra et al, 2002).  However, 95% CIs were wide and 
the upper limit of 81 metres suggests that clinically worthwhile improvements in 6MWD were 
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achieved in some individuals, based on a MCID of 25 metres (95% CI 20 to 61) (Holland et al, 2010).  
Unfortunately, characteristics of the individuals who improved exercise capacity after treatment with 
nocturnal NIV were unable to be determined.  It has recently been suggested that the delivery of ‘high-
intensity’ PS during nocturnal NIV may achieve greater improvements in blood gases and other 
clinical outcomes in people with COPD (Windisch et al, 2009).  While the delivery of ‘high-intensity’ 
nocturnal NIV (mean PS 23 cmH2O) for six weeks in a randomised crossover trial significantly 
improved arterial blood gases and reduced exercise induced dyspnoea (mean difference -2.4 points on 
the Borg scale, 95% CI -4.3 to -0.3) compared to the more commonly used ‘low-intensity’ NIV (mean 
PS 10 cmH2O), these benefits did not translate into an improvement in 6MWD (Dreher et al, 2010). 
 
In contrast, 6MWD increased by a mean of 18% after two months of nocturnal NIV (median 6.4 
h/night) (Schonhofer et al, 2003) and daily physical activity increased twofold after three months of 
nocturnal NIV (6.9 ± 1.8 h/night) (Schonhofer et al, 1997) in people with chronic HRF secondary to a 
variety of aetiologies including very severe COPD.  However, selection bias may have caused an 
overestimation of the treatment effect as both studies were observational.  In addition, heterogeneous 
populations were studied, including individuals with chest wall restriction.  Recent work by 
Schonhofer and colleagues (2008) in people with chronic HRF due to COPD or chest wall restrictive 
disorders, demonstrated that three months of nocturnal NIV (7.1 ± 0.9 h/night) increased constant 
work rate cycling endurance time in individuals with chest wall restriction, but not in participants with 
COPD.  Therefore, the observed improvements in 6MWD (Schonhofer et al, 2003) and physical 
activity (Schonhofer et al, 1997) may have been influenced by the inclusion of people with chest wall 
restriction.  Current evidence suggests that nocturnal NIV in unselected individuals with very severe 
COPD and chronic HRF does not improve exercise capacity in the absence of exercise training. 
  
In conjunction with exercise training 
To date, two RCTs have assessed the short term effects of the combination of nocturnal NIV and 
exercise training compared with exercise training alone.  In addition to improvements in HRQL, the 
addition of nocturnal NIV to exercise training has been shown to increase daily step count (Duiverman 
et al, 2008) and endurance shuttle walk test distance by a mean of 72 metres (Garrod et al, 2000) in 
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people with very severe COPD and mild to moderate chronic HRF.  The mechanisms associated with 
the reported benefits of nocturnal NIV are unclear, particularly in the study by Garrod et al (2000) 
where the median daily usage of NIV was low at 2 hours.  No changes were reported in static 
(Duiverman et al, 2008) or dynamic lung volumes (Garrod et al, 2000), indicating that pulmonary 
hyperinflation did not change with NIV.  In addition, only mild improvements in PaCO2 (Duiverman 
et al, 2008) and PaO2 (Garrod et al, 2000) were detected.  Sham NIV was not used in either study, and 
participants, trainers and assessors were not blinded to group allocation which may have introduced 
bias and led to an overestimation of the treatment effect (Pildal et al, 2007).  In a prospective 
observational trial with matched controls, significant improvements in FEV1 and pulmonary 
hyperinflation were demonstrated with the combination of nocturnal NIV and exercise training in 
people with severe COPD although no correlation was found between the change in hyperinflation and 
functional exercise capacity (Kohnlein et al, 2009).  It appears that nocturnal NIV can augment the 
benefits of pulmonary rehabilitation in people with severe COPD, with and without chronic HRF, 
although the mechanisms involved are unknown.  
 
Daytime Non-Invasive Ventilation 
Daytime NIV may be an alternative to nocturnal NIV in people with very severe stable COPD and 
chronic HRF, particularly if nocturnal NIV is poorly tolerated.  In a RCT with blinded participants and 
assessors, Diaz and coworkers (2005) found that NIV applied for 3 hours during the day, 5 days per 
week for 3 weeks significantly improved arterial blood gases and increased 6MWD by a mean of 76 
metres compared with sham NIV.  Dyspnoea was found to be a stronger predictor of exercise capacity 
than physiological measures, and a strong inverse correlation was found between the reduction in 
dyspnoea and change in 6MWD (Diaz et al, 2005).  The improvements associated with NIV were 
primarily attributed to the reduction in pulmonary hyperinflation and inspiratory muscle loads that 
were observed (Diaz et al, 2005; Diaz et al, 2002).  While the benefits in exercise capacity were 
largely sustained 2 weeks after cessation of daytime NIV, the changes in pulmonary hyperinflation 
and inspiratory load had attenuated (Diaz et al, 2005), indicating that an ongoing regimen of daytime 
NIV may be necessary in order to maintain benefits in the long term. 
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MANAGEMENT OF SEVERE KYPHOSCOLIOSIS  
General management 
The management of kyphoscoliosis varies depending on the severity of the spinal curvature and the 
extent of cardiorespiratory compromise.  In people with mild to moderate kyphoscoliosis, conservative 
management aims to prevent progression of the spinal deformity and may involve observation, bracing 
or physiotherapy (Koumbourlis, 2006; Marks & Qaimkhani, 2009).  However, there is no convincing 
evidence that bracing or physiotherapy alters the severity of the spinal deformity or reduces the need 
for surgery (Donath & Miller, 2009; McMaster & Singh, 2001; Weinstein et al, 2008).  Surgery is 
generally recommended if progression of the spinal curvature worsens symptoms and causes a further 
reduction in functional capacity, or if unrelenting pain occurs that is related to the spinal curvature and 
does not respond to conservative management (Dickson et al, 1995).  Surgery aims to reduce the 
severity of the spinal curvature, minimise progression of the spinal deformity and reduce the risk of 
cardiorespiratory impairment (Weinstein et al, 2008).  However, surgery does not completely alleviate 
symptoms nor restore functional capacity to that of healthy individuals (Dickson et al, 1995).  The 
effect of surgery on respiratory impairment is variable with some studies reporting an improvement in 
aspects of pulmonary function, for example in PImax and peak expiratory flow (Cooper et al, 1984), 
whereas other studies demonstrated no significant change in pulmonary function (Donath & Miller, 
2009; Koumbourlis, 2006).  Severe kyphoscoliosis is essentially an irreversible condition and is often 
associated with severe respiratory impairment, chronic HRF and poor HRQL.  Therefore, management 
of severe kyphoscoliosis often aims to address secondary problems such as dyspnoea, poor exercise 
tolerance and respiratory failure using strategies such as exercise training and nocturnal NIV (Cejudo 
et al, 2009; Martinez-Llorens et al, 2010).  The efficacy of exercise training and NIV in people with 
severe kyphoscoliosis will be discussed in turn. 
 
Exercise training 
While exercise training as a part of pulmonary rehabilitation is recommended for people with a variety 
of chronic respiratory conditions (Nici et al, 2006), limited evidence is available to support the use of 
exercise training in people with severe kyphoscoliosis (Shneerson, 1998).  In adolescents with 
moderate kyphoscoliosis (mean Cobb angle 60°, mean kyphosis angle 39°), a four month pulmonary 
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rehabilitation program was shown to improve pulmonary function and 6MWD (mean increase 128 
metres) (dos Santos Alves et al, 2006).  However, the treatment effect size is likely to be 
overestimated as firstly, the study was observational and prone to selection bias (Pildal et al, 2007), 
and secondly, a practice 6MWT was not performed and subsequently a learning effect may have 
confounded the results (Guyatt et al, 1985; Sciurba et al, 2003).  Even with improvements in exercise 
capacity after pulmonary rehabilitation, exercise capacity was still significantly lower compared with 
age and sex matched controls.  Significant improvements in peak exercise capacity (mean 5 ± 9 watts), 
endurance exercise capacity (mean 75 ± 94%), 6MWD (mean 22 ± 35 metres) and HRQL as measured 
using the CRDQ (mean 10 ± 13 points) have also been reported after completion of an 8 week home-
based cycling exercise program in 16 individuals with moderate to severe chest wall restriction (n = 14 
kyphoscoliosis) and chronic HRF (Borel et al, 2009).  Although the RCT conducted by Borel and 
colleagues (2009) was primarily designed to assess the effects of exercise training with NIV compared 
with exercise training alone, no differences were found between groups and post training data were 
combined.  While the findings of these studies are consistent and suggest that exercise training is 
advantageous in people with kyphoscoliosis, the risk of bias is high due to the lack of control groups 
and consequently the benefits associated with exercise training may be overstated. 
 
The effect of respiratory muscle training (isocapnic hyperpnoea) has also been assessed in 28 
individuals with severe chest wall restriction (86% with kyphoscoliosis) in a double-blind RCT.  
Three months of respiratory muscle training improved inspiratory muscle strength compared to sham 
respiratory muscle training.  However, exercise capacity did not change in the group who performed 
respiratory muscle training (Budweiser et al, 2006).  Therefore, despite the lack of strong evidence, 
whole body exercise training is likely to be an important component of management for people with 
severe kyphoscoliosis given the marked reduction in exercise capacity and functional capacity 
commonly observed, and the relationship between HRQL and indices of exercise capacity (Cejudo et 
al., 2009).  Randomised controlled trials are required to confirm the efficacy of exercise training in 
people with severe kyphoscoliosis and to provide an unbiased estimate of the size of the treatment 
effect.  In addition, assessment of upper limb training is needed in light of the reported difficulty in 
performing functional tasks that involve use of the upper limbs (Dickson et al, 1995).  Investigation of 
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the cost effectiveness of pulmonary rehabilitation, long term follow-up, mechanisms of benefits 
associated with exercise training and the optimal characteristics of exercise training programs are also 
required, although are likely to be difficult to perform due to the relatively low prevalence of people 
with severe kyphoscoliosis compared with conditions such as COPD.  
  
A standard pulmonary rehabilitation program may not be ideal for some individuals with severe 
kyphoscoliosis.  In an observational study, Naji and colleagues (2006) investigated the short and long 
term effects of pulmonary rehabilitation in people with restrictive lung disease secondary to interstitial 
lung disease (n = 35) or chest wall disorders (n = 11).  While improvements in exercise capacity and 
HRQL were identified in people who completed the program, drop out rates were high in participants 
with chest wall disorders compared to those with interstitial lung disease (45% versus 26%), 
suggesting that some individuals with chest wall restriction may have had difficulty tolerating the 
standard exercise program.  This finding highlights the need to identify potential adjuncts for use 
during exercise in people with severe kyphoscoliosis to reduce symptoms such as dyspnoea and 
optimise the benefits of exercise training.  The efficacy of one potential adjunct, supplemental O2, has 
been assessed during ground walking in people with moderate to severe kyphoscoliosis in a 
randomised, double blind, placebo controlled (compressed air) crossover study (Meecham Jones et al, 
1995a).  Oxygen saturation was improved and dyspnoea was reduced with supplemental O2 during 
walking, however no improvement in exercise performance was observed.  While it is feasible that 
ambulatory O2 could increase physical activity in people with moderate to severe kyphoscoliosis as a 
result of reducing exertional dyspnoea, this hypothesis has not been tested.  In light of the failure of 
supplemental O2 to improve exercise capacity, investigation of alternative adjuncts such as NIV or 
rollator frames is warranted. 
 
Non-invasive ventilation 
Chronic hypercapnic respiratory failure  
Domiciliary nocturnal NIV is a well established treatment for chronic HRF in people with severe 
kyphoscoliosis.  While severe kyphoscoliosis is relatively rare in the general population, individuals 
with chest wall restriction (including kyphoscoliosis) constitute approximately one third of the 
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population of home mechanical ventilation users in Europe (Lloyd-Owen et al., 2005).  After 
commencement of nocturnal NIV, numerous uncontrolled observational studies have consistently 
reported improvements in nocturnal and daytime gas exchange (Brooks et al., 2002; Goldstein et al., 
1991; Gonzalez et al., 2003; Leger et al., 1994), exercise capacity (Brooks et al., 2002; Goldstein et 
al., 1991), HRQL (Gonzalez et al., 2003; Nauffal et al., 2002; Windisch, 2008), sleep quality 
(Schonhofer & Kohler, 2000), mean pulmonary arterial pressure (Schonhofer et al, 2001a) and 
symptoms of hypoventilation (Ferris et al., 2000).  Benefits in gas exchange, exercise capacity and 
HRQL have been shown to be sustained in the long term for up to 10 years (Brooks et al., 2002; 
Gonzalez et al., 2003; Simonds & Elliott, 1995).  The effect of nocturnal NIV on pulmonary function 
and respiratory muscle strength is not as clear, with some studies reporting improvements (Ergun et 
al., 2002; Gonzalez et al., 2003) while others observed no significant change (Annane et al., 1999; 
Goldstein et al., 1991).  Treatment with nocturnal NIV may also lead to a substantial reduction in 
health care costs in people with severe kyphoscoliosis and chronic HRF as a result of a reduction in 
both the number of admissions to hospital (Nauffal et al, 2002) and number of days in hospital (Ferris 
et al., 2000; Leger et al., 1994) for respiratory related illnesses compared with the 6-12 months prior to 
commencement of NIV.  People with severe kyphoscoliosis have been shown to have the most 
favourable response to long term NIV in comparison to individuals with lung disease or 
neuromuscular disease, with mean survival of approximately 80% at 5 years (Laub & Midgren, 2007; 
Leger et al., 1994; Simonds & Elliott, 1995).  In addition, NIV alone or NIV in combination with O2 
appears to be superior to O2 therapy alone in people with severe kyphoscoliosis and chronic HRF with 
respect to blood gases and survival (hazard ratio 0.30, 95% CI 0.18 to 0.51) (Buyse et al., 2003; 
Gustafson et al., 2006).  While the survival benefits of NIV in comparison to O2 alone in people with 
severe kyphoscoliosis are promising, the studies by Buyse et al (2003) and Gustafson and colleagues 
(2006) were retrospective or non-randomised observational studies respectively, and consequently 
have an increased risk of bias.  However, given the benefits demonstrated with nocturnal NIV, it is 
unlikely that RCTs will be performed due to ethical reasons, particularly with survival as an end point. 
 
Several mechanisms have been proposed to explain the improvement in daytime blood gases during 
spontaneous breathing after treatment with nocturnal NIV in people with severe kyphoscoliosis and 
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chronic HRF, including respiratory muscle rest, improved pulmonary mechanics or increased 
ventilatory response to CO2.  Non-invasive ventilation has been shown to cause an immediate 
reduction in electromyographic activity of the diaphragm and accessory respiratory muscles despite 
improvements in gas exchange, which is suggestive of respiratory muscle unloading and therefore rest 
(Carrey et al, 1990).  Lung compliance was also observed to increase by a mean of 70% for up to three 
hours after using intermittent positive pressure breathing with an inspiratory pressure of approximately 
22 cmH2O for as little as five minutes (Sinha & Bergofsky, 1972).  However, the primary mechanism 
responsible for improved daytime blood gases during spontaneous breathing after treatment with 
nocturnal NIV is thought to be increased CO2 chemosensitivity, rather than greater respiratory muscle 
strength or altered pulmonary compliance (Annane et al., 1999; Nickol et al., 2005).  Nickol and 
colleagues (2005) reported a significant improvement in blood gases and the ventilatory response to 
CO2 after treatment with nocturnal NIV, whereas no significant changes were observed in pulmonary 
function, respiratory system compliance or inspiratory muscle strength.  A significant correlation 
between the reduction in PaCO2 and the increase in the slope of the ventilatory response to CO2 curve 
has been previously identified (r = -0.68) (Annane et al, 1999), and highlights the importance of 
correcting nocturnal hypoventilation in order to improve daytime spontaneous breathing in this 
population. 
 
Acute hypercapnic respiratory failure  
In light of the benefits associated with NIV in the management of chronic HRF in people with severe 
kyphoscoliosis, NIV is also considered to be the treatment of choice for acute HRF (Liesching et al., 
2003; British Thoracic Society Standards of Care Committee, 2002).  The level of evidence supporting 
the use of NIV for the treatment of acute HRF in severe kyphoscoliosis is similar to that of NIV for the 
treatment of chronic HRF in that no RCTs have been performed to confirm the efficacy of NIV.  
Instead, a small number of uncontrolled observational studies have been performed and demonstrate 
significant improvements in gas exchange, pulmonary function, dyspnoea and level of consciousness 
(Elliott et al., 1990; Finlay et al., 1995) with NIV in combination with maximal medical management 
in the hospital setting.  The benefits associated with NIV in the treatment of acute HRF in severe 
kyphoscoliosis may not be as great as those observed in people with COPD.  In a retrospective study, 
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the NIV failure rate (need for endotracheal intubation) was substantially higher in people with a 
variety of restrictive pulmonary disorders, including severe kyphoscoliosis compared with COPD 
(65% versus 33% respectively), although mortality rates were similar (Robino et al, 2003).   
 
Non-invasive ventilation has also been used to treat acute HRF in the home setting.  Banfi and 
coworkers (2007) reported the successful treatment of acute HRF secondary to a lower respiratory 
tract infection in the home in seven individuals with severe kyphoscoliosis who were already 
established on domiciliary nocturnal NIV.  Treatment consisted of antibiotics, supplemental O2 and 
increased use of NIV (>20 hours/day).  Arterial blood gases significantly improved after one hour of 
treatment (pH 7.29 ± 0.02 to 7.38 ± 0.01; PaCO2 67 ± 4 mmHg to 53 ± 3), returned to baseline after 
four weeks, and none of the participants required hospitalisation.  Similarly, Ellis and colleagues  
(1988) demonstrated correction of a respiratory acidosis in seven individuals with severe 
kyphoscoliosis after three months of nocturnal NIV (pH 7.29 ± 0.04 to 7.36 ± 0.04; PaCO2 62 ± 6 
mmHg to 49 ± 5).  While treatment of acute HRF in the home stands to substantially reduce health 
care costs, the studies by Banfi et al (2007) and Ellis et al (1988) were uncontrolled and prone to 
selection bias.  Randomised controlled trials are therefore required in order to identify potential 
candidates and to assess the safety and efficacy of treatment of acute HRF with NIV in the home.    
 
Effect of non-invasive ventilation on exercise capacity 
In the absence of exercise training, initiation of nocturnal NIV appears to have a positive effect on 
exercise capacity in people with severe kyphoscoliosis.  In an observational study, a significant 
improvement in 6MWD (245 ± 132 metres to 340 ± 122 metres) was reported after as little as one 
week of nocturnal NIV (mean usage 5 ± 0.8 h/night) in six people with severe kyphoscoliosis 
(Fuschillo et al, 2003).  The mechanisms associated with the improvement in exercise capacity were 
unclear as no changes in lung function or respiratory muscle strength occurred and only a small 
reduction in daytime PaCO2 was reported.  In addition, the increase in 6MWD was unlikely to have 
been caused by a learning effect, as practice 6MWTs were performed pre and post intervention 
(Guyatt et al., 1984; Sciurba et al., 2003).  Substantial improvements in cycling endurance time (176 ± 
159%), the endurance shuttle walk test (32 ± 22%) and respiratory muscle endurance were also found 
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after three months of nocturnal NIV (mean usage 7.1 ± 0.9 h/night) in 10 individuals with severe chest 
wall restriction and chronic HRF (n = 8 scoliosis) compared with matched controls (Schonhofer et al, 
2001b).  In this study, improvements in inspiratory muscle strength and daytime blood gases were 
observed, and along with a reduction in pulmonary hypertension, were posited as potential 
mechanisms behind the improvement in exercise capacity with NIV (Schonhofer et al, 2001b).  In 
contrast to inspiratory muscle strength, no increase in quadriceps strength was found after two months 
of nocturnal NIV in people with chronic HRF, suggesting that factors other than changes in peripheral 
muscle strength are responsible for the changes observed in exercise capacity (Schonhofer et al, 2003).  
Changes in exercise performance after treatment with nocturnal NIV may differ between people with 
severe kyphoscoliosis and those with very severe COPD.  For example, three months of nocturnal NIV 
(7.1 ± 0.9 h/night) increased constant work rate cycling endurance time in people with chronic HRF 
due to chest wall restriction (mean 1.89 minutes or 40%), whereas endurance time was not increased 
in people with COPD (Schonhofer et al, 2008).  While short to medium term nocturnal NIV appears to 
have a positive effect on exercise capacity in people with severe kyphoscoliosis, the magnitude of the 
treatment effects reported may be exaggerated due to a lack of control groups (Fuschillo et al., 2003; 
Schonhofer et al., 2008; Schonhofer et al., 2003) or failure to randomly allocate participants to groups 
(Schonhofer et al, 2001b). 
 
Summary  
Clearly, exercise training as a part of pulmonary rehabilitation is an integral component of 
management for people with COPD.  Improvements have been demonstrated in exercise capacity, 
HRQL, symptoms, health care costs, hospital admission rates and mortality.  While the evidence is 
less substantial, individuals with severe kyphoscoliosis also stand to benefit considerably from 
exercise training.  However, people with very severe or severe COPD and people with severe 
kyphoscoliosis both have altered respiratory system mechanics that substantially increase work of 
breathing during exercise and often lead to increased dead space ventilation, O2 desaturation, CO2 
retention, severe dyspnoea and ultimately a ventilatory limitation to exercise.  Consequently, these 
individuals may have difficulty achieving an adequate training stimulus during exercise training, and 
the benefits of pulmonary rehabilitation may be attenuated.   
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Non-invasive ventilation is also an important component of management, particularly in people with 
acute HRF secondary to an AECOPD, or chronic HRF secondary to severe kyphoscoliosis.  Nocturnal 
NIV has been shown to improve exercise capacity in the absence of exercise training in people with 
severe kyphoscoliosis, and to augment the benefits of pulmonary rehabilitation in people with very 
severe COPD.  However, despite optimisation with NIV and exercise training, exercise capacity, 
HRQL and physical activity levels in people with chronic HRF secondary to very severe COPD or 
severe kyphoscoliosis remain well below that of healthy individuals (Borel et al., 2009; Duiverman et 
al., 2008).  Therefore, identification of adjuncts that augment the benefits of exercise training or 
facilitate greater independence in the performance of daily activities may be worthwhile, both in stable 
individuals and those recovering from acute HRF, when ventilatory capacity is reduced even further 
(Conti et al., 1997; Purro et al., 2009).  The acute effects of NIV at rest, such as respiratory muscle 
unloading, a reduction in work of breathing and dyspnoea, and improved pattern of breathing and gas 
exchange are similar in COPD and kyphoscoliosis, and may also be beneficial during exercise.  The 
efficacy of NIV as an adjunct during exercise in people with COPD and people with kyphoscoliosis 
will be discussed in the following section. 
 
NON-INVASIVE VENTILATION DURING EXERCISE 
Immediate effects 
Lower Limb Exercise 
In people with stable COPD, NIV during cycling and treadmill exercise has been shown to increase 
exercise endurance time and decrease isotime dyspnoea compared to exercise without NIV or exercise 
with sham NIV in a systematic review and meta-analysis (van 't Hul et al, 2002).  The pooled effect 
size for the improvement in endurance time with NIV of 3.3 minutes (55% increase) in the best case 
scenario or 1.7 minutes (30% increase) in the worst case scenario, were generally equivalent to or 
above the inferior level of the confidence limit for the suggested MCID change in endurance time of 
1.75 minutes (Casaburi, 2004), indicating a clinically worthwhile effect.  Similarly, the pooled mean 
difference for the improvement in dyspnoea of 2 points on the Borg scale (35% decrease) was above 
the suggested MCID of 1 point (Ries, 2005) and appeared to be clinically significant.  A reduction in 
leg muscle fatigue associated with the use of NIV during cycling (Bianchi et al., 1998; Borghi-Silva et 
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al., 2008) and during high intensity isokinetic quadriceps exercise (Borghi-Silva et al, 2009) has also 
been reported compared to unassisted exercise or exercise with sham NIV.   
 
The acute effects of NIV during cycling in people with severe kyphoscoliosis are similar to those 
reported in people with COPD.  Borel and associates (2008) investigated the effect of NIV during high 
intensity constant work rate cycling in 16 individuals with severe kyphoscoliosis and two individuals 
with chest wall restriction secondary to post tuberculosis sequelae.  A significant improvement in 
endurance time (mean 4 minutes or 71%) and reduction in isotime dyspnoea (mean 1 point on the 
Borg scale) was found for the whole group.  However NIV ‘responders’ (n = 9) with a greater severity 
of pulmonary restriction were identified and treatment effects were larger for both endurance time 
(mean 8.3 minutes or 208%) and dyspnoea (mean 2 points on the Borg scale) compared with ‘non-
responders’.  Individuals with post tuberculosis sequelae and chronic HRF have also previously been 
shown to benefit from NIV (with and without supplemental O2) during cycling with enhanced 
endurance time and decreased dyspnoea compared to exercise with O2 or sham O2 (compressed air) 
(Tsuboi et al., 1997).  In addition, a reduction in leg muscle fatigue (mean 1.75 points on the modified 
Borg scale) was reported during cycling in people with severe kyphoscoliosis (Vila et al., 2007).  In 
contrast to cycling exercise, NIV during treadmill walking was shown to significantly reduce distance 
walked compared to unassisted exercise in 8 individuals with severe scoliosis and chronic HRF 
(Highcock et al, 2002).  However, the trigger and cycle delay on the ventilators used to deliver NIV in 
this study may have contributed to the negative result, particularly in light of the high RR that were 
observed during exercise.  Furthermore, lower levels of PS were used compared with the studies 
performed by Borel et al (2008) and Tsuboi and colleagues (1997) which may also have affected the 
result.  Consequently, it is unknown whether NIV can augment walking exercise capacity in people 
with severe kyphoscoliosis.  
 
Upper Limb Exercise  
In comparison to lower limb exercise, little is known regarding the effect of NIV during upper limb 
exercise.  During an UAE task where participants were required to maintain arm elevation at 90° of 
shoulder flexion for 2 minutes, NIV was shown to unload the diaphragm and increase VE compared to 
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arm elevation without NIV in people with very severe stable COPD and chronic HRF (Poggi et al, 
2006).  The effect of invasive ventilation during arm-ergometry (supported arm exercise) has also 
been assessed in slow to wean tracheotomised patients with COPD and chronic HRF.  Pressure 
support ventilation and PEEP during supported arm exercise (SAE) unloaded the respiratory muscles, 
increased VT, lowered RR, and allowed patients to achieve a higher peak work load compared with 
unassisted exercise (Vitacca et al, 2006).  However, tasks of daily living often require unsupported 
rather than supported arm activity.  Due to the specificity of training, UAE is preferable over SAE for 
functional exercise training (Martinez et al, 1993).  While ventilatory support during upper limb 
exercise appears beneficial, assessment of the effect of NIV on UAE capacity is warranted to 
determine whether NIV can be used as an adjunct during exercise training or to assist severely limited 
people with COPD or kyphoscoliosis in the performance of daily activities.   
 
Functional Exercise  
Studies that have examined the effect of NIV during ground walking in people with COPD have 
yielded conflicting results.  Prior to commencement of the work contained in this thesis, a lightweight 
portable ventilator was used to provide inspiratory PS during ground walking in people with severe 
COPD and was found to impair exercise performance compared with walking unassisted (Highcock et 
al., 1997; Revill et al., 2000).  However, the portable ventilator used to provide NIV did not have the 
capacity to support ventilation during exercise, as indicated by the detection of negative pressure in the 
ventilator circuit during inspiration (Highcock et al, 1997).  If the capacity of the ventilator is 
insufficient for use during exercise, exercise performance can be impeded rather than assisted due to 
the added resistance and dead space of the ventilator circuit (van 't Hul et al, 2002).   
 
Subsequent to the completion of the study described in Chapter 2 of this thesis, Dreher and colleagues 
(2007) demonstrated that the combination of NIV + O2 during ground walking increased distance 
walked and oxygenation, and reduced dyspnoea compared to walking with O2 alone in patients with 
very severe COPD and chronic HRF.  A rollator frame was used to carry the ventilator and O2 cylinder 
in this study, enabling participants to walk independently.  The same group also assessed the 
feasibility of using a portable ventilator and O2 cylinder (carried in a backpack) during ground walking 
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in people with very severe COPD and chronic HRF.  Despite improving oxygenation during walking 
compared with the usual or double the usual dose of O2, the combination of NIV + O2 did not relieve 
dyspnoea and was associated with a reduction in distance walked (Dreher et al, 2009).  Walking with 
the backpack was poorly tolerated, with 8/19 participants refusing to perform the walk test due to the 
weight of the pack (7.3kg).  Walking with double the usual dose of O2 did not decrease dyspnoea, 
prevent exercise-induced O2 desaturation or increase distance walked compared with usual dose O2 
(Dreher et al, 2009).  Therefore, provided the capacity of the ventilator is adequate to support 
ventilation during exercise, and that a rollator or similar device is used to carry the ventilator and 
associated equipment, it appears that ground walking with NIV is superior to walking with O2 alone in 
people with very severe COPD and chronic HRF.  Whether similar benefits can be achieved with NIV 
during ground walking in people with severe kyphoscoliosis remains to be seen. 
 
Mechanisms 
Inspiratory Pressure Support   
Several mechanisms relating to the benefit of NIV during exercise are associated with the application 
of positive pressure during inspiration.  Depending on the mode of ventilatory support, the 
terminology used to describe this parameter may differ.  For example, inspiratory pressure support 
(IPS) during IPS ventilation, IPAP during bilevel ventilation, PS during pressure support ventilation 
(PSV), flow assist and volume assist during proportional assist ventilation (PAV).  Despite minor 
differences in the definitions of these terms, functionally they have the same effect and therefore will 
be discussed collectively as PS in this section.   
 
One of the most important mechanisms of benefit associated with NIV during exercise is respiratory 
muscle unloading.  In 12 people with severe COPD and resting pulmonary hyperinflation, PS has been 
shown to substantially unload both the inspiratory and the expiratory components of the respiratory 
muscle pump during treadmill walking compared with walking unassisted (Kyroussis et al, 2000).  
Similarly, PS (mean 11 cmH2O) during cycling reduced dyspnoea in proportion to inspiratory muscle 
unloading in seven individuals with severe COPD (Maltais et al, 1995).  Despite the considerable 
reduction in inspiratory muscle activity with PS (oesophageal pressure-time product -81 ± 8%, 
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pressure time product of the diaphragm (PTPdi) -52 ± 9% compared with control), VE increased 
significantly, primarily through the augmentation of VT (Maltais et al, 1995).  Delivery of PS during 
an arm elevation task was also associated with substantial diaphragmatic unloading (PTPdi -54% 
compared with control) and increased VE in eight individuals with very severe COPD and chronic 
HRF.  Two of the participants with COPD studied by Poggi et al (Poggi et al, 2006) had concomitant 
kyphoscoliosis; however, no difference was observed in the response to PS during exercise in these 
participants and those exclusively with COPD.   
 
Another important mechanism that has been reported with PS during exercise is a change in the 
pattern of breathing.  A rise in VE and VT with either no change or a reduction in RR have been 
reported in people with severe COPD (Hernandez et al., 2001; Maltais et al., 1995; Poggi et al., 2006) 
and individuals with severe kyphoscoliosis (Borel et al, 2008).  One study found no change in VE as 
increases in VT were negated by a significant drop in RR in people with severe kyphoscoliosis (Vila et 
al., 2007).  Both of these scenarios reflect an improvement in breathing efficiency with PS and cause a 
reduction in dead space ventilation, which in turn improves arterial blood gases.  Improvements in 
arterial blood gases both during and after exercise have been observed with PS during walking and 
cycling exercise compared to unassisted exercise in people with COPD (Dreher et al., 2007; 
Hernandez et al., 2001) and individuals with severe kyphoscoliosis (Vila et al., 2007).  This may be of 
benefit to people with COPD or kyphoscoliosis as acute hypercapnia with a respiratory acidosis has 
been shown to significantly impair respiratory muscle function in healthy individuals (Jonville et al., 
2002; Juan et al., 1984).  In addition, NIV during exercise has been shown to prolong the onset and 
reduce the extent of exercise induced lactic acidosis compared to exercise without NIV (Borghi-Silva 
et al., 2008; Polkey et al., 2000).  This may be advantageous in people with COPD as lactic acidosis 
stimulates ventilation and increases work of breathing (Casaburi et al, 1991).       
 
Another possible mechanism underlying the benefit of PS during exercise is improvement of blood 
supply to the locomotor muscles.  The application of PS during high intensity cycling exercise in 
people with COPD increased locomotor muscle oxygenation and appeared to improve locomotor 
muscle perfusion compared to exercise with sham PS (Borghi-Silva et al, 2008).  The process by 
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which this is thought to occur is a reduction in VO2 of the respiratory muscles (Brochard et al, 1989) 
as a result of respiratory muscle unloading with PS (Kyroussis et al., 2000; Maltais et al., 1995), and a 
redirection of a portion of the available cardiac output from the respiratory muscles to the locomotor 
muscles.  These findings are supported by previous research in elite cyclists who sustained very high 
intensity exercise (near maximum VO2) under three conditions: control; respiratory muscle loading; 
and respiratory muscle unloading (PS during exercise).  An increased work of breathing was 
associated with vasoconstriction of the locomotor muscles with a subsequent reduction in locomotor 
muscle perfusion and maximum VO2 (Harms et al., 1997).  The reduction in locomotor muscle 
perfusion coincided with increased leg muscle fatigue and had a detrimental effect on exercise 
performance (Harms et al, 2000). Unloading of the respiratory muscles with PS significantly improved 
locomotor muscle perfusion, reduced symptoms of leg muscle fatigue, and significantly increased the 
duration of exercise (Harms et al., 1997; Harms et al., 2000). 
 
Expiratory Positive Airway Pressure 
A variety of terms are also used to describe positive expiratory pressure depending on the mode of 
ventilation being used.  During bilevel ventilation, the term EPAP is used, during PSV the terms 
continuous positive airway pressure (CPAP) or PEEP are used, and during PAV both EPAP and CPAP 
have been used.  Despite minor differences in the definitions, functionally these terms have the same 
effect and therefore will be discussed collectively as EPAP in this section.   
 
While inspiratory PS is effective in unloading the respiratory muscles, it does not prevent dynamic 
hyperinflation as indicated by an increase in end expiratory lung volume during exercise (Maltais et al, 
1995).  Dynamic hyperinflation causes PEEPi and imposes an inspiratory threshold load on the 
respiratory muscles, which increases work of breathing and dyspnoea, and leads to activity limitation 
(Chen & Yan, 1999; O'Donnell & Webb, 1993; O'Donoghue et al., 2002).  The combination of PS and 
EPAP during an arm elevation task was shown to reduce PEEPi (mean 30%) compared with unassisted 
arm elevation in people with very severe COPD and chronic HRF (Poggi et al, 2006).  The ability of 
EPAP to reduce dynamic hyperinflation during arm elevation is consistent with observations made in 
people with stable COPD and chronic HRF at rest (Nava et al., 1993), and in those recovering from 
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acute HRF (MacIntyre et al, 1997).  It is feasible that EPAP could decrease dynamic hyperinflation 
and offset PEEPi during lower limb exercise as well in people with COPD, although this mechanism 
has not yet been demonstrated.  Studies that evaluated the effect of CPAP (range 4 to 10 cmH2O) 
during cycling exercise in people with COPD (O'Donnell et al., 1988; Petrof et al., 1990a) and cystic 
fibrosis (Henke et al, 1993) failed to show a reduction in end expiratory lung volume with CPAP 
compared with unassisted exercise.  However, if the level of CPAP applied is greater than PEEPi, an 
increase in expiratory muscle work and dyspnoea occurs, which may impair exercise performance 
(Petrof et al, 1990a).  In light of the effect of PS on respiratory muscle activity, and the potential for 
EPAP to offset PEEPi and provide additional respiratory muscle unloading, the combination of PS and 
EPAP (eg. bilevel NIV) during exercise in people with COPD may be superior to the use of PS alone 
(Maltais et al, 1995). 
 
In addition, the application of positive pressure throughout the expiratory phase has been shown to 
reduce the dynamic dead space of oronasal masks, particularly when the exhalation port is located 
over the nasal bridge (Saatci et al, 2004).  A reduction in dead space reduces CO2 rebreathing 
(Schettino et al, 2003) which may be advantageous in people with HRF secondary to COPD or 
kyphoscoliosis, particularly when a single limb circuit is used as with bilevel NIV or IPS.  
 
Training effects 
The immediate effects of NIV during exercise, namely: respiratory muscle unloading, alterations in 
the pattern of breathing, improvement in blood gases, reduced lactic acid production, improved 
oxygenation and perfusion of working muscles, and the offsetting of PEEPi may allow people with 
COPD to exercise at a higher intensity for a greater duration with less dyspnoea.  Thus, exercise 
training with NIV could lead to greater improvements in exercise capacity compared to exercise 
training alone.  Such improvements in exercise capacity may lead to increased physical activity levels 
and improve quality of life in people with COPD.  Similarly, in individuals with severe 
kyphoscoliosis, the immediate benefits to exercise performance that have been demonstrated with NIV 
could potentially allow greater improvements in exercise capacity and HRQL compared to exercise 
training alone.   
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Chronic Obstructive Pulmonary Disease  
To date, six RCTs (Bianchi et al., 2002; Hawkins et al., 2002; Johnson et al., 2002; Reuveny et al., 
2005; Toledo et al., 2007; van 't Hul et al., 2006) and one quasi-RCT (Costes et al, 2003) have 
investigated the effect of NIV during exercise training in people with moderate to very severe stable 
COPD.  Exercise training programs were similar between studies and comprised centre-based cycling 
or treadmill training for approximately 6-8 weeks, 3 sessions/week, 30-45 minutes of exercise/session 
with an initial training intensity of 50-70% of peak work capacity.  In contrast, the delivery of NIV 
differed between studies.  A variety of ventilatory modes were used, including IPS, bilevel and PAV 
(with and without EPAP), and the level of inspiratory support provided ranged from low to moderate.  
All studies reported the effect of NIV during exercise training on exercise capacity.  However the 
results were conflicting.  Peak exercise capacity improved in participants who trained with NIV in 
three studies (Costes et al., 2003; Hawkins et al., 2002; van 't Hul et al., 2006) but was shown to be no 
different to participants who trained without NIV in two studies (Bianchi et al., 2002; Johnson et al., 
2002).  Similarly, an increase in endurance exercise capacity related to training with NIV during 
training was found in two studies (Hawkins et al., 2002; van 't Hul et al., 2006) but was no different to 
training without NIV in three studies (Bianchi et al., 2002; Costes et al., 2003; Johnson et al., 2002).  
Between group comparisons for exercise capacity outcomes were not reported in two studies 
(Reuveny et al., 2005; Toledo et al., 2007).  Compared to training unassisted or with sham NIV, 
training intensity was significantly higher with NIV in two studies (Hawkins et al., 2002; van 't Hul et 
al., 2006) which may have contributed to the improvements in exercise capacity observed in these 
studies.  Evidence of a greater training effect with NIV, as reflected by a reduction in blood lactate at 
an identical work load, was also found by Toledo and associates (2007).  The effect of NIV during 
exercise training on HRQL was only assessed in two studies (Bianchi et al., 2002; van 't Hul et al., 
2006) and was found to be no different compared to training with sham NIV or training without NIV.   
 
While it appears that NIV during exercise training may improve short term lower limb exercise 
capacity in select individuals with moderate to severe COPD compared to training unassisted or with 
sham NIV, the reported treatment effects may have been exaggerated due to bias.  Only one study 
blinded participants by using sham NIV during training (van 't Hul et al, 2006), and three studies used 
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blinded assessors (Reuveny et al., 2005; Toledo et al., 2007; van 't Hul et al., 2006).  Also, allocation 
concealment was not adequately performed or described in several studies (Costes et al., 2003; 
Johnson et al., 2002; Reuveny et al., 2005; Toledo et al., 2007) which may have introduced selection 
bias and led to an overestimation of the true treatment effect (Pildal et al, 2007).  On the other hand, 
most studies included a small number of participants which may have reduced the power to detect 
significant differences between groups for key outcomes.  For example, Hawkins et al (2002) powered 
their study to detect a 33% reduction in isoload blood lactate.  However, 10 participants dropped out 
(34%) and a significant difference was not detected between groups (mean difference 18%, 95% CI 3 
to 40%, p = 0.09).  Pooling results from RCTs that have assessed the effects of NIV during exercise in 
meta-analyses, with careful interpretation of the treatment effects in light of the risk of bias of 
included trials may help to clarify whether training with NIV is clinically worthwhile in people with 
COPD.  
 
Kyphoscoliosis  
Only one RCT has assessed the effect of NIV during exercise training in people with severe 
kyphoscoliosis.  Borel and coworkers (Borel et al, 2009) compared training with NIV to unassisted 
training during an 8 week home-based cycling exercise program in 16 individuals with chest wall 
restriction (n = 14 kyphoscoliosis, n = 2 post tuberculosis sequelae) who were already established on 
nocturnal NIV.  While significant improvements in 6MWD, peak and endurance cycle exercise 
capacity, and HRQL were achieved in the whole group, no differences were observed between the 
group who trained with NIV and the control group.  Unfortunately participants were not selected on 
the basis of pulmonary function, which may have influenced the results.  Previous work from the same 
group identified a sub-group of individuals with severely reduced lung volumes who exhibited an 
acute improvement in exercise performance with NIV (Borel et al, 2008).  Of the 16 participants in the 
training study, 10 were classified as NIV ‘responders’.  Six ‘responders’ trained with NIV during 
exercise and a trend towards increased 6MWD and HRQL was observed compared with ‘responders’ 
who trained without NIV (Borel et al, 2009).  However, the study was not powered for subgroup 
analyses and therefore a Type II error cannot be excluded.  While it appears that exercise capacity and 
HRQL can improve with exercise training in people with kyphoscoliosis and chronic HRF, this 
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finding is only observational as a control group was not included.  Further studies are required to 
determine the role of NIV during exercise training in people with kyphoscoliosis and should select 
participants with severely reduced lung volumes who demonstrate an acute improvement with NIV 
during exercise.  
  
Factors that may influence the efficacy of non-invasive ventilation during exercise  
Patient Selection  
Disease severity 
Disease severity may play a role in determining the effectiveness of NIV or CPAP during exercise in a 
variety of diagnostic groups.  For example, improvements in work of breathing and exercise endurance 
time with CPAP 5 cmH2O during cycling in people with cystic fibrosis were related to disease severity 
(defined by percent predicted FEV1 and resting pulmonary hyperinflation), with greater benefits 
observed in those individuals with severe disease (Henke et al, 1993).  In people with COPD, the 
efficacy of NIV during exercise has been assessed in individuals with disease severity ranging from 
moderate to very severe, as defined by FEV1 (percent predicted) (Bianchi et al., 2002; Hawkins et al., 
2002; van 't Hul et al., 2006).   While it appears that individuals with greater disease severity may 
derive more benefit from NIV during exercise than those with milder disease (Bianchi et al, 2002), this 
hypothesis has not been formally tested.  In addition, despite selecting participants with a similar level 
of disease severity and a limited ventilatory reserve (VE/MVV >70%) during unassisted exercise, 
considerable variability in the response to NIV during exercise has been reported (van 't Hul et al, 
2004).  A stepwise multiple regression analysis revealed that inspiratory muscle strength was the most 
important factor influencing the response to NIV during exercise in this study, although it explained 
only 24% of the variance in the response to NIV during exercise (van 't Hul et al, 2004).  The impact 
of NIV on haemodynamics has also been shown to influence the effectiveness of NIV during exercise 
in people with moderate to severe COPD (Oliveira et al, 2010).  In people with severe kyphoscoliosis, 
individuals with an improvement in exercise endurance time of 50% or more (‘responders’) had a 
greater restriction in lung volumes compared with non-responders with respect to FVC (1.05 ± 0.06L 
versus 1.57 ± 0.18L respectively) and TLC (2.54 ± 0.38L versus 3.69 ±1.08L respectively) (Borel et 
al, 2008).  In addition, peak exercise VE and VT were significantly reduced, dead space ventilation was 
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increased and baseline PaCO2 was elevated (51 ± 5 mmHg versus 44 ± 5 mmHg) in the NIV 
responders (Borel et al, 2008).  Therefore, individuals with severe kyphoscoliosis and chronic HRF 
present as candidates who are likely to benefit from using NIV during exercise.  While disease 
severity is undoubtedly an important factor in the selection of people with COPD and people with 
kyphoscoliosis who may benefit from NIV during exercise, a number of other factors such as the 
effect of NIV on haemodynamics, choice of ventilator settings, interface selection and the capacity of 
the ventilator may also be important.   
 
Effect of non-invasive ventilation on haemodynamics  
A large degree of individual variability in the response to NIV during exercise has been reported in 
people with COPD, even when participants with a similar level of airflow obstruction and ventilatory 
reserve were selected (van 't Hul et al, 2004).  One possible explanation for this relates to the effect of 
positive pressure NIV on haemodynamics.  Oliveira and colleagues (2010) recently reported the effect 
of IPS 16 cmH2O and PEEP 5 cmH2O during constant work rate cycling on haemodynamics and 
exercise endurance time compared with unassisted exercise in 21 people with moderate to severe 
COPD.  While HR was significantly decreased with IPS and PEEP during exercise, approximately half 
of the participants also experienced a reduction in stroke volume and cardiac output (mean -2.2 L/min, 
95% CI -3.3 to 0.1), which was associated with a lack of improvement in exercise endurance time.  In 
contrast, exercise endurance time was increased with IPS and PEEP in the sub group of participants 
who did not experience a reduction in stroke volume and cardiac output.  The only baseline 
characteristic that differed between the sub groups was resting pulmonary hyperinflation, which was 
greater in participants who experienced a decrease in cardiac output with IPS and PEEP.  A similar 
reduction in cardiac output (from 26.5 ± 0.8 L/min to 24.1 ± 0.8 L/min) secondary to a drop in stroke 
volume has also been reported in elite cyclists when PAV was used during maximal exercise to unload 
the respiratory muscles (Harms et al, 1998).  The decrease in VO2 observed with PAV could have 
accounted for some of the changes observed in cardiac output.  However, the authors cited a reduction 
in venous return caused by an increase in intra-thoracic pressure associated with the use of PAV as a 
likely contributing factor (Harms et al, 1998). Therefore, a reduction in cardiac output during exercise 
with NIV may occur in some individuals with moderate to severe COPD and may help to explain 
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some of the individual variation in the response to NIV observed in this population.  
 
Ventilator Settings and Interface Selection 
Mode of ventilation  
Several different modes of NIV have been used during exercise including IPS, bilevel and PAV.  
During IPS, positive pressure is only applied during the inspiratory phase of the respiratory cycle.  
During bilevel NIV, positive pressure is applied throughout the entire respiratory phase using an IPAP 
that is set higher than the EPAP.  The difference between IPAP and EPAP is often referred to the 
‘swing’ or PS and reflects the true level of inspiratory support delivered to an individual.  During 
PAV, ventilatory support is delivered in proportion to patient effort with the goal of reducing both 
resistive and elastic loads using flow assist and volume assist respectively (Ambrosino & Rossi, 2002).  
Proportional assist ventilation can be used with or without EPAP.  While technically not a mode of 
ventilatory support, CPAP has also been used during exercise and was the first type of positive 
pressure therapy reported to acutely improve exercise tolerance and reduce dyspnoea in people with 
severe COPD (O'Donnell et al, 1988).   
 
The use of CPAP during exercise has largely been superseded by NIV, with several studies reporting 
greater improvements in exercise performance with IPS (Keilty et al, 1994) and PAV (Bianchi et al, 
1998) compared with CPAP in people with COPD.  However, the combination of PAV and CPAP was 
found to be superior to PAV or CPAP alone during cycling exercise in individuals with severe COPD 
(Dolmage & Goldstein, 1997).  No differences in bilevel NIV and IPS during treadmill exercise have 
been reported in people with severe COPD (Highcock et al, 2003) or people with severe scoliosis 
(Highcock et al, 2002).  A significant improvement in cycling endurance time with PAV compared to 
IPS was found in people with very severe COPD and chronic HRF, although the authors suggested 
that the result may have reflected differences in individual settings rather than a true difference 
between the ventilatory modes (Bianchi et al, 1998).  In contrast, in a meta-analysis performed by 
van’t Hul and colleagues  (van 't Hul et al, 2002) a significant summary effect size for exercise 
endurance time was identified for IPS, but not PAV or CPAP in comparison to unassisted exercise.  
Despite statistical significance, the difference in effect sizes between the different modes of ventilation 
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was small.  Presently, no strong evidence exists to support the use of one mode over another.   
 
However, bilevel NIV may be advantageous over IPS in people with COPD as EPAP can be used to 
offset PEEPi and reduce the inspiratory threshold load (Poggi et al, 2006).  In addition, EPAP can 
assist in reducing the dynamic dead space and improve CO2 washout in oronasal masks, particularly 
when the expiratory port is located over the nasal bridge and a single limb circuit is used (Saatci et al, 
2004).  Bilevel machines are also more readily available and cheaper than ventilators that can deliver 
PAV.  Furthermore, knowledge of respiratory system mechanics is required to set PAV appropriately.  
As this is generally not feasible in the clinical setting an alternative method, ‘run-away’ has been 
described (Younes, 1994) but is still time consuming (Bianchi et al, 2002).  While bilevel NIV may be 
simpler to set than PAV, one disadvantage of bilevel compared to PAV relates to IPAP and EPAP 
being fixed.  Levels of pressure that are comfortable at rest may not be sufficient during exercise, and 
conversely, levels of pressure that are adequate during strenuous exercise may not be tolerated at rest.  
Proportional assist ventilation is able to overcome this problem as the level of ventilatory support 
provided is matched to patient effort both at rest and during exercise.   
 
Level of inspiratory pressure support 
Respiratory muscle unloading is important if improvements in exercise capacity are to be achieved 
with NIV (Kyroussis et al., 2000; Maltais et al., 1995).  As respiratory muscle unloading increases 
with the level of PS used at rest in people with severe COPD and people with severe kyphoscoliosis 
(Tuggey & Elliott, 2006), the level of PS provided during exercise may impact on the effectiveness of 
NIV during exercise.  In addition, the degree to which VT is augmented with a given level of pressure 
preset ventilation may vary, both within and between individuals, depending on factors such as 
respiratory system compliance, airways resistance and inspiratory time (Mehta & Hill, 2001).   
 
In people with severe COPD, van’t Hul and colleagues (2004) found that PS of 10 cmH2O during 
constant work rate cycling significantly increased exercise endurance time compared with PS of 5 
cmH2O during cycling and unassisted exercise.  No difference was observed in endurance time 
between PS of 5 cmH2O and unassisted exercise, indicating that the level of PS used does affect the 
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efficacy of NIV during exercise in this population.  Higher levels of PS (mean 25 cmH2O) during 
ground walking have also been shown to improve exercise performance in people with severe COPD 
(Dreher et al, 2007).  Whether high level PS (eg. 25 cmH2O) can improve exercise capacity above that 
of lower levels of PS (eg. 10 cmH2O) in people with COPD is currently unknown but warrants further 
investigation.   
 
Of the few studies that have evaluated the effect of NIV during exercise in people with severe chest 
wall restriction due to kyphoscoliosis or pulmonary tuberculosis sequelae, it appears that exercise 
capacity is improved with high levels of PS (>19 cmH2O) (Borel et al., 2008; Tsuboi et al., 1997) but 
not low levels of PS (mean 9.7 to 13.7 cmH2O) (Highcock et al, 2002) during exercise.  Similar to that 
observed in COPD, this suggests that the level of PS delivered during exercise is important in people 
with severe kyphoscoliosis.  However, the effect of high and low level PS during exercise needs to be 
assessed within people with severe kyphoscoliosis to test this hypothesis.   
 
Type of interface  
A variety of interfaces have been used to deliver NIV during exercise, including oronasal (full face) 
masks, nasal masks and mouthpieces.  With respect to the type of interface used, no differences in the 
response to NIV during exercise have been reported in studies where a combination of interfaces was 
used (Bianchi et al., 2002; Borel et al., 2008; Dreher et al., 2007).  However, formal sub-group 
analyses were not performed and to date no studies have directly compared oronasal masks, nasal 
masks and mouthpieces.  Interface selection may depend on several factors including availability, 
clinician experience and patient preference.  However, oronasal breathing is very common during 
exercise (Chadha et al., 1987; Wheatley et al., 1991) and may affect patient tolerance of the different 
types of interfaces.  In patients with acute HRF secondary to an AECOPD or acute cardiogenic 
pulmonary oedema, oronasal masks were better tolerated than nasal masks, despite similar 
improvements in gas exchange and reduction in intubation rates (Kwok et al, 2003).  Similarly, 
oronasal masks were better tolerated compared with mouthpieces to deliver NIV in patients with acute 
HRF (Schneider et al, 2006).  Ventilatory demand is likely to be similar or even higher during exercise 
compared with acute HRF and consequently, oronasal masks might also be tolerated better during 
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exercise than nasal masks or mouthpieces.  One potential disadvantage relating to oronasal masks is 
increased dead space in comparison to nasal masks and mouthpieces.  Increased dead space in the 
interface may promote CO2 rebreathing, which can stimulate an increase in VE and work of breathing 
(Lofaso et al, 1995). Provided positive pressure is maintained throughout expiration (eg. EPAP) 
dynamic dead space is reduced below physiological dead space in oronasal masks with the expiratory 
port located over the nasal bridge (eg. ResMed Full Face Mask range) (Saatci et al, 2004).  Therefore, 
oronasal masks of this design should be suitable for use during exercise.  However, a comparison 
between oronasal masks, nasal masks and mouthpieces needs to be conducted before one type of 
interface can be recommended over another. 
  
Capacity of the Ventilator 
If the capacity of the ventilator used to deliver NIV during exercise is insufficient to adequately 
support ventilation, exercise performance may be impaired rather than improved (Highcock et al., 
1997; Revill et al., 2000).  Commercially available ventilators used to deliver NIV are primarily 
designed for use at rest, either during sleep or in the acute care setting.  However, ventilatory demand 
during exercise is likely to be far greater than at rest.  The minimum specifications required for NIV 
during exercise with respect to the maximum flow generating capacity, trigger and cycle thresholds, 
minimum pressurisation rate (rise time) and peak inspiratory pressure of a ventilator are unknown.  
The effect of altering pressurisation rate (rise time) has not been assessed while using NIV during 
exercise.  In patients with severe COPD recovering from acute HRF, faster pressurisation rates were 
associated with a greater degree of diaphragmatic unloading (Prinianakis et al., 2004).  As respiratory 
muscle unloading is an important mechanism associated with NIV during exercise (Kyroussis et al., 
2000; Maltais et al., 1995), the ability to set a fast pressurisation rate may also be of benefit during 
exercise.  Similarly, the effect of changing trigger or cycle thresholds has not been investigated while 
using NIV during exercise.  Trigger and cycle delays can increase inspiratory muscle work (Tassaux et 
al, 2005) and were identified as factors that could have contributed to the deterioration in exercise 
performance associated with NIV during treadmill walking in people with severe scoliosis (Highcock 
et al, 2002).  Until further information regarding the minimum specifications required for NIV during 
exercise are available, the capacity of the ventilator to adequately support ventilation during exercise 
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should be considered when interpreting the efficacy of NIV during exercise.   
 
CONCLUSION AND AIMS OF THE THESIS 
Non-invasive ventilation appears to be an effective adjunct to lower limb exercise in people with very 
severe or severe COPD and in people with severe kyphoscoliosis, with short term improvements 
reported in endurance exercise capacity.  The mechanisms of benefit associated with NIV during 
exercise, namely respiratory muscle unloading, improvements in pattern of breathing, gas exchange, 
blood flow and O2 delivery to working muscles, and reduced dyspnoea and muscle fatigue, are similar 
between the two conditions.  By reducing ventilatory load and improving ventilatory capacity, the use 
of NIV during exercise may allow individuals with severe COPD or severe kyphoscoliosis to perform 
exercise training at a higher intensity compared with unassisted exercise, and therefore could result in 
greater training benefits.  Alternatively, NIV may potentially play a role in assisting severely impaired 
individuals to perform daily activities or to facilitate early exercise rehabilitation.  However, little is 
known regarding the effects of NIV during functional exercise such as ground walking or UAE, or the 
optimal method of selecting NIV settings for exercise.  In addition, the effect of NIV during exercise 
training on important outcomes such as exercise capacity, HRQL and physical activity is unclear.  
Furthermore, the effect of NIV during exercise in people recovering from acute on chronic HRF has 
not been reported in the literature. 
 
The general aim of this thesis was to evaluate whether the role of NIV as an adjunct to lower limb 
endurance exercise could be expanded to include functional exercise in people with chronic HRF, 
exercise training in people with COPD, or to facilitate early exercise rehabilitation in people 
recovering from acute on chronic HRF.  Specifically, the study contained in Chapter 2 aimed to 
determine the effect of NIV during UAE and ground walking compared to unassisted exercise in 
people with chronic HRF secondary to severe stable COPD or severe kyphoscoliosis who were already 
established on domiciliary NIV.  The study described in Chapter 3 sought to evaluate the impact of 
varying the level of PS delivered during walking on the efficacy of NIV during exercise in people with 
chronic HRF secondary to severe kyphoscoliosis.  The systematic review presented in Chapter 4 
aimed to determine the effect of NIV during supervised exercise training (as a part of pulmonary 
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rehabilitation) on exercise capacity, HRQL and physical activity levels in people with COPD 
compared to exercise training without NIV, or exercise training with sham NIV.  Finally, the study 
described in Chapter 5 aimed to investigate the immediate effects of NIV and O2 during ground 
walking and UAE compared to exercise with O2 alone in people recovering from acute on chronic 
HRF.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER 2 
 
 
 
 
 
 
 
 
Non-invasive ventilation during unsupported arm exercise and 
ground walking in people with chronic hypercapnic respiratory 
failure 
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INTRODUCTION 
People with chronic hypercapnic respiratory failure (HRF) secondary to chronic obstructive 
pulmonary disease (COPD) or kyphoscoliosis commonly describe severe exertional dyspnoea (Bianchi 
et al., 1998; Borel et al., 2008).  While the mechanisms of exercise limitation are different between 
people with severe or very severe COPD and those with severe kyphoscoliosis, both groups often have 
a ventilatory limitation to exercise (O'Donnell et al., 2001a; Shneerson, 1978b), and a reduced ability 
to perform simple daily activities that involve walking and use of the arms (Velloso et al., 2003).   
 
Strategies such as non-invasive ventilation (NIV) have been used in an attempt to reduce the 
ventilatory limitation to exercise and improve exercise capacity in people with severe COPD (van 't 
Hul et al., 2006) and people with severe kyphoscoliosis (Borel et al., 2008).  A meta-analysis showed 
that NIV during treadmill and cycling exercise increased endurance time and reduced dyspnoea in 
people with severe COPD (van 't Hul et al., 2002), with the reduction in dyspnoea proportional to 
inspiratory muscle unloading (Maltais et al., 1995).  Reports of the effect of NIV during cycle or 
treadmill exercise in people with severe kyphoscoliosis are contradictory.  Endurance time was 
increased and dyspnoea reduced when NIV was used during cycling exercise (Borel et al., 2008) 
whereas distance walked decreased when NIV was used during treadmill walking compared to 
unassisted exercise in people with severe kyphoscoliosis (Highcock et al., 2002).  
 
The role of NIV during functional tasks such as ground walking and unsupported arm activities is not 
as clear in either population.  Studies of ground walking in patients with severe or very severe COPD 
have produced conflicting reports regarding the effect of NIV on exercise performance (Dreher et al., 
2007; Highcock et al., 1997; Revill et al., 2000), and the effect of NIV during ground walking in 
patients with severe kyphoscoliosis has not been assessed.  While NIV during arm elevation has been 
shown to unload the diaphragm in patients with chronic HRF secondary to COPD and kyphoscoliosis 
(Poggi et al., 2006), the effect of NIV during unsupported arm exercise (UAE) on endurance time and 
dyspnoea has not been reported.  If NIV during functional activities such as UAE and ground walking 
can improve exercise performance, NIV may have a role in assisting severely limited patients to 
perform daily activities and may aid exercise training to prevent or reverse muscle deconditioning. 
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The present study aimed to determine the effect of NIV during UAE and ground walking on exercise 
endurance time compared to exercise without NIV in patients with chronic HRF secondary to very 
severe COPD or severe kyphoscoliosis.  It was hypothesised that NIV during UAE and ground 
walking would reduce dyspnoea and allow patients to exercise for longer.   
 
 
METHOD 
Participants   
Participants were recruited from the home ventilation program at Royal Prince Alfred Hospital, 
Sydney.  People with chronic HRF (arterial carbon dioxide tension (PaCO2) > 45 mmHg) secondary to 
COPD or kyphoscoliosis who used domiciliary NIV were invited to participate in the study.  
Additional inclusion criteria were: stable clinical status over the past month with no admissions to 
hospital or change in medications; compliant with domiciliary NIV (> 4 hours/night average usage 
over the past 3 months); dyspnoea as the primary symptom that limited the performance of daily 
activities.  Exclusion criteria were: arterial pH < 7.35, temperature > 38 degrees Celsius, oxygen 
saturation (SpO2) < 88% at rest with a fraction of inspired oxygen ≥ 0.50, resting systolic blood 
pressure (SBP) < 90 millimetres of mercury (mmHg) or >160 mmHg, resting diastolic blood pressure 
(DBP) < 60 mmHg or >100 mmHg, unstable angina or a myocardial infarct during the previous 
month, resting heart rate (HR) > 120 beats/minute, or a major psychiatric illness.  Written informed 
consent was provided by all participants. 
 
Study design 
A randomised crossover study with repeated measures was conducted at Royal Prince Alfred Hospital, 
Sydney.  Participants were asked to perform two endurance UAE tests and two endurance ground 
walking tests.  In those participants who did both the UAE and walk tests, the order of testing was 
randomised.  In addition, the order of UAE tests with and without NIV was randomised, and the order 
of walk tests with and without NIV was randomised.  If a participant was unable to perform both 
series of UAE and walk tests they were randomly assigned to perform one type of test, or in the 
presence of a musculoskeletal or neurological condition that affected the upper or lower limbs, the 
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type of test the participant was able to perform was selected.  The randomisation scheme was 
generated using the web site Randomization.com (http://www.randomization.com) and test order was 
concealed in a sealed, opaque envelope until written consent was obtained from the participant.  
Ethical approval was obtained from the Human Ethics Committee of Sydney South West Area Health 
Service and The University of Sydney.  Recruitment for the present study commenced prior to 1st July 
2005 and therefore the trial was not registered with a Clinical Trials Registry. 
 
Protocol 
Participants completed the UAE tests and walk tests on separate, but consecutive, days.  On the day 
allocated to the UAE tests, participants were asked to rest for 30 minutes prior to performing a practice 
UAE test without NIV.  The purpose of the practice test was to familiarise participants to the test and 
to determine the lifting height and weight of the dowel for the subsequent two UAE tests, one with and 
one without NIV performed in random order.  On the day allocated to the walk tests, participants were 
asked to rest for 30 minutes prior to performing an incremental shuttle walk test (ISWT) (Singh et al., 
1992) with NIV.  Participants performed a short practice ISWT (2-3 shuttles at Level 1 of the test) 
approximately 30 minutes before the complete ISWT to familiarise them to the test and to walking 
with NIV.  This short practice test, rather than a complete practice ISWT (Singh et al., 1992) was 
performed to minimise the effects of fatigue, as participants already needed to perform one 
incremental maximal, and two endurance walk tests within the same day.  Eighty-five percent of the 
maximum ISWT walking speed was used to determine the walking speed for the subsequent two 
endurance shuttle walk tests (ESWT), one performed with and one without NIV in random order.  
Approximately 30 minutes prior to the first ESWT, a short practice ESWT was performed (2-3 
shuttles) to familiarise the subject with the required walking pace.   
 
For both the UAE and the walk tests, supplemental oxygen (O2) was administered, if required, to 
maintain SpO2 at approximately 93% at rest.  Oxygen supplementation was not adjusted further during 
exercise.  Participants were given standardised encouragement each minute during exercise, after 
dyspnoea and perceived exertion scores had been recorded.  The phrases “you are doing well” and 
“keep up the good work” were alternated.  Participants rested while breathing without NIV for at least 
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one hour between each UAE test and at least one hour between each shuttle walk test, and until SpO2, 
HR, dyspnoea, rate of perceived exertion (RPE) and blood pressure (BP) had returned to baseline 
levels. 
 
Exercise Tests 
Unsupported Arm Exercise Test 
An externally paced unsupported arm exercise test as described by Takahashi and colleagues (2003) 
was modified to measure endurance rather than peak exercise capacity.  A practice test was performed 
without NIV in which the seated participant lifted a weighted dowel, held in both hands, from waist 
height to increasingly higher levels on a chart at a rate of one lift every two seconds in time with a 
metronome.  The modification was that after five repetitions (10 seconds) at each level, participants 
progressed through the levels on the chart until they reached a level that they felt represented a 
moderate workload on the RPE scale (a score of 3).  Participants were then asked to exercise at this 
level for as long as possible.  Initially participants were asked to lift a 300 gram (g) weighted dowel.  
If participants progressed to the highest level of the chart that they could reach without leaning 
forward, before reporting an RPE score of 3 (moderate), the weight of the dowel was incrementally 
increased to 500 g, then 1 kilogram (kg), 1.5 kg and 2 kg every five repetitions.  The same level and 
dowel weight achieved in the practice test was used for the two subsequent UAE tests, one with and 
one without NIV.  Participants were instructed to exercise until they felt too breathless or fatigued to 
continue.  The investigator terminated the exercise test if SpO2 fell below 75% or if the participant was 
unable to keep in time with the metronome.  Endurance time, the reason for exercise cessation and the 
primary symptom that limited exercise were recorded.   
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Figure 2.1 A participant performing the unsupported arm exercise test with non-invasive 
ventilation.  Image printed with permission 
 
 
Incremental Shuttle Walk Test 
The ISWT is an externally paced, progressive maximal field walk test (Singh et al., 1992).  
Participants were asked to walk up and down a 10 metre course, marked with a cone placed 0.50 
metres from each end of the course.  Walking speed was determined by a pre-recorded audio signal 
from a cassette (Singh et al., 1992).  The audio signal indicated that the participant needed to turn 
around the cone and walk 10 metres to the opposite end of the course before the next audio signal 
sounded.  Standardised instructions were played to participants from the cassette “Walk at a steady 
pace, aiming to turn around when you hear the signal.  You should continue to walk until you feel that 
you are unable to maintain the required speed without becoming unduly breathless” (Singh et al., 
1992).  The ISWT was performed with NIV.  Participants used their usual walking aid if required 
during the test.  The investigator terminated the exercise test if SpO2 fell below 75% or if the 
participant was unable to complete a shuttle within the allocated time.  Distance walked, peak walking 
speed, and the reason for exercise cessation were recorded.   
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Endurance Shuttle Walk Test 
The ESWT is an externally paced, constant speed, endurance field walk test with a maximum duration 
of 20 minutes (Revill et al., 1999).  The ESWT was performed using the same course as the ISWT and 
at 85% of the maximal walking speed achieved during the ISWT.  Participants were required to walk 
up and down the 10 metre course, turning around the cones in time with the audio signal.  Participants 
did not perform the 100 seconds warm-up at the start of the ESWT as there was concern that the 
duration of the warm-up might have represented a significant proportion of the entire walking time for 
some participants with severely reduced exercise capacity, and that subsequently only a small amount 
of time would be spent walking at target walking speed.  Participants were instructed to continue 
walking for as long as possible until they felt too breathless or fatigued to continue.  Participants used 
their usual walking aid if required during the test.  Participants were instructed to exercise until they 
felt too breathless or fatigued to continue.  The investigator terminated the exercise test if SpO2 fell 
below 75% or if the participant was unable to complete a shuttle within the allocated time.  Endurance 
time, distance walked, the reason for exercise cessation and the primary symptom that limited exercise 
were recorded.   
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Figure 2.2 A participant performing the endurance shuttle walk test with non-invasive 
ventilation.  A research assistant is pushing the trolley containing the bilevel machine 
and related equipment slightly behind the participant.  Image printed with permission 
 
 
Measures 
Participant Characteristics 
Anthropometric data were recorded, a resting arterial blood gas sample was analysed and pulmonary 
function tests were performed on the same day, but prior to, the first series of exercise tests.   
 
Arterial blood gas tensions 
A daytime arterial blood sample was collected at rest while participants were seated and breathing 
room air.  If a participant used continuous daytime supplemental O2, arterial blood was sampled while 
the participant breathed with their usual O2 flow rate.  Arterial blood was sampled from the radial 
artery and stored in ice until it was analysed (Radiometer ABL700, Radiometer Medical, Copenhagen, 
Denmark).  This was typically within 15 minutes of the sample being collected.   
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Pulmonary function tests 
(i) Spirometry 
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured using 
a Microloop hand held spirometer (Micro Medical Limited, Rochester, Kent, England) with a flow 
sensor.  For participants who used daily bronchodilator therapy, spirometry was performed 10-15 
minutes post delivery of the bronchodilator.  A forced expiration from total lung capacity was obtained 
from each participant while in the sitting position with a nose peg in place.  The best of three attempts 
from values of within 5% variability were recorded.  Predicted values for FEV1 and FVC were 
calculated from normal population data (Quanjer et al., 1993).  Participants were encouraged verbally 
to perform a maximum effort during each test. 
   
(ii) Respiratory muscle strength 
Respiratory muscle strength was determined by measuring maximal inspiratory mouth occlusion 
pressure sustained over one second (PImax1.0) from residual volume, and maximal expiratory mouth 
occlusion pressure sustained over one second (PEmax1.0) from total lung capacity using a hand held 
pressure gauge (Morgan Medical Limited, Gilingham, UK) calibrated from 0 ± 200 centimetres of 
water (cmH2O).  The gauge mouthpiece permitted a 1mm air leak in order to prevent glottic closure 
during testing.  Participants were instructed to inhale or exhale with their glottis open and not to use 
their buccal muscles.  The test was performed with participants in the sitting position.  A nose peg was 
worn during the test.  The highest pressure generated over one second of three reproducible attempts 
was recorded. Predicted values were calculated from normal population data (Wilson et al., 1984).  
Participants were encouraged verbally to perform a maximum effort during each test. 
 
Exercise 
Immediately prior to each exercise test, after participants had sat quietly for at least 10 minutes, 
baseline resting measures of SpO2, HR, dyspnoea, RPE and BP were recorded.  Oxygen saturation and 
HR were measured via a finger probe using a pulse oximeter (Radical, Massimo, Irvine CA, USA) and 
data were downloaded after exercise using software provided by the manufacturer (Download 2001, 
Masimo, Irvine CA, USA).  Participants rated their level of dyspnoea and RPE using the modified 
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Borg category-ratio scale (0-10) (Borg, 1982).  During UAE, RPE scores represented arm muscle 
exertion, and during ground walking, RPE scores represented leg muscle exertion.  Blood pressure 
was measured manually with a sphygmomanometer.  During the exercise tests, SpO2 and HR were 
recorded continuously, and dyspnoea and RPE scores were recorded every minute.  During tests with 
NIV, the ability of the bilevel machine to deliver the set level of inspiratory positive airway pressure 
(IPAP) throughout exercise was assessed by measuring mask pressure using a digital manometer 
(Respironics, Murraysville, PA ,USA) attached to a port on the full face mask.  The peak inspiratory 
pressure was recorded approximately every 30 seconds by the investigator.  Immediately at the end of 
exercise, dyspnoea and RPE scores were documented, and BP was remeasured. 
 
Non-invasive ventilation 
Non-invasive ventilation was delivered with a pressure preset bilevel machine (VPAPIII ST, 
ResMed, Sydney, Australia) via a three metre length of corrugated tubing connected to a full face 
mask (Ultra-mirage, ResMed, Sydney, NSW, Australia; or, Comfort-Full, Respironics, 
Murrysville, PA, USA).  The inspiratory trigger threshold was 4.5 litres per minute (L/min) and 
maximal inspiratory flow rate was 170 L/min.  The bilevel machine was set in the spontaneous (self 
triggered) mode with the expiratory positive airway pressure (EPAP) set at 3-4 cmH2O.  For 
participants with chronic airflow limitation, EPAP was increased to a maximum of 5 cmH2O.  
Inspiratory positive airway pressure was set 10 cmH2O above EPAP and was increased at rest until the 
participant felt comfortable.  Rise time (time from EPAP to IPAP once triggered) was 100 
milliseconds.  The investigator fitted the mask so that leak was less than 5 L/min.  If required, 
supplemental O2 was added via a t-piece connected to the air outlet of the machine.  A 12 volt external 
battery (Mini power station, Integra Industries, Tanorama, Australia) powered the bilevel machine 
during ground walking.  A research assistant pushed a trolley (Figure 2.3) that contained the bilevel 
machine, battery, O2 cylinder and digital manometer slightly behind the participant during the walk 
tests with NIV. 
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Figure 2.3 Trolley containing the bilevel machine, external battery, oxygen cylinder and 
digital manometer  
 
 
Outcome measures 
For both UAE and walk tests, the primary outcome measure was exercise endurance time.  Secondary 
outcome measures were isotime dyspnoea and isotime SpO2.  Isotime was defined as the duration of 
the shorter endurance test.  Dyspnoea scores and SpO2 values were compared during exercise with and 
without NIV at this point in time.  In addition, the relationship between the response to NIV during 
UAE and PaCO2, FEV1, FVC and PImax1.0 was assessed to determine whether these baseline measures 
could be used to select subjects who might benefit from using NIV during UAE.  The relationship 
between the response to NIV during UAE and the change in isotime dyspnoea with NIV compared to 
exercise without NIV was also assessed.  The response to NIV during UAE was defined as the change 
in UAE endurance time with NIV compared to UAE without NIV expressed as a percentage: 
 
     Response to NIV
 UAE = (NIVEndurance time - No NIV Endurance time)/No NIV Endurance time x 100/1 
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Similarly, the relationship between the response to NIV during walking and PaCO2, FEV1, FVC and 
PImax1.0 was assessed to determine whether these baseline measures could be used to select subjects 
who might benefit from using NIV during walking.  The relationship between the response to NIV 
during walking and the change in isotime dyspnoea with NIV compared to exercise without NIV was 
also determined.  The response to NIV during walking was defined as the change in endurance time 
with NIV compared to walking without NIV expressed as a percentage:   
 
     Response to NIVESWT  = (NIVEndurance time - No NIV Endurance time)/No NIV Endurance time x 100/1 
 
Data analysis and statistics 
The sample size for UAE was based on data from the first five participants as no published data were 
available.  In addition, the minimum clinically important difference (MCID) in UAE endurance time, 
in order to determine whether an individual is an acute “responder” to NIV during UAE is unknown in 
people with chronic HRF secondary to very severe COPD or severe kyphoscoliosis.  The estimate that 
was selected for the change in UAE endurance time was 60 seconds and was deemed to be worthwhile 
based on clinical experience.  Therefore, in order to detect a 60 second change in UAE endurance time 
with NIV using a standard deviation estimate of 58 seconds based on endurance time data from the 
first five participants, a power of 0.8, and an α of 0.05, the analysis indicated that a sample of 17 
participants was required, including one extra to account for a possible drop out.  Similarly, the MCID 
in walking endurance time, in order to determine whether an individual is an acute “responder” to NIV 
during ground walking is unknown in people with chronic HRF secondary to very severe COPD or 
severe kyphoscoliosis. The estimate that was selected for the change in walking endurance time was 
based on the mean change in endurance time after the acute application of supplemental O2 during 
walking in people with severe COPD (Revill et al., 2000).  To detect a 70 second change in walking 
endurance time using a standard deviation estimate of 47 seconds (Revill et al., 2000), power of 0.8, 
and an α of 0.05, a sample of 15 participants was needed, including one extra to account for a possible 
drop out.   
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Descriptive data for continuous variables with a normal distribution are presented as mean ± standard 
deviation (SD), or median and interquartile range (IQR) for data that failed the Kolmogorob-Smirnov 
normality test.  Paired t-tests, or Wilcoxon signed rank tests for non-parametric data, were conducted 
to determine if there was a significant difference between exercise with and without NIV with respect 
to endurance time, isotime dyspnoea and isotime SpO2.  The effect of test order on the primary and 
secondary outcome measures was also assessed.  For normally distributed data the 95% confidence 
intervals (CI) were given if appropriate.  A significance level of p < 0.05 was used for all comparisons.  
The relationship between the response to NIV during exercise and PaCO2, FEV1, FVC, PImax1.0 and the 
change in isotime dyspnoea with NIV compared to exercise without NIV was determined by 
calculation of Pearson’s correlation coefficient (r) for parametric data or, Spearman’s rho (rS) for non-
parametric data.   
 
 
RESULTS 
Participants  
A total of 23 participants were recruited for the study.  Nine participants performed both the UAE and 
walk tests, an additional eight participants performed the UAE tests only (a total of 17 participants 
performed UAE tests), and a further six participants performed the walk tests only (a total of 15 
participants performed the walk tests) (Figure 2.4).  Participant baseline characteristics and NIV 
settings used during exercise are described in Table 2.1.  There were no drop outs in either arm of the 
study.  Non-invasive ventilation during UAE and ground walking was well tolerated, and all 
participants completed the exercise tests without any adverse events.  Supplemental O2 was used 
during UAE in 10/17 participants during exercise without NIV and with NIV.  Supplemental O2 flow 
rates used during UAE are displayed in Table 2.2.  Supplemental O2 was used during the ESWT 
without NIV in 11/15 participants, and with NIV in 10/15 participants.  Supplemental O2 flow rates 
used during ground walking are displayed in Table 2.5.  The investigator stopped the exercise test due 
to oxygen desaturation below 75% in three participants during the ESWT without NIV.  Peak mask 
pressure was maintained at the preset IPAP level during UAE and ground walking tests with NIV.  
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Figure 2.4 Number of participants who performed unsupported arm exercise tests (UAE), 
endurance shuttle walk tests (ESWT), and both UAE and ESWT.  HRF: 
hypercapnic respiratory failure 
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Table 2.1 Participant characteristics 
 
UAE 
(n=17) 
ESWT  
(n=15) 
 
  Age (yrs) 62 ± 12 62 ± 7 
  F/M 9/8 9/6 
  BMI (kg.m-2) 25.9 ± 6.7 29.4 ± 7.0 
Resting ABG 
  
  pH 7.40 ± 0.03 7.38 ± 0.03 
  PaCO2 (mmHg) 52.1 ± 5.3 51.7 ± 3.8 
  PaO2 (mmHg) 64.6 ± 12.2 65.4 ± 9.5 
  HCO3- (mmol/L) 30.9 ± 3.4 30.1 ± 2.7 
  SaO2 (%) 91 ± 4 92 ± 3 
  Supp O2 (L/min) 0 (0 - 0.5) 0 (0 - 1.0) 
Pulmonary function 
  
  FEV1 (L) 0.50 ± 0.17 0.68 ± 0.38 
  FEV1 (% pred) 19 ± 5 28 ± 12 
  FVC (L) 1.00 ± 0.51 1.35 ± 0.73 
  FVC (% pred) 32 ± 15 45 ± 20 
  FEV1/FVC (%) 57 ± 21 55 ± 19 
  PImax1.0 (cmH2O) -37.3 ± 18.4 -47.4 ± 21.5 
  PImax1.0 (%pred) 52 ± 27 66 ± 28 
  PEmax1.0 (cmH2O) 96.0 ± 43.2 110.2 ± 34.1 
  PEmax1.0 (%pred) 93 ± 47 109 ± 39 
Diagnostic group (n) 
  
  COPD 9 10 
  Kyphoscoliosis 8 5 
NIV settings for sleep 
  
  PS (IPAP-EPAP) (cmH2O) 10.9 ± 2.0 10.7 ± 2.8 
NIV settings for exercise 
  
  IPAP (cmH2O) 15.0 (15.0 - 17.0) 15.0 (15.0 - 17.0) 
  EPAP (cmH2O) 5.0 (4.0 - 5.0) 5.0 (4.0 - 5.0) 
  PS (cmH2O) 11.0 (11.0 - 12.0) 10.0 (10.0 -13.0) 
   
Data are presented as mean ± SD or median (interquartile range). UAE: unsupported arm exercise; ESWT: endurance shuttle 
walk test; F/M: female/male; BMI: body mass index; ABG: arterial blood gas; PaCO2: arterial carbon dioxide tension; PaO2: 
arterial oxygen tension; HCO3-: arterial bicarbonate ion concentration; SaO2: arterial oxygen saturation; Supp O2: 
supplemental oxygen; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; PImax1.0: maximal 
inspiratory mouth occlusion pressure sustained for one second; PEmax1.0: maximal expiratory mouth occlusion pressure 
sustained for one second; COPD: chronic obstructive pulmonary disease; NIV: non-invasive ventilation; PS: pressure 
support; IPAP: inspiratory positive airway pressure; EPAP: expiratory positive airway pressure 
 
 
Unsupported arm exercise   
Non-invasive ventilation during UAE increased endurance time by a mean of 91 seconds (95% CI 10 
to 172, p = 0.031) compared to exercise without NIV (Table 2.2, Figure 2.5a).  In addition, at isotime 
exercise dyspnoea was reduced (-2.3 points, 95% CI -3.7 to -1.0, p = 0.002) (Figure 2.5b), SpO2 was 
greater (1.7%, 95% CI 0.2 to 3.3, p = 0.033) (Figure 2.5c) and RPE was lower (-1.3 points, 95% CI -
2.2 to -0.4, p = 0.009) (Figure 2.5d) with NIV during UAE compared with exercise without NIV.  
Despite UAE endurance time being longer with NIV, end exercise dyspnoea remained lower (-1.9 
points, 95% CI -3.3 to -0.5, p = 0.010) and SpO2 higher (1.8%, 95% CI 0.3 to 3.4, p = 0.023) than 
exercise without NIV (Table 2.2).  The primary symptom associated with exercise cessation was arm 
muscle fatigue (without NIV: n = 15; with NIV: n = 15), arm muscle fatigue and shortness of breath 
(with NIV: n = 2), and shortness of breath alone (without NIV: n = 2) (Figure 2.6).  No significant 
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relationship was found between the response to NIV during UAE and baseline measures of PaCO2, 
FEV1, FVC or PImax1.0 (Table 2.3).  Similarly, no correlation was found between the response to NIV 
during UAE and the change in isotime dyspnoea with NIV compared to UAE without NIV 
(Spearman’s rho = -0.253, p = 0.33, Figure 2.7).  There was no effect of test order on any of the 
primary or secondary outcome measures. 
 
 
Table 2.2 Unsupported arm exercise without non-invasive ventilation (NIV) compared to 
unsupported arm exercise with NIV 
 
 
Without NIV NIV Mean difference (95% CI) 
 
p 
Rest  
    
  Supp O2 (L/min) 1 (0 - 1) 1 (0 - 1) FN 0.18 
  SpO2 (%) 95 ± 3  96 ± 3 1 (0 to 2) 0.017 
  HR (beats/min) 83 ± 17 81 ± 17 -2 (-5 to 2) 0.30 
  Dyspnoea (0-10 scale) 0 (0 - 0.5) 0 (0 - 0.3) FN 0.48 
  RPE (0-10 scale) 0 (0 - 0) 0 (0 - 0) FN 0.32 
  SBP (mmHg) 120 ± 10 117 ± 9 -4 (-6 to -1) 0.011 
  DBP (mmHg) 78 ± 10 77 ± 9 -1 (-5 to 3) 0.52 
  MAP (mmHg) 78 ± 9 77 ± 9 0 (-1 to 0) 0.52 
Isotime 
    
  SpO2 (%) 92 ± 4 93 ± 4 2 (0 to 3) 0.033 
  HR (beats/min) 96 ± 23 98 ± 20 1 (-6 to 9) 0.71 
  Dyspnoea (0-10 scale) 5.9 ± 3.0 3.6 ± 2.7 -2.3 (-1.0 to -3.7) 0.002 
  RPE (0-10 scale) 7.6 ± 2.6 6.3 ± 2.8 -1.3 (-0.4 to -2.2) 0.009 
End exercise 
    
  SpO2 (%) 91 ± 4 93 ± 4 2 (0 to 3) 0.023 
  HR (beats/min) 100 ± 24 98 ± 16 -2 (-8 to 4) 0.47 
  Dyspnoea (0-10 scale) 6.1 ± 3.0 4.1 ± 2.8 -1.9 (-3.3 to -0.5) 0.010 
  RPE (0-10 scale) 9.0 (5.5 - 10) 9.0 (8.0 - 10) FN 0.55 
  SBP (mmHg) 136 ± 15 132 ± 14 -4 (-10 to 1) 0.11 
  DBP (mmHg) 82 ± 14 80 ± 12 -2 (-7 to 2) 0.29 
  MAP (mmHg) 100 ± 13 98 ± 12 -2 (-6 to 1) 0.15 
  Endurance time (s) 277 ± 214 367 ± 318  91 (10 to 172) 0.031 
     
Data are presented as mean ± SD or median (interquartile range). NIV: non-invasive ventilation; Supp O2: supplemental 
oxygen; SpO2: oxygen saturation; HR: heart rate; RPE: rate of perceived exertion; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; MAP: mean arterial pressure; FN: failed normality test 
 
 
 
 
Table 2.3 Relationship between the response to non-invasive ventilation (NIV) during the 
unsupported arm exercise (UAE) test and baseline measures 
 
Relationship between the response to NIV during UAE and: 
 
rS p 
PaCO2 (mmHg) 0.124 0.64 
FEV1 (L) 0.0 1.0 
FEV1 (% predicted) -0.003 1.0 
FVC (L) 0.065 0.80 
FVC (% predicted) -0.071 0.79 
PImax1.0 (cmH2O) -0.152 0.56 
PImax1.0 (% predicted) -0.197 0.45 
   
rS: Spearman’s rho; PaCO2: arterial carbon dioxide tension; FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity; PImax1.0: maximal inspiratory mouth occlusion pressure sustained over one second 
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Figure 2.5 Effect of unsupported arm exercise without non-invasive ventilation (NIV) compared to unsupported arm exercise with NIV on:                  
a) endurance time;   b) isotime dyspnoea; c) isotime oxygen saturation; d) isotime rate of perceived exertion.  Error bars represent standard 
deviation.  Open circles represent individual data points for participants with severe chronic obstructive pulmonary disease.  Closed triangles 
represent individual data points for participants with severe kyphoscoliosis. *: p < 0.05; †: p < 0.01
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Figure 2.6 Relative proportion of participants (n = 17) who ceased the unsupported arm 
exercise test primarily due to arm muscle (mm) fatigue, shortness of breath 
(SOB) alone, or arm muscle fatigue and SOB (Arm mm fatigue & SOB) for 
exercise without non-invasive ventilation (without NIV) and exercise with non-
invasive ventilation (NIV) 
 
 
 
 
 
 
 
Figure 2.7 Relationship between the response to non-invasive ventilation (NIV) during 
unsupported arm exercise (UAE) and the change in isotime dyspnoea with NIV 
compared to UAE without NIV 
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Ground walking 
Incremental Shuttle Walk Test 
Baseline and end exercise data are displayed in Table 2.4.  The reason for exercise cessation with NIV 
during walking was shortness of breath (n = 7), inability to complete a shuttle within the designated 
time period (n = 4), shortness of breath and leg muscle fatigue (n = 2) and leg muscle fatigue alone (n 
= 2).   
 
 
Table 2.4 Incremental shuttle walk test with non-invasive ventilation 
 
 
Baseline End Exercise 
 
SpO2 (%) 94 (93 - 99) 87 ± 5 
HR (beats/min) 88 ± 14 117 ± 18 
Dyspnoea (0-10 scale) 0 (0 - 0.5) 4 (4 - 5) 
RPE (0-10 scale) 0 (0 - 0.5) 5 (4 - 5) 
SBP (mmHg) 115 (110 - 134) 150 ± 18 
DBP (mmHg) 77 ± 11 84 ± 10 
MAP (mmHg) 108 (104 - 122) 106 ± 10 
Total distance walked (m)  193 ± 88  
 
 
 
Data are presented as mean ± SD or median (interquartile range).  SpO2: oxygen saturation; HR: heart rate; RPE: rate of 
perceived exertion; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial blood pressure 
 
 
 
Endurance Shuttle Walk Test 
The mean walking speed for the ESWT was 2.89 ± 0.44 km/h.  There was a trend for ESWT 
endurance time to be greater with NIV during walking compared to exercise without NIV although the 
difference did not reach statistical significance (119 seconds, 95% CI -17 to 254, p = 0.081) (Table 
2.5, Figure 2.8a).  In contrast to UAE, there was no difference in isotime dyspnoea between exercise 
with or without NIV (-1.0 points, 95% CI -3.0 to 1.0, p = 0.29) (Figure 2.8b).  However, an 
improvement was observed in isotime SpO2 (3.6%, 95% CI 0.3 to 6.9, p = 0.033) (Figure 2.8c) and 
there was a trend for isotime RPE to be reduced (-1.6 points, 95% CI -3.3 to 0.1, p = 0.066) (Figure 
2.8d) with NIV during walking compared to exercise without NIV.  Similarly, the improvement in 
SpO2 with NIV during exercise was maintained at end exercise (3.8%, 95% CI 0.1 to 7.5, p = 0.045).  
In addition, at end exercise, HR was significantly higher with NIV compared to walking without NIV 
(Table 2.5).  The primary symptom associated with exercise cessation was shortness of breath (without 
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NIV: n = 8; with NIV: n = 5), a combination of shortness of breath and leg muscle fatigue (without 
NIV: n = 2; with NIV: n = 2), leg muscle fatigue alone (without NIV: n = 1; with NIV: n = 8) and O2 
desaturation below 75% (without NIV: n = 4) (Figure 2.9).  No significant relationship was detected 
between the response to NIV during walking and PaCO2, FEV1 or PImax1.0 (Table 2.6).  However, a 
moderately strong inverse correlation was found between the response to NIV during walking and 
FVC (r = -0.545, p = 0.036) such that 30% of the variance in the response to NIV during walking was 
explained by FVC (Figure 2.10).  No correlation was found between the response to NIV during UAE 
and the change in isotime dyspnoea with NIV compared to exercise without NIV (r = -0.377, p = 0.17, 
Figure 2.11).  In addition, there was no effect of test order on any of the primary or secondary outcome 
measures. 
 
 
 
Table 2.5 Walking without non-invasive ventilation (NIV) compared to walking with NIV 
during the endurance shuttle walk test 
 
 
Without NIV 
 
NIV Mean difference (95% CI) p 
Rest  
    
  Supp O2 (L/min) 1 (0 - 1) 1 (0 - 1) FN 0.32 
  SpO2 (%) 94 ± 3 95 ± 3 1 (0 to 2) 0.025 
  HR (beats/min) 83± 10 86 ± 13 3 (-1 to 7) 0.090 
  Dyspnoea (0-10 scale) 0 (0 - 0) 0 (0 - 0.5) FN 0.18 
  RPE (0-10 scale) 0 (0 - 0) 0 (0 - 0) FN 0.18 
  SBP (mmHg) 119 ± 11 121 ± 13 2 (-4 to 9) 0.45 
  DBP (mmHg) 75 ± 9 77 ± 8 1 (-2 to 5) 0.39 
  MAP (mmHg) 90 ± 9 92 ± 9 2 (-2 to 6) 0.36 
Isotime 
    
  SpO2 (%) 84 ± 6 87 ± 4 4 (0 to 7) 0.033 
  HR (beats/min) 116 ± 15 114 ± 12 -2 (-11 to 7) 0.65 
  Dyspnoea (0-10 scale) 5.9 ± 2.6 4.9 ± 2.8 -1.0 (-3.0 to 1.0) 0.29 
  RPE (0-10 scale) 6.6 ± 2.5 5.0 ± 3.1 -1.6 (-3.3 to 0.1) 0.066 
End exercise 
    
  SpO2 (%) 82 ± 6 86 ± 4 4 (0 to 8) 0.045 
  HR (beats/min) 114 ± 15 119 ± 17 5 (0 to 10) 0.045 
  Dyspnoea (0-10 scale) 5.0 (4.0 - 9.0) 7.0 (5.0 - 10.0) FN 0.19 
  RPE (0-10 scale) 7.0 (5.0 - 10.0) 7.0 (5.0 - 10.0) FN 0.57 
  SBP (mmHg) 140 ± 15 144 ± 13 3 (-2 to 8) 0.17 
  DBP (mmHg) 83 ± 11 84 ± 10 2 (-3 to 6) 0.44 
  MAP (mmHg) 102 ± 10 104 ± 9 2 (-1 to 6) 0.156 
  Endurance time (s) 336 ± 250 454 ± 342 119 (-17 to 254) 0.081 
  Total distance walked (m) 281.4 ± 223.7 390.7 ± 334.3 109.2 (-16.6 to 235.1) 0.084 
     
Data are presented as mean ± SD or median (interquartile range). NIV: non-invasive ventilation; SpO2: oxygen saturation; 
Supp O2: supplemental oxygen; HR: heart rate; RPE: rate of perceived exertion; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; MAP: mean arterial pressure; FN: failed normality test 
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Table 2.6 Relationship between the response to non-invasive ventilation (NIV) during the 
endurance shuttle walk test (ESWT) and baseline measures 
 
Relationship between the response to NIV during the ESWT and: 
 
r p 
PaCO2 (mmHg) -0.267 0.34 
FEV1 (L) -0.323¶ 0.24 
FEV1 (% predicted) -0.339 0.22 
FVC (L) -0.387 0.15 
FVC (% predicted) -0.545 0.036 
PImax1.0 (cmH2O) 0.185 0.51 
PImax1.0 (% predicted) 0.310 0.26 
   
r: Pearson’s correlation coefficient; ¶: Spearman’s rho reported instead of r; PaCO2: arterial carbon dioxide tension; FEV1: 
forced expiratory volume in one second; FVC: forced vital capacity; PImax1.0: maximal inspiratory mouth occlusion pressure 
sustained over one second
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Figure 2.8 Effect of walking without non-invasive ventilation (NIV) compared to walking with NIV during the endurance shuttle walk test on:              
a) endurance time; b) isotime dyspnoea; c) isotime oxygen saturation; d) isotime rate of perceived exertion.  Error bars represent standard 
deviation.  Open circles represent individual data points for participants with severe chronic obstructive pulmonary disease.  Closed triangles 
represent individual data points for participants with severe kyphoscoliosis. *: p < 0.05; †: p < 0.01; NS: non significant 
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Figure 2.9 Relative proportion of participants (n = 15) who ceased the endurance shuttle 
walk test primarily due to oxygen (O2) desaturation, leg muscle (mm) fatigue, 
shortness of breath (SOB) alone, or leg mm fatigue and SOB (SOB & leg mm 
fatigue) for exercise without non-invasive ventilation (NIV) and exercise with 
NIV 
 
 
 
 
 
 
 
 
 
Figure 2.10 Relationship between the response to non-invasive ventilation (NIV) during the 
endurance shuttle walk test and baseline forced vital capacity 
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Figure 2.11 Relationship between the response to non-invasive ventilation (NIV) during the 
endurance shuttle walk test and the change in isotime dyspnoea with NIV 
compared to walking without NIV 
 
 
 
DISCUSSION 
The main finding of the present study was that NIV during UAE increased endurance time, reduced 
dyspnoea and perceived exertion, and improved oxygen saturation compared to exercise without NIV 
in patients with chronic HRF secondary to very severe COPD or severe kyphoscoliosis who use 
domiciliary nocturnal NIV.  There was a trend for ground walking endurance time to be greater with 
NIV during exercise compared to walking without NIV.  However this difference did not reach 
statistical significance.  In contrast with UAE, dyspnoea was not reduced when NIV was used during 
walking.  Similar to UAE, NIV during walking improved oxygenation at isotime and end exercise 
compared to exercise without NIV.   
 
Patients with limited ventilatory capacity may not be able to perform functional exercise tasks.  
Therefore it is important to identify strategies such as NIV that may reduce the ventilatory load during 
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exercise.  Little is known about the effects of NIV during arm exercise on exercise performance, and 
while the immediate effects of NIV during treadmill and cycling exercise are well described in 
patients with severe COPD (Bianchi et al., 1998; Hernandez et al., 2001; Maltais et al., 1995; Polkey 
et al., 2000; Polkey et al., 1996b; van 't Hul et al., 2004; van 't Hul et al., 2002), results regarding the 
use of NIV during the daily functional activity of ground walking are conflicting (Dreher et al., 2007; 
Highcock et al., 1997; Revill et al., 2000).  The current study contributes several novel findings to the 
literature in these areas. 
 
Effect of non-invasive ventilation during unsupported arm exercise 
The present study is the first to show that NIV during UAE reduces dyspnoea and allows patients to 
exercise for longer.  The mechanisms by which NIV improved UAE endurance time may relate to the 
reduction in dyspnoea and perceived exertion, and improvement in oxygenation that was observed 
compared to exercise without NIV.  During UAE, some accessory respiratory muscles have a dual task 
of performing the upper limb activity as well as assisting respiration.  Consequently, some of the 
ventilatory load is shifted to the diaphragm and abdominal muscles (Celli et al., 1988).  Indeed, arm 
elevation has been shown to increase inspiratory muscle work in patients with chronic HRF secondary 
to COPD and kyphoscoliosis (Poggi et al., 2006).  The application of NIV during arm elevation has 
been shown to unload the inspiratory muscles and increase minute ventilation (VE) compared to 
breathing without NIV (Poggi et al., 2006).  An inverse relationship between inspiratory muscle 
unloading and dyspnoea has been demonstrated previously (Maltais et al., 1995).  The reduction in 
dyspnoea that was observed with NIV during UAE both at isotime and end exercise suggests that NIV 
may have improved exercise performance by unloading the inspiratory muscles.  The reduction in 
isotime and end exercise dyspnoea found in the present study is similar to reports of NIV during lower 
limb exercise in people with severe COPD and people with severe kyphoscoliosis where a reduction in 
dyspnoea of approximately two points on a 0-10 dyspnoea scale was associated with an improvement 
in exercise endurance time (Borel et al., 2008; van 't Hul et al., 2002).  However, on examination of 
individual data (Figure 2.7), despite a reduction in isotime dyspnoea with NIV for the majority of 
participants, there was no relationship between the change in dyspnoea and the change in endurance 
time during UAE with NIV compared to exercise without NIV.  This may simply reflect that arm 
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muscle fatigue, rather than dyspnoea, was the primary symptom that limited UAE in participants 
during exercise with or without NIV (Figure 2.6). 
 
In addition, the application of EPAP may have assisted participants with severe COPD by further 
decreasing inspiratory effort.  A reduction in inspiratory capacity, indicative of dynamic hyperinflation 
(Porto et al., 2009), and an increase in intrinsic positive end expiratory pressure (PEEPi) (Poggi et al., 
2006) have previously been reported in people with severe COPD after unsupported arm elevation 
tasks.  The combination of breathing at an  increased operational lung volume, and the inspiratory 
threshold load placed on the inspiratory muscles by PEEPi, causes a substantial increase in work of 
breathing (Poggi et al., 2006) and is strongly correlated with dyspnoea (O'Donnell & Webb, 1993) and 
an increased perception of inspiratory difficulty (Chen & Yan, 1999).  At rest, 5 cmH2O of extrinsic 
positive end expiratory pressure has been shown to offset PEEPi and reduce work of breathing in 
people with stable severe COPD (Nava et al., 1993).  During static arm elevation, 4cmH2O of EPAP 
was also found to reduce PEEPi and inspiratory muscle work in people with chronic HRF due to very 
severe COPD (Poggi et al., 2006).  The application of 4-5 cmH2O of EPAP in the present study may 
have assisted participants with very severe COPD during UAE in a similar manner.  
 
Another possible mechanism by which NIV may have assisted UAE relates to the improvement in 
isotime and end exercise SpO2 compared to exercise without NIV at an equivalent supplemental O2 
flow rate.  In fact, for a given O2 flow rate, the fraction of inspired O2 delivered via NIV has been 
shown to be reduced compared to O2 delivered via nasal prongs or mask due to dilution of the gas with 
high airflow rates (Yoder et al., 2004).  Theoretically, the higher SpO2 associated with NIV during 
exercise may have improved peripheral muscle oxygenation and contributed to the improvement in 
exercise performance.  However the mean difference in SpO2 between exercise with and without NIV 
at isotime and end exercise was low in real terms at approximately 2%, and SpO2 remained above 89% 
for the majority of participants irrespective of whether UAE was performed with or without NIV.  In 
the present study, the clinical relevance of the change in SpO2 is questionable and consequently, is 
unlikely to be an important mechanism by which NIV improved UAE capacity.  
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Finally, the decrease in isotime perceived exertion (arm muscle fatigue) observed with NIV during 
UAE may have enabled participants to exercise for a longer duration compared to UAE without NIV.  
However despite this, the majority of participants eventually terminated exercise due to arm muscle 
fatigue whether UAE was performed with NIV or not, which was most likely attributable to the effect 
of repetitive exercise in a small muscle group.  
  
Effect of non-invasive ventilation during ground walking 
While there was a trend for NIV during ground walking to improve endurance time compared to 
walking without NIV, a statistically significant difference was not demonstrated.  In addition, there 
was no difference in dyspnoea when NIV was used during exercise.  Results from the current study 
differ from previous studies that have shown that a lightweight portable ventilator used during ground 
walking in patients with severe COPD impaired exercise performance compared to walking without 
NIV (Highcock et al., 1997; Revill et al., 2000).  The ventilator used in these studies was unable to 
generate sufficient inspiratory flow rates to deliver the preset level of pressure support (PS) throughout 
exercise (Highcock et al., 1997; Revill et al., 2000).  Without adequate PS, resistance of the circuit can 
worsen dyspnoea and impair exercise performance (van 't Hul et al., 2002).  In the present study, mask 
pressure was monitored throughout exercise and demonstrated that the bilevel machine consistently 
delivered the preset airway pressures during exercise.  Therefore, insufficient ventilator capacity does 
not explain the ineffectiveness of NIV during ground walking in the present study.  The more likely 
explanation is that the level of PS provided was inadequate. 
 
Results from the present study also differ from that of Dreher and colleagues (2007) who found that 
NIV plus O2 during ground walking in patients with chronic HRF secondary to very severe COPD 
significantly improved arterial oxygenation, increased distance walked and reduced dyspnoea 
compared to walking with O2 alone.  An improvement in oxygenation at isotime and end exercise 
when NIV was used during ground walking was also found in the present study.  However, despite 
this, endurance time was not significantly increased.  A striking difference between the present study 
and that of Dreher and colleagues (2007) was the preset level of PS provided during exercise.  While 
the level of EPAP used was similar, the level of IPAP was substantially different resulting in a median 
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PS of 25.6 cmH2O used in the study of Dreher and colleagues (2007) compared to 10.0 cmH2O in the 
present study.  There was no significant reduction in isotime dyspnoea in the present study, and as 
dyspnoea is inversely proportional to inspiratory muscle unloading (Maltais et al., 1995), it is likely 
that the PS provided was insufficient to unload inspiratory muscles and thus improve exercise 
performance during ground walking.  As previously stated, a reduction in isotime dyspnoea of two 
points on a 0-10 dyspnoea scale with NIV during lower limb exercise compared to exercise without 
NIV has been associated with improvements in exercise performance (Borel et al., 2008; van 't Hul et 
al., 2002).  The mean reduction in dyspnoea score in the present study was only one point.  An 
advantage in the study performed by Dreher and associates (2007) was that participants used the same 
ventilator settings during exercise as they used for sleep.  Theoretically patients could independently 
use their ventilators during exercise without having to change the settings.  The level of PS used in the 
current study was also very similar to the level of PS titrated for nocturnal ventilatory support 
(exercise PS: 10.0 cmH2O; sleep PS: 10.7 cmH2O), but was substantially lower than that reported by 
Dreher et al (2007).  The study conducted by Dreher and colleagues (2007) was published after the 
completion of data collection for the current study and therefore the finding that high level PS 
improved ground walking performance in people with chronic HRF secondary to very severe COPD 
was unable to be incorporated into the design of the current study.  At the time that the present study 
was designed, PS of 10 cmH2O had been shown to be beneficial during cycling exercise in people with 
severe COPD (van 't Hul et al., 2004).  During ground walking, a similar level of PS resulted in a 
reduction in exercise performance in people with severe COPD (Revill et al., 2000).  However, the 
capacity of the portable ventilator used was found to be inadequate to support ventilation during 
exercise and consequently, the effect of PS 10 cmH2O during ground walking remained unknown. 
 
The level of PS used in the present study may have been inadequate for use during ground walking for 
several reasons.  Ground walking requires a greater amount of work from larger muscle groups 
compared to treadmill walking (passive hip extension) (Heus et al., 1998) or cycle ergometry (weight 
supported) where the same level of PS (10 cmH2O) has been shown to be effective (van 't Hul et al., 
2004).  Furthermore, participants performed the ESWT at 85% of the maximal walking speed 
achieved during the ISWT in the present study.  This externally paced test may have been performed 
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at a higher intensity than the self paced six minute walk test used by Dreher and colleagues (2007).  
Therefore higher levels of PS may have been required to unload the inspiratory muscles during ground 
walking.  These results indicate that PS set to a level of comfort at rest, similar to settings used for 
nocturnal ventilatory support, are insufficient for use during ground walking in patients with chronic 
HRF.  Higher levels of PS may be required to reduce dyspnoea and improve exercise performance.   
 
In addition, the population in the present study was heterogeneous and included participants with 
severe kyphoscoliosis as well as those with very severe COPD.  Benefit from using NIV during 
exercise has been demonstrated in patients with severe restrictive thoracic disorders when high levels 
of PS (mean 19 to 30 cmH2O) were provided during cycling exercise (Borel et al., 2008; Tsuboi et al., 
1997) but not with lower levels of pressure support (mean 10cmH2O) during treadmill walking 
(Highcock et al., 2002).   Further investigation is warranted to determine whether the level of pressure 
support provided during exercise, or the type of lower limb exercise performed (walking versus 
cycling), has an effect on the efficacy of NIV during exercise in people with severe kyphoscoliosis or 
very severe COPD. 
 
Limitations 
The primary limitation of the present study was that patients and investigators were not blinded to the 
condition of exercise with or without NIV which may have introduced bias.  Adding a sham NIV arm 
to the study would have increased the number of tests that participants needed to perform.  People with 
chronic HRF usually have a substantially reduced exercise capacity (Schonhofer et al., 2003).  The 
performance of another UAE and ground walking test may have resulted in excessive fatigue which 
could have confounded the results, particularly during ground walking tests where an incremental 
maximal test as well as two endurance tests already needed to be performed within one day.  Given the 
limited number of tests that could be performed, it was felt that it was more important to compare 
exercise with NIV to exercise without NIV rather than include a sham intervention for several reasons.  
Firstly, an appropriate sham NIV has not been identified for use during ground walking.  Ineffective 
ventilator settings (sham) can impede exercise performance (Highcock et al., 1997) and therefore may 
exaggerate the effects of NIV during exercise.  Secondly, NIV and sham NIV could both impair 
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exercise performance compared to exercise without NIV, as has been shown in people with severe 
COPD (Revill et al., 2000).   Consequently, comparison of NIV and sham NIV during exercise to 
exercise without NIV is imperative to ensure that the addition of NIV and the ventilator circuit does 
not impede exercise performance.  Moreover, an improvement in endurance time was found with NIV 
during UAE, but not during ground walking.  Therefore, it is unlikely that investigator bias affected 
the results or that there was a placebo effect associated with NIV given that more than half of the 
participants performed both UAE and walk tests.  In an attempt to minimise bias, verbal 
encouragement and instructions given to participants were standardised. 
  
Another potential limitation of the present study relates to the combination of exercise data from 
people with very severe COPD and people with severe kyphoscoliosis.  While the mechanisms that 
lead to exercise limitation are different in people with very severe COPD compared to people with 
severe kyphoscoliosis, both groups often complain of severe exertional dyspnoea (Bianchi et al., 1998; 
Borel et al., 2008) and both tend to have a ventilatory limitation to exercise (O'Donnell et al., 2001a; 
Shneerson, 1978b).  Despite COPD being characterised by airflow obstruction, with dynamic 
hyperinflation, people with severe COPD may also experience a restriction in their ability to achieve 
further increases in tidal volume (VT) with encroachment on the inspiratory reserve volume 
(O'Donnell & Webb, 1993).  During exercise individuals with severe COPD breathe at a very high 
end-inspiratory lung volume to total lung capacity ratio.  This restricts their ability to further increase 
VT to meet the ventilatory requirements of the exercise.  Restriction in the ability to increase VT is also 
a problem faced by people with severe kyphoscoliosis (Shneerson, 1978b), just at a different 
operational lung volume.  Non-invasive ventilation during exercise has been shown to increase VT and 
VE in both of these patient groups (Hernandez et al., 2001; Vila et al., 2007).  In addition, previous 
research has shown that the effects of NIV during exercise in these two populations are similar.  Non-
invasive ventilation has been shown to improve exercise endurance, reduce dyspnoea and improve gas 
exchange during exercise in people with severe COPD (Hernandez et al., 2001; van 't Hul et al., 2002) 
and in people with severe kyphoscoliosis (Borel et al., 2008; Vila et al., 2007).  Examination of 
individual data from the present study in Figures 2.5 and 2.8 suggest that there was not a particular 
pattern of response to NIV during exercise relative to diagnostic group.  Furthermore, disease severity 
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appears to be an important factor that influences an individual’s response to NIV during exercise.  
Variation in the response to NIV during exercise has been reported in subjects from within the same 
diagnostic group in people with COPD (Bianchi et al., 1998; Bianchi et al., 2002) and kyphoscoliosis 
(Borel et al., 2009; Borel et al., 2008), where subjects with more severe disease often gained greater 
benefits from NIV during exercise compared with those subjects with less severe disease.  The 
participants included in the present study all had severe disease with a very limited ventilatory 
capacity, and therefore presented as a group who may benefit from an intervention such as NIV during 
exercise.   
 
Finally, a type II error cannot be ruled out for our results of the effect of NIV during walking on 
endurance time.  However, similar studies have found a statistically significant difference in 
endurance time between exercise with and without NIV from similar sized or smaller populations than 
that used in the present study (Bianchi et al., 1998; Hernandez et al., 2001; Maltais et al., 1995).  
 
Clinical implications 
Non-invasive ventilation during exercise was feasible and well tolerated in patients with chronic HRF 
secondary to very severe COPD or severe kyphoscoliosis.  The individuals included in the present 
study were already accustomed to NIV and consequently, the transition from using NIV during sleep 
to using NIV during exercise was relatively easy.  Non-invasive ventilation during UAE was 
associated with an acute increase in exercise endurance time, a reduction in dyspnoea and arm 
exertion, and a small improvement in SpO2 compared to exercise without NIV.  These findings 
provide evidence that NIV does augment UAE performance in people with chronic HRF secondary to 
COPD or kyphoscoliosis.  Non-invasive ventilation may be a tool that can be used as an adjunct to 
upper limb exercise training or to assist in the performance of daily activities in people who have 
severely limited arm exercise capacity.  Investigation of the role of NIV in these situations is 
warranted.   
 
In contrast, a significant improvement in endurance time was not observed with NIV during walking 
despite an improvement in SpO2 at isotime and end exercise.  Rather than demonstrating the 
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ineffectiveness of NIV during ground walking, this result highlights some important factors regarding 
the use of NIV during exercise in people with severe COPD or severe kyphoscoliosis.  In order for 
NIV to be of benefit during exercise, it appears that selection of ventilator settings that adequately 
unload the respiratory muscles and reduce dyspnoea is crucial.  Objective quantification of respiratory 
muscle loading is difficult and impractical in the clinical setting.  However, a correlation between 
inspiratory muscle unloading and dyspnoea has been described (Maltais et al., 1995).  Several studies 
that report an improvement in exercise performance with NIV also found a mean reduction in isotime 
dyspnoea of approximately two points on a 0-10 dyspnoea scale relative to unassisted exercise (Borel 
et al., 2008; van 't Hul et al., 2002).  In the present study, isotime dyspnoea was only reduced by a 
mean of one point with NIV for the group and endurance time was not significantly increased.  While 
a significant correlation between the change in dyspnoea and change in endurance time with NIV was 
not found in the present study, examination of individual data (Figure 2.9) suggests that those 
individuals with a reduction in dyspnoea of two or more points on the dyspnoea scale achieved an 
increase in walking endurance time by 30% or more, although the sample size was relatively small and 
there was some individual variation.  Whether a minimum level of reduction in dyspnoea exists in 
order for NIV to assist exercise performance is unknown.  However, aiming for a reduction in isotime 
dyspnoea of approximately two points on a 0-10 dyspnoea scale with NIV compared to unassisted 
exercise appears to be a reasonable approach.   
 
While PS 10 cmH2O during cycle ergometry appears adequate to improve exercise capacity in people 
with COPD (van 't Hul et al., 2004, 2006), or PS 11 cmH2O during UAE for people with chronic HRF 
secondary to COPD or kyphoscoliosis as in the present study, it seems that higher levels of PS are 
required for ground walking (Dreher et al., 2007).  The effect of high and low level PS during walking 
needs to be assessed in people with COPD and those with severe kyphoscoliosis in order to guide 
clinicians in the selection of settings for NIV during walking in both populations.  Identification of 
ventilator settings that provide the greatest improvement in exercise performance is important if NIV 
is to assist in the performance of daily activities or be used during exercise training. 
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In addition to the use of appropriate ventilator settings, patient selection is also likely to be important 
for NIV to be of benefit during exercise.  In the present study, a moderately strong inverse correlation 
was found between FVC (% predicted) and the response to NIV during walking.  That is, those 
participants with a lower FVC (% predicted) tended to respond better to NIV during walking 
compared to those participants with a higher FVC.  However, individual responses did vary (Figure 
2.10) and data from participants with very severe COPD and participants with severe kyphoscoliosis 
were combined.  Therefore this relationship should be interpreted with caution.  No other baseline 
factors correlated with the response to NIV during exercise in the current study.  As a result, a trial of 
NIV during exercise would need to be performed in order to determine whether an individual will 
benefit from this technique.  
 
Lastly, the NIV set up used in the current study is too cumbersome for use during everyday activities.  
Ideally, a lightweight, portable ventilator with an internal battery could be used, provided that the 
device had the capacity to generate sufficient airflow to support ventilation during exercise.  With 
further advances in technology and increased accessibility to such devices, the feasibility of using NIV 
during everyday activities in people with severely restricted ventilatory capacity may greatly improve.  
More than half of the participants in the present study also required supplemental O2 during exercise.  
Even with the use of a lightweight portable ventilator, the added weight of an O2 cylinder may reduce 
the portability of the system during some daily activities.  Dreher and colleagues (2009) demonstrated 
that walking with a portable ventilator and O2 cylinder in a backpack (total weight 7.3 kg) improved 
oxygenation but reduced distance walked and increased dyspnoea compared to walking with O2 alone 
(total weight 3.1 kg) in people with chronic HRF secondary to very severe COPD.  The technique was 
poorly accepted with almost half of the subjects refusing to walk with NIV due to the heavy pack 
(Dreher et al., 2009).  Alternatively, the use of a rollator frame to carry the portable ventilator and O2 
cylinder during walking has been shown to be an effective, well accepted strategy (Dreher et al., 
2007).  These findings emphasise the need for a lightweight, portable system if NIV is to be used 
during everyday activities, particularly when supplemental O2 is also required. 
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Conclusion 
In conclusion, NIV during UAE increased exercise endurance time, reduced dyspnoea, improved 
oxygenation and decreased arm muscle fatigue compared to exercise without NIV in people with 
chronic HRF secondary to very severe COPD or severe kyphoscoliosis.  Further research is warranted 
to evaluate the use of NIV as an adjunct to arm exercise training.  Non-invasive ventilation during 
ground walking did not significantly increase exercise endurance time despite improving oxygenation 
at isotime and end exercise.  However, the level of pressure support provided may have been 
inadequate as dyspnoea was not reduced compared to walking without NIV.   
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INTRODUCTION 
Individuals with severe kyphoscoliosis commonly have a ventilatory limitation to exercise (Shneerson, 
1978b) and report severe exertional dyspnoea (Borel et al, 2008).  Inspiratory muscle impairment and a 
marked reduction in vital capacity and total lung capacity are commonly observed (Lisboa et al, 1985) and 
undoubtedly contribute to the reduced ventilatory capacity during exercise.  Significant oxygen (O2) 
desaturation (Meecham Jones et al, 1995a; Vila et al, 2007), higher absolute pulmonary artery pressures 
and greater rates of increase of pulmonary artery pressures during exercise have also been described 
compared to healthy individuals (Shneerson, 1978a).  
 
A number of strategies aimed at improving exercise capacity have been trialled in people with moderate to 
severe kyphoscoliosis.  Supplemental O2 during exercise was shown to reduce breathlessness and improve 
oxygen saturation (SpO2) however exercise capacity remained unchanged (Meecham Jones et al, 1995a).  
Likewise, respiratory muscle training was associated with an increase in respiratory muscle strength but 
did not improve exercise capacity (Budweiser et al, 2006).  In contrast, nocturnal non-invasive ventilatory 
support (NIV) was associated with an improvement in exercise performance in the absence of exercise 
training in people with chronic hypercapnic respiratory failure (HRF) secondary to severe kyphoscoliosis 
(Fuschillo et al, 2003; Schonhofer et al, 2001b).  However, despite this improvement, activity levels 
(Schonhofer et al, 1997) and exercise capacity (Schonhofer et al, 2003) remained well below normal, 
placing these individuals at risk of further deconditioning which may have impacted on their ability to 
perform daily activities.   
 
The effect of NIV during exercise in people with severe kyphoscoliosis is unclear.  In a  randomised 
crossover study, pressure support (PS) of 9.7 to 13.7 centimetres of water (cmH2O) during treadmill 
walking reduced distance walked compared with unassisted exercise in eight people with severe scoliosis 
(Highcock et al, 2002).  In contrast, in another randomised crossover study, PS 19 cmH2O during constant 
work rate cycling increased endurance time compared with unassisted exercise in 18 individuals with 
severe chest wall restriction, 16 of whom had severe kyphoscoliosis (Borel et al, 2008).  In patients with 
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chronic obstructive pulmonary disease (COPD), the level of PS delivered during exercise has been shown 
to significantly affect the response to NIV during exercise.  In a randomised crossover study, PS 10 
cmH2O during cycling increased exercise endurance time compared with unassisted exercise, whereas 
endurance time was no different to unassisted exercise with a lower level of PS (5 cmH2O) (van 't Hul et 
al, 2004).  Whether the level of PS provided during exercise has an effect on the efficacy of PS during 
exercise in people with severe kyphoscoliosis is unknown.   
 
The aim of the present study was to determine the effect of high level, low level and sham PS during 
treadmill walking on endurance time compared with walking unassisted in patients with severe 
kyphoscoliosis who were already established on domiciliary NIV.  It was hypothesised that high level PS 
would be required to increase exercise endurance time due to the high impedance to chest wall inflation 
commonly observed in this population.  If high level PS during treadmill walking can improve exercise 
performance, it may have a role during exercise training or in assisting people with severe kyphoscoliosis 
to perform everyday activities.  
 
 
METHOD 
Participants 
Participants were recruited from the home ventilation program at Royal Prince Alfred Hospital.  
Individuals aged 18 years or older with severe kyphoscoliosis were invited to participate in the study.  
Kyphoscoliosis was defined as severe if daytime chronic HRF was present as a result of chest wall 
restriction.  In addition, participants needed to be compliant with domiciliary NIV with an average usage 
of at least four hours per night over the past three months.  Individuals were excluded from the study if 
any of the following were present: medically unstable over the past month that was sufficient to require an 
admission to hospital; respiratory acidosis (arterial pH <7.35); temperature > 38 degrees Celsius (°C); 
resting systolic blood pressure <90 or >160 millimetres of mercury (mmHg), diastolic blood pressure <60 
or >100 mmHg; unstable angina or a myocardial infarct during the previous month; resting pulse rate 
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(>120 beats/minute); orthopaedic or neurological disorders that were likely to limit walking ability; major 
psychiatric illness.  Written informed consent was provided by all participants. 
 
Study design  
A randomised crossover study with repeated measures was conducted at Royal Prince Alfred Hospital, 
Sydney.  Participants were asked to perform four endurance treadmill exercise tests in random order: one 
unassisted; one with sham PS (continuous positive airway pressure (CPAP) 4 cmH2O); one with low level 
PS of 10 cmH2O (PS 10); and one with high level PS of 20 cmH2O (PS 20).  The randomisation scheme 
was generated using the website http://www.randomization.com and test order was concealed in a sealed 
opaque envelope until written consent was obtained.  For the three tests with PS both participants and the 
assessors were blinded to the level of PS provided.  Participants were told that bilevel machine settings 
would be different for each test with PS and that the best way to set the machine, or whether the machine 
was better than unassisted exercise, was unknown.  The level of PS was set on the bilevel machine by one 
investigator and the settings were concealed.  The investigator did not interact with participants or 
assessors during the exercise tests.  Ethical approval was obtained from the Human Ethics Committee of 
Sydney South West Area Health Service and The University of Sydney.  The study was registered with 
the Australian New Zealand Clinical Trials Registry (ACTRN12608000155392).  
 
Protocol 
The four endurance treadmill tests were completed during one day.  Prior to the treadmill tests, 
participants rested for 10 minutes before performing a two minute walk test (2MWT) (Butland et al, 
1982).  Eighty percent of the average walking speed attained during the 2MWT was set as the target 
walking speed for the treadmill tests.  Prior to each endurance treadmill test, participants sat quietly for at 
least 30 minutes while breathing unassisted.  Participants who used daytime supplemental O2 rested while 
breathing their usual flow rate of O2.   Participants were then asked to rest for a further five minutes at 
baseline while breathing according to the test intervention: unassisted prior to the unassisted treadmill test; 
with sham PS prior to the sham PS test; with PS 10 prior to the PS 10 test; or PS 20 prior to the PS 20 test.   
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If SpO2 was <89% during the five minute baseline period, supplemental O2 was added to achieve a SpO2 
of 90-93%.  The O2 flow rate was not adjusted further during exercise.  Participants were then asked to 
perform the endurance treadmill test according to the test intervention.  An assessor who was blinded to 
the level of PS delivered during exercise gave standardised encouragement to the participant each minute 
during the treadmill test after dyspnoea and rate of perceived exertion (RPE) scores had been recorded.  
The phrases “you are doing well” and “keep up the good work” were alternated.  Participants rested while 
breathing unassisted for at least 30 minutes between endurance treadmill tests and until SpO2, heart rate 
(HR), dyspnoea, RPE (leg muscle exertion), and blood pressure (BP) had returned to baseline levels.  
When all four endurance treadmill tests had been completed, participants were asked to identify the test 
that they felt was the easiest to perform.  The study protocol is summarised in Figure 3.1.   
 
 
 
 
 
Figure 3.1 Study protocol and measures. Sham PS: sham pressure support; PS 10: pressure support 
10 cmH2O; PS 20: pressure support 20 cmH2O; SpO2: oxygen saturation; HR: heart rate; 
RPE: rate of perceived exertion; BP: blood pressure; PavCO2: arterialised venous partial 
pressure of carbon dioxide; La: lactate; VE: minute ventilation; RR: respiratory rate; VT: 
tidal volume 
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In addition, in a subgroup of participants, arterialised venous blood was sampled from the opposite upper 
limb at the same time as arterial blood was collected at rest, prior to the exercise tests, to determine the 
validity of arterialised venous blood pH and partial pressure of arterialised venous carbon dioxide 
(PavCO2) values as surrogate measures for arterial blood pH and partial pressure of carbon dioxide 
(PaCO2) values.   
 
Exercise tests 
Two Minute Walk Test 
The 2MWT is a self paced, timed walk test (Butland et al, 1982).  A 25 metre (m) course was marked 
using two cones placed 0.50 m inside from each end to signal the turn.  Participants received standardised 
instructions that were adapted from the six minute walk test: “the goal is to walk as far as possible for two 
minutes (American Thoracic Society, 2002).  You will walk up and down the corridor, turning tightly 
around each cone.  You can slow down or stop to rest if required, but resume walking as soon as possible.  
Remember, the goal is to walk as far as possible for two minutes”.  Standardised encouragement was 
given at one minute and subjects were informed of the remaining time in the test.  Participants performed 
the 2MWT without PS.  For those participants who used supplemental O2 continuously during the day, the 
same flow rate of O2 was used during the 2MWT.  Participants used their usual walking aid during the 
test.  Total distance walked was recorded and average walking speed was calculated. 
 
Endurance Treadmill Test 
The treadmill test was an externally paced, constant work rate, endurance test.  Walking speed was set at 
80% of the average walking speed that the participant achieved during a 2MWT (Butland et al, 1982).  
Participants were familiarised to the walking speed for approximately 20 seconds, at least 30 minutes 
before the first treadmill test.  If participants were unable to walk at this pace, walking speed was 
decreased incrementally to a pace that participants could safely manage, but no less than 60% of the 
2MWT average walking speed.  Once determined, walking speed remained consistent across the four 
treadmill tests.  Participants were asked to walk for as long as possible and were encouraged to hold onto, 
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but not lean on, the hand rails of the treadmill for stability.  The test was stopped if the participant felt too 
breathless or fatigued to continue.  The investigator stopped the test if SpO2 fell below 75% or if 
bradycardia or tachycardia occurred during exercise (HR <60 or >180).  Endurance time, the reason for 
exercise cessation and the primary symptom that limited exercise were recorded.  Figure 3.2 shows a 
participant walking on the treadmill with PS.   
 
 
 
 
 
 
 
Figure 3.2 A participant performing an endurance treadmill test with pressure support.  Image 
printed with permission 
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Measures 
Participant Characteristics 
Anthropometric data was recorded and pulmonary function tests were performed within one day of the 
endurance treadmill tests.  On the same day as, but prior to the treadmill tests, a resting arterial blood gas 
was analysed.   
 
Anthropometric data 
Age, sex, height, weight and arm span were recorded.  Body mass index (BMI; kg/m2) was calculated 
using vertical height.   
 
Arterial blood gas tensions 
A daytime arterial blood sample was collected at rest while participants were seated and breathing room 
air.  If participants used continuous daytime supplemental O2, arterial blood was sampled while 
participants breathed with their usual O2 flow rate.  Arterial blood was sampled from the radial artery and 
stored in ice until it was analysed (Radiometer ABL700, Radiometer Medical, Copenhagen, Denmark).  
This was typically within 15 minutes of the sample being collected.   
 
Arterialised venous blood gas tensions 
Arterialised venous samples were obtained from a 20 gauge cannula that was inserted into a vein on the 
dorsum of the wrist or forearm.  A 12 centimetre (cm) extension catheter was attached (dead space 0.2 
millilitres (mL)) and pointed distally to allow blood to be sampled away from the hand.  The cannula was 
flushed intermittently with normal saline to prevent clotting.  After demonstration of the ability to sense 
hot and cold on the forearm, an electric heating pad (Theratherm, Chattanooga Group, Hixon, 
Tennessee, USA) was wrapped around the forearm and hand, covering the cannula.  The temperature of 
the forearm was monitored using a thermometer with an external display screen and the probe placed 
adjacent to the cannula.  Skin temperature was maintained between 42-45ºC (Forster et al, 1972; Morgan 
et al, 1979).  The heating pad was in place for a minimum of 20 minutes prior to the sample being taken.  
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To account for dead space within the cannula and extension catheter, one mL of blood was withdrawn and 
discarded prior to collection of the arterialised venous sample.  Two mL of blood was then withdrawn 
from the cannula into a three mL heparinised syringe.  Air bubbles were expelled from the syringe and the 
sample was stored in ice until blood pH, PavCO2 and lactate levels were analysed (Radiometer ABL700, 
Radiometer Medical, Copenhagen, Denmark).  This was typically within 30 minutes of the sample being 
collected.   
 
Pulmonary function tests 
 (i) Spirometry 
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured using a 
mass flow sensor (Sensormedics Vmax 20 Pulmonary Spirometry Instrument, Sensormedics Corporation, 
Yorba Linda, CA, USA).  The Mass Flow Sensor was calibrated using a three litre syringe prior to the 
commencement of pulmonary function tests.  Forced expirations from total lung capacity (TLC) were 
obtained from each participant in the standing position with a nose peg in place.  The best of three 
attempts from values of within 5% variability were recorded.  Subjects were encouraged verbally to 
perform a maximum effort during each test.  Measured values were compared with population reference 
values (Quanjer et al, 1993).  Arm span, rather than height was used to calculate percent predicted values 
for pulmonary function tests (Linderholm & Lindgren, 1978). 
 
(ii) Static lung volumes 
Static lung volumes were determined by body plethysmography (Sensormedics, 6200 Autobox, 
Sensormedics Corporation, Yorba Linda, CA, USA).  Participants were seated in an airtight perspex box 
with the door closed while the test was being conducted.  The test began at least 30 seconds after the door 
was closed to allow internal box temperature to equalise with the ambient temperature.  Participants were 
instructed to breathe through a mouthpiece connected to a mass flow sensor with a nose peg in place.  
After 5-10 stable tidal breaths, a shutter closed across the breathing circuit and participants were 
instructed to pant while placing their hands on their cheeks.  After several seconds the shutter re-opened 
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and participants were instructed to inhale maximally to TLC, then exhale to residual volume (RV) and to 
inhale again.  Functional residual capacity (FRC) was measured using the method of Dubois and 
colleagues (Dubois et al, 1956).  The best of three attempts from values within 5% variability in FRC and 
inspiratory capacity (IC) were recorded.  The best IC was added to FRC to give a measure of TLC. 
Measured vital capacity (VC) was subtracted from TLC to calculate RV.  Results were compared with 
normal predicted values of Quanjer et al (1993).  
 
(iii) Maximum voluntary ventilation 
Maximum voluntary ventilation (MVV) was measured over 12 seconds using a mass flow sensor 
(Sensormedics, 6200 Autobox, Sensormedics Corporation, Yorba Linda, CA, USA).  Participants 
performed the test in standing to match the posture that was used during the endurance treadmill tests.  
Participants were instructed to breathe normally through a mouthpiece attached to a mass flow sensor with 
a nose peg in place and their hands on their cheeks.  Once settled on the mouthpiece, participants were 
asked to breathe as quickly and deeply as possible for 12 seconds.  The importance of maintaining a 
maximal effort for the duration of the collection period was emphasised.  The target respiratory rate was 
70 - 150 breaths/minute with a volume ¼ - ¾ of vital capacity.  Participants rested for approximately 5 
minutes between trials.  The best of three attempts from values of within 10% variability were recorded.  
Subjects were encouraged verbally to perform a maximum effort during each test.  Percent predicted 
values were calculated from reference values for females (Grimby, 1963) and males (Kory et al, 1961). 
 
(iv) Respiratory muscle strength 
Respiratory muscle strength was determined by measuring maximal inspiratory (PImax1.0) and expiratory 
(PEmax1.0) mouth occlusion pressure sustained over one second from residual volume and total lung 
capacity respectively, using a hand held pressure gauge (Morgan Medical Limited, Gilingham, UK) 
calibrated from 0 ± 200 cmH2O.  The gauge mouthpiece permitted a 1mm air leak in order to prevent 
glottic closure during testing.  Participants were instructed to inhale or exhale with their glottis open and 
not to use their buccal muscles.  The test was performed with participants in the sitting position.  A nose 
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peg was worn during the test.  The highest pressure generated over one second of three reproducible 
attempts was recorded.  Measured values were compared with reference values from Wilson et al (Wilson 
et al, 1984).  Participants were encouraged verbally to perform a maximum effort during each test. 
 
Exercise 
Two minute walk test 
Oxygen saturation and HR were measured continuously via a finger probe and pulse oximeter (Radical, 
Masimo, Irvine CA, USA).  Data were downloaded after exercise using software provided by the 
manufacturer (Download 2001, Masimo, Irvine CA, USA).  Rate of perceived exertion, which reflected 
leg muscle exertion, and dyspnoea were measured on a 0-10 category-ratio scale (Borg, 1982) before and 
immediately after the 2MWT.  Blood pressure was measured manually with a sphygmomanometer before 
and immediately after the 2MWT. 
 
Endurance treadmill test 
(i) Rest 
At the end of the 30 minute rest period prior to each treadmill test, resting measures of SpO2, HR,  
dyspnoea scores, RPE scores and BP were recorded using the same techniques as described for the 
2MWT.  Measures of pH, PavCO2 and lactate were obtained from analysis of a three mL sample of 
arterialised venous blood collected from a cannula located on the dorsum of the participant’s forearm as 
previously described.  
 
(ii) Baseline 
At the end of the five minute baseline period prior to each treadmill test, SpO2, HR, dyspnoea scores, RPE 
scores and BP were recorded, and another sample of arterialised venous blood was collected for analysis 
of pH, PavCO2 and lactate.  In addition, flow was measured continuously to permit calculation of minute 
ventilation (VE), tidal volume (VT) and respiratory rate (RR).  Expiratory flow was measured via a mesh 
screen pneumotachograph (3830B Hans Rudolph, Shawnee, Kansas, USA) placed between the oronasal 
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mask and the expiratory port within the bilevel circuit (Figure 3.3a).  During unassisted exercise, flow was 
also measured using the oronasal mask and pneumotachograph in order to keep dead space (195 mL 
between the mask and expiratory port) consistent between the interventions (Fig 3.3b).  The 
pneumotachograph was connected to a differential pressure transducer (Validyne DP45-14, ± 2.25 
cmH2O, Validyne Engineering Corporation, Northridge, CA, USA).  The pressure transducer voltage 
output was amplified, displayed real time and recorded on a laptop using a data acquisition program 
(PhysioDAQxs, University of Sydney, NSW, Australia) with a sampling frequency of 100 Hertz.  The 
pneumotachograph was calibrated prior to each test using a three litre syringe (Tang et al, 2003).  The 
calibration file was used to determine whether an offset needed to be applied to zero the baseline, and the 
magnitude of the offset.  A linear relationship between voltage and flow was assumed, and a conversion 
factor was obtained by calculating the average voltage output for one litre/second from the calibration file.  
Voltage output was converted to flow (litres/minute (L/min)), and flow was integrated to give VT.  
Respiratory rate was calculated by counting the number of breaths on the flow trace during the final 20 
seconds of the baseline period, at isotime exercise and at end exercise.  Minute ventilation was calculated 
by multiplying VT and RR.  If isotime occurred at the same time that participants were asked to score 
dyspnoea and RPE, the 20 seconds of flow data was selected as close as possible to isotime while avoiding 
any obvious fluctuations in flow that may have occurred while participants reported the scores.  The data 
acquisition program was synchronised in time with the pulse oximeter and digital markers were placed 
within the data files to mark the beginning and end of exercise.   
 
If participants could not tolerate breathing on the oronasal mask and pneumotachograph during the 
unassisted five minute baseline period, ventilation was measured at baseline and during exercise using a 
mouthpiece system with breath by breath automated analysis of VT (Sensormedics, Vmax 29N, 
Sensormedics Corporation, Yorba Linda, CA, USA) attached to a mouthpiece (Fig 3.3c).  Participants 
wore a noseclip while breathing via the mouthpiece.  The total dead space was 100 mL.   
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 a)                                                                    b)                                                                     c) 
  
Figure 3.3 Equipment used to measure flow during exercise: a) configuration for exercise with 
sham pressure support, pressure support 10 cmH2O and pressure support 20 cmH2O 
tests with the oronasal mask; b) configuration for unassisted exercise with the 
oronasal mask (expiratory port and tubing were removed); c) configuration for 
unassisted exercise with the mouthpiece (if the oronasal mask was not tolerated).  
Images printed with permission 
 
 
(iii) During exercise 
During each treadmill test, SpO2, HR and flow were recorded continuously.  Dyspnoea and RPE scores 
were measured and recorded each minute.  
 
(iv) End exercise 
 Immediately at end exercise, dyspnoea scores, RPE scores and BP were measured and recorded, and an 
arterialised venous blood sample was collected.  Endurance treadmill test measures are summarised in 
Figure 3.1.  At the end of each test with PS, participants were also asked to score the effect of PS during 
exercise compared with usual unassisted walking by placing a mark on 10 cm long visual analogue scales 
(VAS).  One VAS had “did not help me” at one end and “helped me” at the other.  The second had “made 
me feel more breathless” at one end and “made me feel less breathless” at the other.  The centre of the 
VAS (5 cm) represented no difference between PS and usual unassisted walking.  
 
Pressure support 
Pressure support was delivered via an oronasal mask (Ultra-Mirage Full Face Mask, ResMed, Sydney, 
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Australia) using a pressure preset bilevel machine (VPAPIII STA, ResMed, Sydney, Australia) set in 
the spontaneous (self triggered) mode.  The inbuilt expiratory port on the mask was sealed and the mask 
elbow removed to allow attachment of a mesh screen pneumotachograph with a silicon straight connector.  
An expiratory port (Ultra-Mirage Nasal Mask elbow, ResMed, Sydney, Australia) was placed after the 
pneumotachograph (Fig 3.4).  A three metre length of tubing connected the expiratory port to the bilevel 
machine. 
 
During sham PS the device was set at CPAP 4 cmH2O.  For PS 10 and PS 20, expiratory positive airway 
pressure (EPAP) was set at 4 cmH2O.  For PS 10, PS was set 10 cmH2O above EPAP (ie. inspiratory 
positive airway pressure (IPAP) 14 cmH2O).  For PS 20, PS was set 20 cmH2O above EPAP (ie. IPAP 24 
cmH2O).  The inspiratory trigger threshold of the bilevel machine was set to “high” (2.5 L/min).  Rise 
time (time from EPAP to IPAP once triggered) of 100 milliseconds (ms) was used.  The maximum 
duration that the machine could maintain IPAP (IPAPmax) was set at 1.3 seconds, and the minimum 
duration of IPAP (IPAPmin) was 0.1 seconds.  The maximum inspiratory flow rate capacity was > 220 
L/min.  If required, supplemental O2 was added via a t-piece connector placed between the air outlet of the 
machine and the tubing.  The investigator fitted the oronasal mask to prevent leak.  
 
 
 
Figure 3.4 Configuration of the tubing, expiratory port, pneumotachograph and oronasal mask 
Expiratory port 
Full face mask 
Tubing 
Pneumotachograph 
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Outcome measures 
Endurance Treadmill Test 
The primary outcome measure for the endurance treadmill test was endurance time.  Explanatory variables 
of interest included isotime exercise SpO2, HR, dyspnoea, RPE, VE, VT and RR, where isotime was 
defined as the duration of the shortest treadmill test.  Variables were compared at this point in time for the 
unassisted, sham PS, PS 10 and PS 20 endurance treadmill tests.  Dyspnoea and RPE scores that were 
documented closest to isotime were used for the analysis.  To determine ventilatory reserve during 
unassisted exercise, the ratio of peak VE to MVV was calculated.  Visual analogue scale scores for the 
amount of help provided by PS during exercise and the effect of PS on breathlessness were expressed as a 
percentage and compared between sham PS, PS 10 and PS 20.  In addition, the relationship between the 
response to PS during walking and VC, PImax1.0 and MVV was also assessed in order to determine whether 
these baseline measures could be used to select subjects who might benefit from PS during exercise.   
The response to PS was expressed as the percentage change in treadmill walking endurance time with PS 
compared with unassisted exercise.  Finally, the relationship between the response to PS during walking 
and the change in isotime dyspnoea with PS compared with unassisted exercise was determined.   
 
Validity of Arterialised Venous Blood Gas Analysis for Measurement of Arterial pH and the Partial 
Pressure of Carbon Dioxide 
To determine the validity of arterialised venous blood pH and PavCO2 as a surrogate measure of arterial 
pH and PaCO2 in patients with chronic HRF due to severe kyphoscoliosis, arterial and arterialised venous 
blood pH and PavCO2 were compared. 
 
Data analysis and statistics 
Endurance Treadmill Test 
An estimate of the required sample size was calculated using data from the first five participants.  To 
detect a 60 second change in endurance time (equivalent to 50%) with PS, using a standard deviation (SD) 
estimate of 49 seconds, power of 0.8, and α of 0.05, a sample of 13 participants was required.  Descriptive 
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data for continuous variables are presented as mean ± SD or median (interquartile range (IQR)).  Linear 
mixed model analyses were performed to determine firstly, if there was a difference between unassisted 
exercise, exercise with sham PS, PS 10 or PS 20 with respect to treadmill walking endurance time, and 
secondly, to determine if there was a difference between the four interventions at different time points 
(baseline, rest, isotime, end exercise, and change from rest to end exercise) with respect to physiological 
and subjective responses to PS during exercise.  In addition, the effect of test order on the primary and 
secondary outcome measures was determined.  The difference between sham PS, PS 10 and PS 20 at end 
exercise with respect to VAS scores was also assessed with linear mixed model analyses.  A significance 
level of α < 0.05 was used.  If a significant difference was detected between the interventions for a 
specific variable, pairwise comparisons were performed.  A sharper Bonferroni correction (Hochberg, 
1988) was applied to p values obtained from all multiple pairwise comparisons.  In practice, the correction 
involves ranking p values from smallest to largest.  The first p value is multiplied by one, the second p 
value is multiplied by two, the third by three and so on.  When the adjusted p value is > 0.05, no further 
corrections are made.  Both raw and adjusted p values are presented.  Mean difference and 95% 
confidence intervals (CI) are reported for pairwise comparisons.  The relationship between the response to 
PS during exercise and VC, MVV, PImax1.0 and the change in isotime dyspnoea was determined by 
calculation of Pearson’s correlation coefficient (r) for parametric data or, Spearman’s rho (rS) for non-
parametric data.  
 
Validity of Arterialised Venous Blood Gas Analysis for Measurement of Arterial pH and the Partial 
Pressure of Carbon Dioxide 
The correlation between arterialised venous and arterial blood sample analysis of pH and PCO2 was 
determined by calculation of an intra-class correlation coefficient (ICC 3,1) (Shrout, 1979).  Mean 
differences and 95% CI are reported.  Bland Altman plots (Bland & Altman, 1986) were used to present 
individual data.  All statistical analyses were conducted using the statistical package, SPSS Version 14.0.   
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RESULTS 
Participants 
Thirteen participants with severe kyphoscoliosis were recruited for the study.  All participants  
completed all exercise tests without any adverse events.  Static lung volumes and MVV were unable to be 
measured in one participant due to intolerable dyspnoea while breathing on the mouthpiece and therefore 
data are reported for 12 participants.  Participant characteristics are described in Table 3.1. 
 
Table 3.1 Participant characteristics (n = 13 unless otherwise stated) 
 
 
Value 
 
Percent predicted 
  Age (yrs) 59 (55 - 62)  
  F/M 7/6  
  Height (m) 1.46 ± 0.10  
  Arm span (m) 1.66 ± 0.15  
  BMI (kg.m-2) 25.3 ± 5.2  
Resting ABG 
  
  pH 7.40 (7.36 - 7.42)  
  PaCO2 (mmHg) 48.6 (46.0 - 56.1)  
  PaO2 (mmHg) 67.5 (60.0 - 79.0)  
  HCO3- (mmol/L) 30.0 ± 2.3  
  Base excess (mmol/L) 4.3 ± 2.1  
  SaO2 (%) 93 ± 3  
  Supp O2 (L/min) 0 (0 - 0.5)  
Pulmonary function 
  
  FEV1 (L) 0.51 (0.48 - 0.62) 20 ± 6 
  FVC (L) 0.72 ± 0.31 22 ± 7 
  FEV1/FVC (%) 83 (74 - 88)  
  PImax1.0 (cmH2O) -34.8 ± 15.5 45 ± 19 
  PEmax1.0 (cmH2O) 87.7 ± 45.0 78 ± 33 
  MVV (L/min) (n = 12) 23.7 ± 6.1 23 ± 5 
  TLC (L) (n = 12) 1.92 ± 1.03 35 ± 15 
  VC (L) (n = 12) 0.79 ± 0.35 23 ± 8 
  FRC (L) (n = 12) 1.38 ± 0.81 46 ± 23 
  IC (L) (n = 12) 0.54 ± 0.26 22 ± 9 
  RV (L) (n = 12) 1.13 ± 0.71  57 ± 31 
Domiciliary NIV 
  
  Time on NIV (years) 11.9 ± 4.7  
  Compliance (hours/night) 8.9 ± 2.6  
  Pressure/volume preset devices 11/2  
  Pressure preset mode (S/ST) (n = 11) 3/8  
  Rate (breaths/min) 18.0 (18.0 - 18.5)  
  IPAP (cmH2O) (n = 11) 17.0 ± 2.4  
  EPAP (cmH2O) (n = 11) 6.0 ± 1.1  
  PS (cmH2O) (n = 11) 11.0 ± 2.9  
  VT (L) (n = 2) 0.650 ± 0.212  
  Nocturnal supp O2 (L/min)  (n = 2) 3.0 (2.0 - 4.0)  
   
Data are presented as mean ± SD or median (interquartile range).  F/M: female/male; BMI: body mass index; ABG: arterial blood 
gas; PaCO2: arterial carbon dioxide tension; PaO2: arterial oxygen tension; HCO3- arterial bicarbonate ion concentration; SaO2: 
arterial oxygen saturation; Supp O2: supplemental oxygen; FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity; PImax1.0: maximal inspiratory mouth occlusion pressure over one second; PEmax1.0: maximal expiratory mouth occlusion 
pressure over one second; MVV: maximum voluntary ventilation; TLC: total lung capacity; VC: vital capacity; FRC: functional 
residual capacity; IC: inspiratory capacity; RV: residual volume; NIV: non-invasive ventilation; S/ST: spontaneous or 
spontaneous timed mode of bilevel non-invasive ventilation; IPAP: inspiratory positive airway pressure; EPAP: expiratory 
positive airway pressure; PS: pressure support; VT: tidal volume; Nocturnal supp O2: nocturnal supplemental oxygen 
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Exercise tests 
Two Minute Walk Test 
Thirteen participants performed the 2MWT.  One participant used a rollator frame, and two participants 
used two L/min of supplemental O2 during the test.  Eleven participants completed the 2MWT without 
stopping.  One participant stopped at 82 seconds, and another at 95 seconds due to intolerable dyspnoea.  
Average walking speed was calculated by dividing distance walked by two minutes and was converted to 
kilometres per hour (km/h).  For the two participants who stopped the 2MWT early, average walking 
speed was calculated by dividing distance walked with actual time walked, rather than dividing it by two 
minutes (Table 3.2). 
 
 
Table 3.2 Two minute walk test 
 
 
Baseline End Exercise 
 
SpO2 (%) 96 ± 3 84 ± 9 
HR (beats/min) 82 ± 15 101 ± 23 
Dyspnoea (Borg) 0 (0 - 0.5) 3.0 (3.0 - 4.0) 
RPE (Borg) 0 (0 - 0.3) 4.0 (2.8 - 4.0) 
SBP (mmHg) 122 ± 10 151 ± 17 
DBP (mmHg) 81 ± 10 92 (86 - 95) 
MAP (mmHg) 95 ± 9 110 ± 12 
Total distance walked (m)  121.5 ± 31.3 
Mean walking speed 2MWT (km/h)  3.9 ± 0.9 
 
 
 
Data are presented as mean ± SD or median (interquartile range).  SpO2: oxygen saturation; HR: heart rate; RPE: rate of perceived 
exertion; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial blood pressure 
 
 
Endurance Treadmill Test 
Mean treadmill walking speed was 2.9 ± 0.6 km/h (median intensity 80% (IQR 75 - 80) of the 2MWT 
average walking speed).  Individual and group endurance time data for each of the four interventions is 
displayed in Figure 3.5.  Endurance time data was not normally distributed and was transformed using 
log(x) prior to analysis.  A linear mixed model analysis indicated that there was a difference in endurance 
time between walking unassisted, with sham PS, PS 10 and PS 20 (p=0.02).  Pairwise comparisons 
revealed that endurance time was significantly greater with PS 20 (median 217 seconds, IQR 168-424) 
compared with walking unassisted (139 seconds, IQR 111-189), with sham PS (103 seconds, IQR 88-155) 
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and PS 10 (159 seconds, IQR 131-206) after a sharper Bonferroni adjustment (Hochberg, 1988) for 
multiple comparisons.  Endurance time was also greater with PS 10 compared with sham PS.  Pressure 
support 10 did not increase endurance time relative to unassisted walking, and endurance time achieved 
during walking with sham PS was not different to that of unassisted walking (Table 3.3).  There was no 
effect of test order on endurance time. 
 
 
 
 
Figure 3.5 Treadmill test endurance time for unassisted exercise (UnA), exercise with sham 
pressure support (PS), pressure support 10 cmH2O (PS 10) and pressure support 20 
cmH2O (PS 20).  Individual data are represented by open circles and group data (median) 
are represented by closed squares.  *: p < 0.05; †: p < 0.01 after a sharper Bonferroni 
correction (Hochberg, 1988) 
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Table 3.3 Pairwise comparisons of walking unassisted, with sham pressure support, pressure 
support 10 cmH2O and pressure support 20 cmH2O for endurance time (seconds) 
after transformation using log(x)  
 
Comparison 
 
Log(x) endurance time 
Mean (SD) vs Mean (SD) 
Mean difference 
(95% CI) 
p value Adjusted  
p value 
 
PS 20 vs UnA   2.446 (0.3456) vs 2.137 (0.234)  0.309 (0.078 to 0.540) 0.013 0.039 
PS 20 vs PS 10   2.446 (0.3456) vs 2.217 (0.1548) 0.229 (0.080 to 0.378) 0.006 0.012 
PS 10 vs UnA   2.217 (0.1548) vs 2.137 (0.234) 0.080 (-0.079 to .240) 0.295 NS 
PS 20 vs Sham   2.446 (0.3456) vs 2.071 (0.2376) 0.375 (0.235 to 0.515) <0.001 <0.001 
PS 10 vs Sham   2.217 (0.1548) vs 2.071 (0.2376) 0.146 (0.057 to 0.235) 0.004 0.008 
Sham vs UnA   2.071 (0.2376) vs 2.137 (0.234) -0.066 (-0.273 to 0.141) 0.499 NS 
     
Log(x) of endurance time data (seconds) are presented.  PS 20: pressure support 20 cmH2O; UnA: unassisted exercise; PS 10: 
pressure support 10 cmH2O; Sham: sham pressure support; CI: confidence interval; Adjusted p: p value adjusted using a sharper 
Bonferroni correction (Hochberg, 1988); NS: not significant 
 
 
 
 
 
 
 
Physiological and Subjective Responses to Pressure Support during Exercise 
Ventilation data were unable to be retrieved for one participant, and another participant was unable to 
breathe through the oronasal mask or the mouthpiece at baseline prior to the unassisted exercise test.  
Therefore ventilation data are reported for 12 participants for sham PS, PS 10 and PS 20, and 11 
participants for unassisted exercise.  Three participants used 1 L/min of supplemental O2 during the 
treadmill tests as room air SpO2 was <89% at rest.  During unassisted exercise, four participants breathed 
via an oronasal mask and eight breathed via a mouthpiece.  Descriptive data for physiological responses at 
rest, baseline, isotime and end exercise are presented in Table 3.4.  While breathing unassisted at rest prior 
to each endurance treadmill test, a linear mixed model analysis demonstrated that there were no 
differences between interventions with respect to SpO2, HR, dyspnoea, RPE, pH, PavCO2, lactate, or BP 
(p >0.05 for all comparisons).  There was no effect of test order on any of the physiological or subjective 
outcome measures. 
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Table 3.4 Descriptive data for physiological and subjective responses at rest, baseline, isotime 
and end exercise  
 
 
Unassisted Sham PS PS 10 
 
PS 20 
SpO2  (%)     
   Rest 94 ± 4 94 ± 2 94 ± 3 94 ± 2 
   Baseline 94 ± 4 92 ± 3 94 ± 2 96 ± 2 
   Isotime 84 ± 7 82 ± 7 87 ± 5 88 ± 5 
   End exercise 82 ± 10 80 ± 7 81 ± 7 82 ± 8 
HR (beats/min) 
    
   Rest 87 ± 15 86 ± 11 85 ± 12 85 ± 15 
   Baseline 87 ± 15 88 ± 13 86 ± 14 87 ± 14 
   Isotime 116 ± 20 115 ± 20 113 ± 16 109 ± 14 
   End exercise 118 ± 23 118 ± 18 118 ± 16 120 ± 18 
Dyspnoea (Borg) 
    
   Rest 0 (0 - 0.5) 0 (0 - 0.8) 0 ( 0 - 0.5) 0 (0 - 0.3) 
   Baseline 0 (0 - 0.5) 0 (0 - 2.5) 0 (0 - 1) 0.5 (0 - 1) 
   Isotime 3.7 ± 2.7 4.4 ± 2.6 2.7 ± 1.8 2.0 ± 2.2 
   End exercise 6.0 ± 2.9 5.4 ± 2.4 5.4 ± 2.6 6.0 ± 2.7 
RPE (Borg) 
    
   Rest 0 (0 - 0.3) 0 (0 – 1.0) 0 ( 0 - 0.5) 0 (0 - 0.3) 
   Baseline 0 (0 - 0.3) 0 (0 - 2.0) 0 (0 - 0.8) 0 (0 - 1.0) 
   Isotime 4.5 ± 2.8 4.5 ± 2.4 2.9 ± 2.2 2.8 ± 2.1 
   End exercise 6.3 ± 2.8 5.5 ± 2.3 5.5 ± 2.7 7.1 ± 3.0 
VE (L/min)     
   Baseline 9.24 ± 2.87 8.04 ± 1.69 9.77 ± 2.02 10.45 ± 3.74 
   Isotime 18.11 ± 5.06 15.27 ± 2.75 17.39 ± 3.39 17.26 ± 4.35 
   End exercise 19.54 ± 6.33 15.59 ± 2.72 19.02 ± 4.06 21.34 ± 5.29 
RR (breaths/min) 
    
   Baseline 29 ± 6  30 ± 8 28 ± 9 25 ± 9 
   Isotime 42 ± 9 40 ± 10 38 ± 9 34 ± 8 
   End exercise 47 ± 10 41 ± 10 42 ± 11 40 ± 9 
VT (L)     
   Baseline 0.33 ± 0.11 0.30 ± 0.09 0.38 ± 0.11 0.45 ± 0.18 
   Isotime 0.46 ± 0.14 0.41 ± 0.12 0.48 ± 0.14 0.54 ± 0.17 
   End exercise 0.47 ± 0.13 0.42 ± 0.13 0.51 ± 0.16 0.57 ± 0.17 
pH 
    
   Rest 7.379 ± 0.046 7.383 ± 0.039 7.379 ± 0.039 7.382 ± 0.031 
   Baseline 7.379 ± 0.046 7.374 ± 0.040 7.389 ± 0.040 7.421 ± 0.043 
   End exercise 7.352 ± 0.051 7.359 ± 0.039 7.356 ± 0.038 7.355 ± 0.048 
PavCO2 (mmHg)     
   Rest 50.7 ± 7.2 49.7 ± 7.4 49.5 ± 7.9 49.9 ± 6.6 
   Baseline 50.7 ± 7.2 50.3 ± 8.7 47.8 ± 7.1 43.9 ± 6.0 
   End exercise 53.9 ± 9.5 53.1 ± 8.2 53.4 ± 8.0 51.9 ± 8.6 
La (mmol/L) 
    
   Rest 1.1 ± 0.3 1.0 ± 0.2 1.1 ± 0.4 1.2 ± 0.5 
   Baseline 1.1 ± 0.3 0.9 ± 0.1 1.1 ± 0.4 1.2 ± 0.6 
   End exercise 1.7 ± 0.9 1.3 ± 0.4 1.7 ± 0.5 2.2 ± 1.0 
SBP (mmHg) 
    
   Rest 124 ± 13 124 ± 11 121 ± 11 125 ± 14 
   Baseline 124 ± 13 125 ± 13 123 ± 14 118 ± 11 
   End exercise 158 ± 24 145 ± 23 150 ± 23 150 ± 20 
DBP (mmHg) 
    
   Rest 88 ± 11 85 ± 11 85 ± 10 86 ± 10 
   Baseline 88 ± 11 89 ± 10 87 ± 11 85 ± 11 
   End exercise 90 ± 11 85 ± 13 90 ± 10 93 ± 11 
MAP (mmHg) 
    
   Rest 100 ± 11 98 ± 10 97 ± 9 99 ± 11 
   Baseline 100 ± 11 101 ± 10 99 ± 11 96 ± 11 
   End exercise 113 ± 3 105 ± 14 110 ± 12 112 ± 12 
     
Data are presented as mean ± SD or median (interquartile range). SpO2: oxygen saturation; HR: heart rate; RPE: rate of perceived 
exertion; VE: minute ventilation; RR: respiratory rate; VT: tidal volume; PavCO2: arterialised venous carbon dioxide partial 
pressure; La: lactate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; UnA: unassisted 
exercise; Sham PS: sham pressure support, PS 10: pressure support 10 cmH2O; PS 20: pressure support 20 cmH2O 
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At baseline, a linear mixed model analysis indicated that there was a difference between breathing  
unassisted, with sham PS, PS 10 and PS 20 with respect to SpO2, pH, PavCO2 and VT (Table 3.5).  
Pairwise comparisons of the four interventions with a sharper Bonferroni correction of p values 
(Hochberg, 1988), revealed that SpO2 was higher with PS 20 compared with unassisted breathing or sham 
PS, and greater with PS 10 compared with sham PS.  Compared with unassisted breathing, sham PS or PS 
10, PS 20 increased pH (less acidic) and reduced PavCO2.  Pressure support 10 cmH2O at baseline 
increased pH compared with sham PS, and reduced PavCO2 compared with unassisted breathing and with 
sham PS.  Tidal volume was higher with PS 20 compared with unassisted breathing and sham PS (Table 
3.6). 
 
 
 
 
 
Table 3.5 Linear mixed model analyses for the effect of breathing unassisted, with sham 
pressure support, pressure support 10 cmH2O and pressure support of 20 cmH2O on 
physiological and subjective variables at rest, isotime, end exercise and change from 
rest to end exercise 
 
 
Baseline 
 
 
p 
Isotime 
 
 
p 
End Exercise 
 
 
p 
Change from rest 
to end exercise  
 
p 
 
SpO2  <0.001 <0.001 0.38 0.32 
HR 0.89 0.16 0.79 0.15 
Dyspnoea 0.16 0.006 0.67 0.31 
RPE 0.68 0.013 0.061 0.045 
SBP 0.073 - 0.092 0.014 
DBP 0.43 - 0.002 0.001 
MAP 0.12 - 0.007 0.001 
pH <0.001 - 0.94 <0.001 
PavCO2 <0.001 - 0.27 0.010 
La 0.16 - 0.002 0.047 
RR 0.11 <0.001 <0.001 0.031 
VT 0.002 0.018 0.003 0.84 
VE 0.09 0.13 0.015 0.22 
     
SpO2: oxygen saturation; HR: heart rate; RPE: rate of perceived exertion; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; MAP: mean arterial pressure; PavCO2: arterialised venous carbon dioxide tension; La: lactate; RR: respiratory rate; VT: 
tidal volume; VE: minute ventilation 
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Table 3.6    Pairwise comparisons of breathing unassisted, with sham pressure support, pressure 
support 10 cmH2O and pressure support 20 cmH2O at baseline for oxygen saturation, 
pH, partial pressure of carbon dioxide and tidal volume 
 
 Comparison Mean (SD) vs Mean (SD) Mean difference  
  (95% CI) 
 
p 
 
Adjusted 
p 
SpO2  (%) PS 20 vs UnA 96 (2) vs 94 (4) 2 (1 to 4) 0.005 0.02 
 PS 20 vs PS 10 96 (2) vs 94 (2) 2 (0 to 3) 0.030 NS 
 PS 10 vs UnA 94 (2) vs 94 (4) 1 (-1 to 2) 0.48 NS 
 PS 20 vs Sham 96 (2) vs 92 (3) 5 (3 to 6) <0.001 <0.001 
 PS 10 vs Sham 94 (2) vs 92 (3) 3 (1 to 4) 0.001 0.002 
 Sham vs UnA 92 (3) vs 94 (4) -2 (-4 to -1) 0.004 0.012 
 
     
pH PS 20 vs UnA 7.421 (0.043) vs 7.379 (0.046) 0.039 (0.03 to 0.05) <0.001 <0.001 
 PS 20 vs PS 10 7.421 (0.043) vs 7.389 (0.040) 0.026 (0.01 to 0.04) 0.001 0.003 
 PS 10 vs UnA 7.389 (0.040) vs 7.379 (0.046) 0.013 (0 to 0.03) 0.087 NS 
 PS 20 vs Sham 7.421 (0.043) vs 7.374 (0.040) 0.047 (0.03 to 0.06) <0.001 <0.001 
 PS 10 vs Sham 7.389 (0.040) vs 7.374 (0.040) 0.021 (0.01 to 0.04) 0.012 0.048 
 Sham vs UnA 7.374 (0.040) vs 7.379 (0.046) -0.01 (-0.02 to 0.01) 0.33 NS 
 
     
PavCO2 (mmHg) PS 20 vs UnA 43.9 (6.0) vs 50.7 (7.2) -6.3 (-8.3 to -4.3) <0.001 0.001 
 PS 20 vs PS 10 43.9 (6.0) vs 47.8 (7.1) -3.4 (-5.4 to -1.4) 0.002 0.006 
 PS 10 vs UnA 47.8 (7.1) vs 50.7 (7.2) -2.9 (-4.9 to -0.9) 0.006 0.030 
 PS 20 vs Sham 43.9 (6.0) vs 50.3 (8.7) -6.8 (-8.9 to -4.7) <0.001 <0.001 
 PS 10 vs Sham 47.8 (7.1) vs 50.3 (8.7) -3.4 (-5.5 to -1.3) 0.003 0.012 
 Sham vs UnA 50.3 (8.7) vs 50.7 (7.2) -0.4 (-1.7 to 2.5) 0.68 NS 
 
     
VT (L) PS 20 vs UnA 0.45 (0.18) vs 0.32 (0.11) 0.13 (0.05 to 0.21) 0.004 0.008 
 PS 20 vs PS 10 0.45 (0.18) vs 0.38 (0.11) 0.07 (-0.01 to 0.15) 0.099 NS 
 PS 10 vs UnA 0.38 (0.11) vs 0.32 (0.14) 0.06 (-0.02 to 0.15) 0.145 NS 
 PS 20 vs Sham 0.45 (0.18) vs 0.30 (0.09) 0.16 (0.08 to 0.24) <0.001 <0.001 
 PS 10 vs Sham 0.38 (0.11) vs 0.30 (0.09) 0.09 (0.01 to 0.17) 0.034 NS 
 Sham vs UnA 0.30 (0.09) vs 0.32 (0.14) -0.03 (-0.11 to 0.06) 0.511 NS 
 
     
SpO2: oxygen saturation; PavCO2: arterialised venous carbon dioxide tension; VT: tidal volume (L); PS 20: pressure support 20 
cmH2O; UnA: unassisted exercise; PS 10: pressure support 10 cmH2O; Sham: sham pressure support; CI: confidence interval; 
Adjusted p: p value adjusted using a sharper Bonferroni correction (Hochberg, 1988); NS: not significant 
 
 
At isotime exercise, the linear mixed model analysis revealed that there was a difference between 
interventions with respect to SpO2, dyspnoea, RPE, RR and VT (Table 3.5).  Pairwise comparisons 
demonstrated that isotime SpO2 was higher during exercise with PS 20 compared with unassisted exercise 
and sham PS, and greater with PS 10 compared with sham PS.  Prior to the sharper Bonferroni adjustment 
(Hochberg, 1988) for multiple comparisons, isotime SpO2 was also greater with PS 10 compared with 
unassisted exercise (Figure 3.6a).  Isotime dyspnoea was reduced with PS 20 and PS 10 compared with 
sham PS.  Prior to the sharper Bonferroni adjustment (Hochberg, 1988), isotime dyspnoea was also lower 
with PS 20 compared with unassisted exercise (Figure 3.6b).  Isotime RPE was reduced with PS 20 
compared with unassisted exercise and sham PS.  Similarly, isotime RPE was lower with PS 10 compared 
with unassisted exercise, and prior to the sharper Bonferroni correction (Hochberg, 1988), was also 
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reduced compared with sham PS (Figure 3.6c).  Isotime RR was lower with PS 20 compared with 
unassisted exercise, sham PS and PS 10.  Prior to the adjustment for multiple comparisons, isotime RR 
was lower with PS 10 compared with unassisted exercise (Figure 3.6d).  Isotime VT was greater with PS 
20 compared with sham PS.  Prior to the sharper Bonferroni adjustment (Hochberg, 1988), a trend for 
higher VT  with PS 20 compared with unassisted exercise, and with PS 10 compared to sham PS was 
observed.  Mean differences and 95% CI are reported in Table 3.7.  There was no effect of test order on 
either of the physiological or subjective outcome measures. 
 
 
Table 3.7 Pairwise comparisons of unassisted exercise, exercise with sham pressure support, 
pressure support 10 cmH2O and pressure support 20 cmH2O at isotime for oxygen 
saturation, dyspnoea, rate of perceived exertion, respiratory rate and tidal volume 
 
 Comparison Mean (SD) vs Mean (SD) Mean difference  
 (95% CI) 
 
p Adjusted p 
SpO2  (%) PS 20 vs UnA 88 (5) vs 84 (7) 4 (1 to 7) 0.007 0.021 
 PS 20 vs PS 10 88 (5) vs 87 (5) 1 (-2 to 4) 0.45 NS 
 PS 10 vs UnA 87 (5) vs 84 (7) 3 (0 to 6) 0.041 NS 
 PS 20 vs Sham 88 (5) vs 82 (7) 6 (4 to 9) <0.001 <0.001 
 PS 10 vs Sham 87 (5) vs 82 (7) 5 (3 to 8) 0.001 0.002 
 Sham vs UnA 82 (7) vs 84 (7) -2 (-5 to 0) 0.112 NS 
 
     
Dyspnoea (Borg) PS 20 vs UnA 2.0 (2.2) vs 3.7 (2.7) -1.7 (-3.0 to -0.3) 0.018 NS 
 PS 20 vs PS 10 2.0 (2.2) vs 2.7 (1.8) -0.7 (-2.0 to 0.6) 0.31 NS 
 PS 10 vs UnA 2.7 (1.8) vs 3.7 (2.7) -1.0 (-2.3 to 0.4) 0.160 NS 
 PS 20 vs Sham 2.0 (2.2) vs 4.4 (2.6) -2.4 (-3.7 to -1.1) 0.001 0.001 
 PS 10 vs Sham 2.7 (1.8) vs 4.4 (2.6)  -1.7 (-3.0 to -0.4) 0.016 0.032 
 Sham vs UnA 4.4 (2.6) vs 3.7 (2.7) 0.7 (-0.6 to 2.0) 0.28 NS 
 
     
RPE (Borg) PS 20 vs UnA 2.8 (2.1) vs 4.5 (2.8) -1.8 (-3.1 to -0.5) 0.012 0.012 
 PS 20 vs PS 10 2.8 (2.1) vs 2.9 (2.2) -0.2 (-1.5 to 1.2) 0.82 NS 
 PS 10 vs UnA 2.9 (2.2) vs 4.5 (2.8) -1.6 (-2.9 to -0.3) 0.012 0.024 
 PS 20 vs Sham 2.8 (2.1) vs 4.5 ( 2.4) -1.7 (-3.0 to -0.4) 0.014 0.042 
 PS 10 vs Sham 2.9 (2.2) vs 4.5 ( 2.4) -1.6 (-2.9 to -0.3) 0.025 NS 
 Sham vs UnA 4.5 ( 2.4) vs 4.5 (2.8) 0 (-1.4 to 1.3) 0.96 NS 
 
     
RR (breaths/min) PS 20 vs UnA 34 (8) vs 42 (9) -8 (-11 to -5) <0.001 <0.001 
 PS 20 vs PS 10 34 (8) vs 38 (9) -4 (-7 to -1) 0.008 0.024 
 PS 10 vs UnA 38 (9) vs 42 (9) -4 (-7 to 0) 0.032 NS 
 PS 20 vs Sham 34 (8) vs 40 (10) -6 (-9 to -3) <0.001 <0.001 
 PS 10 vs Sham 38 (9) vs 40 (10) -2 (-5 to 1) 0.253 NS 
 Sham vs UnA 40 (10) vs 42 (9) -2 (-5 to 1) 0.272 NS 
 
     
VT (L) PS 20 vs UnA 0.54 (0.17) vs 0.46 (0.14) 0.08 (-0.01 to 0.16) 0.058 NS 
 PS 20 vs PS 10 0.54 (0.17) vs 0.48 (0.14) 0.06 (-0.02 to 0.13) 0.151 NS 
 PS 10 vs UnA 0.48 (0.14) vs 0.46 (0.14) 0.02 (-0.01 to 0.16) 0.588 NS 
 PS 20 vs Sham 0.54 (0.17) vs 0.41 (0.12) 0.13 (0.05 to 0.20) 0.002 0.002 
 PS 10 vs Sham 0.48 (0.14) vs 0.41 (0.12) 0.07 (-0.01 to 0.15) 0.059 NS 
 Sham vs UnA 0.41 (0.12) vs 0.46 (0.14) -0.05 (-0.13 to 0.03) 0.183 NS 
 
     
SpO2 : oxygen saturation; RPE: rate of perceived exertion (Borg); RR: respiratory rate; VT: tidal volume (L); PS 20 : pressure 
support 20 cmH2O; UnA: unassisted exercise; PS 10: pressure support 10 cmH2O; Sham: sham pressure support; CI: confidence 
interval; Adjusted p: p value adjusted using a sharper Bonferroni correction (Hochberg, 1988); NS: not significant 
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Figure 3.6 Comparison of unassisted exercise (UnA), exercise with sham pressure support (PS), 
pressure support 10 cmH2O (PS 10) and pressure support 20 cmH2O (PS 20) at 
isotime exercise for: a) oxygen saturation; b) dyspnoea; c) rate of perceived exertion; 
d) respiratory rate.  Group mean is shown for each intervention and the error bars 
represent 95% confidence intervals.  *: p < 0.05; †: p < 0.01 after the sharper Bonferroni 
correction (Hochberg, 1988);  * (light grey): p < 0.05 prior to the sharper Bonferroni 
correction (Hochberg, 1988) 
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At end exercise (where exercise endurance time varied between conditions), a linear mixed model analysis 
demonstrated that there was a difference between interventions with respect to VE, RR, VT, lactate, 
diastolic blood pressure (DBP) and mean arterial pressure (MAP) (Table 3.5).  Pairwise comparisons of 
the four interventions revealed that VE was greater at end exercise with PS 20 compared with sham PS.  
Prior to the sharper Bonferroni correction (Hochberg, 1988), VE was also greater with unassisted exercise 
compared with sham PS.  Respiratory rate at end exercise was lower with PS 20 (despite exercising for 
longer) and PS 10 compared with unassisted exercise, and was reduced with sham PS compared with 
unassisted exercise.  End exercise VT was greater with PS 20 compared with sham and unassisted 
exercise.  Prior to adjustment for multiple comparisons, VT was also greater with PS 10 compared with 
sham PS.  Lactate was higher at end exercise with PS 20 compared with sham PS.  Prior to the sharper 
Bonferroni correction (Hochberg, 1988), lactate was higher at end exercise with PS 20 compared with PS 
10 and unassisted exercise, higher with PS 10 compared with sham PS, and higher with unassisted 
exercise compared with sham PS.  Lastly, DBP and MAP were greater at end exercise with PS 20 
compared with sham PS, and were higher with unassisted exercise compared with sham PS.  Before 
adjustment for multiple comparisons, DBP and MAP were higher at end exercise with PS 10 compared 
with sham PS.  Mean differences and 95% CI are reported in Table 3.8.  The ratio of peak VE during 
unassisted exercise to MVV (VE/MVV) was a mean of 95 ± 49%.  Individual VE/MVV and percentage of 
predicted maximum heart rate (220 - age) achieved at peak unassisted exercise are displayed in Figure 3.7.   
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Table 3.8 Pairwise comparisons of unassisted exercise, exercise with sham pressure support, 
pressure support 10 cmH2O and pressure support 20 cmH2O at end exercise for 
minute ventilation, respiratory rate, tidal volume, lactate and blood pressure 
 
 Comparison Mean (SD) vs Mean (SD) Mean difference  
 (95% CI) 
 
p Adjusted 
p 
VE (L/min) PS 20 vs UnA 21.33 (5.29) vs 19.54 (6.33) 1.78 (-1.74 to 5.30) 0.31 NS 
 PS 20 vs PS 10 21.33 (5.29) vs 19.02 (4.06) 2.30 (-1.13 to 5.73) 0.18 NS 
 PS 10 vs UnA 19.02 (4.06) vs 19.54 (6.33) -0.52 (-4.04 to 3.00) 0.77 NS 
 PS 20 vs Sham 21.33 (5.29) vs 15.59 (2.72) 5.74 (2.31 to 9.17) 0.002 0.002 
 PS 10 vs Sham 19.02 (4.06) vs 15.59 (2.72) 3.44 (0.01 to 6.87) 0.05 NS 
 Sham vs UnA 15.59 (2.72) vs 19.54 (6.33) -3.96 (-7.47 to -0.44) 0.029 NS 
 
     
RR (breaths/min) PS 20 vs UnA 40 (9) vs 47 (10) -7 (-10 to -4) <0.001 <0.001 
 PS 20 vs PS 10 40 (9) vs 42 (11) -2 (-4 to 1) 0.21 NS 
 PS 10 vs UnA 42 (11) vs 47 (10) -5 (-8 to -3) <0.001 <0.001 
 PS 20 vs Sham 40 (9) vs 41 (10) -1 (-3 to 2) 0.70 NS 
 PS 10 vs Sham 42 (11) vs 41 (10) 1 (-2 to 4) 0.38 NS 
 Sham vs UnA 41 (10) vs 47 (10) -7 (-9 to -4) <0.001 <0.001 
 
     
VT (L) PS 20 vs UnA 0.57 (0.17) vs 0.47 (0.13) 0.10 (0.02 to 0.18) 0.016 0.032 
 PS 20 vs PS 10 0.57 (0.17) vs 0.51 (0.16) 0.06 (-0.01 to 0.14) 0.098 NS 
 PS 10 vs UnA 0.51 (0.16) vs 0.47 (0.13) 0.03 (-0.05 to 0.11) 0.39 NS 
 PS 20 vs Sham 0.57 (0.17) vs 0.42 (0.13) 0.15 (0.07 to 0.23) <0.001 <0.001 
 PS 10 vs Sham 0.51 (0.16) vs 0.42 (0.13) 0.09 (0.01 to 0.16) 0.029 NS 
 Sham vs UnA 0.42 (0.13) vs 0.42 (0.13) -0.05 (-0.13 to 0.03) 0.19 NS 
 
     
La (mmol/L) PS 20 vs UnA 2.0 (0.9) vs 1.7 (0.8) 0.4 (0.3 to 0.7) 0.035 NS 
 PS 20 vs PS 10 2.0 (0.9) vs 1.7 (0.5) 0.4 (0 to 0.7) 0.043 NS 
 PS 10 vs UnA 1.7 (0.5) vs 1.7 (0.8) 0 (-0.3 to 0.4) 0.93 NS 
 PS 20 vs Sham 2.0 (0.9) vs 1.3 (0.4) 0.7 (0.4 to 1.1) <0.001 <0.001 
 PS 10 vs Sham 1.7 (0.5) vs 1.3 (0.4) 0.4 (0 to 0.7) 0.035 NS 
 Sham vs UnA 1.3 (0.4) vs 1.7 (0.8) -0.4 (-0.7 to -0) 0.043 NS 
 
     
DBP (mmHg) PS 20 vs UnA 93 (11) vs 90 (11) 3 (-1 to 7) 0.17 NS 
 PS 20 vs PS 10 93 (10.5) vs 90 (10) 4 (0 to 8) 0.063 NS 
 PS 10 vs UnA 90 (10) vs 90 (11) -1 (-5 to 3) 0.64 NS 
 PS 20 vs Sham 93 (11) vs 85 (13) 9 (5 to 13) <0.001 <0.001 
 PS 10 vs Sham 90 (10) vs 85 (13) 5 (1 to 9) 0.025 NS 
 Sham vs UnA 85 (13) vs 90 (11) -6 (-10 to -2) 0.009 0.018 
 
     
MAP (mmHg) PS 20 vs UnA 112 (12) vs 113 (13) 0 (-5 to 4) 0.88 NS 
 PS 20 vs PS 10 112 (12) vs 110 (12) 3 (-2 to 7) 0.27 NS 
 PS 10 vs UnA 110 (12) vs 113 (13) -3 (-8 to 2) 0.22 NS 
 PS 20 vs Sham 112 (12) vs 105 (14) 7 (3 to 12) 0.003 0.006 
 PS 10 vs Sham 110 (12) vs 105 (14) 5 (0 to 10) 0.042 NS 
 Sham vs UnA 105 (14) vs 113 (13) -8 (-13 to -3) 0.002 0.002 
 
     
VE: minute ventilation (L/min); RR: respiratory rate; VT: tidal volume (L); La: lactate (mmol/L); DBP: diastolic blood pressure 
(mmHg); MAP: mean arterial pressure (mmHg); PS 20: pressure support 20 cmH2O; UnA: unassisted exercise; PS 10: pressure 
support 10 cmH2O; Sham: sham pressure support; CI: confidence interval; Adjusted p: p value adjusted using a sharper 
Bonferroni correction (Hochberg, 1988); NS: not significant 
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Figure 3.7 Group and individual data for unassisted exercise peak minute ventilation (VE) to 
maximum voluntary ventilation (MVV) ratio (VE/MVV) and percent predicted 
maximum heart rate (HRmax) achieved at peak unassisted exercise (n = 11).  
Individual VE/MVV data points above the dashed line at 80% indicate a limited 
respiratory reserve at peak unassisted exercise.  Error bars represent standard deviation 
 
 
For the change from baseline to end exercise (where exercise endurance time varied between 
interventions), the linear mixed model analysis demonstrated that there was a difference between 
unassisted exercise, exercise with sham PS, PS 10 and PS 20 with respect to rate of perceived exertion, 
RR, pH, PavCO2, lactate, systolic blood pressure (SBP), DBP and MAP (Table 3.5).  Pairwise 
comparisons of the four interventions revealed that the change in RPE was greater with PS 20 compared 
with sham PS.  The change in RR from baseline to end exercise was significantly lower with sham PS 
compared with unassisted exercise.  Despite exercising for longer with PS 20, there was no difference in 
the change in RR compared with unassisted exercise, sham PS and PS 10.  Arterialised venous pH 
decreased to a greater extent with PS 20 during walking compared with unassisted exercise, sham PS and 
PS 10, and a greater increase in PavCO2 occurred when PS 20 was used during exercise compared with 
VE/MVV 
(Mean) 
HRpeak/HRmax 
(Mean) 
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unassisted exercise and sham PS.  In addition, change in blood lactate was significantly higher with PS 20 
compared with sham PS, and a trend for a greater change in lactate with PS 20 compared to unassisted 
exercise was observed.  Lastly, changes in blood pressure were greater with PS 20 and unassisted exercise 
compared with sham PS.  Mean differences and 95% CI are reported in Table 3.9. 
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Table 3.9 Pairwise comparisons of walking unassisted, with sham pressure support, pressure 
support 10 cmH2O and pressure support 20 cmH2O for the change from baseline to 
end exercise for rate of perceived exertion, respiratory rate, pH, partial pressure of 
carbon dioxide, lactate and blood pressure 
 
 Comparison Mean change (SD) vs mean change (SD) Mean difference   
  (95% CI) 
 
p Adjusted 
p 
RPE (Borg) PS 20 vs UnA 6.4 (2.8) vs 5.7 (2.7) 0.7 (-0.8 to 2.1) 0.38 NS 
 PS 20 vs PS 10 6.4 (2.8) vs 4.8 (2.5) 1.6 (0.2 to 3.1) 0.035 NS 
 PS 10 vs UnA 4.8 (2.5) vs 5.7 (2.7) -1.0 (-2.4 to 0.5) 0.20 NS 
 PS 20 vs Sham 6.4 (2.8) vs 4.4 (2.3) 2.0 (0.5 to 3.4) 0.011 0.011 
 PS 10 vs Sham 4.8 (2.5) vs 4.4 (2.3) 0.3 (-1.1 to 1.8) 0.64 NS 
 Sham vs UnA 4.4 (2.3) vs 5.7 (2.7) -1.3 (-2.8 to 0.1) 0.084 NS 
 
     
RR (breaths/min) PS 20 vs UnA 14.8 (5.9) vs 17.8 (7.7) -3.1 (-7.4 to 1.2) 0.17 NS 
 PS 20 vs PS 10 14.8 (5.9) vs 13.9 (7.5) 0.8 (-3.3 to 5.0) 0.70 NS 
 PS 10 vs UnA 13.9 (7.5) vs 17.8 (7.7) -3.9 (-8.2 to 0.3) 0.081 NS 
 PS 20 vs Sham 14.8 (5.9) vs 11.0 (6.0) 3.4 (-0.4 to 7.9) 0.086 NS 
 PS 10 vs Sham 13.9 (7.5) vs 11.0 (6.0) 2.9 (-1.2 to 7.1) 0.18 NS 
 Sham vs UnA 11.0 (6.0) vs 17.8 (7.7) -6.8 (-11.1 to 2.6) 0.004 0.004 
 
     
pH PS 20 vs UnA -0.059 (0.040) vs -0.024 (0.027) -0.04 (-0.05 to -0.02) 0.001 0.002 
 PS 20 vs PS 10 -0.059 (0.040) vs -0.033 (0.027) -0.03 (-0.04 to -0.01) 0.008 0.024 
 PS 10 vs UnA -0.033 (0.027) vs -0.024 (0.027) -0.01 (-0.03 to 0.01) 0.34 NS 
 PS 20 vs Sham -0.059 (0.040) vs -0.015 (0.022) -0.05 (-0.06 to -0.03) <0.001 <0.001 
 PS 10 vs Sham -0.033 (0.027) vs -0.015 (0.022) -0.02 (-0.04 to 0) 0.062 NS 
 Sham vs UnA -0.015 (0.022) vs -0.024 (0.027) 0.010 (-0.01 to 0.03) 0.32 NS 
 
     
PavCO2 (mmHg) PS 20 vs UnA 7.2 (5.9) vs 3.1 (4.7) 4.1 (1.3 to 6.9) 0.005 0.005 
 PS 20 vs PS 10 7.2 (5.9) vs 5.8 (3.7) 1.5 (-1.3 to 4.3) 0.30 NS 
 PS 10 vs UnA 5.8 (3.7) vs 3.1 (4.7) 2.7 (-0.1 to 5.5) 0.062 NS 
 PS 20 vs Sham 7.2 (5.9) vs 2.5 (4.5) 4.3 (1.3 to 7.2) 0.006 0.012 
 PS 10 vs Sham 5.8 (3.7) vs 2.5 (4.5) 2.8 (-0.1 to 5.8) 0.060 NS 
 Sham vs UnA 2.5 (4.5) vs 3.1 (4.7) -0.2 (-3.1 to 2.8) 0.91 NS 
 
     
La (mmol/L) PS 20 vs UnA 0.9 (0.7) vs 0.6 (0.6) 0.3 (0 to 0.6) 0.087 NS 
 PS 20 vs PS 10 0.9 (0.7) vs 0.6 (0.4) 0.3 (0 to 0.6) 0.097 NS 
 PS 10 vs UnA 0.6 (0.4) vs 0.6 (0.6) 0 (-0.3 to 0.3) 0.96 NS 
 PS 20 vs Sham 0.9 (0.7) vs 0.5 (0.4) 0.5 (0.2 to 0.8) 0.006 0.006 
 PS 10 vs Sham 0.6 (0.4) vs 0.5 (0.4) 0.2 (-0.1 to 0.5) 0.20 NS 
 Sham vs UnA 0.5 (0.4) vs 0.6 (0.6) -0.2 (-0.5 to 0.1) 0.22 NS 
 
     
SBP (mmHg) PS 20 vs UnA 32 (17) vs 35 (26) -2 (-11 to 7) 0.66 NS 
 PS 20 vs PS 10 32 (17) vs 27 (16) 5 (-3 to 14) 0.23 NS 
 PS 10 vs UnA 27 (16) vs 35 (26) -7 (-16 to 1) 0.108 NS 
 PS 20 vs Sham 32 (17) vs 20 (20) 12 (4 to 21) 0.009 0.018 
 PS 10 vs Sham 27 (16) vs 20 (20) 7 (-2 to 15) 0.135 NS 
 Sham vs UnA 20 (20) vs 35 (26) -14 (-23 to -5) 0.003 0.003 
 
     
DBP (mmHg) PS 20 vs UnA 8 (9) vs 4 (7) 4 (-1 to 9) 0.139 NS 
 PS 20 vs PS 10 8 (9) vs 3 (4) 5 (0 to 11) 0.060 NS 
 PS 10 vs UnA 3 (4) vs 4 (7) -1 (-6 to 4) 0.67 NS 
 PS 20 vs Sham 8 (9) vs -4 (8) 12 (7 to 17) <0.001 <0.001 
 PS 10 vs Sham 3 (4) vs -4 (8) 7 (1 to 12) 0.020 NS 
 Sham vs UnA -4 (8) vs 4 (7) -8 (-13 to -2) 0.007 0.014 
 
     
MAP (mmHg) PS 20 vs UnA 16 (10) vs 13 (12) 3 (-3 to 8) 0.31 NS 
 PS 20 vs PS 10 16 (10) vs 11 (8) 5 (0 to 11) 0.068 NS 
 PS 10 vs UnA 11 (7.9) vs 13 (12) -2 (-8 to 3) 0.40 NS 
 PS 20 vs Sham 16 (10) vs 4 (10) 12 (6 to 17) <0.001 <0.001 
 PS 10 vs Sham 11 (8) vs 4 (10) 7 (1 to 12) 0.024 NS 
 Sham vs UnA 4 (10) vs 13 (12) -9 (-15 to -4) 0.003 0.006 
 
   
  
RPE: rate of perceived exertion (Borg); RR: respiratory rate; PavCO2: arterialised venous carbon dioxide tension; La: lactate 
(mmol/L); SBP: systolic blood pressure (mmHg); DBP: diastolic blood pressure (mmHg); MAP: mean arterial pressure (mmHg); 
PS 20: pressure support 20 cmH2O, UnA: unassisted exercise; PS 10: pressure support 10 cmH2O; Sham: sham pressure support; 
CI: confidence interval; Adjusted p: p value adjusted using a sharper Bonferroni correction (Hochberg, 1988); NS: not significant 
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After completion of the endurance treadmill tests, participants selected the test that they felt was the 
easiest to perform prior to test order being disclosed.  The easiest test to perform coincided with the test in 
which the greatest endurance time was achieved in 12/13 (92%) participants (PS 20: n = 11; PS 10: n = 1).  
One participant selected unassisted exercise as the easiest test despite walking longer with PS 20.  Group 
VAS scores for the amount that PS helped during exercise and the effect of PS during exercise on 
breathlessness are shown in Figure 3.8.  A repeated measures ANOVA revealed that there was a 
difference between exercise with sham PS, PS 10 and PS 20 with respect to “help during exercise” and 
“breathlessness”.  Pairwise comparisons between the three interventions are displayed in Table 3.10.  
During unassisted exercise, shortness of breath was the primary cause of exercise cessation in 10/13 
participants while no participants ceased exercise due to leg muscle fatigue. In contrast, 6/13 participants 
stopped exercise due to shortness of breath and 5/13 due to leg muscle fatigue during exercise with PS 20 
(Figure 3.9).   
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Figure 3.8 Visual analogue scale scores representing the effect of sham pressure support (PS), pressure support 10 cmH2O (PS 10) 
and pressure support 20 cmH2O (PS 20) on: a) “help during exercise”; b) “breathlessness during exercise”.  Mean scores 
are presented and the whiskers represent standard deviation.  Scores above the horizontal dashed line at 50% represent an 
advantage relative to unassisted walking, and scores below the dashed line represent a disadvantage relative to unassisted 
walking.   *: p < 0.05; †: p < 0.01; ‡: p < 0.001;  * (light grey): p < 0.05 prior to the sharper Bonferroni correction (Hochberg, 
1988)
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Table 3.10 Pairwise comparisons of walking with sham pressure support, pressure support 10 
cmH2O and pressure support 20 cmH2O for “help during exercise” and 
“breathlessness” 
 
 Comparison Mean (SD) vs Mean (SD) Mean difference  
 (95% CI) 
 
p Adjusted p 
Help during exercise PS 20 vs PS 10 73.6 (21.0) vs 54.3 (24.4) 19.3 (2.7 to 35.9) 0.026 NS 
 PS 20 vs Sham 73.6 (21.0) vs 36.0 (22.0) 37.6 (25.7 to 49.5) <0.001 <0.001 
 PS 10 vs Sham 54.3 (24.4) vs 36.0 (22.0) 18..3 (3.5 to 33.0) 0.019 0.038 
 
     
Breathlessness PS 20 vs PS 10 74.7 (20.5) vs 64.8 (17.9) 9.8 (-2.1 to 21.8) 0.097 NS 
 PS 20 vs Sham 74.7 (20.5) vs 40.9 (17.1) 33.8 (19.4 to 48.1) <0.001 <0.001 
 PS 10 vs Sham 64.8 (17.9) vs 40.9 (17.1) 23.9 (10.4 to 37.4) 0.002 0.004 
 
     
Data are presented as a percentage of the 10 cm visual analogue scale.  Zero represents no help during exercise and no reduction 
in breathlessness.  One hundred represents maximum help during exercise and maximum reduction in breathlessness.  PS 20: 
pressure support 20 cmH2O; UnA: PS 10: pressure support 10 cmH2O; Sham: sham pressure support; CI: confidence interval; 
Adjusted p: p value adjusted using a sharper Bonferroni correction (Hochberg, 1988); NS: not significant  
 
 
 
 
 
 
Figure 3.9 Relative proportion of participants (n = 13) who ceased exercise primarily due to leg 
muscle (mm) fatigue, shortness of breath and leg muscle fatigue (SOB + leg mm 
fatigue), shortness of breath alone (SOB) or oxygen (O2) desaturation below 75% for 
unassisted exercise (UnA), exercise with sham pressure support (Sham PS), pressure 
support 10 cmH2O (PS 10) and pressure support 20 cmH2O (PS 20)  
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Relationship between the Response to Pressure Support 20 cmH2O during Exercise and Baseline 
Respiratory Function or Exercise Variables 
The response to PS 20 was defined as the percentage change in endurance time with PS 20 compared with 
unassisted exercise.  The relationship between the response to PS 20 during exercise and several baseline 
respiratory function variables was unremarkable: VC (rS = -0.189,  p = 0.56); PImax1.0 (rS = -0.289, p = 
0.34); MVV (rS = -0.332, p = 0.27).  The relationship between VE/MVV during unassisted walking and the 
response to PS 20 during exercise is displayed in Figure 3.10.  While a significant relationship was not 
observed (Spearman’s rho 0.391, p = 0.24), investigation of individual data suggests that the majority of 
participants with a peak VE/MVV >80% during unassisted exercise had an improvement in endurance 
time of greater than 50% with PS 20.  A moderately strong inverse correlation was found between the 
change in endurance time and the change in isotime dyspnoea with PS 20 during walking compared with 
unassisted exercise (Spearman’s rho -0.651, p = 0.016, Figure 3.11).   
 
 
 
 
Figure 3.10 Change in endurance time while walking with pressure support 20 cmH2O 
compared with walking unassisted versus the ratio of peak minute ventilation during 
unassisted exercise to maximum voluntary ventilation (VE/MVV) (n = 11).   Vertical 
dashed line = VE/MVV 80%. Horizontal dashed line = 50% increase in endurance time  
rS = 0.39 
p  = 0.24 
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Figure 3.11 Relationship between the change in isotime dyspnoea (Borg scale) and the change in 
endurance time (%) with pressure support 20 cmH2O during walking compared 
with unassisted exercise.  rS: Spearman’s rho 
 
 
Validity of arterialised venous blood gas analysis for measurement of arterial pH and partial 
pressure of carbon dioxide  
Simultaneous samples of arterialised venous blood and arterial blood were taken from seven participants.  
Participant characteristics are displayed in Table 3.11.  Skin temperature adjacent to the cannula used to 
sample arterialised venous blood was maintained at a mean of 43.8 ± 1.0 °C.  A very strong correlation 
was found between measurements of arterial pH and arterialised venous pH (ICC 3,1 .983) within a pH 
range of 7.34 to 7.43, and between arterial PCO2 and arterialised venous PCO2 (ICC 3,1 .959) within a 
PCO2 range of 46 mmHg to 62 mmHg.  Mean arterial pH was 7.39 ± 0.03, and mean arterialised venous 
pH was 7.37 ± 0.03.  The mean difference between arterialised venous and arterial pH was 0.01 (95% CI 
0.01 to 0.02), indicating that a systematic bias of -0.01 pH units is associated with measurement of 
arterialised venous pH.  This is demonstrated on a Bland Altman plot (Bland & Altman, 1986) (Fig 3.12).  
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Mean arterial PCO2 was 51.6 ± 5.6 mmHg, and mean arterialised venous PCO2 was 52.2 ± 5.6 mmHg.  
The mean difference between arterial and arterialised venous PCO2 was -0.7 mmHg (95% CI -2.0 to 0.6).  
There was no systematic bias associated with arterialised venous measurement of PCO2 as demonstrated 
on a Bland Altman plot (Bland & Altman, 1986) (Fig 3.13). 
 
 
 
 
 
 
 
Table 3.11 Subgroup participant characteristics 
 
 
  (n = 7) 
Value 
 
Percent predicted 
  Age (yrs) 59 ± 4.2  
  F/M 4/3  
  Height (m) 1.47 ± 0.13  
  Armspan (m) 1.68 ± 0.18  
  BMI (kg.m-2) 24.0 ± 5.3  
Pulmonary function 
  
  FEV1 (L) 0.53 ± 0.13 20 ± 6 
  FVC (L) 0.64 (0.62 - 0.87) 22 ± 8 
  FEV1/FVC % 75 ± 16  
  PImax1.0 (cmH2O) -36 ± 21 47 ± 23 
  PEmax1.0 (cmH2O) 85 ± 52 75 ± 35 
  TLC (L) 1.743 (1.566 - 2.160) 37 ± 17 
  VC (L) 0.890 (0.405 - 0.890) 24 ± 9 
  FRC (L) 1.420 (1.051 - 1.520) 49 ± 28 
  IC (L)  0.594 ± 0.325 24 ± 11 
  RV (L) 0.970 (0.757 - 1.370) 61 ± 38 
   
Data are presented as mean ± SD or median (interquartile range).  F/M: female/male; BMI: body mass index; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; PImax1.0: maximal inspiratory mouth occlusion pressure sustained for 
one second; PEmax1.0: maximal expiratory mouth occlusion pressure sustained for one second; TLC: total lung capacity; VC: vital 
capacity; FRC: functional residual capacity; IC: inspiratory capacity; RV: residual volume 
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Figure 3.12 Bland Altman plot for pH.  The mean of arterialised venous and arterial pH are plotted 
against the mean difference between arterialised venous and arterial pH.  The dashed line 
represents the level of systematic bias that was associated with measurement of 
arterialised venous pH 
 
 
 
 
 
 
 
 
        
Figure 3.13 Bland Altman plot for the partial pressure of carbon dioxide (PCO2).  The mean of 
arterialised venous and arterial PCO2 are plotted against the mean difference between 
arterialised venous and arterial PCO2.  There was no systematic bias associated with 
measurement of arterialised venous PCO2 
 
(mmHg) 
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DISCUSSION 
The main finding of the present study was that high level PS (PS 20 cmH2O) during treadmill walking 
significantly increased exercise endurance time compared with walking unassisted, with sham PS and with 
low level PS (PS 10) in people with severe kyphoscoliosis.  Endurance time was also increased with PS 10 
compared to sham PS.  There was no difference in endurance time between walking with low level PS and 
unassisted exercise, or walking with sham PS compared with unassisted exercise.  High level PS during 
walking also reduced isotime RR, RPE and dyspnoea, and improved SpO2 compared with walking 
unassisted.  The secondary finding was that analysis of arterialised venous pH and PavCO2 was very 
strongly correlated to arterial pH and PaCO2 in people with severe kyphoscoliosis and chronic HRF, and 
therefore could be used as a surrogate measure of arterial pH and PaCO2 in situations where arterial access 
is difficult or repeated samples are required. 
 
Effect of high and low level pressure support during walking on endurance time 
The current study is the first double blind, randomised, crossover study to examine the effects of different 
levels of PS during exercise in people with severe kyphoscoliosis.  Of the few studies that report the 
effects of PS during exercise in people with severe chest wall restriction, high level PS appears to be a 
common feature of those studies that demonstrate an improvement in exercise performance compared with 
unassisted exercise (Borel et al, 2008; Tsuboi et al, 1997).  Whereas the one study that used low level PS 
during exercise reported a negative effect on exercise endurance (Highcock et al, 2002).  The advantage of 
the present study is that the effect of both high and low level PS during exercise was examined in the same 
subjects.  Furthermore, both participants and assessors were blinded to the level of PS provided during 
exercise thereby reducing the risk of bias. 
 
The finding that PS 20 during treadmill walking improved endurance time is consistent with other studies 
that have found that similar or higher levels of PS (19-37 cmH2O) during cycling exercise increased 
endurance time compared to unassisted exercise in individuals with chronic HRF, primarily due to 
kyphoscoliosis (Borel et al, 2008), or pulmonary tuberculosis sequalae (Tsuboi et al, 1997).  In the present 
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study, treadmill exercise was performed rather than cycling exercise as treadmill walking closely 
resembles a functional daily activity.  However walking is more likely to be limited by breathlessness 
(Man et al, 2003), and a greater degree of oxygen desaturation tends to occur in comparison to cycling 
exercise, as has been shown in people with COPD (Turner et al, 2004).  Therefore the finding that high 
level PS improves treadmill walking endurance time may be important when considering the specificity of 
training for a functional task such as walking. 
 
The finding that PS 10 did not increase exercise endurance time compared with unassisted exercise is 
consistent with the study of Highcock et al (2002) who also found that low level PS during treadmill 
walking did not improve distance walked compared with unassisted exercise in eight people with severe 
scoliosis.  Augmentation of VT varies with pressure preset ventilation and depends on a number of factors 
including respiratory system compliance (Mehta & Hill, 2001).  As chest wall compliance is greatly 
reduced in people with severe kyphoscoliosis (Grassi & Tantucci, 1993), high inflationary pressures may 
be required to achieve an adequate VT and to unload the respiratory muscles.  Respiratory muscle 
unloading appears crucial for NIV to be of benefit during exercise in people with COPD (Maltais et al, 
1995) and therefore, relatively low levels of PS during exercise may not unload the respiratory muscles 
sufficiently to assist exercise performance in individuals with severe kyphoscoliosis and reduced chest 
wall compliance.  
 
While the combination of NIV and O2 during exercise has previously been shown to improve endurance 
time above that of NIV or O2 alone during exercise in patients with severe chest wall restriction secondary 
to post tuberculosis sequelae (Tsuboi et al, 1997), no consistent effect on endurance time was observed in 
the three subjects who used supplemental O2 in the present study.  For example, the change in endurance 
time with PS 20 plus O2 compared to unassisted exercise with O2 ranged between -37% and 90% for these 
individuals, which spanned the results from the whole group (Figure 3.11).  However, a larger sample size 
would be required to draw definitive conclusions about the effect of PS plus O2 during exercise in people 
with severe kyphoscoliosis. 
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Potential mechanisms of benefit of high level pressure support during exercise 
The mechanisms by which PS 20 increased exercise endurance time may relate to the improvement in 
breathing pattern and oxygenation, and the reduction in dyspnoea and RPE that were demonstrated, which 
is in keeping with previous literature (Vila et al, 2007).  One striking effect of PS 20 during exercise was 
the marked reduction in RR at isotime compared with sham PS, PS 10 and unassisted exercise.  Despite 
exercising for longer with PS 20 compared with unassisted exercise, the reduction in RR of almost eight 
breaths per minute at isotime was also maintained at end exercise.  Interestingly, only a small increase in 
VT was observed with PS 20 compared to unassisted exercise, such that overall isotime VE did not 
significantly change. Nonetheless, by adopting a more efficient pattern of breathing, dead space 
ventilation would be reduced and gas exchange improved (Vila et al, 2007). 
 
Isotime SpO2 was higher with PS 20, and to a lesser extent with PS 10, compared with unassisted exercise 
and sham PS.  Consequently, increased O2 delivery to the peripheral muscles may have contributed to the 
improved performance with PS 20.  It was surprising that isotime SpO2 was higher with PS 20 compared 
with unassisted exercise despite the marked fall in RR, small rise in VT, and small fall in VE that was 
observed with PS 20.  However, even though VE was higher during unassisted exercise, dead space 
ventilation was also likely to be higher due to the faster RR and therefore alveolar ventilation may not 
have increased as might have been expected.  Also, no consistent pattern was observed between individual 
changes in VE and isotime SpO2, suggesting that factors other than an increase in VE contributed to the 
improvement in isotime SpO2 with PS 20 in some individuals.  A major improvement in ventilation-
perfusion matching is an unlikely explanation, although the short term effect of PS on ventilation-
perfusion matching has not been assessed in severe kyphoscoliosis.  It is possible that PS 20 unloaded the 
respiratory muscles and reduced the O2 cost of breathing (VO2resp) compared with unassisted exercise 
resulting in a higher SpO2 at isotime.  The VO2resp can represent a substantial proportion of total oxygen 
consumption in patients with cardiorespiratory disease (Field et al, 1982).  In severe COPD, NIV has been 
shown to unload the respiratory muscles during exercise (Kyroussis et al, 2000; Maltais et al, 1995).  
Whether the same effect occurs in severe kyphoscoliosis remains to be demonstrated.  Finally, despite 
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endurance time being greater with PS 20, there was no difference in end exercise SpO2 between 
interventions, indicating that participants performed more exercise with PS 20 before reaching the same 
level of oxygen desaturation.  The detrimental effects of decreased O2 supply to exercising muscle have 
been demonstrated in patients with chronic respiratory failure (Thompson et al, 1993).  Consequently, 
better oxygenation may have contributed to the improvement in performance with PS 20.   
  
People with severe kyphoscoliosis and chronic HRF develop a combined respiratory and metabolic 
acidosis during exercise (Vila et al, 2007), which could impair respiratory muscle function (Jonville et al, 
2002; Juan et al, 1984).  Vila and colleagues (2007) found that PS 15 cmH2O during cycling decreased the 
extent of exercise induced hypercapnia and respiratory acidosis as determined by arterial blood gas 
analysis in people with severe kyphoscoliosis.  In a subgroup of participants arterialised venous pH and 
PavCO2 levels were shown to correlate very highly (ICC .98 and .96 respectively) with arterial pH and 
PaCO2.  The mean differences found between samples of arterialised venous blood and arterial blood of    
-0.01 pH units, and 0.7 mmHg of CO2 were similar to previously reported differences of -0.005 pH units 
and 1.0 mmHg of CO2 (Forster et al, 1972).  Thus analysis of pH and PavCO2 from arterialised venous 
blood did appear to be a valid surrogate measure of arterial pH and PaCO2 within the range of 7.34 to 7.43 
pH units and 46 to 62 mmHg for CO2 in these individuals with severe kyphoscoliosis.  Group mean pH 
and PCO2 values at rest and end exercise were generally within this range.  These results should be 
confirmed however in a larger population and with a wider pH and PaCO2 range.  While measurement of 
isotime arterialised venous pH and PavCO2 was not feasible in the present study, end exercise pH and 
PavCO2 were no worse with PS 20 compared with the other three interventions despite having exercised 
for longer with PS 20.  This suggests that PS 20 delayed the development of exercise induced hypercapnia 
compared with unassisted exercise, consistent with the findings of Vila and colleagues (2007).  At end 
exercise, blood lactate was higher with PS 20 compared with sham PS, and tended to be greater than 
unassisted exercise or with PS 10.  This is likely to be a reflection of the longer endurance time associated 
with PS 20 compared with other interventions.  In addition, higher blood lactate at end exercise with PS 
20 indicates that participants were exercising at a high intensity.  As high intensity exercise may induce 
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greater training benefits (Casaburi et al, 1991), PS 20 could have a role as an adjunct to exercise training 
in people with severe kyphoscoliosis.  
 
Although detailed assessment of the effect of PS during exercise on the cardiovascular system was beyond 
the scope of the present study, one potential side effect of high level PS is a reduction in venous return 
which may also decrease cardiac output.  In the present study, there was no change in HR at isotime 
exercise between interventions, and end exercise MAP was not reduced with PS 20 compared with sham 
PS, PS 10 or unassisted exercise suggesting no observable detrimental cardiovascular effects of high level 
PS occurred.  However, a previous study showed that people with thoracic scoliosis develop exercise 
induced pulmonary hypertension inversely proportional to VC, FRC and TLC (Shneerson, 1978a).  
Subjects in the present study had significantly reduced static lung volumes and may have been at risk of 
developing severe exercise induced pulmonary hypertension.  In COPD, pulmonary hypertension limits 
stroke volume during exercise (Holverda et al, 2009) and has a detrimental effect on exercise capacity 
(Sims et al, 2009).  While long term nocturnal NIV was found to reduce pulmonary hypertension in people 
with severe restrictive thoracic disorders (Schonhofer et al, 2001a), presumably through the reversal of 
hypoxaemia and hypercapnia, the acute effect of high level PS on the development of exercise induced 
pulmonary hypertension and the resultant effect on stroke volume and exercise tolerance is unknown in 
patients with severe kyphoscoliosis but may warrant investigation. 
 
Another potential benefit of improved oxygenation during exercise in people with severe kyphoscoliosis is 
to minimise pulmonary hypoxic vasoconstriction.  Exercise induced pulmonary hypertension has been 
documented in people with thoracic scoliosis and is inversely proportional to TLC, VC and FRC 
(Shneerson, 1978a).  The participants in the present study had severely reduced lung volumes at 35%, 
23% and 46% predicted for TLC, VC and FRC respectively and therefore would be at risk of significant 
exercise induced pulmonary hypertension.  People with severe kyphoscoliosis also desaturate markedly 
during exercise (Meecham Jones et al, 1995a).  Theoretically, O2 desaturation could lead to hypoxic 
vasoconstriction of the pulmonary vasculature which in turn could worsen pulmonary hypertension.  
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Interestingly, the addition of 100% O2 during exercise had little effect on the development of pulmonary 
hypertension in subjects with thoracic scoliosis and no correlation was found between PaO2 and 
pulmonary artery pressure (Shneerson, 1978a).  It appeared that the effect of structural abnormalities of 
the pulmonary vasculature in people with congenital scoliosis were more important than hypoxic 
vasoconstriction in the development of exercise induced pulmonary hypertension in these subjects 
(Shneerson, 1978a).  However, a wide range of disease severities were tested and the extent of O2 
desaturation during exercise was not reported.  Whether the use of PS 20 or supplemental O2 during 
exercise can reduce the role of hypoxic vasoconstriction in the development of exercise induced 
pulmonary hypertension in people with severe O2 desaturation during exercise is unclear. 
 
Subjective responses to PS during exercise largely reflected the physiological responses to PS during 
exercise.  By reducing unpleasant symptoms such as breathlessness and perceived exertion, PS 20 enabled 
participants to tolerate exercise for longer.  Isotime dyspnoea was reduced by both PS 20 and PS 10 
compared with sham PS.  Pressure support 20 cmH2O also reduced isotime dyspnoea by a mean of almost 
two points on the Borg scale compared with unassisted exercise.  The reduction in isotime dyspnoea 
appeared to be an important mechanism influencing the response to PS 20 during exercise.  A moderate 
inverse relationship was found between the change in isotime dyspnoea and the change in walking 
endurance time with PS 20 compared with unassisted exercise (Figure 3.11), whereby those subjects with 
the greatest reduction in dyspnoea tended to have the greatest increase in endurance time with PS 20.  
Knowledge of this relationship may assist clinicians to titrate optimal, individualised high levels of PS 
during walking in people with severe kyphoscoliosis in order to maximise the response to PS during 
exercise.  There was no difference in dyspnoea between interventions at end exercise despite participants 
exercising for longer with PS 20.  In contrast, PS 10 did not reduce dyspnoea compared with unassisted 
exercise.  This may explain, in part, the difference in results between exercise with PS 20 and exercise 
with PS 10 when compared to unassisted exercise.  
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An important effect of NIV during exercise in patients with stable COPD is the alleviation of  
dyspnoea in proportion to respiratory muscle unloading (Kyroussis et al, 2000; Maltais et al, 1995).  The 
only study that examined respiratory muscle unloading during exercise in people with kyphoscoliosis was 
a pilot study performed by Poggi and associates (Poggi et al, 2006) where NIV during arm elevation was 
found to reduce the pressure time product of the diaphragm compared with unassisted breathing in eight 
people with COPD, two of whom had concomitant kyphoscoliosis.  While transdiaphragmatic pressure 
was not measured, PS 20 did reduce isotime dyspnoea compared with unassisted exercise which suggests 
that respiratory muscle unloading did occur.  Nonetheless, confirmation of this potentially important 
mechanism is required in people with severe kyphoscoliosis.  Breathlessness is usually the symptom that 
limits exercise in people with severe kyphoscoliosis.  The reduction in breathlessness during exercise may 
explain why participants could exercise for longer with PS 20.  Indeed, almost half of the participants 
stopped exercise with PS 20 due to leg muscle fatigue rather than breathlessness (Fig 3.9).  This suggests 
that the reduction in breathlessness allowed a greater amount of work to be performed by the locomotor 
muscles, to the point of fatigue in some cases, which may be important during exercise training.  
 
The relationship between high respiratory muscle work and blood flow to, and fatigue of, the locomotor 
muscles has been examined in healthy subjects (Harms et al, 1997) and in people with COPD (Borghi-
Silva et al., 2008).  During sustained high intensity exercise in competitive cyclists, high level respiratory 
muscle work reduced blood flow to exercising limb muscles (Harms et al, 1997) and decreased exercise 
endurance time (Harms et al, 2000).  When respiratory muscle work was reduced by using proportional 
assist ventilation (PAV) during cycling, endurance time was increased, perception of dyspnoea and leg 
muscle effort decreased (Harms et al, 2000) and locomotor muscle blood flow increased (Harms et al, 
1997) compared with control interventions.  Similarly, in patients with advanced COPD, unloading of the 
respiratory muscles with PAV during high intensity cycling was shown to prolong exercise endurance 
time, increase locomotor muscle oxygenation and blood volume compared with sham ventilation (Borghi-
Silva et al, 2008).  A redirection of a portion of the available cardiac output from respiratory to locomotor 
muscles when the respiratory muscles are unloaded is thought to be involved.  Isotime RPE was reduced 
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by a mean of almost two points on the Borg scale with PS 20 and PS 10 compared with unassisted 
exercise and sham PS, with a slightly greater effect observed during exercise with PS 20.  This lower 
perception of respiratory and locomotor effort during exercise most likely allowed participants to tolerate 
exercise for longer.  Whether the reduction in perceived exertion (leg effort) at isotime that was observed 
with PS 20 was accompanied by improved locomotor muscle oxygenation and blood flow is unknown. 
Finally, despite being blinded to the level of PS provided during exercise and the study hypothesis, 
participants rated PS 20, the intervention that resulted in the greatest increase in exercise endurance time, 
as the intervention that provided the most help during exercise.  Patient perception of benefit of PS 20 
during exercise is important and may improve adherence to longer term use of PS, such as during exercise 
training or during activities of daily living.  
 
Ventilator capacity and interfaces 
The present study highlights the need to ensure that the capacity and characteristics of the  
ventilator are adequate to deliver appropriate levels of ventilatory support during exercise.  In light of the 
current findings, the use of low level of PS may explain why exercise performance did not improve in the 
study performed by Highcock and associates (2002). However, it does not explain why exercise 
performance was worse with PS compared with unassisted walking.  One factor that may have contributed 
relates to the capacity of the ventilators used during exercise in that study.  A trigger delay of up to 250 ms 
and cycle delay of up to 400 ms were reported by Highcock and colleagues (2002) which could have 
considerably reduced the effectiveness of ventilatory support, particularly towards end exercise where RR 
was high at a mean of 40 breaths per minute.  At this RR, the duty cycle time was 1.5 s.  At best, with an 
inspiratory to expiratory time ratio of 1:1, participants received the peak level of PS for less than two 
thirds of the duration of inspiration.  In addition to having sensitive inspiratory and expiratory trigger 
thresholds, the minimum rise time setting is also likely to be important, as faster rise times provide greater 
respiratory muscle unloading (Prinianakis et al, 2004).  This may be particularly relevant during exercise 
when RR is fast.  The maximum flow generating capacity of one ventilator used by Highcock et al (2002) 
was 140 L/min, whereas the machine used in the present study had a maximum flow generating capacity 
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of >220 L/min.  The maximum flow generating capacity of the ventilator needs to be sufficient to support 
breathing during exercise, particularly when high levels of PS are being provided and RR is fast.  If the 
capacity of a ventilator is inadequate for use during exercise, the added resistance of the ventilator circuit 
can increase the load placed on the respiratory system and impair rather than augment exercise 
performance (Highcock et al, 1997).  
 
A range of interfaces including oronasal masks, nasal masks and mouthpieces have been used to  
provide ventilatory support during exercise.  It is not known whether the type of interface  
influences the efficacy of ventilatory support during exercise as direct comparisons of different types of 
interfaces in the same group of subjects have not been performed.  In the study performed by Highcock 
and associates (2002), a mouthpiece was used.  Breathing via the mouthpiece without PS impeded 
exercise performance compared with unassisted exercise.  Rather than overcoming the burden of the 
mouthpiece, the addition of PS during exercise caused a further decline in distance walked (Highcock et 
al, 2002).  While the additional dead space from the mouthpiece and the pneumotachograph was small in 
absolute terms, the increase in respiratory load appears to have contributed to the impairment of exercise 
performance in these subjects with severe scoliosis.  In the current study, an oronasal mask was used as 
oronasal breathing appears to be universal during exercise (Chadha et al, 1987).  The dead space of the 
oronasal mask and pneumotachograph in the present study was much larger at 195 mL. However, the 
ventilator used had the capacity to overcome the increase in respiratory load as evidenced by the increase 
in endurance time with PS 20 and no change in endurance time with PS 10 compared with unassisted 
walking.   
 
Patient selection 
Participants in the current study had severe chest wall restriction with a mean FVC and TLC of 22% and 
35% predicted respectively, an extremely reduced ventilatory reserve during unassisted exercise 
(VE/MVV = 95 ± 49%), and mild daytime hypercapnia despite nocturnal NIV.  While Borel et al (2008) 
reported an improvement in cycling endurance time for a group of participants with chest wall restriction, 
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subgroups of “responders” and “non-responders” were identified, with responders having a lower baseline 
FVC and TLC compared with “non-responders” (Borel et al, 2009; Borel et al, 2008).  In addition, 
individuals with a peak VE/MVV > 80% during unassisted exercise tended to have a greater than 50% 
improvement in endurance time with PS 20 compared with unassisted walking (Fig 3.10).  This suggests 
that people with more severe chest wall restriction, lower lung volumes and a smaller ventilatory reserve 
are more likely to benefit from high level PS during exercise than those with moderate restriction. 
 
Is continuous positive airway pressure of 4 cmH2O an appropriate sham pressure support? 
There was no statistically significant difference between sham PS and unassisted exercise with respect to 
endurance time, nor any of the physiological or subjective responses recorded at isotime exercise.  
However, as endurance time data was transformed using log(x), it was difficult to interpret the mean 
difference and 95% CI in real terms.  When using sham PS, it is important that performance is not 
impaired relative to unassisted exercise, otherwise comparisons between sham PS and PS 10 or PS 20 
could falsely inflate the effects of PS during exercise.  Identification of an appropriate sham PS for use 
during exercise in people with severe kyphoscoliosis is useful and may assist to reduce the risk of bias in 
future studies.  The use of CPAP 4 cmH2O as sham PS in the present study appears to have been 
appropriate, although this needs to be verified using a larger sample size, preferably with individuals who 
are naïve to NIV.  
 
Limitations 
A limitation of the present study was that two thirds of the participants breathed via a mouthpiece rather 
than the oronasal mask during unassisted exercise due to intolerable dyspnoea.  A lower dead space could 
potentially reduce CO2 rebreathing and improve exercise performance.  However, despite two thirds of 
participants using the mouthpiece during unassisted exercise, endurance time for the group was not 
significantly different compared with sham PS or PS 10 where the oronasal mask with a considerably 
greater dead space was used. That endurance time was significantly greater with PS 20 compared with 
unassisted exercise despite the larger dead space further reinforces the benefit of PS 20.  In clinical 
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practice, dead space is reduced as firstly, the oronasal mask is used without a pneumotachograph, and 
secondly, location of the expiratory port over the nasal bridge of the oronasal mask permits a further 
reduction in dynamic dead space provided that positive pressure is maintained throughout expiration 
(Saatci et al, 2004).   
 
The difficulty of blinding participants and assessors to the different levels of PS used in the present study 
is acknowledged.  Recruitment of participants who were naïve to positive airway pressure therapy may 
appear preferable to participants who are already accustomed to NIV when trying to blind participants to 
different levels of PS as in the present study.  However, the aim of the study was to specifically target 
individuals with severe disease whose exercise capacity was already optimised with domiciliary nocturnal 
NIV (Fuschillo et al, 2003; Schonhofer et al, 2001b).  Even if participants were naïve to NIV, a period of 
acclimatisation to NIV should occur prior to using NIV during exercise in order to improve tolerance of 
the intervention and to prevent drop outs (van 't Hul et al, 2006).  In addition, none of the participants in 
the current study had previously experienced CPAP.  Participants were told that the bilevel machine 
would be set differently for each of the three treadmill tests with the machine and that the best way to set 
the machine, or if using the machine was better than unassisted exercise was not known.  Thus, 
participants were not aware of the protocol details or study hypothesis.  If previous experience with NIV 
was going to bias participant’s responses to PS during exercise, it would most likely occur with the level 
of PS that closely resembled their nocturnal settings.  The mean level of PS titrated during overnight 
polysomnography that was required to prevent nocturnal hypoventilation was 11 ± 2.9 cmH2O, which was 
closest to PS 10.  Despite this, endurance time was longer with PS 20 compared with PS 10, and 11/13 
participants identified PS 20 as the easiest test to perform which suggests that prior experience did not bias 
the findings of the current study.  Every attempt was made to achieve adequate blinding, including the 
randomisation of test order and concealment of ventilator settings from assessors and participants. In 
addition, the instructions and encouragement given to participants was standardised to reduce potential 
bias. 
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Clinical implications  
The findings of the current study provide evidence that the efficacy of PS during exercise in people with 
severe kyphoscoliosis depends on the level of PS that is provided.  Pressure support of 20 cmH2O may not 
be the optimal level of PS for every individual with severe kyphoscoliosis.  Rather than being prescriptive, 
the findings of this study serve as a guide for clinicians and indicate that high levels of PS (of at least 20 
cmH2O) are required in this population in order to improve exercise endurance time.  Whether levels of 
PS even higher than 20 cmH2O could result in greater improvements in exercise performance is unknown.  
However, the delivery of very high levels of PS may be limited by mask leak, patient discomfort and the 
possible cardiovascular consequences of larger positive intra-thoracic pressure.  Identification of ventilator 
settings that provide the greatest improvement in exercise performance is important if PS is to be used as 
an adjunct to exercise training, or to assist in the performance of daily activities.  Based on the relationship 
that was observed between the change in isotime dyspnoea and the response to PS 20 during walking, 
titration of individualised levels of PS in response to changes in isotime dyspnoea is a simple strategy that 
could be used in the clinical setting.  Patient selection may also affect the response to PS during exercise.  
The current study demonstrated the efficacy of high level PS in people with severe chest wall restriction, a 
finding supported by Borel et al (2008) who showed that subjects with severe chest wall restriction had a 
greater response to high level PS during exercise compared to those with moderate restriction (Borel et al, 
2009; Borel et al, 2008).  In addition, ventilator capacity (Highcock et al, 2002) and the type of interface 
used may also impact on an individual’s response to NIV-assisted exercise.  
 
Conclusion 
High level pressure support (20 cmH2O) during treadmill walking in people with severe  
kyphoscoliosis increases endurance time, improves pattern of breathing and oxygenation, and reduces the 
perception of leg muscle fatigue and dyspnoea compared with unassisted exercise.  Low level PS (10 
cmH2O) did not increase endurance time compared with unassisted exercise, indicating that the level of 
PS provided during exercise does influence the efficacy of the intervention.  Investigation of the role of 
high level PS during exercise training or during daily activities in people with severe chest wall restriction 
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who demonstrate an acute improvement in exercise performance with PS is warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER 4 
 
 
 
 
 
 
 
 
Non-invasive ventilation during exercise training in people with 
chronic obstructive pulmonary disease: a systematic review and 
meta-analysis 
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INTRODUCTION 
Quality of life and exercise capacity are commonly reduced in people with chronic obstructive 
pulmonary disease (COPD) (Garrod et al., 2006) and physical activity levels are lower compared with 
age matched healthy subjects (Pitta et al., 2005).  Dyspnoea is the hallmark symptom of COPD (Viegi 
et al., 2007) and is more common in severe disease (Killian et al., 1992).  Dyspnoea can lead to a cycle 
of activity avoidance, deconditioning and reduced participation in society, which in turn may cause a 
further decline in health related quality of life (HRQL) and exercise capacity. 
 
Exercise training as part of a multidisciplinary pulmonary rehabilitation program is supported by a 
high level of evidence as one of the few effective interventions in the management of COPD (Rabe et 
al., 2007; Ries et al., 2007).  Pulmonary rehabilitation has been shown to improve exercise capacity 
(Cambach et al., 1999; Troosters et al., 2000), and to increase HRQL (Lacasse et al., 2006). There is 
also growing evidence that pulmonary rehabilitation reduces health care resource utilisation (Ries et 
al., 2007).  While there is no direct evidence that pulmonary rehabilitation improves survival in people 
with COPD, strong associations have been described between physical activity levels and the risk of 
an exacerbation, risk of readmission to hospital after an acute exacerbation, and mortality (Garcia-
Aymerich et al., 2003; Garcia-Aymerich et al., 2006). A strong correlate of physical activity is six 
minute walk distance (Pitta et al., 2005), which has been shown to improve after exercise training in 
people with COPD (Garrod et al., 2006). 
 
High intensity exercise training has been shown to produce greater physiological improvements 
compared to lower intensity exercise training in people with COPD (Casaburi et al., 1991; Gimenez et 
al., 2000).  However, patients with severe exertional dyspnoea or a marked reduction in ventilatory 
capacity may not be able to perform exercise at high intensities for an adequate duration.  
Consequently, these patients may not achieve the same improvements in exercise capacity with 
exercise training as those without a significant ventilatory limitation, particularly if peripheral muscle 
strength is relatively preserved (Garrod et al., 2006; Plankeel et al., 2005; Troosters et al., 2001). 
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In people with stable COPD, non-invasive ventilation (NIV) during lower limb exercise has been 
shown to acutely increase exercise endurance time and decrease dyspnoea compared to exercise 
without NIV or exercise with sham NIV in a meta-analysis (van 't Hul et al., 2002). Unloading of both 
the inspiratory and expiratory components of the respiratory muscle pump have been observed with 
NIV during exercise (Kyroussis et al., 2000), with the reduction in dyspnoea being proportional to 
respiratory muscle unloading (Maltais et al., 1995).  Non-invasive ventilation also unloads the 
inspiratory muscles during unsupported arm elevation in people with COPD (Poggi et al., 2006).  
Improvements in gas exchange both during and after exercise have been found with NIV during 
walking and cycling exercise compared to exercise without NIV (Dreher et al., 2007; Hernandez et al., 
2001).  This may be of benefit to people with COPD as acute hypercapnia with a respiratory acidosis 
has been shown to significantly impair respiratory muscle function in healthy individuals (Jonville et 
al., 2002; Juan et al., 1984).  In addition, NIV during exercise prolongs the onset and reduces the 
extent of exercise induced lactic acidosis compared to exercise without NIV (Borghi-Silva et al., 2008; 
Polkey et al., 2000), and may also improve blood supply to the locomotor muscles compared to 
exercise with sham NIV (Borghi-Silva et al., 2008).   
 
The effects of NIV during exercise, namely: respiratory muscle unloading, improved arterial blood 
gases, reduced lactic acid production and improved oxygenation and perfusion of working muscles 
may allow people with COPD to exercise at a higher intensity for a greater duration with less 
dyspnoea.  Thus, exercise training with NIV may potentially lead to greater improvements in exercise 
capacity compared to exercise training alone.  Such improvements in exercise capacity may increase 
physical activity levels and improve quality of life in people with COPD.  While pulmonary 
rehabilitation clinical practice guidelines state that NIV may have a role during exercise training in 
select patients with severe disease (Nici et al., 2006; Ries et al., 2007), there is no clear body of 
evidence to determine whether NIV during exercise training is associated with clinically worthwhile 
changes in important outcomes such as exercise capacity, HRQL and physical activity levels.  In 
addition, evidence regarding the characteristics of suitable candidates, optimal levels of ventilatory 
support, or appropriate types of exercise for this technique is limited.  Therefore, the aim of this 
systematic review was to determine the effect of NIV during supervised exercise training (as a part of 
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pulmonary rehabilitation) on exercise capacity, HRQL and physical activity levels in people with 
COPD compared to exercise training without NIV, or exercise training with sham NIV.  It was 
hypothesised that NIV during exercise training would permit greater post rehabilitation improvements 
in exercise capacity, quality of life and physical activity in select people with COPD.  
 
 
METHOD  
The protocol for the current review was published in The Cochrane Library (Menadue et al., 2009a) 
before the review was conducted (Appendix B, Part iii). 
 
Criteria for considering studies for this review 
Types of Studies 
Randomised controlled trials (RCTs) comparing NIV during exercise training to exercise training 
alone, or exercise training with sham NIV (control group) were considered for inclusion in this review.  
Randomised crossover trials were also considered for inclusion.  Quasi randomised controlled trials, 
for example those with alternate randomisation, were excluded. 
 
Types of Participants 
Inclusion 
Studies with participants with stable COPD were considered for inclusion.  Participants were 
considered to be stable if there was no history of an exacerbation over the past month (Rabe et al., 
2007).  The definition of COPD was based on: 
i) a clinical diagnosis of COPD, and 
ii) a best recorded ratio of forced expiratory volume during one second (FEV1) over forced 
vital capacity (FVC) for individual study participants of <70%, and  
iii) a best recorded FEV1 <80% predicted for individual study participants  
 
Exclusion 
Studies that included patients with non-COPD respiratory disease or patients with concomitant 
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neuromuscular disease, a restrictive thoracic disorder, significant cardiac failure or cardiac disease 
were excluded if data from subjects with COPD could not be analysed separately.  
 
Types of Interventions 
Inclusion 
The intervention for the actively treated group was non-invasive positive pressure ventilation (NIV), 
which included bilevel ventilation, proportional assist ventilation (PAV) or inspiratory pressure 
support (IPS) provided via a mask or mouthpiece during all supervised exercise training sessions.  The 
intervention for the control group was either exercise training alone or exercise training with sham 
NIV during all supervised exercise training sessions.  Exercise training needed to include lower limb 
and/or upper limb endurance exercise and be greater than or equal to four weeks in duration with a 
minimum of two supervised sessions per week.  Studies that involved the delivery of supplemental 
oxygen (O2) during exercise training in the actively treated group (that is, exercise training with 
NIV+O2) were included provided that supplemental O2 was also delivered to the control group (that is, 
exercise training with O2 alone or exercise training with sham NIV+O2) and vice versa.  Similarly, 
studies that involved the use of nocturnal NIV were only included if both the actively treated group 
and control group received nocturnal NIV. 
 
Exclusion 
Studies that used continuous positive airway pressure during exercise as the active treatment were 
excluded.  
 
Types of Outcome Measures 
Primary outcomes   
i) Exercise capacity (maximal and/or endurance exercise capacity) 
ii) Health related quality of life  
iii) Physical activity  
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Secondary outcomes   
i) Physiological changes related to exercise training 
ii) Dyspnoea  
iii) Adverse events/drop-outs 
iv) Training intensity 
v) Cost 
 
Search methods for identification of studies 
Electronic Searches 
Trials were identified with assistance from the Cochrane Airways Group Trials Search Co-ordinator 
using the Cochrane Airways Group Specialised Register of trials.  The Register was derived from 
systematic searches of bibliographic databases including the Cochrane Central Register of Controlled 
Trials (CENTRAL), MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Allied and Complimentary Medicine Database (AMED), and PsycINFO, and 
handsearching of respiratory journals and meeting abstracts, including annual meetings of the 
American Thoracic Society, European Respiratory Society and the British Thoracic Society.  All 
records in the Cochrane Specialised Register coded as 'COPD' were searched using the following 
terms: (exercis* or physical* or train* or rehabilitat* or conditioning or ergometry or treadmill or 
endurance or "upper limb") AND (noninvasive* or non-invasive* or "non invasive*" or NIV or 
"positive pressure" or NIPPV or NPPV or "pressure support" or IPS or "assist* ventilation" or PAV or 
"ventilatory support" or bilevel or BVS or "mechanical ventilation" or "artificial ventilation" or 
"artificial respiration" or mask* or BiPAP or IPAP or EPAP or nasal* or "positive airway*"). 
 
To reduce the risk of missing eligible studies, separate searches were also conducted using the 
following electronic databases between 1987 and December 2009:  AMED, CENTRAL, CINAHL, 
EMBASE, Latin American and Caribbean Health Science Information Database (LILACS), 
MEDLINE, Physiotherapy Evidence Database (PEDro), PsycINFO and PubMed.  There were no 
language restrictions.  The search screened studies that were published during or after 1987 as the first 
reports of non-invasive positive pressure ventilation delivered via a mask in the literature were in 1987 
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(Ellis et al., 1987; Kerby et al., 1987).  A RCT filter was applied to all database searches except for 
CENTRAL and PEDro as these databases only contained controlled trials or systematic reviews.  The 
filter was developed by grouping database specific terms for ‘RCT’ using ‘or’.  Then, database 
specific search terms for ‘NIV’ were grouped using ‘or’, database specific search terms for ‘Exercise’ 
were grouped using ‘or’, and database specific search terms for ‘COPD’ were grouped using ‘or’.  
Afterwards, the following four search strategies were used in each database: (i) ‘RCT’ and ‘COPD’ 
and ‘NIV’ and ‘Exercise’; (ii) ‘RCT’ and ‘COPD’ and ‘NIV’; (iii) ‘RCT’ and ‘COPD’ and ‘Exercise’; 
(iv) ‘NIV’ and ‘Exercise’.  A detailed list of search strategies for each database is located in Appendix 
A, Part (i).  Conference abstracts from the following meetings were also screened: American College 
of Chest Physicians, Asia Pacific Society of Respirology, German Society for Pneumology and 
Respiratory Medicine, and the Thoracic Society of Australia and New Zealand.  Finally, several 
clinical trials registers and search engines were screened for potential studies, including: Australian 
New Zealand Clinical Trials Register (www.anzctr.org.au), ClinicalTrials.gov, International Standard 
Randomised Controlled Trial Number Register (www.controlled-trials.com/isrctn/), Netherlands Trial 
Register (www.trialregister.nl/trialreg/index.asp), University hospital Medical Information Network 
(UMIN) (www.umin.ac.jp/ctr/index/), Google Scholar (www.scholar.google.com), and Web of 
Science.  Abstracts were included in this review. 
 
Searching Other Sources 
Reference lists of all included studies as well as any review articles that were obtained from the initial 
search were screened for additional studies that potentially met the inclusion criteria.  Authors of the 
included trials and international experts in the field of NIV were contacted and asked to identify any 
other published or unpublished studies involving NIV during exercise training in COPD.  Four out of 
the six authors of included trials responded (van’t Hul 2006, Hawkins 2002, Bianchi 2002, Toledo 
2007).  Of the 19 experts contacted, 10 responded.  No additional trials were identified for inclusion in 
the review.   
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Data collection and analysis 
Selection of Studies 
Two reviewers independently selected studies for inclusion in the review.  Initially, titles and abstracts 
were reviewed and studies that obviously did not fit the inclusion criteria were discarded.  Full papers 
of the remaining studies were then retrieved for closer evaluation.  Studies that met the inclusion 
criteria were selected from the group of full papers.  A list of excluded trials from the group of full 
papers was made, including the primary reason for exclusion.  Any discrepancies in the studies that 
were selected for inclusion were discussed between the two reviewers and if a resolution could not be 
found, the decision was made by a third reviewer.  To determine the agreement between the reviewers 
for study inclusion from the initial selection and second selection (abstracts and complete articles), 
Cohen’s kappa coefficient was calculated.  The strength of agreement was described using the 
following categories: 
 
 
Kappa statistic 
 
 
Strength of agreement 
<0.00 Poor 
0.00 – 0.20 Slight 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Substantial 
0.81 – 1.00 Almost Perfect 
 
         (Landis & Koch, 1977)    
 
 
Data Extraction and Management 
Data were independently extracted by two reviewers using a standardised form and crosschecked.  The 
following information was recorded: a) general study information (eg study design, location, inclusion 
criteria), b) participant characteristics, c) description of the active intervention (NIV mode and 
settings), d) description of the exercise training program (eg program duration, frequency, type, 
intensity), e) description of outcome measures (eg exercise capacity, HRQL and physical activity), and 
f) methodological quality including drop-outs and withdrawals.  Although NIV was used during 
exercise training in the actively treated groups, post training primary and secondary outcome data 
were only extracted if study participants were evaluated off NIV (eg unassisted test of exercise 
capacity).  Any discrepancies in the extracted data were discussed between the two reviewers and if a 
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resolution could not be found, the decision was made by a third reviewer.  A software program 
(Engauge Digitizer, http://digitizer.sourceforge.net/) was used by one reviewer to convert graphical 
images to numerical data when individual or group data were not presented numerically.  The total 
number of graphs converted was 15 (n = 3 (Bianchi et al., 2002), n = 7 (Hawkins et al., 2002), n = 1 
(Reuveny et al., 2005), n = 3 (van 't Hul et al., 2006) and n = 1 (Toledo et al., 2007)).  Two reviewers 
also independently manually extracted the numerical data from each graph using enlarged copies of 
the images.  Any discrepancies in the manually extracted data and that extracted using the software 
program were discussed between the two reviewers and if a resolution could not be found, the decision 
was made by a third reviewer.  Two authors (Hawkins et al., 2002; Toledo et al., 2007) were contacted 
and asked to clarify the type of statistics that were presented in several tables and figures (eg standard 
error (SE) or standard deviation (SD)).  Both responded and provided the necessary information.  One 
study (Johnson et al., 2002) randomised participants to one of three groups (two intervention groups or 
one control group).  Data was only extracted from the intervention group who used NIV during 
exercise training and the control group who performed exercise training alone. 
 
Assessment of Methodological Quality of Included Studies 
Two approaches were used to assess the methodological quality of the included studies.  Firstly, two 
reviewers assessed the risk of bias within each study with respect to sequence generation, allocation 
concealment, blinding, incomplete outcome data (eg dropouts and withdrawals) and selective outcome 
reporting.  An additional category ‘other bias’ was also assessed and allowed reviewers to identify 
potential sources of bias specific to each study that were not previously covered.  Unblinded studies 
were included in this review.  Every item was graded as: high, low, or unclear risk of bias.  Each item 
in the risk of bias quality assessment was considered independently without an attempt to collate and 
assign an overall score.  Risk of bias tables were created as recommended by the Cochrane 
Collaboration (Higgins & Altman, 2008).  Agreement between the two reviewers for risk of bias 
assessment was reported.  Consensus was obtained from a third reviewer if there was a disagreement 
in quality between the two reviewers.  
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Secondly, methodological quality was assessed independently by two reviewers using the PEDro scale 
(Appendix A, Part ii).  The PEDro scale consists of 11 items.  One item assesses external validity 
(generalisability), eight items assess internal validity and two items assess statistical reporting.  Scores 
were determined using information obtained from the written report and correspondence with 
individual authors (Bianchi et al., 2002; Hawkins et al., 2002; Toledo et al., 2007; van 't Hul et al., 
2006).  Two authors did not respond (Johnson et al., 2002; Reuveny et al., 2005).  Scores from items 
that assessed internal validity and statistical reporting were aggregated to give a score out of 10.  
Agreement between the two reviewers was determined by calculation of Cohen’s kappa coefficient.  
 
Measures of Treatment Effect 
The treatment effect was defined as the mean difference (MD) when continuous data measured on the 
same scale was used.  When dichotomous data were combined, the treatment effect was defined as the 
odds ratios (OR).   
 
Dealing with Missing Data 
Drop-out rates for included studies ranged from 18-39%, except in one study (Toledo et al., 2007) 
where drop-outs were not reported.  Two studies (Bianchi et al., 2002; van 't Hul et al., 2006) 
performed intention to treat (ITT) analyses.  However, the authors of both studies stated that there was 
no difference between ITT and per protocol analyses and reported results for per protocol analyses 
only.  Incomplete statistical results for training intensity were reported in one study (Johnson et al., 
2002) where a point estimate was given for each group without a measure of variability.  The author 
was contacted and asked for the missing data.  The author did not respond, therefore data was not 
extracted from this study for training intensity.  
 
Assessment of Heterogeneity 
Heterogeneity was assessed using the Cochrane chi-squared (χ2) test of homogeneity and with the I2 
statistic using Review Manager software (Computer program. Version 5.0. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2008).  A p value of 0.10 rather than 0.05 was used as 
the χ2 test has low power when a small number of studies with relatively small sample sizes are 
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included in the analysis.  A higher χ2 statistic (relative to its degree of freedom) or a low p value is 
indicative of heterogeneous treatment effects (variation in treatment effects above that of chance 
alone) (Deeks et al., 2008).  The I2 statistic was used to examine inconsistencies across studies and 
indicates the percentage of the total variation across studies due to heterogeneity rather than chance 
(Higgins et al., 2003).  A value of 0% indicates no heterogeneity, and descriptors for low, moderate 
and high levels of heterogeneity have been suggested at 25%, 50% and 75% respectively (Higgins et 
al., 2003).   
 
Assessment of Reporting Biases 
The presence of publication bias could not be assessed as the number and size of included studies was 
small which precluded meaningful interpretation of funnel plots. 
 
Data Synthesis  
Study data were combined using Review Manager software (Computer program. Version 5.0. 
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008).  A random effects 
model was used and forest plots were created to present results across studies.  Five studies presented 
pre and post training means and SDs (Hawkins et al., 2002; Johnson et al., 2002; Reuveny et al., 2005; 
Toledo et al., 2007; van 't Hul et al., 2006).  Three of these studies also presented change from baseline 
means and SDs (Johnson et al., 2002; Reuveny et al., 2005; van 't Hul et al., 2006).  In one study, SD 
for change from baseline data was calculated from 95% confidence intervals (CI), and for post 
intervention data was calculated using SE (Hawkins et al., 2002).  Post intervention data and change 
data were combined in the same analyses  (Higgins & Deeks, 2008).  However, if post intervention 
and change data were both reported within a study, post intervention data was used in the analysis.  An 
exception was made for one study (Johnson et al., 2002), where a significant difference between 
groups at baseline was reported.  In this case, change from baseline data was used instead.  Mean 
difference (change from baseline) between groups and 95% CI were reported in one study (Bianchi et 
al., 2002) and data for the change from baseline within groups was incomplete (point estimate without 
a measure of variance).  Therefore analyses that included data from this study were performed using 
generic inverse variance (GIV) rather than inverse variance (IV) method.  For GIV analyses, 95% CI 
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and SD were converted to SE.  Where possible, treatment effects are discussed in relation to the 
minimal clinically important difference (MCID).  
 
Subgroup Analysis and Investigation of Heterogeneity 
If I2 indicated that more than a low level of heterogeneity was present (that is more than 25%), the 
following subgroup analyses were considered: 
i) Study population (eg disease severity, ventilatory limitation to exercise)  
ii) Blinding of study participants, personnel and/or outcome assessors  
iii) Type of exercise (eg upper limb versus lower limb, treadmill versus cycling)  
iv) Settings (eg level of ventilatory assistance, mode of ventilation)  
v) Additional use of supplemental O2 during exercise  
vi) Duration of the training program 
 
However, as the number of studies included in the present review was small, subgroup analyses could 
not be performed.  Instead, possible impacts of these factors on heterogeneity are discussed. 
 
Sensitivity Analysis 
Due to the small number of trials included in the review, the ability to perform sensitivity analyses was 
limited.  To determine the robustness of the results, sensitivity analyses were performed by re-running 
analyses without data from particular studies.  Sensitivity analyses were considered based on the 
following factors: 
a) Participant characteristics (eg disease severity) 
b) Methodological quality (eg blinding, allocation concealment) 
c) Characteristics of the exercise training program (eg duration) 
 
Sensitivity analyses were also considered for outcomes that included data from studies where 
significant baseline differences between groups were accounted for by using change from baseline 
data rather than post intervention data.  Analyses were re-run using post intervention values to 
determine whether the initial results were robust.  
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Differences between the published protocol and the review 
Several slight changes were made to the published protocol (Menadue et al., 2009a) during the review 
process.  Firstly, two additions were made to the criteria relating to the types of interventions that were 
eligible for inclusion in the review: 
 
i) Studies that involved the delivery of supplemental O2 during exercise training in the 
actively treated group (that is, exercise training with NIV+O2) were included provided that 
supplemental O2 was also delivered to the control group (that is, exercise training with O2 
alone or exercise training with sham NIV+O2) and vice versa 
ii) Similarly, studies that involved the use of nocturnal NIV were only included if both the 
actively treated group and control group received nocturnal NIV 
Secondly, rather than data extraction being performed by one reviewer and verified by another 
reviewer, data from the included studies were extracted independently by the two reviewers.  Thirdly, 
ventilator settings (including the level of ventilatory assistance and mode of ventilation) was added as 
a factor to consider for sub-group analyses.  In addition to determining the risk of bias within included 
studies, methodological quality was also assessed using the PEDro scale.  Finally, sensitivity analyses 
were performed for outcomes that included data from studies where baseline differences between 
groups were accounted for by using change from baseline data rather than post intervention data. 
 
 
RESULTS 
Results of the search 
The initial search of electronic databases identified 7478 potentially relevant publications.  Of these, 
7404 were excluded by title and abstract.  Full papers of the remaining 74 publications were retrieved 
for closer inspection.  Agreement between the two reviewers was ‘substantial’ for the first round 
selection of studies using titles and abstracts (kappa = 0.80).  After examination of the full papers, an 
additional article was identified from the list of references and retrieved for detailed evaluation.  From 
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the 75 full papers, six met the inclusion criteria of the present review.  Agreement between the two 
reviewers for the second round selection of studies using full papers was ‘perfect’ (kappa = 1.0).  A 
flow chart of the study selection process is displayed in Figure 4.1.
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Figure 4.1  Flowchart of the study selection process 
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Included studies 
In total, six RCTs were included in the review (Bianchi et al., 2002; Hawkins et al., 2002; Johnson et 
al., 2002; Reuveny et al., 2005; Toledo et al., 2007; van 't Hul et al., 2006).  All studies used a parallel-
group design.  Combining all studies, data from a total of 126 participants were analysed (control: n = 
63; NIV during exercise training: n = 63).  The majority of studies recruited participants with severe to 
very severe COPD, and one study recruited participants with moderate to severe COPD (Bianchi et al., 
2002).  All exercise training programs were outpatient and centre based.  The exercise training 
programs were similar between studies, with the majority running for 6-8 weeks, with 2-3 sessions per 
week of 30-45 minutes exercise training duration per session at a moderately high intensity.  All 
studies involved lower limb exercise training.  No studies assessed upper limb exercise training.  A 
variety of modes of NIV were used during exercise training including bilevel, PAV and IPS with a low 
to moderate level of ventilatory support.  All studies used exercise capacity to evaluate treatment 
effects.  Two studies also evaluated HRQL.  Physical activity was not used to evaluate the effect of the 
intervention.  Detailed characteristics of the included studies are outlined in Table 4.1.  References of 
all published reports of the included studies identified in the search are listed in Appendix A (Part iii).  
All included trials were written in English.   
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Table 4.1  Characteristics of included studies 
 
 
Study 
 
Methods 
 
Participants 
 
 
NIV group                                  Control/Sham NIV group 
 
 
Interventions 
 
     
NIV group                                Control/Sham NIV group 
 
 
Outcome measures* 
 
 
Training with PAV:  
Flow assist 3.5 ± 1.6 
cmH2O, volume assist 6.6 ± 
2.2 cmH2O/L with EPAP  
2 cmH2O 
 
 
 
 
Unassisted training 
 
 
 
 
Bianchi 
et al 
(2002) 
 
Design: Parallel RCT 
 
Inclusion criteria:  
a) Diagnosis of COPD   
b) Referred to pulmonary  
    rehabilitation   
c) Stable  
 
Exclusion criteria: 
a) Chronic respiratory failure 
b) Other organ failure   
c) Cancer   
d) Inability to cooperate   
e) Exercise-induced HT 
 
 
n 
Age (yr (range))  
F:M  
FEV1 (% pred) 
FVC (% pred) 
RV (% pred) 
PaO2 (kPa) 
PaCO2 (kPa)  
MIP (cmH2O)  
MEP (cmH2O) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
9 
64 (61-67) 
0:9 
48 ± 19 
77 ± 15 
161 ± 69 
10.0 ± 1.1 
5.2 ± 0.6 
83 ± 26 
148 ± 27 
 
18 
9 
50 
 
n 
Age (yr (range))  
F:M  
FEV1 (% pred) 
FVC (% pred) 
RV (% pred) 
PaO2 (kPa) 
PaCO2 (kPa)  
MIP (cmH2O)  
MEP (cmH2O) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
10 
65 (61-69) 
0:10 
40 ± 12 
74 ± 19 
181 ± 49 
10.0 ± 1.1 
5.2 ± 0.5 
72 ± 23 
139 ± 25 
 
15 
5 
33 
 
Type of exercise training:  cycle ergometry 
Intensity of training:  Initially 50-70% Wmax 
Sessions/week:  3 
Session duration:   30 minutes, supervised 
Duration of training:  6 weeks 
 
 
 
 
a) Incremental maximal cycle test  
b) Six minute walk test 
c) Dyspnoea 
d) Leg discomfort 
e) St George’s Respiratory  
     Questionnaire 
 
Training with PAV:  
Flow assist 3.6 ± 0.7 
cmH2O, volume assist 12.7 
± 1.5 cmH2O/L 
 
 
 
 
 
 
Unassisted training 
 
 
Hawkins 
et al  
(2002) 
 
Design: Parallel RCT 
 
Inclusion criteria:  
a) Diagnosis of severe COPD 
b) Current or ex-smoker  
 
Exclusion criteria: 
a) Orthopaedic or  
    cardiovascular contra- 
    indications to exercise 
 
 
n 
Age (yr)  
F:M  
FEV1 (% pred) 
RV/TLC  
(% pred) 
PaO2 (kPa) 
PaCO2 (kPa)  
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
10 
66 ± 7 
0:10 
28 ± 7 
62 ± 9 
 
8.6 ± 0.9 
5.6 ± 0.7 
 
14 
4 
29 
 
 
n 
Age (yr)  
F:M  
FEV1 (% pred) 
RV/TLC 
(% pred) 
PaO2 (kPa) 
PaCO2 (kPa)  
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
9 
68 ± 9 
2:7 
26 ± 7 
59 ± 15 
 
8.1 ± 1.2 
5.8 ± 0.9 
 
15 
6 
40 
 
Type of exercise training:  cycle ergometry 
Intensity of training:  Initially 70% Wmax  
Sessions/week:  3 
Session duration:   30 minutes, supervised 
Duration of training:  6 weeks 
 
 
 
 
a) Isoload lactate concentration  
b) Incremental maximal cycle test 
c) Constant work rate cycle test 
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Study 
 
 
Methods 
 
 
 
 
Participants 
 
 
NIV group                                  Control/Sham NIV group 
 
 
Interventions 
 
     
NIV group                                Control/Sham NIV group 
 
 
Outcome measures* 
 
 
Training with Bilevel NIV: 
IPAP 8-12 cmH2O 
EPAP 2 cmH2O 
 
Unassisted training: 
Humidified air 10 L/min via 
NRBM 
 
(Third group trained with 
Heliox -  10 L/min 
humidified heliox: 79% He, 
21% O2 via NRBM)  
 
 
 
Johnson 
et al  
(2002) 
 
Design: Parallel RCT 
 
Inclusion criteria:  
a) Diagnosis of COPD   
b) FEV1 <50% predicted 
c) Ability to walk on a treadmill 
d) Referred to pulmonary  
    rehabilitation    
 
Exclusion criteria: 
a) Exertional angina 
b) Congestive cardiac failure   
c) Valvular heart disease   
d) Uncontrolled cardiac  
     dysrhythmias  
e) Other conditions limiting  
    ability to exercise or use a  
    mask 
 
n 
Age (yr)  
F:M  
FEV1 (% pred) 
FVC (% pred) 
RV (% pred) 
PaO2 (mmHg) 
PaCO2 (mmHg)  
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
11 
69 ± 9 
3:8 
32 ± 9 
57 ± 15 
203 ± 63 
72 ± 10 
42 ± 4 
 
15 
4 
27 
 
n 
Age (yr)  
F:M  
FEV1 (% pred) 
FVC (% pred) 
RV (% pred) 
PaO2 (mmHg) 
PaCO2 (mmHg)  
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
11 
72 ± 9 
4:7 
31 ± 11 
53 ± 10 
199 ± 73 
69 ± 9 
43 ± 5 
 
13 
2 
15 
 
Type of exercise training:  Treadmill 
Intensity of training:  Initially 50-60% maximum METs 
Sessions/week:  2 
Session duration:  20 minutes, supervised 
Duration of training:  6 weeks 
 
 
a) Incremental maximal treadmill  
     test  
 
 
 
Training with Bilevel NIV: 
IPAP 8-12 cmH2O 
EPAP 2 cmH2O 
9/9 participants used 
supplemental O2 with NIV 
 
 
 
 
 
 
 
Unassisted training: 
8/10 participants used 
supplemental O2  
 
Reuveny 
et al  
(2005) 
 
 
Design: Parallel RCT 
 
Inclusion criteria:  
a) Diagnosis of COPD 
b) FEV1 <40% predicted and  
    <12% reversibility 
c) Ventilatory limitation to  
    exercise 
 
Exclusion criteria: 
a) Cardiovascular, orthopaedic  
    or neuromuscular diseases  
    that could limit exercise 
 
 
n 
Age (yr)  
FEV1 (% pred) 
FEV1/FVC (%) 
RV (% pred) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
 
 
 
 
 
 
 
 
 
 
9 
64 ± 9 
32 ± 4 
59 ± 16 
194 ± 34 
 
12 
3 
25 
 
n 
Age (yr)  
FEV1 (% pred) 
FEV1/FVC (%) 
RV (% pred) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
10 
63 ± 9 
33 ± 9 
58 ± 16 
165 ± 17 
 
12 
2 
17 
 
Type of exercise training:  Treadmill 
Intensity of training:  Initially >2 km/h  
Sessions/week:  2 
Session duration:  45 minutes 
Duration of training:  8 weeks 
 
 
 
a) Incremental maximal cycle test  
 
 166 
 
Study 
 
 
Methods 
 
 
 
 
Participants 
 
 
NIV group                                  Control/Sham NIV group 
 
 
Interventions 
 
     
NIV group                                Control/Sham NIV group 
 
 
Outcome measures* 
 
 
Training with IPS:  
10 cmH2O 
 
 
 
 
 
 
 
Training with sham IPS: 
5 cmH2O 
 
van’t 
Hul et al  
(2006) 
 
 
Design: Parallel RCT 
 
Inclusion criteria:  
a) Diagnosis of COPD   
b) FEV1 <60% predicted   
c) Peak exercise ventilatory  
    reserve <20% of MVV  
d) Peak exercise VE <50L/min 
e) Resting PaO2 >60mmHg 
f) Peak exercise SpO2 >85% 
g) 40-75 years of age 
 
 
n 
Age (yr)  
F:M  
FEV1 (% pred) 
FEV1/FVC (%) 
RV (% pred) 
MIP (cmH2O)  
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
15 
70 ± 5 
4:11 
41 ± 10 
34 ± 6 
161 ± 18 
58 ± 20 
 
19 
4 
21 
 
n 
Age (yr)  
F:M  
FEV1 (% pred) 
FEV1/FVC (%) 
RV (% pred) 
MIP (cmH2O) ) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
14 
71 ± 4 
1:13 
38 ± 9 
36 ± 8 
164 ± 50 
59 ± 21 
 
18 
4 
22 
 
Type of exercise training:  cycle ergometry 
Intensity of training:  Initially 65% Wmax 
Sessions/week:  3 
Session duration:  45 minutes, supervised 
Duration of training:  8 weeks 
 
  
 
 
a) Incremental maximal shuttle  
     walk test  
b) Constant work rate cycle test 
c) St George’s Respiratory  
     Questionnaire 
 
 
Bilevel NIV: 
IPAP 10-15 cmH2O 
EPAP 4-6 cmH2O 
 
 
 
 
 
 
Unassisted training 
 
Toledo 
et al 
(2007) 
 
 
Design: Parallel RCT 
 
Inclusion criteria:  
a) Diagnosis of COPD  
b) FEV1 <60% predicted and  
    FEV1/FVC <70%   
c) Stable for ≥ 6 months  
 
Exclusion criteria: 
a) Cardiovascular, orthopaedic  
     or neuromuscular diseases  
     that could limit exercise  
b) Exercise-induced HT 
 
 
n 
Age (yr)  
FEV1 (% pred) 
FVC (% pred) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
9 
67 ± 11 
33 ± 10 
63 ± 18 
  
No report 
No report 
No report 
 
n 
Age (yr)  
FEV1 (% pred) 
FVC (% pred) 
 
Recruited (n) 
Drop-outs (n) 
Drop-outs (%) 
 
9 
67 ± 9 
34 ± 8 
55 ± 11 
 
No report 
No report 
No report 
 
Type of exercise training:  treadmill 
Intensity of training:  70% of maximum walking speed  
Sessions/week:  3 
Session duration:  30 minutes 
Duration of training:  12 weeks 
 
 
 
a) Incremental maximal treadmill  
     test  
b) Lactate concentration 
c) Respiratory muscle strength 
 
*Outcome measures: all outcome measures were obtained post training during unassisted exercise (that is, for the group allocated to NIV during exercise training as well as the group allocated to control 
or sham NIV).  Data are presented as mean±SD unless otherwise indicated. RCT: randomised controlled trial; COPD: chronic obstructive pulmonary disease; HT: hypertension; MVV: maximum 
voluntary ventilation; VE: minute ventilation; PaO2: arterial oxygen tension; SpO2: oxygen saturation; F:M: ratio of females to males; FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity; RV: residual volume; PaCO2: arterial carbon dioxide tension; MIP: maximum inspiratory occlusion mouth pressure; MEP: maximum expiratory mouth occlusion pressure; TLC: total lung 
capacity; PAV: proportional assist ventilation; EPAP: expiratory positive airway pressure; Wmax: maximum workload; NIV: non-invasive ventilation; IPAP: inspiratory positive airway pressure; NRBM: 
non-rebreather mask; He: Helium; O2: oxygen; MET: metabolic equivalent; IPS: inspiratory pressure support 
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Excluded studies 
A list of studies that were excluded (n = 69) during the second round selection (i.e. from the list of full 
papers that were evaluated in detail) and reasons for exclusion are presented in Appendix A (Part vi 
and Part v respectively).  The primary reasons for exclusion were: exercise training was not evaluated 
(n = 30); not a RCT (n = 29); NIV was not used during exercise (n = 5); not COPD (n = 4); wrong 
comparison (n = 1).  The trial that was excluded on the basis that the wrong comparison was made 
(Pires Di Lorenzo et al., 2003) compared nocturnal NIV + exercise training to NIV during exercise 
training without nocturnal NIV.  The study was excluded because nocturnal NIV has been shown to 
augment the benefits of pulmonary rehabilitation (Duiverman et al., 2008; Garrod et al., 2000; 
Kohnlein et al., 2009) and therefore could have potentially confounded the results.  Three of the 
excluded studies were written in Portuguese, two in German, one in Russian and one in Norwegian.  
The abstract and method sections of these studies were translated prior to exclusion.  The remainder of 
the studies were written in English.   
 
Methodological quality assessment 
Risk of Bias Assessment 
Agreement between the two reviewers for risk of bias assessments of the included studies was 
‘substantial’ (kappa = 0.79).  Randomisation sequence generation was adequate in half of the studies 
(Bianchi et al., 2002; Hawkins et al., 2002; van 't Hul et al., 2006) and unclear in the remaining studies 
(Johnson et al., 2002; Reuveny et al., 2005; Toledo et al., 2007).  Allocation concealment was 
generally sufficient however inadequate reporting and the inability to contact authors prevented a 
conclusive assessment of bias in two studies.  Personnel who trained participants were not blinded to 
group allocation in any of the studies.  Similarly, participants were not blinded to NIV during exercise 
training in the majority of trials, which largely reflects the difficulty of providing an adequate sham 
intervention for NIV.  One study (van 't Hul et al., 2006) did however blind participants using sham 
NIV.  The sham NIV used (IPS 5 cmH2O) has previously been shown to be equivalent to unassisted 
exercise with respect to exercise performance in people with severe COPD (van 't Hul et al., 2004).  In 
half of the studies (Reuveny et al., 2005; Toledo et al., 2007; van 't Hul et al., 2006), blinded assessors 
were used to evaluate clinical outcomes.  Most studies adequately addressed incomplete outcome data 
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although the number of drop-outs was not reported in one study (Toledo et al., 2007).  While most 
studies were free from selective outcome reporting, two studies (Reuveny et al., 2005; Toledo et al., 
2007) did not report results for between group comparisons for exercise capacity or a number of 
physiological variables despite reporting post-training within group differences.  Detailed tables of 
risk of bias analyses of included studies are presented in Appendix A (Part vi).  A summary of risk of 
bias analyses are displayed in Figure 4.2.   
 
Assessment of Methodological Quality using the PEDro Scale 
The mean ± SD PEDro score for included trials was 5.5 ± 1.6 and ranged from 3/10 to 8/10.  All but 
one study (Johnson et al., 2002) received a score of ≥ 5/10.  Scores for individual items on the PEDro 
scale are presented for each study in Table 4.2.  There was complete agreement between the two 
reviewers for methodological quality assessment using the PEDro scale (kappa = 1.0).  
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a)  
 
 
 
 
 
b) 
 
 
 
 
Figure 4.2 Summary of: a) Risk of bias analysis for individual studies, and b) Combined 
risk of bias of included studies for each risk of bias item  
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Table 4.2 Methodological quality assessment of included studies using the PEDro scale 
 
 
* Item does not contribute to total score. 
 
 
 
Effects of non-invasive ventilation during exercise training 
Primary Outcomes 
Exercise capacity 
Exercise capacity was measured in a variety of ways including incremental peak exercise tests, 
constant work-rate endurance tests and functional walk tests.  Each will be reported in turn.  All six 
trials included in the review reported the effect of NIV during exercise training on peak exercise 
capacity.  Three studies (Bianchi et al., 2002; Hawkins et al., 2002; Reuveny et al., 2005) assessed 
peak exercise capacity using an incremental cycle ergometer test in a combined total of 28 participants 
who trained with NIV and 29 control subjects.  The common effect (mean difference) was 6.34 watts 
(95% CI -1.66 to 14.34).  Two studies evaluated peak exercise capacity using incremental treadmill 
tests.  One study used a protocol that increased both walking speed and the incline, with performance 
measured in metabolic equivalents (METs) (Johnson et al., 2002) while the other study used a protocol 
that increased walking speed only and performance was measured in km/h (Toledo et al., 2007).  
 
 
 
 
Bianchi 
2002 
 
Hawkins  
2002 
 
Johnson  
2002 
 
Reuveny  
2005 
 
van’t Hul  
2006 
 
Toledo 
2007 
 
Eligibility criteria* 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Random allocation 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Concealed allocation 
 
Yes 
 
Yes 
 
No 
 
Yes 
 
Yes 
 
No 
 
Baseline comparability 
 
Yes 
 
Yes 
 
No 
 
Yes 
 
Yes 
 
Yes 
 
Participant blinding 
 
No 
 
No 
 
No 
 
No 
 
Yes 
 
No 
 
Therapist blinding 
 
No 
 
No 
 
No 
 
No 
 
No 
 
No 
 
Assessor blinding 
 
No 
 
No 
 
No 
 
Yes 
 
Yes 
 
Yes 
 
< 15% dropouts 
 
No 
 
No 
 
No 
 
No 
 
No 
 
No 
 
Intention-to-treat analysis 
 
Yes 
 
No 
 
No 
 
No 
 
Yes 
 
No 
 
Between-group difference 
reported 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Point estimates and 
variability reported 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Total score (/10) 
 
6/10 
 
5/10 
 
3/10 
 
6/10 
 
8/10 
 
5/10 
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Despite both studies using incremental treadmill tests to assess peak exercise capacity, study results 
were not combined as different constructs were measured (one protocol measured peak work, the other 
measured peak walking speed).  Peak O2 consumption (VO2) during an incremental treadmill test was 
also reported in two studies (Reuveny et al., 2005; Toledo et al., 2007).  The pooled effect size (mean 
difference) was 0.12 L/min (95% CI -0.08 to 0.31).  The remaining study (van 't Hul et al., 2006) 
measured peak exercise capacity using the incremental shuttle walk test (ISWT).  While a meta-
analysis was not performed for this outcome, the individual study effect size of 17.0 metres (95% CI -
2.4 to 36.4) was lower than the MCID of 47.5 metres (95% CI 38.6 to 56.8) for this test (Singh et al., 
2008).  A significant difference in peak exercise capacity was observed when the percentage change in 
peak work rate was assessed in three studies (Hawkins et al., 2002; Johnson et al., 2002; Reuveny et 
al., 2005) in a combined total of 30 subjects who received NIV during exercise training and 30 control 
subjects who received exercise training alone.  The common effect (mean difference) was 17.0% (95% 
CI 6.8 to 27.2) in favour of training with NIV.  However, as the MCID is unknown the clinical 
significance of this finding remains uncertain. 
 
Endurance exercise capacity was assessed using a constant work rate cycle ergometer test in two 
studies (Hawkins et al., 2002; van 't Hul et al., 2006) in a combined total of 25 subjects who trained 
with NIV and 23 control subjects.  The common effect size (mean difference) for endurance time was 
3.62 minutes (95% CI -0.17 to 7.41).  The inferior limit of the CI was lower than the suggested MCID 
of 1.75 minutes for a constant work rate endurance test (Casaburi, 2004).  When the summary effect 
size was expressed as the percentage change from baseline, the pooled effect size (mean difference) 
was 58.7% (95% CI 3.7 to 113.6) in favour of training with NIV.  Similar to the finding for percent 
change in peak exercise capacity, the clinical significance of this finding is unknown.  
 
Functional exercise capacity was measured in one study (Bianchi et al., 2002) using the six minute 
walk test (6MWT).  The MCID for the 6MWT is 25 metres in people with COPD (95% CI 20 to 61) 
(Holland et al., 2010).  A meta-analysis could not be performed for this outcome however the 
individual study results demonstrate that no statistically significant difference was found between 
training with NIV or exercise training alone (mean difference 4.3 metres, 95% CI -64.1 to 72.7).  
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Detailed results for exercise capacity are displayed in Table 4.3 and forest plots are presented in 
Figure 4.3.1. 
 
Health related quality of life 
Health related quality of life was measured in two studies (Bianchi et al., 2002; van 't Hul et al., 2006) 
using the St George’s Respiratory Questionnaire (SGRQ).  A combined total of 24 subjects who 
trained with NIV and 24 control subjects who trained unassisted were analysed. For the SGRQ, a 
reduction of 4 units in the total score has been shown to represent a clinically worthwhile 
improvement in HRQL (Jones, 2002).  No statistically significant change in HRQL was found 
between training with or without NIV with a pooled effect size (mean difference) for the SGRQ total 
score of 2.5 (95% CI -2.3 to 7.2).  Similar results were also found for the three sub-scales of the 
SGRQ: symptoms, activity, and impact (Table 4.3, Figure 4.3.2).   
 
Physical activity 
None of the included studies reported physical activity as an outcome. 
 
Secondary Outcomes 
Physiological outcomes 
There was no evidence of an effect between exercise training with NIV and exercise training alone for 
post training peak exercise minute ventilation (VE), isotime exercise VE, peak exercise lactate, or the 
change in VO2 at the anaerobic threshold.  However, a significant decrease in isoload lactate was 
observed, in favour of training with NIV, when data was combined from two studies (Hawkins et al., 
2002; Toledo et al., 2007).  A pooled effect (mean difference) of -0.96 mmol/L (95% CI -1.60 to -
0.33) was observed, providing evidence of an added training effect associated with the use of NIV 
during exercise (Table 4.4, Figure 4.3.3). 
 
Dyspnoea 
Isotime exercise dyspnoea was measured in three studies (total of 28 subjects who trained with NIV, 
28 subjects who performed exercise training alone).  No evidence of an effect was detected between 
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exercise training with NIV and exercise training alone, with a pooled effect size (mean difference) of -
0.33 points on the Borg dyspnoea scale (95% CI -0.83 to 0.16) which was well below the MCID (1 
point) for this outcome (Ries, 2005) (Table 4.4, Figure 4.3.4).   
 
Adverse events/drop-outs 
No adverse events were reported.  Drop-outs were no greater when participants used NIV during 
exercise training compared to exercise training alone, or exercise training with sham NIV (OR 1.30 
(0.62 to 2.71), indicating that the addition of NIV during exercise training was acceptable to 
participants (Table 4.4, Figure 4.3.5). 
 
Training intensity 
Four studies reported the percentage change in training intensity during the final training session 
(compared to baseline) in a combined total of 43 subjects who trained with NIV and 43 control 
subjects who performed exercise training alone.  The pooled effect (mean difference) was 17.8% (95% 
CI 3.1 to 32.5) indicating that a higher training intensity was achieved with NIV (Table 4.4, Figure 
4.3.6). 
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Table 4.3 Effect of non-invasive ventilation (NIV) during exercise training on exercise capacity and health related quality of life compared to exercise 
training alone or exercise training with sham NIV 
 
 
References: 1Bianchi et al (2002); 2Hawkins et al (2002); 3Johnson et al (2002); 4Reuveny et al (2005), 5van’t Hul et al (2006); 6Toledo et al (2007). METs: metabolic equivalents; VO2: oxygen uptake; 
CWR: constant work rate; 6MWD: six minute walk distance; ISWT: incremental shuttle walk test; SGRQ: St George’s Respiratory Questionnaire; IV: inverse variance; GIV: generic inverse variance 
 
Outcome 
 
Studies (n) 
 
Participants (n) 
 
References 
 
Statistical method 
 
Effect size 
 
Heterogeneity  
 
     
 
p value 
 
I2 (%) 
 
Exercise capacity 
 
 
    
 
 
 
 
 
Peak cycle work rate (watts) 
 
3 
 
57 
 
1, 2, 4 
 
Mean Difference (IV, Random, 95% CI) 
 
6.34 (-1.66, 14.34) 
 
0.95 
 
0 
 
Peak treadmill walking speed (km/h) 
 
1 
 
18 
 
6 
 
Mean Difference (IV, Random, 95% CI) 
 
0 (-0.92, 0.92) 
 
1.00 
 
N/A 
 
Peak work rate (METs) 
 
1 
 
22 
 
3 
 
Mean Difference (IV, Random, 95% CI) 
 
0.18 (-0.80, 1.16) 
 
0.72 
 
N/A 
 
Peak work rate (% change) 
 
3 
 
60 
 
2, 3, 4 
 
Mean Difference (IV, Random, 95% CI) 
 
17.01 (6.83, 27.19) 
 
0.92 
 
0 
 
Peak VO2 (L/min) 
 
2 
 
37 
 
4, 6 
 
Mean Difference (IV, Random, 95% CI) 
 
0.12 (-0.08, 0.31) 
 
0.61 
 
0 
 
Peak VO2 (% change) 
 
1 
 
19 
 
4 
 
Mean Difference (IV, Random, 95% CI) 
 
21.10 (5.19, 37.01) 
 
0.009 
 
N/A 
 
CWR endurance time (min) 
 
2 
 
48 
 
2, 5 
 
Mean Difference (IV, Random, 95% CI) 
 
3.62 (-0.17, 7.41) 
 
0.89 
 
0 
 
CWR endurance time (% change) 
 
2 
 
48 
 
2, 5 
 
Mean Difference (IV, Random, 95% CI) 
 
58.7 (3.7, 113.6) 
 
0.64 
 
0 
 
6MWD (m) 
 
1 
 
19 
 
1 
 
Mean Difference (IV, Random, 95% CI) 
 
4.30 (-64.07, 72.67) 
 
0.90 
 
N/A 
 
ISWT distance  (m) 
 
1 
 
29 
 
5 
 
Mean Difference (IV, Random, 95% CI) 
 
17.0 (-2.41, 36.41) 
 
0.09 
 
N/A 
  
ISWT distance (% change) 
 
1 
 
29 
 
5 
 
Mean Difference (IV, Random, 95% CI) 
 
13.0 (2.03, 23.97) 
 
0.02 
 
N/A 
 
Incremental treadmill test distance (m) 
 
1 
 
18 
 
6 
 
Mean Difference (IV, Random, 95% CI) 
  
30.9 (-250.6, 312.4) 
 
0.83 
 
N/A 
 
Health related quality of life 
 
 
 
 
    
 
SGRQ – Total score  
 
2 
 
48 
 
1, 5 
 
Mean Difference (GIV, Random, 95% CI) 
 
2.45 (-2.30, 7.20) 
 
0.77 
 
0 
 
SGRQ – Symptoms 
 
2 
 
48 
 
1, 5 
 
Mean Difference (GIV, Random, 95% CI) 
 
0.87 (-10.19, 11.93) 
 
0.63 
 
0 
 
SGRQ – Activity 
 
2 
 
48 
 
1, 5 
 
Mean Difference (GIV, Random, 95% CI) 
 
0.05 (-14.92, 15.02) 
 
0.04 
 
77 
 
SGRQ – Impact 
 
2 
 
48 
 
1, 5 
 
Mean Difference (GIV, Random, 95% CI) 
 
0.11 (-6.82, 7.05) 
 
 
0.99 
 
0 
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Table 4.4 Effect of non-invasive ventilation (NIV) during exercise training on physiological outcomes, dyspnoea, dropout rate and training intensity 
compared to exercise training alone or exercise training with sham NIV 
 
 
References: 1Bianchi et al (2002); 2Hawkins et al (2002); 3Johnson et al (2002); 4Reuveny et al (2005), 5van’t Hul et al (2006); 6Toledo et al (2007). VE: minute ventilation; La: lactate; VO2: oxygen 
uptake; AT: anaerobic threshold; O2: oxygen; GIV: generic inverse variance; IV: inverse variance; M-H: Mantel-Haenszel; N/A: not applicable 
 
 
Outcome 
 
Studies (n) 
 
Participants (n) 
 
References 
 
Statistical method 
 
Effect size 
 
Heterogeneity 
       
p value 
 
I2 (%) 
 
Physiological 
 
 
      
 
Peak exercise VE 
 
3 
 
57 
 
1, 2, 4 
 
Mean Difference (GIV, Random, 95% CI) 
 
2.68 (-2.02, 7.37) 
 
0.99 
 
0 
 
Peak exercise VE (% change) 
 
1 
 
19 
 
4 
 
Mean Difference (IV, Random, 95% CI) 
 
- 
 
- 
 
N/A 
 
Isotime exercise VE 
 
3 
 
67 
 
1, 2, 5 
 
Mean Difference (GIV, Random, 95% CI) 
 
-0.08 (-2.82, 2.67) 
 
0.83 
 
0 
 
Peak exercise La (mmol/L) 
 
3 
 
56 
 
2, 4, 6 
 
Mean Difference (IV, Random, 95% CI) 
 
-0.35 (-1.10, 0.41) 
 
0.09 
 
59 
 
Isoload exercise La (mmol/L) 
 
2 
 
37 
 
2, 6 
 
Mean Difference (IV, Random, 95% CI) 
 
-0.96 (-1.60, -0.33) 
 
0.30 
 
7 
 
Change in VO2 at AT 
 
2 
 
38 
 
1, 4 
 
Mean Difference (GIV, Random, 95% CI) 
 
0.05 (-0.10, 0.20) 
 
0.28 
 
15 
 
Peak exercise AT (% change) 
 
1 
 
19 
 
4 
 
Mean Difference (IV, Random, 95% CI) 
 
6.30 (-8.03, 20.63) 
 
0.39 
 
N/A 
 
Peak exercise O2 pulse (mL/beat) 
 
1 
 
19 
 
4 
 
Mean Difference (IV, Random, 95% CI) 
 
1.00 (-0.80, 2.80) 
 
0.28 
 
N/A 
 
Dyspnoea 
 
 
 
 
    
 
Isotime dyspnoea (Borg) 
 
3 
 
56 
 
1, 2, 6 
 
Mean Difference (GIV, Random, 95% CI) 
 
-0.33 (-0.83, 0.16) 
 
0.82 
 
0 
 
Drop-outs 
  
 
    
 
Drop-outs 
 
5 
 
169 
 
1, 2, 3, 4, 5 
 
Odds ratio (M-H, Random, 95% CI) 
 
1.30 (0.62, 2.71) 
 
0.80 
 
0 
 
Training intensity 
  
 
    
 
Peak cycle training intensity (watts) 
 
1 
 
19 
 
2 
 
Mean Difference (IV, Random, 95% CI) 
 
5.00 (-3.99, 13.99) 
 
0.28 
 
N/A 
 
Peak treadmill training speed (km/h) 
 
1 
 
19 
 
4 
 
Mean Difference (IV, Random, 95% CI) 
 
0 (-0.47, 0.47) 
 
1.00 
 
N/A 
   
Training intensity last session (% change) 
 
4 
 
86 
 
1, 2, 4, 5 
 
Mean Difference (IV, Random, 95% CI) 
 
17.8 (3.1, 32.5) 
 
 
0.009 
 
74 
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1a) Exercise capacity: Peak cycle work rate (watts) 
 
 
 
 
1b) Exercise capacity: Peak treadmill walking speed (km/h) 
 
 
 
 
1c) Exercise capacity: Peak work rate (METs) 
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1d) Exercise capacity: Peak work rate (% change) 
 
 
 
 
1e) Exercise capacity: Peak VO2 (L/min) 
 
 
 
 
1f) Exercise capacity: Peak VO2 (% change) 
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1g) Exercise capacity: Constant work rate endurance time (min) 
 
 
 
 
1h) Exercise capacity: Constant work rate endurance time (% change) 
 
 
 
 
1i) Exercise capacity: Six minute walk distance (m) 
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1j) Exercise capacity: Incremental shuttle walk distance (m) 
 
 
 
 
1k) Exercise capacity: Incremental shuttle walk distance (% change) 
 
 
 
 
1l) Exercise capacity: Incremental treadmill test distance (m) 
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2a) Health related quality of life: St George’s Respiratory Questionnaire (Total score) 
 
 
 
 
2b) Health related quality of life: St George’s Respiratory Questionnaire (Symptoms) 
 
 
 
 
2c) Health related quality of life: St George’s Respiratory Questionnaire (Activity) 
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2d) Health related quality of life: St George’s Respiratory Questionnaire (Impact) 
 
 
 
 
3a) Physiological: Peak exercise minute ventilation 
 
 
 
 
3b) Physiological: Peak exercise minute ventilation (% change) 
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3c) Physiological: Isotime exercise minute ventilation 
 
 
 
 
3d) Physiological: Peak exercise lactate (mmol/L) 
 
 
 
 
3e) Physiological: Isoload exercise lactate (mmol/L) 
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3f) Physiological: Change in VO2 at anaerobic threshold    
 
 
 
3g) Physiological: Peak exercise anaerobic threshold (% change) 
 
 
 
 
3h) Physiological: Peak exercise O2 pulse (mL/beat) 
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4) Dyspnoea: Isotime exercise dyspnoea (Borg) 
 
 
 
 
5) Drop-outs 
 
 
 
 
6a) Training intensity: Peak cycle training intensity (watts) 
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6b) Training intensity: Peak treadmill training speed (km/h) 
 
 
 
 
6c) Training intensity: Training intensity last session (% change) 
 
 
 
 
Figure 4.3  Forest plots of effect sizes for primary and secondary outcome measures: 1) Exercise capacity; 2) Health related quality of life;  
 3) Physiological outcomes; 4) Dyspnoea; 5) Drop-outs; and 6) Training intensity
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Heterogeneity 
Significant statistical heterogeneity across studies was found in three analyses: Activity sub-section of 
the SGRQ (χ2 = 4.44, p = 0.04, I2 = 77%); peak exercise lactate (χ2 =4.93, p = 0.09, I2 = 59%); and 
percentage change in training intensity during the final training session (χ2 = 11.59, p = 0.009, I2 = 
74%) (Table 4.3, Figure 4.3).  As the number of included trials for each outcome was small (range 2 - 
4) sub-group analyses could not be performed.  Factors that were specified a priori as a potential basis 
for sub-group analyses are summarised for each included study in Table 4.5. 
 
 
Table 4.5 Summary of factors considered as a basis for sub-group analyses where 
heterogeneity was detected across studies 
 
GOLD: Global initiative for chronic obstructive lung disease (Gold, 2009); O2: oxygen; PAV: proportional assist ventilation; 
PS: pressure support  
 
 
Sensitivity analyses 
Sensitivity analyses were limited to those outcomes that included data from three or more studies in 
the initial analysis. 
  
Disease 
severity 
(GOLD 
criteria) 
 
 
Ventilatory 
limitation 
to exercise 
 
Level of 
ventilatory 
support 
 
Blinding 
 
O2 
during 
training 
 
Duration 
of 
program 
(weeks) 
 
Lower 
limb 
or 
upper 
limb 
 
Treadmill 
or cycle 
training 
 
Treadmill 
or cycle 
testing 
 
Bianchi 
‘02 
 
 
Moderate 
- Severe 
 
No 
 
“Low”  
PAV 
 
 
No 
 
No 
 
6 
 
Lower 
limb 
 
Cycle 
 
Cycle +  
field walk 
 
Hawkins 
‘02 
 
 
Very 
severe 
 
No 
 
“Moderate”  
PAV 
 
 
No 
 
No 
 
6 
 
Lower 
limb 
 
Cycle 
 
Cycle 
 
Johnson 
‘02 
 
 
Severe 
 
No 
 
“Low-
moderate” 
PS 6-10 
cmH2O 
 
 
No 
 
No 
 
6 
 
Lower 
limb 
 
Treadmill 
 
Treadmill 
 
Reuveny 
‘05 
 
 
Severe 
 
Yes 
 
“Low”  
PS 5-8 
cmH2O 
 
 
Yes  
(assessors) 
 
Yes 
 
8 
 
Lower 
limb 
 
Treadmill 
 
Cycle 
 
van’t Hul 
‘06 
 
 
Severe 
 
Yes 
 
“Moderate”  
PS 10 
cmH2O 
 
Yes 
(subjects 
and 
assessors) 
 
No 
 
8 
 
Lower 
limb 
 
Cycle 
 
Cycle +  
field walk 
 
 
Toledo 
‘07 
 
 
Severe 
 
No 
 
“Low-
moderate” 
PS 5-10 
cmH2O 
 
 
Yes 
(assessors) 
 
No 
 
12 
 
Lower 
limb 
 
Treadmill 
 
Treadmill 
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Participant Characteristics   
One study recruited subjects with moderate to severe COPD (Bianchi et al., 2002) whereas the other 
included studies recruited subjects with severe to very severe COPD.  Sensitivity analyses were 
performed by re-running analyses without data from Bianchi and colleagues (2002) in order to 
determine the robustness of the results.  Sensitivity analyses were performed on the following 
outcomes: peak cycle work rate; peak exercise VE; isotime exercise VE; isotime exercise dyspnoea; 
training intensity for the last training session (% change from baseline).  For each outcome, the 
direction and magnitude of the pooled effect generally did not change when the analysis was 
performed without data from Bianchi et al (2002), which suggests that the results are robust (Table 
4.6).       
 
Methodological Quality 
Blinding 
Only one study blinded both participants and assessors to training with NIV (van 't Hul et al., 2006).  
Analyses were re-run after data from this study was excluded in order to see whether the effect size 
was substantially different (eg overestimated) in the remaining trials.  Two outcomes were assessed, 
isotime exercise VE and training intensity for the last training session (% change from baseline).  For 
both outcomes, the direction and magnitude of the combined effect did not change substantially (Table 
4.6). 
 
Allocation concealment 
Allocation concealment was not adequately described in two studies (Johnson et al., 2002; Reuveny et 
al., 2005).  In addition, another study (Hawkins et al., 2002) used block randomisation and was 
unblinded, which may have enabled the prediction of future group allocation for a small number of 
subjects (n = 4/29) as the block size was fixed (Berger, 2005).  To determine whether the treatment 
effect had been overestimated due to inclusion of studies without adequate allocation concealment, 
analyses of peak cycle work rate (watts), peak exercise VE, peak exercise blood lactate and training 
intensity for the last training session were re-run after removal of data from Reuveny et al (2005).  The 
magnitude of the effect size for training intensity was slightly reduced with the re-analysis, whereas 
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minimal change was detected in the estimates for the other outcomes (Table 4.6). 
 
Characteristics of the Exercise Training Program 
As previously discussed, the duration of the exercise training program in the study conducted by 
Toledo and colleagues (2007) was approximately twice as long as the other studies included in the 
review.  Sensitivity analyses were performed after removal of data from this study for the following 
outcomes: peak exercise lactate; isotime exercise dyspnoea.  No substantial difference was found in 
the pooled effect for either outcome (Table 4.6). 
 
Change from Baseline Data versus Post Intervention Data 
For the outcome peak work rate, one of the three studies included in the analysis (Johnson et al., 2002) 
reported a statistically (and possibly clinically) significant difference between groups at baseline with 
respect to exercise capacity.  To account for the baseline differences between groups, percentage 
change from baseline data was used in the primary analysis for peak work rate rather than post 
intervention values.  A statistically significant effect size was found in favour of training with NIV 
(mean difference 17%, 95% CI 7 to 27).  To determine whether this result was robust, a sensitivity 
analysis was performed using post intervention data rather than change from baseline data.  Two 
studies reported peak work rate in watts (Hawkins et al., 2002; Reuveny et al., 2005) whereas Johnson 
and coworkers (2002) reported peak work rate in METs.  In order to combine study data, the results 
were standardised using the pooled SD within each study and the treatment effect was defined as the 
standardised mean difference.  When post intervention data was used in the analysis, no statistically 
significant effect size was found (standardised mean difference 0.09, 95% CI -0.43 to 0.61), indicating 
that the result was not robust when baseline differences were not accounted for. 
 
 189 
Table 4.6 Sensitivity analyses 
 
Sensitivity analyses were performed for: a) Participant characteristics: after removal of a study that recruited a milder group of subjects (Bianchi et al., 2002); b)i) Methodological quality: after removal 
of a study that blinded participants and assessors (van 't Hul et al., 2006); b)ii) Methodological quality: after removal of a study with inadequate reporting of allocation concealment; c) Characteristics of 
the exercise training program: after removal of a study with a longer training program duration (Toledo et al., 2007).  References: 1Bianchi et al (2002); 2Hawkins et al (2002); 3Johnson et al (2002); 
4Reuveny et al (2005), 5van’t Hul et al (2006); 6Toledo et al (2007).  VE: minute ventilation; SGRQ: St George’s Respiratory Questionnaire
 
Outcome 
 
Full analysis 
 
Sensitivity analysis 
  
Studies included in analysis 
 
Effect size 
 
Studies included in analysis 
 
Effect size 
 
a) Participant characteristics 
 
Peak cycle work rate (watts) 
 
1, 2, 4 
 
6.34 (-1.66 to 14.34) 
 
2, 4 
 
6.33 (-2.02 to 14.67) 
 
Peak exercise VE (L/min) 
 
1, 2, 4 
 
2.68 (-2.02 to 7.37) 
 
2, 4 
 
2.60 (-2.35 to 7.55) 
 
Isotime exercise VE (L/min) 
 
1, 2, 5 
 
-0.08 (-2.82 to 2.67) 
 
2, 5 
 
-0.68 (-4.89 to 3.52) 
 
Isotime exercise dyspnoea (Borg) 
 
1, 2, 6 
 
-0.33 (-0.83 to 0.16) 
 
2, 6 
 
-0.34 (-0.86 to 0.17) 
 
Training intensity last session (%) 
 
1, 2, 4, 5 
 
17.78 (3.12 to 32.45) 
 
2, 4, 5 
 
21.17 (13.28 to 29.05) 
 
b) Methodological quality 
 
(i) Isotime exercise VE (L/min) 
 
1, 2, 5 
 
-0.08 (-2.82 to 2.67) 
 
1, 2 
 
0.30 (-2.70 to 3.30) 
 
(i) Training intensity last session (%) 
 
1, 2, 4, 5 
 
17.78 (3.12 to 32.45) 
 
1, 2, 4 
 
13.12 (5.83 to 20.40) 
 
(ii) Peak cycle work rate (watts) 
 
1, 2, 4
 
 
6.34 (-1.66 to 14.34) 
 
1 2
 
 
5.45 (-4.48 to 15.37) 
 
(ii) Peak exercise VE (L/min) 
 
1, 2, 4
 
 
2.68 (-2.02 to 7.37) 
 
1, 2
 
 
2.54 (-3.09 to 8.48) 
 
(ii) Peak exercise lactate (mmol/L) 
 
2, 4, 6
 
 
-0.35 (-1.10 to 0.41) 
 
2,6 
 
-0.62 (-1.22 to -0.01) 
 
(ii) Training intensity last session (%) 
 
1, 2, 4, 5
 
 
17.78 (3.12 to 32.45) 
 
1, 2, 5 
 
13.43 (6.75 to 20.12) 
 
c) Characteristics of exercise training program 
 
Peak exercise lactate (mmol/L) 
 
2, 4, 6 
 
-0.35 (-1.10 to 0.41) 
 
2, 4 
 
-0.04 (-0.55 to 0.62) 
 
Isotime exercise dyspnoea (Borg) 
 
 
1, 2 , 6
 
 
-0.33 (-0.83 to 0.16) 
 
1, 2
 
 
-0.39 (-0.92 to 0.14) 
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DISCUSSION 
Summary of main results 
Pulmonary rehabilitation, with exercise training as a key component, is well established as a standard 
of care for patients with COPD, with demonstrated improvements in exercise capacity, HRQL and 
dyspnoea (Lacasse et al., 2006).  The aim of this systematic review was to determine whether NIV 
during exercise training could provide benefits to exercise capacity, HRQL and physical activity levels 
above that of exercise training alone in people with COPD.  This review provides evidence that NIV 
during exercise training results in greater percentage improvements in both peak (mean 17%) and 
endurance exercise capacity (mean 59%) compared with exercise training alone or exercise training 
with sham NIV.  However, a statistically significant treatment effect was only found when peak 
exercise capacity was reported as percentage change from baseline, rather than peak watts or VO2 
peak.  One possible explanation for this difference in results is that if large inter-individual or inter-
group differences in baseline performance were present, the use of change from baseline values rather 
than post intervention values would provide greater statistical power to detect treatment effects.  For 
example, a sensitivity analysis demonstrated that the results for the percentage change in peak work 
rate were not robust when the analysis was re-run using post intervention data and baseline differences 
were not accounted for.  In addition, the effect size that was calculated for the percentage change in 
peak exercise capacity may have been overestimated for several reasons.  Firstly, participants were not 
blinded in any of the three studies included in the analysis, and only one study used a blind assessor.  
In addition, it is unclear whether allocation concealment was adequate in two studies (Johnson et al., 
2002; Reuveny et al., 2005) and the study by Hawkins et al (2002) used block randomisation which 
may have compromised allocation concealment for a small number of participants, as the study was 
unblinded.  Significant differences in baseline peak exercise capacity between groups were also 
reported by Johnson et al (2002) which could have biased participants responses to the intervention.  
Consequently, the finding that NIV during exercise training increased peak exercise capacity is 
weakened due to the increased risk of bias within the included studies. 
 
Similarly, a statistically significant treatment effect for constant work rate endurance exercise capacity 
was only found when endurance time was expressed as percentage change rather than time in minutes.  
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As previously discussed, greater statistical power may have been achieved by using percentage change 
values rather than post intervention values if large inter-individual differences in baseline performance 
were present.  In contrast to analyses of peak exercise capacity, one of the two studies included in 
these analyses (van 't Hul et al., 2006) blinded both participants and assessors to the intervention.  
While the remaining study (Hawkins et al., 2002) was unblinded and allocation concealment may have 
been compromised for some participants, no heterogeneity was detected across the studies.  Therefore, 
this finding can be interpreted with a greater level of confidence.  Furthermore, endurance exercise 
capacity may be more relevant to people with COPD than peak exercise capacity given that most daily 
activities are performed at a submaximal level (Oga et al., 2000).  However, interpretation of the 
clinical significance of these results is difficult, as the MCID for percentage change in peak or 
endurance exercise capacity is unknown.  
 
No evidence was found to indicate that HRQL was better or worse with NIV during exercise training 
compared with exercise training alone or exercise training with sham NIV.  However, the number of 
studies included in the analysis was small and as a result, statistical power to detect differences 
between training with and without NIV was likely to have been poor, particularly given the variety of 
factors that could have affected HRQL.  In addition, significant heterogeneity was found across studies 
for the ‘Activity’ sub-section of the SGRQ and could not be investigated further due to the small 
number of studies included in the analysis.  Consequently, the effect of NIV during exercise training 
on this domain remains uncertain.   
 
The ability to achieve greater improvements in exercise capacity may relate to the following findings.  
Firstly, NIV during exercise allowed participants to exercise at a significantly higher training intensity 
(mean 18%) compared to exercise training alone or exercise training with sham NIV.  There was 
significant heterogeneity in treatment effects across the studies, and differences relating to blinding.  
Nevertheless the results appear to be robust as the effect size did not vary significantly after sensitivity 
analyses were performed.  Secondly, significantly lower lactate levels were observed at isoload 
exercise (mean -0.96 mmol/L) after training with NIV, which demonstrates a physiological training 
effect above that of exercise training alone or exercise training with sham NIV.  Of the two studies 
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included in this analysis, participants were not blinded to the intervention and only one study (Toledo 
et al., 2007) used a blinded assessor.  While measurement of an objective physiological outcome such 
as isoload blood lactate may be less prone to bias during the performance of post-training exercise 
tests, neither study blinded trainers to group allocation which still could have introduced performance 
bias.  In addition, allocation concealment may have been compromised in the other study (Hawkins et 
al., 2002).  As a result, the reported effect size may be exaggerated.  Although isoload lactate was 
found to be reduced to a greater extent after training with NIV compared to exercise training alone, 
there was no evidence of a significant effect on isotime VE or isotime dyspnoea. 
 
Overall, participants were no more likely to drop-out, or complete the exercise training program when 
NIV was used during exercise.  Thus, it appears that NIV during exercise training is as acceptable to 
people with COPD as exercise training alone.  On closer examination, the reasons for dropping out did 
vary between groups in some studies.  For example, van’t Hul and colleagues (2006) recruited a highly 
selected population who were tolerant of NIV and had a ventilatory limitation to exercise.  None of 
these subjects dropped out due to issues relating to NIV.  Whereas, almost one third of the subjects 
allocated to training with NIV in the study by Bianchi and associates (2002) dropped out due to 
intolerance of NIV.  The impact of factors such as acclimatisation to NIV, NIV mode and settings, or 
subject characteristics on the reason for dropping out is unclear.  In the combined total of 63 subjects 
who trained with NIV, no adverse events were reported which suggests that NIV is safe to use during 
exercise training in people with moderate to very severe COPD. 
 
Overall completeness and applicability of evidence 
While the present review provides some evidence that NIV during exercise training allows people with 
COPD to exercise at a higher intensity, achieve a greater physiological training effect and improve 
lower limb exercise capacity compared to exercise training alone, many questions still remain.  Firstly, 
it is unclear whether the improvements in peak and endurance lower limb exercise capacity are 
clinically meaningful.  In addition, tests of functional exercise capacity were only reported in two 
studies. However different tests were used and therefore data could not be combined.  Bianchi and 
colleagues (2002) used the 6MWT (Butland et al., 1982) and van’t Hul and coworkers (2006) used the 
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ISWT (Singh et al., 1992).  The 6MWT reflects daily activities better than other walk tests (Solway et 
al., 2001) and has been shown to correlate highly with physical activity (Pitta et al., 2005).  The 
addition of a functional exercise test such as the 6MWT to the assessment of exercise capacity in 
future trials, particularly when the MCID is known, may assist to assess whether a treatment effect is 
clinically worthwhile.  Secondly, none of the included studies reported the effect of NIV during upper 
limb exercise training.  In addition, there is no evidence that HRQL is better or worse with NIV during 
exercise training however this was only assessed in two studies.  Of note, significant heterogeneity 
was found between the two included studies (Bianchi et al., 2002; van 't Hul et al., 2006) for the 
activity sub-section of the SGRQ, which requires further investigation.  Finally, physical activity was 
not reported in any of the included studies.  Clearly, additional RCTs are required to address these 
questions. 
 
The characteristics of individuals who are most likely to benefit from NIV during exercise training, 
and the optimal mode of ventilation and settings for exercise remain unclear.  The studies included in 
the current review recruited participants with a mean FEV1 (% predicted) of 26 - 41%, or severe to 
very severe COPD (Gold, 2009), with the exception of one study (Bianchi et al., 2002) that recruited 
participants with moderate to severe COPD.  In addition, two studies (Reuveny et al., 2005; van 't Hul 
et al., 2006) selected participants who demonstrated a very limited ventilatory reserve at peak 
unassisted exercise, suggestive of a ventilatory limitation to exercise.  In the later study (van 't Hul et 
al., 2006), participants were also only included if they were tolerant of NIV, indicating that 
participants were highly selected.  Two studies reported drop-outs due to poor tolerance of NIV 
(Bianchi et al., 2002; Reuveny et al., 2005).  Poor tolerance of NIV could have related to selection of 
subjects with less severe COPD (Bianchi et al., 2002) or the provision of lower levels of ventilatory 
support (Bianchi et al., 2002; Reuveny et al., 2005) compared with other studies (Hawkins et al., 2002; 
van 't Hul et al., 2006).  While the studies included in the present review were reasonably 
homogeneous with respect to the exercise training programs, there was a substantial degree of 
diversity with respect to the delivery of NIV.  Three different NIV modes were used (bilevel, PAV and 
IPS) and level of ventilatory support ranged from a low to a medium level.  None of the included 
studies assessed high level pressure support which has shown promising results during walking in 
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people with very severe COPD (Dreher et al., 2007).  During pressure preset ventilation, the amount of 
tidal volume assistance delivered will vary depending on factors such as respiratory system 
compliance, airways resistance and inspiratory time (Mehta & Hill, 2001).  As a result, a given level 
of pressure support can have a different effect between subjects and even within a subject, for example 
if dynamic hyperinflation occurs during exercise and respiratory system compliance is reduced.  
However, as sub-group analyses could not be performed, the influence of these factors on the 
treatment effects associated with NIV during exercise training are unknown.  Consequently, the 
findings of this review may not be applicable to all people with moderate to very severe COPD, and 
the optimal mode and settings for ventilatory support remain are unknown.  Furthermore, while NIV 
during exercise training may benefit select individuals with COPD, implementation of this technique 
does have resource implications and would require experienced staff, access to appropriate equipment 
and may involve extra costs which could limit the feasibility of this technique in some settings.  
 
Quality of the evidence 
Six studies with a combined total of 126 subjects (63 trained with NIV during exercise; 63 performed 
exercise training alone or exercise training with sham NIV) were included in the current review.  
Methodological quality of the included studies ranged from low to high (PEDro scores 3/10 to 8/10).  
There were limitations in the literature in terms of the small number of studies that were included in 
the analyses, the small numbers of subjects within the included studies and issues relating to 
methodological quality such as a lack of blinding or inadequate reporting of allocation concealment.   
 
The key methodological limitation of the studies was the lack of blinding.  Only one study blinded 
participants, three used blinded assessors and none of the included studies blinded trainers which may 
have introduced bias.  Important outcomes reported in the present review, such as exercise capacity 
and HRQL, could be influenced by bias if the studies included in the analyses were unblinded.  
Unblinded studies have been shown to overestimate treatment effect size by 9% compared with 
blinded studies (Pildal et al., 2007).  Blinding an intervention such as NIV is difficult but may be 
achieved with the use of sham NIV.  However, if an inappropriate sham NIV is used, the treatment 
effect size could be altered due to sham NIV either impeding exercise performance or assisting 
 195 
exercise performance compared to what would have occurred during unassisted exercise.  That is, 
either falsely inflating or reducing the true effect of NIV during exercise training.  Therefore a sham 
NIV would need to be shown to be appropriate for a given patient population prior to commencement 
of a training study.  For example, the sham used by van’t Hul et al (2006) was previously 
demonstrated to have an equivalent effect on exercise performance as unassisted exercise (van 't Hul et 
al., 2004).  Sensitivity analyses were performed to determine whether a lack of blinding exaggerated 
effect sizes in the present review.  Due to the small number of included studies, this could only be 
performed for isotime exercise VE and the last session training intensity.  No substantial changes in 
effect size were observed, suggesting that these results are robust. 
 
Allocation concealment was adequately performed and reported in most of the trials.  However, two 
studies (Johnson et al., 2002; Reuveny et al., 2005) did not provide an adequate description of 
allocation concealment in the paper and the authors were unable to be contacted for additional 
information.  In addition, while allocation concealment was adequately described by Hawkins et al 
(2002), it may have been compromised for a small number of subjects as a result of block 
randomisation.  If the size of the blocks used during block randomisation are fixed and known, it may 
be possible to predict future group allocation for some participants in an unblinded trial, even if 
allocation concealment is satisfactory (Berger, 2005).  Inclusion of studies without adequate allocation 
concealment has been reported to overestimate effect size by 18-37% (Moher et al., 1998; Pildal et al., 
2007).  In the present review, only a limited number of sensitivity analyses could be conducted to 
assess the impact of including trials without adequate description of allocation concealment.  The 
change in effect size was small to negligible for the outcomes that were assessed, indicating that these 
results were also robust. 
 
Another factor which may have impacted the results of the current review is a lack of statistical power.  
Only six studies were eligible for inclusion in the review, and within each study, sample sizes were 
generally small with drop-out rates ranging from 21 - 42%.  In addition, a variety of measurement 
tools were used to assess outcomes of interest.  Consequently, only a small number of meta-analyses 
could be performed, often combining results from only 2-4 studies, occasionally with data from as few 
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as 37 subjects.  Statistical power also was probably compromised in individual studies.  Two studies 
(Reuveny et al., 2005; Toledo et al., 2007) failed to present results for post training between group 
comparisons of expected outcomes such as exercise capacity, despite conducting parallel RCTs to 
assess the effect of training with NIV versus exercise training alone.  This reporting bias may have 
occurred because significant results were not detected between groups.  Another study (Hawkins et al., 
2002) was powered to assess post training isoload blood lactate, however a combination of drop-outs 
and difficulty gaining vascular access in some subjects reduced the power of the study to detect a 
difference between groups.  However, when isoload blood lactate data from Hawkins and colleagues 
(2002) was combined with data from Toldeo et al (2007) in the present review, statistical power was 
improved and a difference was detected between interventions in favour of training with NIV.  A 
larger number of RCTs with greater numbers of participants are needed in order to achieve sufficient 
statistical power to confidently assess the effect of NIV during exercise training on key outcomes.     
 
Significant heterogeneity across studies was detected in only three analyses: HRQL (Activity sub-
section of the SGRQ), peak exercise blood lactate and training intensity.  The most likely reason for 
heterogeneity for the activity sub-section of the SGRQ was a difference in disease severity between 
the two studies.  Subjects recruited by van’t Hul and coworkers (2006) were more severe (based on 
FEV1 and ventilatory reserve at peak exercise) than those recruited by Bianchi et al (2002) and the 
authors of this first study found a trend for improvement in this outcome favouring training with NIV.  
In contrast, Bianchi and colleagues (2002) reported a trend for improvement in this outcome in favour 
of the control group.  It is unlikely that the treatment effect was overestimated by van’t Hul et al 
(2006) as allocation concealment was adequate and both participants and assessors were blinded.  
However sub-group and sensitivity analyses could not be performed to investigate the cause of 
heterogeneity as only two studies reported this outcome.  Three studies were included in the analysis 
of peak exercise blood lactate.  The training program in one study (Toledo et al., 2007) was 
substantially longer (12 weeks) than the programs in the other two studies (6-8 weeks) (Hawkins et al., 
2002; Reuveny et al., 2005).  Greater training effects can be achieved with a training program duration 
of 12 weeks or longer in comparison to programs with a duration of 6-8 weeks (Ries et al., 2007).  
This factor appeared to account for the difference in effect sizes between studies as demonstrated in a 
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sensitivity analysis where data from Toledo et al (2007) was removed and the effect size was 
decreased and the I2 reduced to zero.  Finally, two factors were likely to have contributed to 
heterogeneity across studies in the analysis of training intensity.  Firstly, differences in disease severity 
may have caused the differences in effect sizes.  As outlined above, a ‘milder’ group of subjects were 
recruited by Bianchi et al (2002) and no difference in training intensity was found between those who 
trained with NIV and the control group.  It appears that subjects with less severe disease may derive 
less benefit from NIV during exercise and subsequently NIV may not have augmented training 
intensity in this population.  Secondly, a larger effect size was reported by Reuveny et al (2005) 
compared with the other three studies included in the analysis.  Reuveny and colleagues (2005) 
recruited subjects with severe COPD and a very limited ventilatory reserve at peak exercise (ie a 
ventilatory limitation to exercise).  In contrast to the other studies included in the analysis where 
participants performed cycle training, participants in the study by Reuveny et al (2005) performed 
treadmill training.  Treadmill exercise is more likely to be limited by dyspnoea compared with cycling 
exercise (Man et al., 2003).  An important mechanism of NIV during exercise is the reduction of 
dyspnoea which is inversely proportional to respiratory muscle unloading (Maltais et al., 1995).  
Consequently, there might have been greater scope for respiratory muscle unloading and a reduction in 
dyspnoea in the study conducted by Reuveny et al (2005), which may have allowed patients to train at 
a higher intensity compared with unassisted exercise.  In addition, the study performed by Reuveny 
and colleagues (2005) used supplemental O2 during exercise training with and without NIV, whereas 
the other studies included in the analysis trained participants using room air.  As supplemental O2 
during exercise can allow subjects with COPD to exercise at a higher intensity compared to exercise 
without supplemental O2 (Emtner et al., 2003), the combination of NIV and O2 during exercise could 
have had an additive effect and may help to explain the larger effect size reported for training intensity 
by Reuveny et al (2005).    
 
Potential biases in the review process 
Strengths of the review process include: an ‘a priori’ design that was published (Menadue et al., 
2009a) prior to the review being conducted (several small alterations were made to the published 
protocol and are listed in the Method section under the heading ‘Differences between the protocol and 
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the review’); two independent reviewers extracted data and a consensus procedure for disagreement 
was outlined in advance; a comprehensive literature search was conducted (including non-English 
trials and grey literature); a list of included and excluded studies was provided; characteristics of the 
included studies were described; the scientific quality of the included studies was assessed, 
documented and incorporated into the formulation of conclusions; appropriate methods were used to 
combine data from studies; heterogeneity was assessed; and potential conflicts of interest were 
disclosed.  All of these factors are considered important in the assessment of methodological quality of 
a systematic review (Shea et al., 2007).  A potential weakness of the review process was the inability 
to assess for the likelihood of publication bias.  This was due to the small number of included studies 
in the present review, whereby meaningful funnel plots were not able to be produced  (Sterne et al., 
2008).  Publication bias can lead to overestimation of treatment effects (Sterne et al., 2008).  In an 
attempt to reduce the risk of publication bias in the current review, a number of clinical trials registers 
were searched, conference abstracts were reviewed and international experts in the field of NIV were 
asked to identify further published or unpublished trials.  However, no additional potential studies 
were found.  Not all of the studies included in the present review reported statistically significant 
results in favour of NIV during exercise training.  Nevertheless, publication bias cannot be excluded.     
 
Agreements and disagreements with other studies or reviews 
Similar to a systematic review that investigated the acute effects of NIV on exercise endurance time in 
COPD (van 't Hul et al., 2002), the present review found evidence that when this technique is 
employed over time, that is, NIV during exercise training, endurance exercise capacity is improved.  
In contrast to the current review, van’t Hul and coworkers (2002) also found evidence of a reduction in 
isotime dyspnoea with NIV during exercise.  The studies included in the review by van’t Hul and 
colleagues (2002) measured dyspnoea while subjects used NIV during exercise, whereas the studies 
included in the present review measured dyspnoea during unassisted exercise (after completion of 
exercise training with NIV).  The difference in results may simply reflect that the reduction in isotime 
dyspnoea with NIV is a temporary phenomenon related to respiratory muscle unloading (Maltais et al., 
1995) as a direct result of the application of NIV.   
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To date, one literature review has addressed the role of NIV during exercise training as part of a 
pulmonary rehabilitation program (Corner & Garrod, 2010).  In contrast to the current review, the 
review performed by Corner and Garrod (2010) excluded non-English trials and meta-analyses were 
not conducted.  While the same number of studies were included in each review (n = 6), Corner and 
Garrod (2010) included one quasi-randomised study (Costes et al., 2003) that was excluded from the 
present review, and excluded one RCT (Toledo et al., 2007) that was included in the present review.  
The findings of the present review generally support the conclusions drawn by Corner and Garrod 
(2010), who stated that NIV may allow patients with moderate to severe COPD to exercise at a higher 
intensity for a longer duration, which could in turn permit greater training effects and improvements in 
exercise capacity.  Similar to the current review, Corner and Garrod (2010) suggest that the benefits of 
NIV during exercise training appear greater in those subjects with more severe airflow obstruction.   
 
Recent pulmonary rehabilitation practice guidelines have included recommendations regarding the 
role of NIV as an adjunct to exercise training during pulmonary rehabilitation.  In 2006, the American 
Thoracic Society/ European Respiratory Society Statement on Pulmonary Rehabilitation 
recommended that “in selected patients with severe chronic respiratory disease and suboptimal 
response to exercise, NIV may be considered as adjunctive therapy since it may allow for greater 
training intensity through unloading respiratory muscles.  Because NIV is a very difficult and labour-
intensive intervention, it should be used only in those with demonstrated benefit from this therapy” 
(Nici et al., 2006).  In 2007, The Joint American College of Chest Physicians/ American Association 
of Cardiovascular and Pulmonary Rehabilitation Evidence-Based Clinical Practice Guidelines stated 
that NIV during exercise training may be of benefit to select patients with severe COPD and permit 
modest improvements in exercise performance above that of exercise training alone (Ries et al., 2007).  
The current review provides evidence to support some of these recommendations, for example that 
NIV during exercise allows a greater training intensity to be achieved and may lead to improvements 
in exercise performance above that of exercise training alone or exercise training with sham NIV.  The 
current review also suggests that greater benefits may be found in those subjects with more severe 
disease and a very limited ventilatory reserve at peak (unassisted) exercise.  However, more 
information is required to assist with appropriate selection of candidates for this technique.  While 
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some guidelines (Nici et al., 2006) recommend selecting subjects to train with NIV who have 
previously demonstrated an acute benefit from exercise with NIV, there is currently no evidence to 
suggest that selecting subjects on these grounds will result in greater training effects with NIV as the 
predictive validity of the acute response is low (van 't Hul et al., 2006).  Although a number of review 
articles (Nici et al., 2006; Troosters et al., 2005; Troosters et al., 2010c) allude to NIV during exercise 
training as being a difficult, costly and time consuming intervention, none of the studies included in 
the present review formally reported the additional costs associated with using NIV during exercise 
training when compared to exercise training alone.  Bianchi and colleagues (2002) did report that staff 
spent an average of 11 ± 3 minutes setting up the ventilator.  However, it is unclear whether this time 
was during each session or the duration of the rehabilitation program, or how this compared to the 
amount of time spent with the group who performed exercise training without NIV.  The issue of cost, 
in terms of staff time and additional resources, requires further investigation before conclusions can be 
drawn as to whether NIV could or could not be a cost effective adjunct to exercise training in people 
with COPD.  
 
Conclusions 
Implications for Practice 
This review provides evidence that NIV during exercise training allows people with COPD to exercise 
at a higher training intensity and to achieve a greater physiological training effect compared with 
exercise training alone or exercise training with sham NIV.  While there was evidence of improvement 
in some aspects of peak and endurance exercise capacity with NIV during exercise training, it is 
unknown whether these effects are clinically worthwhile.  In addition, most studies included in the 
meta-analyses that assessed effects on peak exercise capacity were unblinded, and one study did not 
provide an adequate description of allocation concealment which may have resulted in an 
overestimation of the effect size (Moher et al., 1998).  In contrast, both participants and assessors were 
blinded in one of the two studies included in the meta-analyses that assessed effects on endurance 
exercise capacity, and as no statistical heterogeneity was detected between studies, the results can be 
interpreted with a greater level of confidence.  No evidence was found to suggest that HRQL was 
better or worse with NIV during exercise training compared to exercise training alone or exercise 
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training with sham NIV.  Disease severity may be an important factor in patient selection for this 
technique, with greater benefits reported in subjects with severe airflow obstruction (defined by FEV1) 
compared to those with moderate airflow obstruction (Bianchi et al., 2002).  Although, the impact of 
disease severity on the efficacy of training with NIV could not be formally assessed in the present 
review.  Non-invasive ventilation during exercise training appears to be acceptable to people with 
COPD, however it is currently unknown whether the demonstrated benefits are clinically worthwhile 
or cost effective. 
 
Implications for Research 
In order to conclusively determine the effects of NIV during exercise training, further studies with 
larger numbers of participants are needed.  It is essential that studies use a strong methodological 
design that minimises the risk of bias, with a high quality of reporting to enable accurate assessment of 
the risk of bias.  In particular, blinding of study participants (eg using sham NIV), trainers and 
assessors is required, although this is arguably difficult with an intervention such as NIV.  Important 
outcomes that should be evaluated include HRQL and physical activity.  The effect of NIV during 
upper limb exercise training is yet to be reported, and assessment of lower limb exercise capacity 
using functional walk tests (eg 6MWT, ISWT) where the MCID is known, may help to clarify whether 
clinically significant improvements in exercise capacity are associated with the use of NIV during 
exercise training.  In addition to evaluation of these outcomes immediately after completion of the 
training program, longer term follow-up (eg 12 months) should be performed.   
 
Future studies also need to quantify the extra time and costs associated with using NIV during exercise 
so that this potential barrier can be weighed up against the potential benefits of training with NIV.  A 
larger number of high quality studies are required before sub-group analyses can be performed to tease 
out the effect of ventilator mode (bilevel, IPS or PAV) or ventilator settings (eg the level of ventilatory 
support, or the additional use of various levels of EPAP) on important outcomes.  Finally, while it 
appears that subjects with severe to very severe COPD may derive more benefit from NIV during 
exercise training than those with moderate COPD, additional information regarding patient selection 
for this technique is necessary.  Evaluation of the effect of NIV during exercise training in sub-groups 
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of individuals, including those with and without a limited ventilatory reserve at peak (unassisted) 
exercise, or those with and without chronic hypercapnic respiratory failure (HRF), may help to better 
define a target population for this intervention.  Nocturnal NIV has been shown to augment the effects 
of pulmonary rehabilitation in patients with chronic HRF secondary to COPD (Duiverman et al., 2008; 
Garrod et al., 2000; Kohnlein et al., 2009).  To date, no studies have investigated the use of NIV 
during exercise training in addition to nocturnal NIV.  However, patients with chronic HRF who are 
considered appropriate candidates for nocturnal NIV are a group that may respond well to NIV during 
exercise training and should be assessed in future studies.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER 5 
 
 
 
 
 
 
 
 
Non-invasive ventilation during ground walking and unsupported 
arm exercise in people recovering from acute on chronic 
hypercapnic respiratory failure 
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INTRODUCTION 
People with chronic hypercapnic respiratory failure (HRF) have a reduced exercise capacity (Foster et 
al, 1988; Schonhofer et al, 2003) and exhibit decreased levels of physical activity in the community 
compared with healthy age matched controls (Schonhofer et al, 1997).  They frequently report severe 
exertional dyspnoea and often have a ventilatory limitation to exercise (Bianchi et al, 1998; Shneerson, 
1978b; Vila et al, 2007).  With the development of acute on chronic HRF, ventilatory capacity 
decreases further (Conti et al, 1997; Purro et al, 2009).  Consequently, severe dyspnoea (Nava, 1998) 
and unstable gas exchange may delay the onset of exercise rehabilitation and place patients at risk of 
further deconditioning while recovering from their acute illness.  
 
Non-invasive ventilation (NIV) during exercise has been shown to reduce dyspnoea in proportion to 
respiratory muscle unloading (Kyroussis et al, 2000; Maltais et al, 1995), improve arterial blood gases 
(Dreher et al, 2007; Hernandez et al, 2001; Vila et al, 2007), and increase endurance time compared to 
exercise without NIV in patients with chronic HRF secondary to severe chronic obstructive pulmonary 
disease (COPD) (Bianchi et al, 1998; Dreher et al, 2007) and severe restrictive chest wall disorders 
(Borel et al, 2008; Menadue et al, 2009b; Tsuboi et al, 1997).  While invasive mechanical ventilation 
during walking has been described in stable hospitalised ventilator-dependent patients (Bailey et al, 
2007; Make et al, 1984; Nava, 1998) and during supported arm exercise (SAE) in difficult to wean 
patients with COPD and HRF (Vitacca et al, 2006), the effect of NIV plus oxygen (NIV+O2) during 
ground walking or during functional (unsupported) arm exercise compared to standard therapy 
(exercise with oxygen alone) is unknown in patients recovering from acute on chronic HRF.  If 
NIV+O2 during exercise can provide similar benefits to patients recovering from acute HRF as in 
stable patients with HRF, it may permit exercise rehabilitation to be commenced earlier in the hospital 
stay, thus reducing the risk of further deconditioning.  
 
The present study aimed to determine the effect of NIV+O2 during ground walking and unsupported 
arm exercise (UAE) on exercise capacity compared to exercise with oxygen (O2) alone in people 
recovering from acute on chronic HRF.  We hypothesised that NIV+O2 during exercise would reduce 
dyspnoea, improve oxygenation and allow patients to exercise for longer compared with O2 alone.    
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METHOD 
Participants 
Participants were recruited from the inpatient Respiratory Medicine ward at Royal Prince Alfred 
Hospital, Sydney.  To be included in the present study, individuals needed to: be admitted to hospital 
with acute on chronic HRF (pH < 7.35, arterial partial pressure of carbon dioxide tension (PaCO2) >45 
millimetres of mercury (mmHg) and bicarbonate > 26 millimoles/litre) that required ongoing treatment 
with NIV; have a history of severe chronic lung disease including COPD, bronchiectasis or cystic 
fibrosis, or a severe restrictive chest wall disorder; report dyspnoea as the primary symptom that 
limited the performance of daily activities; be tolerant of NIV for more than one hour of continuous 
use after a short period of acclimatisation.  For the treatment of acute on chronic HRF, bilevel NIV 
was only commenced if the respiratory acidosis (pH < 7.35) persisted despite judicious use of 
supplemental O2 therapy.  Standard medical therapy was instituted in conjunction with NIV and 
included, but was not limited to, supplemental O2, bronchodilators, antibiotics, corticosteroids and 
diuretics where indicated.  Individuals were excluded from the study if any of the following were 
present: unable to tolerate at least one continuous hour off NIV; arterial pH < 7.35 at the time of 
exercise testing; temperature > 38 degrees Celsius (ºC); oxygen saturation (SpO2) < 88% at rest 
despite a fraction of inspired oxygen (FiO2) ≥ 0.5; resting systolic blood pressure (SBP) < 90 mmHg 
or > 160 mmHg; resting diastolic blood pressure (DBP) < 60 mmHg or > 100 mmHg; resting heart 
rate (HR) > 120 beats/minute; unstable angina or a myocardial infarct during the previous month; 
decreased level of consciousness; major psychiatric illness.  Written informed consent was provided 
by all participants. 
 
Study design 
A randomised crossover study with repeated measures was performed on the ambulatory respiratory 
medicine ward at Royal Prince Alfred Hospital, Sydney.  Participants were asked to perform two six-
minute walk tests (6MWT) and two UAE tests.  In those participants who performed both 6MWT and 
UAE tests, the order of testing was randomised.  In addition, the order of 6MWT with O2 alone and 
with NIV+O2 was randomised, and the order of UAE with O2 alone and with NIV+O2 was 
randomised.  If a participant was unable to perform both series of 6MWT and UAE tests due to a 
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musculoskeletal or neurological condition that affected the upper or lower limbs, the type of test the 
participant was able to perform was selected.  The randomisation scheme was generated using a web 
site (http://www.randomization.com) and test order was concealed in a sealed, opaque envelope until 
written consent was obtained from the participant.  Ethics approval was obtained from the Human 
Ethics Committee of Sydney South West Area Health Service and The University of Sydney.  The 
study was registered as part of a larger trial with the Australian New Zealand Clinical Trials Registry 
(ACTRN12605000215628).  
 
Protocol 
All 6MWT and UAE tests were completed within one day in an to attempt to reduce the variability in 
clinical status that often occurs from day to day in patients recovering from acute on chronic HRF.  
One hour prior to the two 6MWT, a practice 6MWT was conducted with NIV+O2 to familiarise 
participants to the test (Guyatt et al, 1985) and to walking with NIV.  Participants were then asked to 
perform two 6MWT, one with O2 alone and one with NIV+O2 in random order.  Similarly, one hour 
prior to the two UAE tests, a practice UAE test was conducted with O2 alone to familiarise participants 
to the test and to determine the lifting height and weight of the dowel for the subsequent two UAE 
tests, one performed with O2 alone and one with NIV+O2 in random order.   
 
For both 6MWT and UAE tests, supplemental O2 was titrated to achieve a resting SpO2 of 
approximately 93% and was not adjusted further during exercise.  Participants were given standardised 
encouragement each minute during exercise, after dyspnoea and perceived exertion scores had been 
recorded.  The phrases “you are doing well” and “keep up the good work” were alternated.  
Participants rested while breathing with O2 alone for at least one hour between each 6MWT and at 
least one hour between each UAE test, and until SpO2, HR, dyspnoea, rate of perceived exertion 
(RPE) and BP had returned to baseline.   
 
Exercise tests 
Six Minute Walk Test 
Functional (ground) walking capacity was measured using the 6MWT. The 6MWT is a self paced, 
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timed walk test.  Participants were asked to walk up and down a 25 metre course, marked with a cone 
placed 0.5 metres from each end of the course.  The 6MWT was performed according to the American 
Thoracic Society guidelines (American Thoracic Society, 2002) with the following exceptions.  
Firstly, a 25 metre corridor was used.  Secondly, to enable the participant to walk unencumbered, a 
trolley that contained the bilevel machine, battery and O2 cylinder was pushed by a research assistant, 
slightly behind the participant during each 6MWT.  Thirdly, rather than using their usual walking aid, 
all participants used a forearm support frame during each 6MWT to allow the participant to perform 
the test independently and safely.  Participants were instructed to walk as far as possible in six 
minutes.  However, participants were permitted to slow down, to stop and to rest if they felt too 
breathless or fatigued to continue and were encouraged to resume walking as soon as possible.  The 
6MWT was selected for use in people recovering from acute on chronic HRF as the ability to slow 
down or rest was thought to have made the test more tolerable and sensitive to change in this 
population.  The investigator paused the 6MWT if SpO2 fell below 75% and after resting, only 
allowed the participant to recommence walking if SpO2 increased above 75%.  The total distance 
walked in 6 minutes, time and distance to first rest were recorded.  In addition, the reason for exercise 
cessation and the primary symptom that limited exercise were documented.  A picture of a participant 
walking with NIV+O2 is displayed in Figure 5.1.  
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Figure 5.1 A participant performing the six minute walk test with a forearm support frame 
while breathing with non-invasive ventilation plus oxygen.  A research assistant is 
pushing the trolley with the bilevel machine and associated equipment slightly behind 
the participant.  Image printed with permission 
 
 
Unsupported Arm Exercise Test 
An externally paced UAE test as described by Takahashi and colleagues (Takahashi et al, 2003) was 
modified to measure endurance rather than peak exercise capacity.  A practice test was performed 
while breathing supplemental O2 (without NIV) in which the participant lifted a weighted dowel from 
waist height to increasingly higher levels on a chart.  The pace of lifting was one lift every two 
seconds in time with a metronome.  The modification was that after five repetitions (10 seconds) at 
each level, participants progressed through the levels on the chart until they reached a level that they 
deemed to be a moderate workload on the rate of perceived exertion (RPE) scale (score of 3).  
Participants were then instructed to exercise at this level for as long as possible.  Initially, participants 
were asked to lift a 300 gram (g) weighted dowel.  If participants progressed to the highest level of the 
chart that they could reach without leaning forward, before achieving moderate workload on the RPE 
scale, the weight of the dowel was incrementally increased to 500 g, then 1 kilogram (kg), 1.5 kg and 
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2 kg every five repetitions.  The same level and dowel weight achieved in the practice test was used 
for the two subsequent endurance tests, one with O2 alone and one with NIV+O2.  Participants were 
asked to exercise until they felt too breathless or fatigued to continue.  The investigator stopped the 
UAE test if SpO2 fell below 75% or if the participant was unable to keep in time with the metronome.  
Unsupported arm exercise endurance time, the reason for exercise cessation and primary symptom that 
limited exercise was recorded.  A picture of a participant performing the UAE test with NIV+O2 is 
shown in Figure 5.2. 
 
 
 
 
 
                             
Figure 5.2 A participant performing the unsupported arm exercise test with non-invasive 
ventilation plus oxygen.  Image printed with permission 
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Measures 
Participant Characteristics 
Anthropometric data were recorded, a resting arterial blood gas (off NIV) was analysed and 
pulmonary function tests were conducted prior to the performance of the exercise tests.   
 
Arterial blood gas tensions 
A resting daytime arterial blood sample was collected while participants were seated and breathing 
with supplemental O2 that was titrated to achieve a SpO2 of 90-93%.  Arterial blood was sampled from 
the radial artery and stored in ice until it was analysed (Radiometer ABL700, Radiometer Medical, 
Copenhagen, Denmark).  This was typically within 15 minutes of the sample being collected.   
 
Pulmonary function tests 
(i) Spirometry 
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured using 
a hand held spirometer (Microloop, Micro Medical Limited, Rochester, Kent, England) with a flow 
sensor.  Spirometry was performed 10-15 minutes post bronchodilator.  A forced expiration from total 
lung capacity was performed by each participant while in the sitting position with a nose peg in situ.  
The best of three attempts from values of within 5% variability were recorded.  Predicted values for 
FEV1 and FVC were calculated from normal population data (Quanjer et al, 1993).  Participants were 
encouraged verbally to perform a maximum effort during each test. 
   
(ii) Respiratory muscle strength 
Respiratory muscle strength was determined by measuring maximal inspiratory mouth occlusion 
pressure sustained over one second (PImax1.0) from residual volume, and maximal expiratory mouth 
occlusion pressure sustained over one second (PEmax1.0) from total lung capacity using a hand held 
pressure gauge (Morgan Medical Limited, Gilingham, UK) calibrated from 0 ± 200 centimetres of 
water (cmH2O).  The gauge mouthpiece permitted a one millimetre air leak in order to prevent glottic 
closure during testing.  Participants were instructed to inhale or exhale with their glottis open and not 
to use their buccal muscles.  The test was performed in the sitting position.  A nose peg was worn 
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during the test.  The highest pressure generated over one second of three reproducible attempts was 
recorded.  Predicted values were calculated from normal population data (Wilson et al, 1984).  
Participants were encouraged verbally to perform a maximum effort during each test. 
 
Exercise 
After sitting quietly for at least 10 minutes breathing either O2 (prior to exercise with O2 alone) or 
NIV+O2 (prior to exercise with NIV+O2), baseline resting measures of SpO2, HR, dyspnoea, RPE and 
blood pressure (BP) were recorded immediately prior to each exercise test.  Oxygen saturation and HR 
were measured using a pulse oximeter (Radical, Masimo, Irvine CA, USA) with a finger probe.  
Data were downloaded after exercise using software provided by the manufacturer (Download 2001, 
Masimo, Irvine CA, USA).  Participants rated their level of dyspnoea and RPE on a 0-10 category 
ratio scale (Borg, 1982).  During ground walking, RPE scores reflected leg muscle exertion, and 
during UAE, RPE scores reflected arm muscle exertion.  Blood pressure was measured manually using 
a sphygmomanometer.  During exercise, SpO2 and HR were recorded continuously.  Dyspnoea and 
RPE scores were recorded every 30 seconds.  During exercise with NIV+O2, mask pressure was 
measured using a digital manometer (Respironics, Murraysville, PA, USA) attached to a port on the 
full face mask and the peak inspiratory pressure was recorded approximately every 30 seconds by the 
investigator.  Immediately at the end of exercise, dyspnoea and RPE scores were recorded, and BP 
was remeasured. 
 
Non-invasive ventilation  
Non-invasive ventilation was delivered with a pressure preset bilevel machine (VPAPIII ST, 
ResMed, Sydney, Australia) via a three metre length of corrugated tubing connected to a full face 
mask (Ultra-mirage, ResMed, Sydney, NSW, Australia; or, Comfort-Full, Respironics, 
Murraysville, PA, USA).  The inspiratory trigger threshold was 4.5 litres/minute (L/min) and maximal 
inspiratory flow rate was 170 L/min.  The bilevel machine was set in the spontaneous (self triggered) 
mode with the expiratory positive airway pressure (EPAP) set at 4 cmH2O.  For participants with 
chronic airflow limitation, EPAP was increased to a maximum of 5 cmH2O.  Inspiratory positive 
airway pressure (IPAP) was set 10 cmH2O above EPAP and was increased at rest to a level of comfort.  
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Pressure support (PS) (the difference between IPAP and EPAP) was initially set at 10 cmH2O in order 
to reduce the risk of negative haemodynamic side effects associated with the application of positive 
pressure in participants recovering from acute on chronic HRF.  In addition, PS 10 cmH2O has 
previously been shown to improve exercise capacity in people with COPD (van’t Hul et al, 2004).  
Rise time (time from EPAP to IPAP once triggered) was 100 milliseconds.  The investigator fitted the 
mask to prevent leak.  If required, supplemental O2 was added via a t-piece connected to the air outlet 
of the machine.  A 12 volt external battery (Mini power station, Integra Industries, Panorama, 
Australia) powered the bilevel machine during ground walking.   
 
Outcome measures 
The primary outcome measure for the 6MWT was total distance walked.  Secondary outcome 
measures were time and distance to first rest, isotime SpO2 and isotime dyspnoea.  Isotime was 
defined as the earliest time-point where the participant rested during either 6MWT.  Dyspnoea scores 
and SpO2 values from walk tests with O2 alone and with NIV+O2 were compared at this point in time.  
In addition, the relationship between the response to NIV+O2 during walking and PaCO2, FEV1, FVC 
and PImax1.0 was assessed to determine whether these baseline measures could be used to select 
subjects who might benefit from using NIV+O2 during walking.  The relationship between the 
response to NIV+O2 during walking and the change in isotime dyspnoea with NIV+O2 compared to 
exercise with O2 alone was also determined.  The response to NIV+O2 during walking was defined as 
the change in total distance walked with NIV+O2 compared to walking with O2 alone expressed as a 
percentage: 
 
     Response to NIV+O2 Walking = (NIV+O2 Total distance – O2 Total distance)/O2 Total distance x 100/1 
 
For UAE, the primary outcome measure was endurance time.  Secondary outcome measures were 
isotime SpO2 and isotime dyspnoea, where isotime was defined as the end point of the shorter 
endurance test.  The relationship between the response to NIV+O2 during UAE and PaCO2, FEV1, 
FVC and PImax1.0 was assessed to determine whether these baseline measures could be used to select 
subjects who might benefit from using NIV+O2 during UAE.  The relationship between the response 
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to NIV+O2 during UAE and the change in isotime dyspnoea with NIV+O2 compared to exercise with 
O2 alone was also assessed.  The response to NIV+O2 during UAE was defined as the change in UAE 
endurance time with NIV+O2 compared to UAE with O2 alone expressed as a percentage: 
 
     Response to NIV+O2 UAE = (NIV+O2 Endurance time – O2 Endurance time)/O2 Endurance time x 100/1 
 
In a subgroup of participants who performed both series of 6MWT and UAE tests, the relationship 
between the response to NIV+O2 during walking and the response to NIV+O2 during UAE was 
determined to identify whether the response to exercise with NIV+O2 differed between these two 
modes of exercise within each participant.  The response to NIV+O2 during walking and UAE was 
determined for each individual using the above equations.    
 
Data analysis and statistics 
To detect a 48 metre change in six minute walk distance (6MWD) (Lacasse et al, 2006) with NIV+O2, 
using a standard deviation (SD) estimate of 51 metres (based on data from the first 5 participants), 
power of 0.8, and an α of 0.05, the analysis indicated that a sample of 18 participants was required.  
To detect a 30 second change in UAE endurance time with NIV+O2, using a SD estimate of 39 
seconds (based on data from the first 5 participants), a power of 0.8, and an α of 0.05, a sample of 16 
participants was needed.   
 
Descriptive data for continuous variables with a normal distribution are presented as mean ± SD, or 
median and interquartile range (IQR) for data that failed the Kolmogorob-Smirnov normality test.  
Paired t-tests, or Wilcoxon signed rank tests for non-parametric data, were conducted to determine if 
there was a significant difference between exercise with O2 alone and exercise with NIV+O2 with 
respect to the primary and secondary outcome measures.  The effect of test order was also assessed.  
For normally distributed data the 95% confidence intervals (CI) were given if appropriate.  A 
significance level of p < 0.05 was used for all comparisons.  The relationship between the response to 
NIV+O2 during exercise and PaCO2, FEV1, FVC, PImax1.0 and the change in isotime dyspnoea with 
NIV+O2 compared to exercise with O2 alone was determined by calculation of Pearson’s correlation 
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coefficient (r) for parametric data or, Spearman’s rho (rS) for non-parametric data.  Similarly, the 
relationship between the response to NIV+O2 during walking and the response to NIV+O2 during 
UAE in those participants who performed both series of 6MWT and UAE tests was determined by 
calculation of r for parametric data, or rS for non-parametric data.  
 
 
RESULTS 
Participants 
Twenty participants recovering from acute on chronic HRF were recruited for the study.  Of the 20 
participants, 14 performed both series of 6MWT and UAE tests.  An additional four participants 
performed the 6MWT only (giving a total of 18 participants who performed 6MWT), and an 
additional two participants performed UAE tests only (giving a total of 16 participants who performed 
UAE tests) (Figure 5.3).  Participant characteristics and NIV settings used during exercise are 
described in Table 5.1.  The median time from admission to hospital to performance of the exercise 
tests was 4 days [IQR 2 - 7].  All participants completed the exercise tests without any adverse events.  
The investigator stopped the exercise test due to O2 desaturation below 75% in three participants 
during the 6MWT with O2 alone.  Peak mask pressure was maintained at the preset IPAP level during 
ground walking and UAE tests with NIV+O2. 
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Figure 5.3 Number of participants who performed six minute walk tests (6MWT), 
unsupported arm exercise (UAE) tests, and both 6MWT and UAE tests.  HRF: 
hypercapnic respiratory failure 
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Table 5.1 Participant characteristics  
 
 
6MWT 
(n=18)  
UAE test 
(n=16) 
6MWT & UAE test 
(n=14) 
 
  Age (yrs) 65 (61 - 68) 64 (56 - 66) 64 (57 - 67) 
  F/M 10/8 8/8 7/7 
  BMI (kg.m-2) 27.2 ± 8.3 27.6 ± 8.0 27.6 ± 8.6 
Diagnostic group (n) 
   
  COPD 12 12 10 
  Bronchiectasis 2 2 2 
  Cystic Fibrosis 1 1 1 
  Kypho/scoliosis 3 1 1 
Previous domiciliary NIV (n) 4 5 4 
Reason for acute on chronic HRF (n) 
   
  AECOPD 12 11 9 
  Respiratory tract infection 6 6 6 
  Pulmonary oedema 1 1 1 
  Hyperoxia 6 5 3 
ABG on admission 
   
  pH 7.30 ± 0.05 7.30 ± 0.04 7.30 ± 0.04 
  PaCO2 (mmHg) 73.8 ± 15.3 71.6 ± 15.0 72.7 ± 14.8 
  PaO2 (mmHg) 68.5 (51.0 - 95.0) 76.5 (58.0 - 97.0) 70.5 (54.0 - 94.5) 
  HCO3- (mmol/L) 32.0 (29.0 - 39.0) 32.8 ± 5.3 33.4 ± 5.4 
  SaO2 (%) 94 (89 - 97) 92 (90 - 97) 95 (90 - 97) 
  Supp O2 (L/min) 2.7 ± 2.1 2.0 (1.0 - 2.5) 2.0 (0.5 - 2.5) 
NIV use 24 hours prior to the study 
   
  Participants on NIV (n) 18 16 14 
  Hours 10.9 ± 5.1 11.0 ± 4.6 9.7 ± 4.3 
ABG prior to exercise tests 
   
  pH 7.39 ± 0.03 7.39 ± 0.03 7.38 ±  0.03 
  PaCO2 (mmHg) 58.6 ± 9.1 57.9 ± 8.9 59.0 ±  9.0 
  PaO2 (mmHg) 70.3 ± 17.8 72.9 ± 17.5 72.8 ±  18.0 
  HCO3- (mmol/L) 34.0 ± 5.8 33.9 ± 5.0 34.2 ±  5.1 
  SaO2 (%) 92 ± 5 93 ± 4 93 ±  4 
  Supp O2 (L/min) 1.9 ± 1.8  2.1 ± 1.9  2.1 ± 2.1   
Pulmonary function 
   
  FEV1 (L) 0.57 ± 0.28 0.60 ± 0.28 0.63 ± 0.29 
  FEV1 (% predicted) 21 (16 - 27) 21 (16 - 24) 21 (18 - 30) 
  FVC (L) 1.36 ± 0.74 1.47 ± 0.72 1.55 ± 0.75 
  FVC (% predicted) 45 ± 21 48 ± 22 50 ±  23 
  FEV1/FVC (%) 46 ± 17 43 ±13 43 ± 14 
  PImax1.0 (cmH2O) -40.7 ± 21.8 -47.9 ± 21.4 -45.6 ± 21.8 
  PImax1.0 (% predicted) 54 ± 28 65 ± 27 61 ±  26 
  PEmax1.0 (cmH2O) 116.9 ± 30.5 112.7 ± 24.6 110.7 ± 23.6 
  PEmax1.0 (% predicted) 100 ± 24 108 ± 28 105 ± 22 
NIV settings during exercise 
   
  IPAP (cmH2O) 15.5 (15.0 - 18.0) 15.8 ± 1.6 15.0 (14.5 - 17.5) 
  EPAP (cmH2O) 5.0 (4.0 - 5.0) 5.0 (5.0 - 5.0) 5.0 (4.5 - 5.0) 
  PS (IPAP-EPAP) (cmH2O) 11.0 (10.0 - 13.0) 10.5 (10.0 - 12.0) 10.0 (10.0 - 12.5) 
    
Data are presented as mean ± SD or median (interquartile range).  6MWT: six minute walk test; UAE: unsupported arm 
exercise; F/M: female/male; BMI: body mass index; COPD: chronic obstructive pulmonary disease; NIV: non-invasive 
ventilation; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; ABG: arterial blood gas; PaCO2: arterial 
carbon dioxide tension; PaO2: arterial oxygen tension; HCO3-: arterial bicarbonate ion concentration; SaO2: oxygen 
saturation; Supp O2: supplemental oxygen; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; 
PImax1.0: maximal inspiratory mouth occlusion pressure sustained over one second; PEmax1.0: maximal expiratory mouth 
occlusion pressure sustained over one second; IPAP: inspiratory positive airway pressure; EPAP: expiratory positive airway 
pressure; PS: pressure support 
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Ground walking 
Non-invasive ventilation plus O2 during the 6MWT increased total distance walked by a mean of 43.4 
metres (95% CI 14.1 to 72.8, p = 0.006) compared to exercise with O2 alone (Figure 5.4a).  In 
addition, distance and time to first rest were greater (Figure 5.4b), isotime dyspnoea was reduced 
(Figure 5.4c) and SpO2 was higher both at rest and isotime exercise (Figure 5.4d) when NIV+O2 was 
used during walking compared to O2 alone.  Mean differences and 95% CI are reported in Table 5.2.  
The primary symptom associated with exercise cessation was dyspnoea (O2 alone: n = 16; NIV+O2: n 
= 16), dyspnoea and leg muscle fatigue (O2 alone: n = 2; NIV+O2: n = 1), or leg muscle fatigue alone 
(NIV+O2: n = 1) (Figure 5.5).  No significant relationship was found between the response to NIV+O2 
during walking and baseline measures of PaCO2, FEV1, FVC or PImax1.0 (Table 5.3).  In contrast, a 
moderately strong inverse relationship was found between the change in isotime dyspnoea and the 
percentage change in total distance walked with NIV+O2 (r = -0,52, p = 0.026), where 27% of the 
variance in the change in distance walked was explained by the change in isotime dyspnoea with 
NIV+O2 (Figure 5.6).  There was no effect of test order on any of the primary or secondary outcome 
measures. 
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Table 5.2 Walking with oxygen alone (O2) compared to walking with non-invasive 
ventilation plus oxygen (NIV+O2) during the six minute walk test 
 
 
O2 NIV+O2 
 
Mean difference (95% CI) p 
Rest  
    
  SpO2 (%) 93 (92 - 96) 95 (93 - 98) FN <0.000 
  Supp O2 (L/min) 1.5 (0.5 - 3.0) 1.5 (0.5 - 3.0) FN 0.75 
  HR (beats/min) 90 ± 14 91 ± 17 1 (-3 to 4) 0.61 
  Dyspnoea (Borg) 0.5 (0 - 0.8) 0.3 (0 - 0.8) FN 0.32 
  RPE (Borg) 0 (0 - 0.5) 0 (0 – 0.5) FN 0.28 
  SBP (mmHg) 125 ± 18 124 ± 14 -1 (-9 to 6) 0.68 
  DBP (mmHg) 73 ± 13 78 ± 7 5 (-2 to 11) 0.14 
  MAP (mmHg) 90 ± 12 93 ± 9 3 (-3 to 8) 0.32 
Isotime 
    
  SpO2 (%) 87 ± 6 92 ± 5 5 (2 to 7) 0.001 
  HR (beats/min) 109 ± 14 108 ± 15 -2 (-4 to 1) 0.15 
  Dyspnoea (Borg) 4.0 (3.0 - 5.0) 2.0 (1.0 - 4.0) FN 0.028 
  RPE (Borg) 3.0 (2.0 - 5.0) 3.0 (1.0 - 3.0) FN 0.46 
End exercise 
    
  SpO2 (%) 89 ± 7 90 ± 6 2 (-2 to 6) 0.26 
  HR (beats/min) 109 ± 14 108 ± 20 -1 (-8 to 6) 0.72 
  Dyspnoea (Borg) 4.9 ± 2.9 5.4 ± 3.0 0.4 (-0.6 to 1.5) 0.37 
  RPE (Borg) 4.4 ± 3.1 4.9 ± 3.0 0.8 (-0.8 to 1.8) 0.41 
  SBP( mmHg) 140 ± 17 140 ± 16 -1 (-6 to 4) 0.76 
  DBP (mmHg) 80 ± 12 84 ± 10 3 (-1 to 7) 0.086 
  MAP (mmHg) 100 ± 13 102 ± 11 2 (-1 to 5) 0.24 
  Total distance (m) 187.5 ± 89.9 230.9 ± 114.8 43.4 (14.1 to 72.8) 0.006 
  Distance to 1st rest (m) 159.8 ± 97.1 221.4 ± 119.8 61.6 (19.6 to 103.6) 0.007 
  Time to 1st rest (s) 188 (151 - 360) 360 (284 - 360) FN 0.012 
     
Data are presented as mean ± SD or median (interquartile range). NIV: non-invasive ventilation; SpO2: oxygen saturation; 
Supp O2: supplemental oxygen; HR: heart rate; RPE: rate of perceived exertion; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; MAP: mean arterial pressure; FN: failed normality test 
 
 
 
 
 
 
 
 
 
Table 5.3 Relationship between the response to non-invasive ventilation plus oxygen 
(NIV+O2) during the six minute walk test (6MWT) and baseline measures 
 
Relationship between the response to NIV+O2 during the 6MWT and: 
 
r p 
PaCO2 (mmHg) -0.059 0.82 
FEV1 (L) -0.158 0.53 
FEV1 (% predicted) -0.348 0.16 
FVC (L) -0.169¶ 0.50 
FVC (% predicted) -0.207 0.41 
PImax1.0 (cmH2O) 0.028 0.91 
PImax1.0 (% predicted) 0.006 0.98 
   
r: Pearson’s correlation coefficient; ¶: Spearman’s rho reported instead of r; PaCO2: arterial carbon dioxide tension; FEV1: 
forced expiratory volume in one second; FVC: forced vital capacity; PImax1.0: maximal inspiratory mouth occlusion pressure 
sustained over one second
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Figure 5.4  Effect of walking with oxygen (O2) alone compared to walking with non-invasive ventilation plus oxygen (NIV+O2) during the six minute 
walk test on: a) total distance walked; b) time to first rest; c) isotime dyspnoea; d) isotime oxygen saturation.  Error bars represent standard 
deviation where the mean is reported and interquartile range where median is reported.  Open circles represent individual data points for participants 
with severe chronic lung disease.  Closed triangles represent individual data points for participants with severe chest wall restriction.  *: p < 0.05;   
†: p < 0.01
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Figure 5.5 Relative proportion of participants (n = 18) who ceased the six minute walk test 
(either to rest or at the end of the test) primarily due to oxygen (O2) desaturation 
below 75%, leg muscle (mm) fatigue, shortness of breath (SOB) or leg muscle 
fatigue and shortness of breath (leg mm fatigue & SOB) during exercise with 
oxygen alone (O2) and exercise with non-invasive ventilation plus oxygen 
(NIV+O2) 
 
 
 
 
 
 
 
 
Figure 5.6 Relationship between the change in isotime dyspnoea and the percentage change 
in total distance walked with non-invasive ventilation (NIV) plus oxygen 
compared to walking with oxygen alone 
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Unsupported arm exercise 
Unsupported arm exercise endurance time was greater when participants used NIV+O2 during exercise 
compared with O2 alone (median 201 seconds (IQR 93 – 414) versus 157 seconds (90 – 342), p = 
0.033) (Figure 5.7a).  There was no difference in isotime dyspnoea (Figure 5.7b) or isotime SpO2 
(Figure 5.7c) during UAE tests with NIV+O2 and O2 alone, whereas isotime RPE was reduced when 
NIV+O2 was used during exercise compared with O2 alone (Figure 5.7d).  In addition, mean arterial 
pressure was reduced at end exercise when participants used NIV+O2 during UAE compared to O2 
alone.  Mean differences and 95% CI are reported in Table 5.4.  The primary symptom associated with 
exercise cessation was arm muscle fatigue (O2 alone: n = 14; NIV+O2: n = 15), shortness of breath 
alone (O2 alone: n = 1; NIV+O2: n = 1, or a combination of arm muscle fatigue and shortness of breath 
(O2 alone: n = 1) (Figure 5.8).  No significant relationship was detected between the response to 
NIV+O2 during UAE and baseline measures of PaCO2, FEV1, FVC or PImax1.0 (Table 5.5).  Similarly, 
no significant relationship was found between the change in isotime dyspnoea and the percentage 
change in UAE endurance time with NIV+O2 (r = -0.173, p = 0.514) (Figure 5.9).  There was no effect 
of test order on any of the primary or secondary outcome measures.  
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Table 5.4 Unsupported arm exercise with oxygen alone (O2) compared to unsupported arm 
exercise with non-invasive ventilation plus oxygen (NIV+O2) 
 
 
O2 NIV + O2 
 
Mean difference (95% CI) p 
Rest  
    
  SpO2 (%) 93 ± 2 94 ± 2 1 (0 to 2) 0.087 
  Supp O2 (L/min) 2.0 (1.0 - 3.0) 1.0 (1.0 - 3.0) FN 0.068 
  HR (beats/min) 91 ± 14 92 ± 16 1 (-2 to 4) 0.57 
  Dyspnoea (Borg) 0.8 (0 - 1.0) 0.8 (0 - 1.0) FN 0.92 
  RPE (Borg) 0 (0 - 1.0) 0 (0 - 0.5) FN 1.0 
  SBP (mmHg) 122 ± 15 121 ± 16 -2 (-6 to 3) 0.48 
  DBP (mmHg) 78 ± 11 78 ± 10 0 (-3 to 3) 0.96 
  MAP (mmHg) 93 ± 12 92 ± 12 -1 (-3 to 2) 0.68 
Isotime 
    
  SpO2 (%) 92 ± 3 93 ± 3 1 (1 to 3) 0.21 
  HR (beats/min) 100 ± 14 98 ± 19 -2 (-6 to 2) 0.26 
  Dyspnoea (Borg) 4.9 ± 3.1 4.0 ± 2.7 -1.0 (-2.2 to 0.3) 0.11 
  RPE (Borg) 6.6 ± 3.0 5.6 ± 3.1 -1.0 (-1.9 to -0.1) 0.037 
End exercise 
    
  SpO2 (%) 92 ± 2 93 ± 3 1 (-1 to 3) 0.20 
  HR (beats/min) 101 ± 16 102 ± 16 1 (-1 to 3) 0.29 
  Dyspnoea (Borg) 5.1 ± 3.0  5.0 ± 2.8 -0.2 (-1.6 to 1.3) 0.82 
  RPE (Borg) 6.9 ± 2.8  6.7 ± 2.9 -0.3 (-1.1 to 0.6) 0.53 
  SBP( mmHg) 139 ± 19 135 ± 19 -4.7 (-10 to 0) 0.054 
  DBP (mmHg) 85 ± 11 82 ± 10 -2.7 (-6 to 0) 0.074 
  MAP (mmHg) 103 ± 12 99 ± 12 -3 (-6 to 0) 0.031 
  Endurance time (s) 157 (90 - 342) 201 (93 - 414) FN 0.033 
     
Data are presented as mean ± SD or median (interquartile range). NIV: non-invasive ventilation; SpO2: oxygen saturation; 
Supp O2: supplemental oxygen; HR: heart rate; RPE: rate of perceived exertion; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; MAP: mean arterial pressure; FN: failed normality test 
 
 
 
 
 
 
 
 
 
 
Table 5.5 Relationship between the response to non-invasive ventilation plus oxygen 
(NIV+O2) during the unsupported arm exercise (UAE) test and baseline 
measures 
 
Relationship between the response to NIV+O2 during UAE and: 
 
r p 
PaCO2 (mmHg) 0.154 0.57 
FEV1 (L) 0.104 0.70 
FEV1 (% predicted) 0.093¶ 0.73 
FVC (L) -0.153 0.57 
FVC (% predicted) -0.025 0.93 
PImax1.0 (cmH2O) -0.356 0.18 
PImax1.0 (% predicted) -0.342 0.12 
   
r: Pearson’s correlation coefficient; ¶: Spearman’s rho reported instead of r; PaCO2: arterial carbon dioxide tension; FEV1: 
forced expiratory volume in one second; FVC: forced vital capacity; PImax1.0: maximal inspiratory mouth occlusion pressure 
sustained over one second 
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Figure 5.7 Effect of unsupported arm exercise with oxygen (O2) alone compared with non-invasive ventilation plus oxygen (NIV+O2) on:  a) endurance 
time; b) isotime dyspnoea; c) isotime oxygen saturation; d) isotime rate of perceived exertion.  Error bars represent standard deviation where 
the mean is reported and interquartile range where median is reported.  Open circles represent individual data points for participants with severe 
chronic lung disease.  Closed triangles represent individual data points for participants with severe chest wall restriction.  *: p < 0.05; NS: non-
significant
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Figure 5.8 Relative proportion of participants (n = 18) who ceased the unsupported arm 
exercise test primarily due to arm muscle (mm) fatigue, shortness of breath 
(SOB), or a combination of arm muscle fatigue and shortness of breath (arm mm 
fatigue & SOB) during exercise with oxygen (O2) alone and exercise with non-
invasive ventilation plus oxygen (NIV+O2) 
 
 
 
 
 
Figure 5.9 Relationship between the change in isotime dyspnoea and the percentage change 
in endurance time with non-invasive ventilation (NIV) plus oxygen compared to 
unsupported arm exercise with oxygen alone
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Relationship between the response to non-invasive ventilation during walking and the response 
to non-invasive ventilation during unsupported arm exercise 
The relationship between the response to NIV during walking and the response to NIV during UAE 
was assessed in a subgroup of 14 participants who performed both series of walk and UAE tests.  
Participant characteristics of the subgroup are outlined in Table 5.1 and descriptive data for 6MWT 
and UAE tests with O2 alone and NIV+O2 at rest, isotime exercise and end exercise are displayed in 
Table 5.6.  Similar to the results for the whole group (n = 18), in the subgroup of participants (n = 14), 
NIV+O2 during walking increased total distance walked, time to first rest and distance to first rest 
compared to walking with O2 alone.  In contrast, no change in UAE endurance time or isotime 
dyspnoea was observed with NIV+O2 during UAE compared to exercise with O2 alone (Table 5.7).  
No relationship was detected between the response to NIV+O2 during walking and the response to 
NIV+O2 during UAE    (r = -0.310, p = 0.28) (Figure 5.10).   
 
 
 
 
Table 5.6  Exercise with oxygen alone (O2) compared to exercise with non-invasive 
ventilation plus oxygen (NIV+O2) for participants who performed six minute 
walk tests and unsupported arm exercise tests  
 
 
Six minute walk test 
 (n=14) 
 
               O2                               NIV + O2 
Unsupported arm exercise test 
 (n=14) 
 
               O2                                NIV + O2     
Rest  
    
  SpO2 (%) 93 (91 - 94) 95 (93 - 96) 93 ± 2 94 ± 2 
  Supp O2 (L/min) 2.0 (0.5 - 3.0) 2.0 (0.5 - 3.5) 2.0 (1.0 - 3.3) 1.5 (1.0 -3.0) 
  HR (beats/min) 90 ± 15 92 ± 18 91 ± 14 91 ± 17 
  Dyspnoea (Borg) 0.5 (0 – 0.8) 0 (0 – 0.5) 0.8 (0 - 1.0) 0.8 (0 - 1.0) 
  RPE (Borg) 0 (0 - 0.8) 0 (0 – 0.5) 0 (0 - 0.8) 0 (0 – 0.5) 
  SBP (mmHg) 126 ± 20 125 ± 15 122 ± 16 122 ± 15 
  DBP (mmHg) 75 ± 8 77 ± 7 79 ± 10 78 ± 8 
  MAP (mmHg) 92 ± 11 93 ± 9 93 ± 12 93 ± 10 
Isotime 
    
  SpO2 (%) 86 ± 6 90 ± 4 91 (91 - 95) 92 (91 - 95) 
  HR (beats/min) 108 ± 14 105 ± 13 99 ± 13 96 ± 18 
  RPE (Borg) 3.0 (1.5 - 5.0) 3.0 (1.5 - 3.0) 7.0 (4.0 - 10.0) 5.0 (3.5 - 9.5) 
End exercise 
    
  SpO2 (%) 87 ± 6 90 ± 5 92 ± 2 93 ± 3 
  HR (beats/min) 112 (101 - 121) 107 (100 - 117) 98 ± 14 100 ± 16 
  Dyspnoea (Borg) 5.0 ± 3.2 5.3 ± 3.2 4.0 (3.0 - 9.5) 4.5 (3.0 - 7.0) 
  RPE (Borg) 4.4 ± 3.6 4.7 ± 3.1 8.5 (4.0 - 10.0) 7.0 (4.0 - 10.0) 
  SBP( mmHg) 140 ± 18 138 ± 17 139 ± 19 134 ± 19 
  DBP (mmHg) 80 ± 13 82 ± 10 85 ± 10 83 ± 10 
  MAP (mmHg) 100 ± 14 101 ± 12 103 ± 12 100 ± 12 
     
Data are presented as mean ± SD or median (interquartile range). SpO2: oxygen saturation; Supp O2: supplemental oxygen; 
HR: heart rate; RPE: rate of perceived exertion; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean 
arterial pressure 
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Table 5.7 Effect of oxygen alone (O2) compared with non-invasive ventilation plus oxygen 
(NIV+O2) during the six minute walk test and the unsupported arm exercise test 
on exercise capacity and isotime dyspnoea in a subgroup of participants (n = 14) 
who performed both series of tests 
 
 
O2 NIV+O2 
 
Mean difference (95% CI) 
 
p 
Six minute walk test 
    
  Total distance (m) 136.6 ± 96.8 224.2 ± 122.2 31.7 (1.1 to 62.2) 0.043 
  Distance to 1st rest (m) 164.9 ± 107.5 220.5 ± 127.0 55.6 (10.0 to 101.1) 0.021 
  Time to 1st rest (s) 205 (161 - 360) 360 (333 - 360) FN 0.021 
  Isotime dyspnoea (Borg)  4.0 (2.5 - 4.5) 2.0 (1.0 - 5.0) FN 0.17 
     
Unsupported arm exercise 
    
  Endurance time (s) 194 (92 – 419) 191 (92 – 419) FN 0.10 
  Isotime dyspnoea (Borg) 3.5 (2.5 - 9.5) 3.5 (2.0 - 6.0) FN 0.17 
     
Data are presented as mean ± SD or median (interquartile range).  O2: oxygen; NIV+O2: non-invasive ventilation plus 
oxygen; FN: failed normality test 
 
 
 
 
 
Figure 5.10 Relationship between the response to non-invasive ventilation plus oxygen 
(NIV+O2) during the six minute walk test and the response to NIV+O2 during 
unsupported arm exercise (UAE) in a subgroup of fourteen participants who 
performed both series of tests.  The response to NIV+O2 during exercise was 
expressed as the percentage change in six minute walk distance (6MWD) with 
NIV+O2 compared to walking with oxygen (O2) alone, and the percentage change in 
UAE endurance time with NIV+O2 compared to O2 alone 
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DISCUSSION 
The main findings of the present study were that NIV+O2 during ground walking increased distance 
walked, improved SpO2 and reduced dyspnoea compared to exercise with O2 alone in patients 
recovering from acute on chronic HRF.  An improvement in UAE endurance time was also found with 
NIV+O2 compared to exercise with O2 alone, and was associated with a reduction in arm muscle 
fatigue.  Exercise performed several days after admission to hospital with acute on chronic HRF was 
safe and well tolerated.   
 
Improvements in exercise capacity and dyspnoea have been observed after exercise training in patients 
recovering from acute respiratory failure (Nava, 1998; Porta et al, 2005).  However, severe dyspnoea 
(Nava, 1998) and unstable gas exchange can delay activity and place patients at risk of further 
deconditioning in the early stages of recovery.  The detrimental effects of prolonged bed rest on 
muscle strength and function are well described (Haines, 1974).  Currently, there are no evidence-
based recommendations regarding strategies to alleviate dyspnoea and improve functional exercise 
performance in the early stages of recovery from acute on chronic HRF.  The present study provides 
novel information in this area.   
      
Effect of non-invasive ventilation plus oxygen during ground walking 
The present study is the first to demonstrate the benefits of NIV+O2 during walking in patients 
recovering from acute on chronic HRF.  Total distance walked increased by a mean of approximately 
43 metres, and distance to first rest increased by a mean of approximately 62 metres with NIV+O2 
compared to walking with O2 alone.  The minimal clinically important difference in 6MWD is not 
known in patients recovering from acute on chronic HRF.  However, the change in 6MWD with 
NIV+O2 is comparable to the mean change in 6MWD of 48 metres (95% CI 32 to 65) after at least 
four weeks of supervised outpatient pulmonary rehabilitation in patients with COPD (Lacasse et al, 
2006).  Median time to “first rest” was 6 minutes with NIV+O2 compared to 3.1 minutes with O2 
alone, indicating that many participants completed the 6MWT with NIV+O2 without stopping to rest.  
While it is unknown whether the changes observed are clinically significant, the reduction in dyspnoea 
and improvement in oxygenation observed suggest that NIV+O2 during walking may allow patients to 
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commence exercise earlier in the recovery phase, thus reducing the risk of deconditioning.   
 
The mechanisms of improved walking performance with NIV+O2 most likely relate to the reduction in 
dyspnoea and improvement in SpO2 compared to walking with O2 alone that was observed at isotime 
exercise.  These findings are in keeping with the effects of NIV during exercise in stable patients with 
COPD or chest wall restrictive disorders (Hernandez et al, 2001; van 't Hul et al, 2002; Vila et al, 
2007).  As dyspnoea was the primary symptom that limited walking in our participants, reduction of 
this unpleasant symptom with NIV+O2 probably played a key role in allowing participants to walk 
further with fewer rests.  The moderately strong inverse correlation that was found between the change 
in total distance walked and the change in isotime dyspnoea with NIV+O2 compared to walking with 
O2 alone, where 27% of the variation in endurance time was explained by the change in isotime 
dyspnoea provides further support for this mechanism.  In stable patients with COPD, NIV during 
exercise was found to reduce dyspnoea in proportion to respiratory muscle unloading (Kyroussis et al, 
2000; Maltais et al, 1995).  Similarly in patients recovering from acute on chronic HRF, NIV may 
have unloaded the respiratory muscles, thereby reducing dyspnoea.   
 
The detrimental effect of decreased O2 supply to exercising muscle has been described in patients with 
chronic respiratory failure (Thompson et al, 1993).  As isotime SpO2 was higher with NIV+O2 during 
exercise, this may have resulted in improved muscle oxygenation and contributed to the improvement 
in exercise performance with NIV+O2 compared to exercise with O2 alone.  Locomotor muscle 
oxygenation and exercise endurance time were also improved when NIV was used during high 
intensity cycling compared to exercise with sham NIV in stable patients with COPD (Borghi-Silva et 
al, 2008).  Interestingly, rather than an increase in systemic O2 delivery, the proposed mechanism of 
improved peripheral muscle oxygenation was a redirection of a fraction of cardiac output from the 
respiratory muscles to the locomotor muscles as a result of respiratory muscle unloading associated 
with the application of NIV (Borghi-Silva et al, 2008).  A similar phenomenon has also been 
demonstrated in elite athletes with NIV during very high intensity exercise (Harms et al, 1998).  In 
addition, stable patients with severe COPD or severe chest wall restriction can develop a combined 
respiratory and metabolic acidosis during exercise (Hernandez et al, 2001; Vila et al, 2007).  The 
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development of acute hypercapnia and a respiratory acidosis during exercise has been shown to 
significantly impair respiratory muscle function (Jonville et al, 2002; Juan et al, 1984).  In stable 
patients with chronic HRF, NIV during exercise reduced the magnitude of exercise induced 
hypercapnia and improved exercise performance (Hernandez et al, 2001; Vila et al, 2007).  Non-
invasive ventilation may play a similar role during exercise in patients recovering from acute on 
chronic HRF.  However the potential advantage of NIV+O2 during walking over O2 alone in 
preventing carbon dioxide retention in patients recovering from acute on chronic HRF is yet to be 
confirmed.  Oxygen saturation was also significantly higher at rest while breathing with NIV+O2 
compared to breathing with O2 alone, despite the same flow rate of O2 being used.  In fact, the FiO2 
delivered with NIV would have been lower than the FiO2 delivered with nasal prongs due to the 
dilution effect of high airflow rates associated with NIV (Yoder et al, 2004).   
 
Situations that cause an increase in respiratory rate, such as an acute exacerbation (Barbera et al., 
1997) or exercise, reduce the time available for expiration.  In the majority of patients with severe 
airflow limitation, this reduction in expiratory time is associated with an increase in end expiratory 
lung volume, that is, dynamic hyperinflation (O'Donnell et al, 2001a).  Dynamic hyperinflation causes 
an increase in intrinsic positive end expiratory pressure (PEEPi), which imposes an inspiratory 
threshold load on the respiratory muscles and increases the elastic work of breathing (Sliwinski et al, 
1998).  The application of extrinsic positive end expiratory pressure (PEEPe) has been shown to reduce 
the inspiratory threshold load and elastic work of breathing in patients with acute HRF secondary to 
COPD during weaning from mechanical ventilation without worsening pulmonary hyperinflation, 
provided that PEEPe is less than PEEPi (Nava et al, 1995; Petrof et al, 1990b).  Similarly, the 
application of NIV, and in particular the EPAP, may have assisted participants with expiratory flow 
limitation and PEEPi during walking by reducing the inspiratory threshold load and elastic work of 
breathing.  However this is speculative only and further investigation of this potential mechanism is 
required.  Furthermore, in stable patients with moderate to severe COPD, NIV during exercise has 
been shown to cause a change in the pattern of breathing with an augmentation of tidal volume and a 
reduction in respiratory rate compared to unassisted exercise or exercise with sham NIV (van 't Hul et 
al, 2004).  The relative slowing of the respiratory rate allows a greater time for expiration to occur.  
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Whether this permits a delay in the onset, or a reduction in the magnitude of dynamic hyperinflation in 
patients recovering from acute on chronic HRF and expiratory flow limitation is yet to be evaluated. 
 
Although it is beyond the scope of the present study, the impact of exercise on systemic inflammation 
and oxidative stress in patients recovering from acute on chronic HRF, particularly those with COPD, 
is unknown.  In stable patients with COPD and severe muscle wasting, performance of the 6MWT 
induced systemic inflammation (van Helvoort et al, 2007).  Markers of systemic inflammation and 
oxidative stress have been associated with a loss of muscle mass and muscle dysfunction (Barreiro et 
al, 2005; Schols et al, 1996).  Interestingly, the use of supplemental O2 prevented the increase of some 
of these markers in patients with COPD and severe muscle wasting who were not hypoxaemic at rest 
but who did desaturate during exercise (van Helvoort et al, 2006).  The effect of exercise in patients 
recovering from acute on chronic HRF on markers of systemic inflammation and oxidative stress 
needs to be explored to ensure that early exercise rehabilitation does not have a detrimental effect in 
this population, and to investigate the effect of NIV+O2 during exercise on these markers. 
 
Effect of non-invasive ventilation plus oxygen during unsupported arm exercise 
While a statistically significant improvement in UAE endurance time was found with NIV+O2 
compared to exercise with O2 alone, examination of individual data (Figure 5.7a) revealed that only a 
few participants demonstrated a substantial increase in endurance time.  This is in contrast to a 
previous study performed in patients with stable chronic HRF, where NIV increased UAE endurance 
time by a mean of 91 seconds compared to exercise without NIV (Menadue et al, 2009b).  Pressure 
support (PS) during exercise has previously been shown to improve SAE capacity (arm cranking) in 
people recovering from acute on chronic HRF who were slow to wean from mechanical ventilation 
(Vitacca et al, 2006).  In the study performed by Vitacca and colleagues (Vitacca et al, 2006), exercise 
was performed much later in the recovery phase compared with the present study (>15 days versus 
median 4 days) and a different form of arm exercise was used.  Upper limb exercise rehabilitation 
appears to be important in patients receiving mechanical ventilation, as a strong inverse correlation 
between upper limb strength and time to wean from mechanical ventilation has been demonstrated 
(Martin et al, 2005).  Many tasks of daily living require unsupported rather than supported arm 
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activity.  Due to the specificity of training, UAE is preferable over SAE for functional exercise 
training (Martinez et al, 1993).  However, UAE is more difficult to perform than SAE because during 
UAE, some accessory respiratory muscles have a dual task of performing the upper limb activity as 
well as assisting respiration.  Consequently, some of the ventilatory load is shifted to the diaphragm 
and abdominal muscles (Celli et al, 1988).  As a result, a large proportion of ventilatory reserve may 
be used during functional unsupported arm activities, as has been shown in stable patients with 
moderate to severe COPD (Velloso et al, 2003).   
 
In the current study, despite arm muscle fatigue being the primary symptom that limited UAE, severe 
dyspnoea (mean 4.9) was reported at isotime exercise with O2 alone.  Non-invasive ventilation has 
previously been shown to unload the diaphragm during arm elevation in patients with chronic HRF 
(Poggi et al, 2006).  An inverse relationship between respiratory muscle unloading and dyspnoea 
(Maltais et al, 1995) has also been demonstrated.  While a small non-significant reduction in isotime 
dyspnoea (mean 1.0) was found with NIV+O2 compared to UAE with O2 alone, this change was 
considerably lower than the mean reduction in isotime dyspnoea of 2.3 points on a 0-10 category ratio 
scale that was achieved with NIV during UAE in stable patients with chronic HRF using a similar 
level of PS (Menadue et al, 2009b).  It is possible that the level of PS delivered in the current study 
was too low to sufficiently unload the respiratory muscles during UAE in the majority of participants 
recovering from acute on chronic HRF, and therefore to significantly reduce dyspnoea and cause a 
substantial increase in exercise endurance time.  In addition, dynamic hyperinflation often occurs 
during upper limb exercise in stable patients with moderate to severe COPD (Gigliotti et al, 2005) or 
cystic fibrosis (Alison et al, 1998) and may also be expected to occur when these patients are 
recovering from acute on chronic HRF.  Although the application of EPAP during UAE has the 
potential to unload the respiratory muscles by offsetting the inspiratory threshold load imposed by 
exercise induced dynamic hyperinflation and PEEPi, the level of EPAP used in the present study may 
not have been optimal given the general lack of improvement in endurance time.    
 
In the present study, isotime RPE (arm muscle fatigue) was reduced by a mean of 1.0 points on a 0-10 
category ratio scale with NIV+O2 during UAE, which was similar to the reduction observed in stable 
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patients with chronic HRF (Menadue et al, 2009b).  Despite this reduction, the majority of participants 
eventually terminated UAE due to arm muscle fatigue whether NIV+O2 or O2 alone was used.  The 
fatigue was most likely attributable to the effect of repetitive exercise in a small muscle group.  
However, even a small reduction of arm muscle fatigue may enable patients recovering from acute on 
chronic HRF to better tolerate UAE early in the recovery period.   
 
Levels of IPAP and EPAP similar to those used in the current study have been shown to reduce 
cardiac output at rest in some patients with acute HRF secondary to COPD (Confalonieri et al, 1998).  
In the present study, there was no difference in blood pressure between NIV+O2 and O2 alone at rest.  
However there was a statistically significant drop in mean arterial pressure (mean 3 mmHg) at end 
exercise with NIV+O2 compared with O2 alone.  The change in blood pressure was small and unlikely 
to be of clinical significance, which suggests that the application of NIV+O2 during exercise did not 
have an adverse effect on venous return in this cohort of patients recovering from acute on chronic 
HRF. 
 
Relationship between the response to non-invasive ventilation during walking and the response 
to non-invasive ventilation during unsupported arm exercise 
In a subgroup of fourteen participants who performed both 6MWT and UAE tests, no significant 
correlation was found between the response to NIV+O2 during walking and the response to NIV+O2 
during UAE.  Thus the magnitude of the response to NIV during one type of exercise cannot be 
predicted using the response to NIV during a different type of exercise for a given level of PS in 
patients recovering from acute on chronic HRF.  A difference in ventilatory requirements, exercise 
intensity and muscle mass utilisation between walking and UAE in the present study is likely and 
these factors may help to explain the poor relationship that was found between the response to 
NIV+O2 during walking and UAE.  Alternatively, the level of PS required to assist exercise 
performance may vary between different types of exercise within an individual.  In which case, NIV 
settings should be titrated separately for each type of exercise and for each individual.    
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Safety and feasibility 
Exercise performed early in the recovery phase was safe and generally well tolerated in patients 
recovering from acute on chronic HRF.  Participants who performed both series of 6MWT and UAE 
tests were able to complete the six exercise tests within one day.  Participants who performed either 
the 6MWT or UAE tests completed three exercise tests within one day.  No adverse events occurred 
during or after testing in any of the participants.  While early mobilisation on the second day after 
admission to hospital has been previously described in patients with COPD (Yohannes & Connolly, 
2003), patients with severe hypercapnia were excluded from the study.  In patients recovering from 
acute respiratory failure, mobilisation has also been reported as a safe intervention (Bailey et al, 2007).  
However, the mean time from admission to the intensive care unit to mobilisation was 11 days, which 
is considerably longer than the median of four days from hospital admission to mobilisation reported 
in the present study.  
 
The use of NIV+O2 during exercise was safe and effective in patients recovering from acute on 
chronic HRF, but is it feasible in the clinical setting?  In stable patients, NIV during treadmill or 
cycling exercise has been shown to be both beneficial and feasible (Borel et al, 2009; Keilty et al, 
1994; van 't Hul et al, 2006).  However, in the acute care setting, equipment such as treadmills and 
cycle ergometers are not usually available.  While ground walking is an alternative and an important 
type of functional exercise, walking with NIV+O2 does require additional equipment compared to 
walking with O2 alone.  Forearm support frames and trolleys (to carry the equipment) are usually 
readily available in the general ward environment.  Alternatively, a rollator frame could be substituted 
and has previously been used to carry the ventilator and O2 cylinder during ground walking in stable 
patients with very severe COPD (Dreher et al, 2007).  In addition, rollator frames have been shown to 
reduce the ventilatory limitation to exercise (Probst et al, 2004) and improve exercise performance 
(Solway et al, 2002) in stable patients with severe COPD and a reduced exercise capacity.  The main 
additional piece of equipment that is required for this strategy is the bilevel machine.  Selection of 
individuals who are already receiving NIV for the management of acute HRF will often ensure ready 
access to a ventilator and mask that could be used during exercise.  In the present study, an external 
battery was used to power the bilevel machine during ground walking.  Some bilevel machines do 
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have an internal battery and provided the capacity of the machine is adequate to support ventilation 
during exercise, would reduce the amount of equipment that is required.  As technology advances, the 
development of lightweight portable bilevel machines with internal batteries and the capacity to 
support ventilation during exercise may allow exercise with NIV to be as simple as using portable O2.  
The set up time for exercise with NIV+O2 is likely to be longer compared with that of exercise with O2 
alone.  However, this was not measured in the present study.  In addition, the assistance of one or two 
clinicians who are familiar with NIV is usually required when NIV+O2 is used during exercise.   
 
The bilevel device used in the present study was able to generate sufficient airflow to maintain the 
preset inspiratory and expiratory positive airway pressure during exercise in patients recovering from 
acute on chronic HRF.  The bilevel device is readily available and commonly used to treat acute HRF, 
thus increasing the feasibility of using NIV during exercise.  The ability of a ventilator to maintain 
preset positive airway pressure during exercise is crucial in order for NIV to assist exercise 
performance.  For example, a severe drop in mask pressure was associated with a reduction in exercise 
capacity when a lightweight portable ventilator was used during ground walking in patients with stable 
COPD (Highcock et al, 1997; Revill et al, 2000).  In contrast, distance walked increased and gas 
exchange was improved when a different portable ventilator was used during ground walking in stable 
patients with very severe COPD (Dreher et al, 2007).  Ensuring that the device used to provide 
ventilatory assistance during exercise has the capacity to support higher levels of ventilation during 
exercise is imperative when determining an individual’s response to NIV during exercise. 
 
Limitations 
The main limitation of the present study was that participants and investigators were not blinded to the 
use of NIV during exercise which may have introduced bias.  If a significant bias had occurred, it 
might be expected that participants would have a similar response to NIV+O2 during 6MWT and UAE 
tests compared to exercise with O2 alone.  In contrast, in the subgroup of 14 participants who 
performed both series of 6MWT and UAE tests, the response to NIV+O2 during walking was positive, 
whereas the response to NIV+O2 during UAE was generally not different to exercise with O2 alone.  
This suggests firstly that investigator bias was unlikely to have occurred, and secondly that any 
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placebo effect associated with NIV+O2 was minimal.  In order to minimise the potential effects of bias, 
a standardised set of test instructions and terms for encouragement were used.  Sham NIV was not 
used during exercise because an effective sham has not been demonstrated in patients recovering from 
acute on chronic HRF.  In addition, the population included in the present study were acutely unwell 
and consequently the number of exercise tests that needed to be performed was kept to a minimum in 
order to minimise the risk of excessive fatigue.  Given the limited number of exercise tests, it was 
deemed to be more important to compare exercise with NIV+O2 to exercise with O2 alone rather than 
with sham NIV, as ineffective ventilator settings (sham) could impede exercise performance 
(Highcock et al, 1997) and therefore may exaggerate the effects of NIV+O2 during exercise.   
  
Another potential limitation of the present study was that a heterogeneous group of patients were 
studied.  While the mechanisms that contribute to dyspnoea and exercise limitation differ between 
patients with severe chronic lung disease and those with severe chest wall restriction, both groups 
often have very limited ventilatory reserve during exercise (Montes de Oca & Celli, 2000; Shneerson, 
1978b), both have been shown to derive benefit from NIV during exercise when stable (Bianchi et al, 
1998; Borel et al, 2008; Dreher et al, 2007; Menadue et al, 2009b), and examination of individual data 
(Figures 5.4 and 5.7) does not suggest a particular pattern of response to NIV+O2 during exercise 
based on diagnostic group alone.  In addition, disease severity appears to be an important factor that 
affects the response to NIV during exercise, even within patients from the same diagnostic group.  
This has been demonstrated in people with stable COPD (Bianchi et al, 1998; Bianchi et al, 2002), 
kyphoscoliosis (Borel et al, 2008) and with continuous positive airway pressure (CPAP) during 
exercise in people with cystic fibrosis (Henke et al, 1993), where those subjects with more severe 
disease achieved greater improvements with NIV or CPAP during exercise than those with less severe 
disease.  The participants included in the present study all had severe disease with a greatly reduced 
ventilatory capacity, and therefore presented as a group who may benefit from NIV+O2 during 
exercise. 
 
Clinical implications 
Compared to exercise with O2 alone, NIV+O2 during walking and UAE was associated with an 
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improvement in exercise performance in patients recovering from acute in chronic HRF.  
Consequently, NIV is a tool that clinicians could use as an adjunct to exercise in this population.  
However, the improvement in UAE endurance time with NIV+O2, while statistically significant, was 
generally small and unlikely to be of clinical significance.  Exercise performed early in the recovery 
phase was safe and well tolerated with NIV+O2.  For example, three subjects experienced severe O2 
desaturation (<75%) during walking with O2 alone but not with NIV+O2 during exercise.  
Furthermore, as dyspnoea and arm muscle fatigue were the primary symptoms that limited walking 
and UAE respectively, the reduction in isotime dyspnoea during walking and the reduction in isotime 
arm muscle fatigue during UAE that was observed with NIV+O2 may help patients to better tolerate 
exercise early in the recovery period.  
 
Although walking performance improved for the group as a whole with NIV+O2, individual responses 
did vary with some subjects walking less with NIV+O2.  The change in total distance walked with 
NIV+O2 compared to walking with O2 alone ranged from -18% to 106% (Figure 5.6).  As previously 
discussed, the magnitude of the change in isotime dyspnoea with NIV+O2 seems to be important and 
accounted for 27% of the variance in the change in total distance walked with NIV+O2 compared to 
walking with O2 alone (Figure 5.6).  In order for NIV to be of benefit during exercise, it appears that 
selection of ventilator settings that adequately unload the respiratory muscles and reduce dyspnoea is 
crucial.  Currently there are no recommendations regarding the best way to select NIV settings for 
exercise in a patient with acute on chronic HRF.  Of note, NIV settings for exercise in the present 
study were determined while participants were at rest.  However, the level of PS required to alleviate 
dyspnoea and reduce the ventilatory limitation during exercise may not be the same level of PS that 
participants perceived as comfortable at rest.  In clinical practice further improvements may have 
occurred if individuals were tested to determine if higher pressures were tolerated and led to greater 
improvements in exercise performance during the acclimatisation phase.  In order to determine 
whether an individual would benefit from NIV+O2 during exercise, a test with NIV+O2 during the 
specific type of exercise could be conducted, with PS titrated to maximally alleviate dyspnoea during 
exercise compared to exercise O2 alone.  Identification of ventilator settings that provide the greatest 
improvement in exercise performance is important if NIV+O2 is to be used during exercise 
                                                                                                                       
 
237 
rehabilitation or to assist in the performance of daily activities. 
 
Ideally, subjects who are likely to respond to NIV+O2 during exercise would be selected using resting 
measures that are easy to perform in the clinical setting.  In the present study, no relationship was 
found between the response to NIV+O2 during walking and baseline measures of PaCO2, FEV1, FVC 
or PImax1.0.  This suggests that these variables may not be of assistance in the selection of individuals 
recovering from acute on chronic HRF who might benefit from NIV+O2 during exercise.  This finding 
is in contrast to a study conducted in stable patients with COPD where baseline inspiratory muscle 
weakness was shown to be an important factor in determining the response to NIV during exercise 
(van’t Hul et al, 2004).  Until alternative baseline measures that can assist with patient selection are 
identified, a trial of NIV+O2 during exercise is unavoidable in order to determine the response to 
NIV+O2 during exercise in this population.  
 
Although NIV+O2 during exercise appeared to improve a number of immediate outcomes compared to 
exercise with O2 alone, it remains unclear whether NIV+O2 in conjunction with a early exercise 
rehabilitation program has a clinically significant effect on longer term outcomes such as quality of 
life, exercise capacity or level of physical activity after discharge from hospital in patients recovering 
from acute on chronic HRF.  Furthermore, the use of NIV+O2 during exercise as part of routine 
clinical practice does have resource implications.  Investigation of the cost-benefit relationship of such 
a strategy during early exercise rehabilitation is warranted and should evaluate outcome measures 
including staff time, length of stay, functional exercise capacity, physical activity and quality of life 
following discharge. 
 
Conclusion 
Non-invasive ventilation plus O2 during ground walking resulted in an immediate improvement in 
distance walked and SpO2, and a reduction in dyspnoea compared to exercise with O2 alone in people 
recovering from acute on chronic HRF.  While UAE endurance time was also statistically significantly 
greater with NIV+O2 compared with O2 alone, the clinical significance of this change is unclear.  
However, the combination of NIV+O2 during exercise reduced dyspnoea during walking and reduced 
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arm muscle fatigue during UAE compared to exercise with O2 alone and therefore may assist patients 
to tolerate exercise rehabilitation early in the recovery phase in an attempt to avoid deconditioning.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER 6 
 
 
 
 
 
 
 
 
Conclusions 
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General overview 
The use of continuous positive airway pressure (CPAP) during exercise was first described in the 
literature over 20 years ago in patients with severe chronic obstructive pulmonary disease (COPD) by 
O’Donnell and colleagues (1988), and reports of non-invasive ventilation (NIV) during exercise soon 
followed.  When the research contained in this thesis began in 2004, the majority of the literature 
regarding NIV during exercise had investigated the immediate effects of NIV during cycling or 
treadmill exercise (Bianchi et al, 1998; Dolmage & Goldstein, 1997; Hernandez et al, 2001; Highcock 
et al, 2003; Highcock et al, 2002; Keilty et al, 1994; O'Donnell et al, 1999; Pinto et al, 1999; Tsuboi et 
al, 1997; van 't Hul et al, 2004; van 't Hul et al, 2002), or examined the possible mechanisms of benefit 
related to using NIV during exercise (Kyroussis et al, 2000; Maltais et al, 1995; Polkey et al, 2000; 
Polkey et al, 1996b).  Two studies (Highcock et al, 1997; Revill et al, 2000) had examined the effect 
of NIV during functional exercise (ground walking) and found that NIV impeded exercise 
performance compared with unassisted exercise.  However, the capacity of the portable ventilator used 
to provide NIV in these studies was insufficient to support ventilation during exercise (Highcock et al, 
1997), and most likely contributed to the negative results.  Several studies investigated the effects of 
NIV during cycling or treadmill exercise training (Bianchi et al, 2002; Costes et al, 2003; Hawkins et 
al, 2002; Johnson et al, 2002), although sample sizes were small and the results were inconsistent 
between studies.  The population most frequently studied were individuals with severe COPD.  In 
contrast, subjects with chronic hypercapnic respiratory failure (HRF), who are commonly prescribed 
nocturnal NIV, were often excluded from trials.  Only two studies assessed the effect of NIV during 
exercise in people with restrictive chest wall disorders (Highcock et al, 2002; Tsuboi et al, 1997) and 
again, results were conflicting.   
 
While NIV during exercise was generally shown to improve exercise capacity in patients with COPD 
(Hawkins et al, 2002; van 't Hul et al, 2002), primarily through unloading the respiratory muscles and 
reducing dyspnoea (Kyroussis et al, 2000; Maltais et al, 1995), individual variability was frequently 
observed and many questions remained unanswered.  For example, it was not known whether NIV 
could assist the performance of functional exercise such as unsupported arm exercise (UAE) or ground 
walking when a ventilator capable of supporting ventilation during exercise was used.  Limited 
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information was available regarding baseline characteristics that could be used to assist with the 
selection of candidates who may benefit from this technique.  In addition, little was known about the 
optimal ventilator mode and settings for particular diagnostic groups during different types of exercise.  
The role of NIV during exercise training and the use of NIV during exercise in different contexts, such 
as the acute care setting or during daily activities was unclear.  The work contained in this thesis 
aimed to address some of these issues.  In particular, to determine the immediate effects of NIV during 
functional exercise in patients with stable chronic HRF secondary to very severe COPD or severe 
kyphoscoliosis, to investigate whether the level of pressure support (PS) provided during exercise 
alters the response to NIV during exercise in people with severe kyphoscoliosis and chronic HRF, to 
clarify the effect of NIV during exercise training in people with COPD, and finally to examine the 
immediate effects of NIV and oxygen (NIV+O2) during functional exercise in people recovering from 
acute on chronic HRF.  In addition, the relationship between the response to NIV during exercise and 
baseline characteristics, exercise induced dyspnoea, and ventilatory reserve were assessed in an 
attempt to identify factors that may help with the selection of patients for this intervention. 
 
Summary of findings and implications for clinical practice 
The aim of the randomised crossover study presented in Chapter 2 was to determine whether NIV 
during UAE and ground walking could improve exercise performance compared to exercise without 
NIV in patients with chronic HRF secondary to very severe COPD or severe kyphoscoliosis.  The 
main and novel findings of this study were that NIV during UAE significantly reduced dyspnoea and 
increased exercise endurance time compared to exercise without NIV.  The mechanisms of benefit 
associated with using NIV during UAE appeared similar to those previously reported with NIV during 
lower limb exercise, and included a reduction in dyspnoea and muscle fatigue, and improved 
oxygenation.  No significant relationship was observed between the response to NIV during UAE and 
baseline pulmonary function, arterial blood gases, or the change in isotime dyspnoea when NIV was 
used during exercise, which suggests that these measures can not be used to assist in the selection of 
individuals who are likely to benefit most from using NIV during UAE.  It is not known whether the 
increase in UAE endurance time reported in this study (mean 91 seconds) is clinically worthwhile.  
Nonetheless, NIV is a tool that clinicians can use as an adjunct during UAE to reduce the symptoms of 
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dyspnoea and arm muscle fatigue, and improve short term exercise performance in people with stable 
chronic HRF secondary to very severe COPD or severe kyphoscoliosis. 
 
In contrast to the effect of NIV during UAE, NIV during ground walking did not significantly increase 
exercise endurance time, although a trend was observed in favour of walking with NIV.  A moderate 
inverse correlation was found between forced vital capacity (FVC) (% predicted) and the response to 
NIV during ground walking (r2 = 0.30), indicating that those participants with the greatest reduction in 
FVC (% predicted) tended to gain more benefit from NIV during walking than individuals with a 
milder reduction in FVC.  However, interpretation of this finding is difficult as data from participants 
with very severe COPD and participants with severe kyphoscoliosis were combined.  In people with 
moderate to severe kyphoscoliosis, Borel and colleagues (Borel et al, 2008) found that only 
individuals with severely reduced total lung capacity and FVC benefited from using NIV during 
exercise (“responders”).  Therefore, baseline FVC (% predicted) may assist in the selection of 
individuals with kyphoscoliosis who may benefit from NIV during exercise.   
 
Notably, isotime dyspnoea was not reduced with NIV during ground walking in the study described in 
Chapter 2.  As dyspnoea has been shown to be inversely proportional to inspiratory muscle unloading 
(Maltais et al, 1995), it is likely that the level of inspiratory PS provided (median 10 cmH2O) was 
insufficient to unload the respiratory muscles and significantly improve exercise performance during 
ground walking.  Subsequent to the completion of the present study, high level PS (mean 25cmH2O) 
and O2 during ground walking was shown to reduce dyspnoea and significantly improve oxygenation 
and distance walked in patients with very severe COPD compared to walking with O2 alone (Dreher et 
al, 2007).  While it appears that PS 10 cmH2O is sufficient to improve cycling exercise capacity in 
people with severe COPD (van 't Hul et al, 2004, 2006), or PS 11 cmH2O to improve UAE capacity as 
outlined above, it seems that higher levels of PS may be required to improve exercise performance 
during ground walking in people with COPD.  Similarly, individuals with severe kyphoscoliosis may 
also require a high level of PS during walking.  At the conclusion of the present study, only two 
reports regarding the effect of NIV during exercise in people with chest wall restriction had been 
published in the literature.  One study found that very high level NIV (mean peak airway pressure of 
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approximately 37 cmH2O delivered via a volume-cycled ventilator) during cycling exercise reduced 
dyspnoea and increased endurance time in people with severe chest wall restriction secondary to post 
tuberculosis sequelae (Tsuboi et al, 1997).  The other study reported that low level PS (mean 9.7 to 
13.7 cmH2O) during treadmill walking impeded exercise performance in individuals with severe 
scoliosis (Highcock et al, 2002), although the authors conceded that the ventilators used in this study 
may not have had the capacity to adequately support ventilation during exercise.  Consequently, the 
question remained as to whether NIV during walking could improve exercise performance in people 
with severe kyphoscoliosis, and if so, whether the level of PS provided during exercise was important. 
 
The aim of the double blind randomised crossover trial described in Chapter 3 was to determine 
whether the level of PS provided during treadmill walking had an effect on the efficacy of NIV during 
exercise in people with chronic HRF secondary to severe kyphoscoliosis.  The main findings of this 
study were that high level PS (20 cmH2O) during treadmill walking increased endurance time, 
improved pattern of breathing and oxygenation, and reduced the perception of leg muscle fatigue and 
dyspnoea compared to walking unassisted.  Low level PS (10 cmH2O) did not increase endurance time 
compared with unassisted exercise, indicating that the level of PS provided during exercise does 
influence the efficacy of using NIV during walking in this population.  This finding may help to 
explain the lack of a significant improvement in walking endurance time found in Chapter 2, as the 
median level of PS provided during ground walking was low at 10 cmH2O and some of the 
participants had a history of severe kyphoscoliosis.  Not only was the level of PS provided during 
walking important in order to increase exercise endurance time, the effect that high level PS had on 
isotime dyspnoea also influenced exercise performance, as demonstrated by the moderately strong 
inverse correlation that was found between the change in endurance time and the change in isotime 
dyspnoea with high level PS relative to unassisted exercise (rS = -0.651).  This finding highlights the 
importance of reducing dyspnoea in order for NIV to improve exercise capacity in people with severe 
kyphoscoliosis.  Rather than being prescriptive, the findings of this study indicate that high levels of 
PS (of at least 20 cmH2O) are required during walking to improve short term exercise capacity in 
people with severe kyphoscoliosis.  Some individuals may require more than 20 cmH2O during 
exercise to adequately unload the respiratory muscles and reduce dyspnoea.  Based on the relationship 
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that was observed between dyspnoea and the response to PS 20 cmH2O during walking, titration of 
individualised levels of PS in response to changes in isotime dyspnoea is a simple strategy that could 
be used in the clinical setting.  A reduction in isotime dyspnoea of approximately two points on a 0-10 
category ratio scale (Borg, 1982) with NIV during exercise compared to exercise without NIV, has 
previously been associated with short term improvements in exercise performance (Borel et al, 2008; 
van 't Hul et al, 2002) and may be a reasonable target during individualised titration of PS.   
 
The studies described in Chapter 2 and Chapter 3 examined the acute effects of NIV during exercise 
on short term exercise capacity.  Investigation of the acute effects of NIV during exercise provides 
valuable information regarding patient selection, ventilator modes and settings, mechanisms and 
identification of the types of exercise where NIV may be used as an adjunct.  However, in clinical 
practice, NIV is unlikely to be used during a single session of exercise.  Instead, NIV could potentially 
be used over a longer period of time in one of two ways.  Firstly, as an adjunct to exercise training, or 
secondly to assist severely limited individuals to perform activities of daily living.   
 
Several randomised controlled trials (RCTs) investigated the effects of NIV during exercise training 
compared to exercise training alone in people with COPD (Bianchi et al, 2002; Hawkins et al, 2002; 
Johnson et al, 2002; Reuveny et al, 2005; Toledo et al, 2007; van 't Hul et al, 2006).  However, the 
findings were inconsistent across studies and participant numbers were generally small which may 
have reduced the power to detect important differences between groups.  In order to improve statistical 
power and determine whether NIV during exercise training (as part of pulmonary rehabilitation) can 
improve exercise capacity, health related quality of life (HRQL) or physical activity in people with 
COPD above that of exercise training alone or exercise training with sham NIV, a systematic review 
was performed (Chapter 4) and data from studies that met the inclusion criteria were combined in 
meta-analyses.  The review provides evidence that NIV during exercise training allows people with 
COPD to exercise at a higher training intensity and to achieve a greater physiological training effect 
compared with exercise training alone or exercise training with sham NIV.  While there was also 
evidence that training with NIV improved peak and endurance exercise capacity above that of exercise 
training alone (mean increase of 17% and 59% respectively), significant treatment effects were only 
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found when baseline inter-individual differences were taken into account by analysing change from 
baseline data rather than post intervention data.  Interpretation of the clinical significance of these 
results is difficult, as the minimal clinically important difference for the percentage change in peak or 
endurance exercise capacity is unknown.  In addition, there was no evidence that HRQL was better or 
worse with NIV during exercise training, although this outcome was only assessed in two studies.  
Physical activity was not reported in any of the included studies and the effect of NIV during upper 
limb training has not been assessed. 
 
In people with COPD, disease severity appears to be an important factor in patient selection for NIV 
during exercise training, with greater benefits observed in those subjects with more severe airflow 
obstruction (defined by forced expiratory volume over one second) (Bianchi et al., 2002).  However, 
the small number of studies included in the review precluded a formal subgroup analysis of this 
observation.  In addition, some studies specifically selected subjects who could tolerate NIV, or 
subjects with a very limited ventilatory reserve at peak exercise, and consequently the findings of this 
review may not be applicable to all people with moderate to very severe COPD.  While NIV during 
exercise training may benefit select individuals with COPD, implementation of this technique does 
have resource implications and would require experienced staff, access to appropriate equipment and 
may involve extra costs which could limit the feasibility of this technique in some settings.  
 
To date, all of the studies published in the literature regarding the use of NIV during exercise have 
reported the immediate effects or training effects of NIV in stable subjects.  However, based on the 
mechanisms of benefit of NIV during exercise in stable patients, NIV may also have a role as an 
adjunct to exercise in the acute care setting.  In people with COPD, it is well known that acute 
exacerbations that require hospitalisation are associated with significant reductions in HRQL (Esteban 
et al, 2009), exercise capacity (Carr et al, 2007) and physical activity (Pitta et al, 2006).  If the 
exacerbation is severe and patients require treatment with NIV for acute HRF, the risk of re-admission 
to hospital, or of another life threatening event is high (Chu et al, 2004).  Patients with COPD and very 
low levels of physical activity also have a greater risk of being re-admitted to hospital and a greater 
risk of mortality than people with higher levels of physical activity (Garcia-Aymerich et al, 2006).   
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Strategies that aim to improve exercise capacity and physical activity are an important part of the 
management of people with COPD, and probably also individuals with other chronic respiratory 
diseases (Ries et al, 2007).  Functional exercise capacity is the strongest correlate of physical activity 
(Pitta et al, 2005) and along with HRQL, has been shown to improve with exercise training as a 
component of pulmonary rehabilitation in stable patients with COPD (Lacasse et al, 2006).  In 
addition to improving HRQL and exercise capacity, early pulmonary rehabilitation following an acute 
exacerbation of COPD also reduces the risk of re-admission to hospital and mortality (Puhan et al, 
2005).  There is growing evidence that even earlier physical activity and rehabilitation is of benefit to 
patients recovering from acute respiratory failure, including those who require ongoing mechanical 
ventilation (Bailey et al, 2007; Morris et al, 2008; Nava, 1998; Schweickert et al, 2009).  However, the 
commencement of exercise rehabilitation in patients recovering from respiratory failure can be 
delayed due to severe exertional dyspnoea.  Therefore, identification of adjuncts that can facilitate 
early exercise rehabilitation is important, particularly in people recovering from acute on chronic HRF 
who have an increased risk of mortality and re-admission to hospital, and often lower baseline levels 
of exercise capacity and physical activity (Schonhofer et al, 1997; Schonhofer et al, 2003).  
 
The randomised crossover study presented in Chapter 5 aimed to determine whether NIV+O2 during 
ground walking and UAE could improve short term functional exercise performance in people 
recovering from acute on chronic HRF compared to exercise with O2 alone.  The main findings of this 
study were that NIV+O2 during ground walking resulted in an immediate improvement in distance 
walked (mean 43 metres) and oxygenation, and a reduction in dyspnoea compared to exercise with O2 
alone.  Therefore, NIV is a tool that clinicians can use during ground walking to improve exercise 
performance in people recovering from acute on chronic HRF.  While an overall increase in distance 
walked was found with NIV+O2 during exercise, individual responses varied.  One explanation for this 
may relate to the moderately strong inverse correlation that was found between the change in total 
distance walked and the change in isotime dyspnoea with NIV+O2 compared to walking with O2 
alone, where 27% of the variation in endurance time was explained by the change in isotime dyspnoea.  
This relationship suggests that in order for NIV to be of benefit during exercise, selection of ventilator 
settings that adequately unload the respiratory muscles and reduce dyspnoea is important.  No 
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correlation was found between the response to NIV+O2 during walking and baseline measures of 
arterial blood gases, spirometry, or inspiratory muscle strength, which suggests that these variables 
may not be of assistance in the selection of individuals who might benefit most from NIV+O2 during 
ground walking.  Until alternative baseline measures that can assist with patient selection are 
identified, a trial of NIV+O2 during exercise is required in order to determine whether an individual 
will benefit from using NIV during exercise. 
 
While a statistically significant increase in UAE endurance time was also found with NIV+O2 
compared with UAE with O2 alone, the effect size was small and unlikely to be of clinical 
significance.  Of note, isotime dyspnoea was not significantly reduced with NIV+O2 during UAE 
which may have contributed to the small effect size.  A subgroup of participants also performed both 
series of ground walking and UAE tests using the same level of PS.  No relationship was found 
between the response to NIV+O2 during ground walking and the response to NIV+O2 during UAE 
which suggests that within an individual, different levels of PS may be required for different types of 
exercise.  Nonetheless, NIV+O2 during exercise reduced dyspnoea during walking and reduced arm 
muscle fatigue during UAE compared to exercise with O2 alone which may assist patients to better 
tolerate exercise rehabilitation early in the recovery phase in an attempt to avoid deconditioning.   
 
Suggestions for future research 
Additional research is required to conclusively determine whether NIV during exercise training can 
result in clinically worthwhile treatment effects in important outcomes.  In stable patients with COPD, 
further studies with larger numbers of participants are needed.  Ideally, exercise training with NIV 
should be compared to exercise training with sham NIV rather than exercise training alone in order to 
blind participants, trainers and assessors to group allocation and minimise bias.  Furthermore, adequate 
reporting of allocation concealment, randomisation sequence generation and blinding is necessary to 
allow accurate judgement of the risk of bias in future studies and therefore to determine the strength of 
the results.  Important outcomes that should be evaluated include exercise capacity, HRQL, physical 
activity and the additional costs associated with using NIV during exercise training.  In addition to 
evaluation of these outcomes immediately after completion of the exercise training program, longer 
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term follow-up (eg 12 months) should also be performed.  Pulmonary rehabilitation guidelines 
recommend that rehabilitation programs include both upper and lower limb exercise training (Nici et 
al, 2006).  Given the short term benefits of NIV during UAE (Menadue et al, 2009b), investigation of 
the effect of NIV during upper limb training is warranted.  The effect that the level of ventilatory 
support provided during exercise training has on important outcomes should be evaluated, as the level 
of PS used during a single bout of exercise has previously been shown to affect exercise performance 
in people with COPD (van 't Hul et al, 2004).  Currently, only low to moderate levels of ventilatory 
support have been used during exercise training in people with COPD.  However, the short term 
effects of high level PS (mean 30 cmH2O) during exercise in people with very severe COPD and 
chronic HRF appear beneficial (Dreher et al, 2007) and should also be assessed during training.  In 
addition, it is unknown whether the mode of ventilatory support or type of interface used during 
exercise alters the efficacy of NIV during exercise training.  A variety of ventilator modes have been 
used during exercise training in people with COPD, including proportional assist ventilation (Hawkins 
et al., 2002; Bianchi et al., 2002), bilevel ventilation (Johnson et al., 2002; Reuveny et al., 2005; 
Toledo et al., 2007) and inspiratory pressure support (van’t Hul et al., 2006).  Similarly, a range of 
interfaces have been used, including nasal masks (Bianchi et al., 2002; Johnson et al., 2002; Toledo et 
al., 2007), oronasal masks (Hawkins et al., 2002; Bianchi et al., 2002; Reuveny et al., 2005) and 
mouthpieces (van’t Hul et al., 2006).  However, to determine the influence of the mode of ventilation 
or type of interface used during exercise training on important outcomes, larger numbers of RCTs are 
required in order to perform subgroup analyses in future systematic reviews. 
 
Many of the RCTs that assessed the role of NIV during exercise training in people with COPD 
actively excluded individuals with chronic HRF.  People with COPD and chronic HRF can benefit 
from pulmonary rehabilitation (Carone et al, 2007), and while the evidence supporting the use of 
nocturnal NIV in stable patients with COPD is inconclusive (Wijkstra et al, 2002), select patients may 
derive benefit (Kolodziej et al, 2007) and many are currently being treated with long term NIV 
(Lloyd-Owen et al, 2005).  Several studies have demonstrated that nocturnal NIV in addition to 
pulmonary rehabilitation confers greater improvements in HRQL, functional status and gas exchange 
compared to pulmonary rehabilitation alone in people with severe or very severe COPD (Duiverman et 
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al, 2008; Garrod et al, 2000; Kohnlein et al, 2009).  To date, no studies have investigated the use of 
nocturnal NIV in combination with NIV during exercise training in patients with very severe COPD 
and chronic HRF.  However, patients with chronic HRF who are considered appropriate candidates for 
nocturnal NIV will have access to equipment, are acclimatised to NIV and are a group that may 
respond to NIV during exercise training and should be assessed in future studies.   
 
To date one RCT has assessed the effect of NIV during exercise training in people with chest wall 
restriction, primarily due kyphoscoliosis.  Borel and colleagues (Borel et al, 2009) conducted a home-
based cycling training program and compared exercise training with NIV to exercise training alone.  
Exercise capacity improved in all participants, however no difference was found between groups.  
Subject numbers were small and subsequently a type II error cannot be excluded.  Only half of the 
participants in the study had severely restricted lung volumes and were classified as NIV ‘responders’ 
(Borel et al, 2008), which also may have contributed to the non-significant difference between groups.  
Consequently, additional RCTs are required to evaluate the effects of NIV during exercise training in 
people with kyphoscoliosis.  Participants with severely reduced lung volumes who demonstrate an 
acute benefit with NIV during exercise (Borel et al, 2008) should be selected, and high level PS of at 
least 20 cmH2O (Menadue et al, 2010a) should be provided during exercise.  Similar to the 
recommendations made for people with COPD, high quality RCTs are required, and outcomes that 
include exercise capacity, HRQL, physical activity and cost should be evaluated immediately post 
training and in the long term.  In addition, both lower limb and upper limb training should be assessed.  
An important finding of the study by Borel et al (Borel et al, 2009) was that a home-based exercise 
training program with NIV is feasible in people with chronic HRF.  A large multi-centre RCT recently 
reported that self-monitored, home-based rehabilitation is equivalent to outpatient centre-based 
rehabilitation in people with COPD (Maltais et al, 2008).  A comparison between centre-based and 
home-based training with NIV may be valuable, both in people with severe or very severe COPD and 
those with severe kyphoscoliosis in order to determine the cost-benefit relationship of training with 
NIV in these different settings.   
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The combination of NIV+O2 may be a useful adjunct to exercise in people recovering from acute on 
chronic HRF (Menadue et al, 2010b).  However it is unclear whether NIV+O2 in conjunction with an 
early exercise rehabilitation program has a clinically significant effect on longer term outcomes such 
as HRQL, exercise capacity or physical activity levels after discharge from hospital.  Investigation of 
the cost-benefit relationship of NIV during early exercise rehabilitation is warranted, particularly in 
people with COPD and a history of frequent exacerbations, and should evaluate outcomes such as staff 
time, length of stay, functional exercise capacity, physical activity and HRQL following discharge. 
 
While it appears that people with severe to very severe COPD gain greater benefits from NIV during 
exercise than those with mild to moderate disease, individual variability in the response to NIV during 
exercise is frequently reported, even within groups of subjects with similar levels of pulmonary 
function (Hernandez et al, 2001; Keilty et al, 1994; van 't Hul et al, 2004).  Ideally, baseline measures 
that are easily performed in the clinic could be used to predict which individuals are likely to benefit 
most from NIV during exercise.  However, only a few characteristics have been identified at present.  
Inspiratory muscle weakness was shown to account for 24% of the variance in the response to NIV 
during exercise in people with severe COPD (van 't Hul et al, 2004).  Other studies specifically 
selected patients with a ventilatory limitation to exercise (Reuveny et al, 2005; van 't Hul et al, 2006), 
and although the effects of NIV during exercise were generally positive, the magnitude of the effects 
were still variable.  One potential mechanism of benefit of NIV during exercise that has not yet been 
fully elucidated is the effect of NIV on intrinsic positive end expiratory pressure (PEEPi) and exercise 
induced dynamic hyperinflation.  In a pilot study, NIV was shown to unload the respiratory muscles 
and reduce PEEPi during a static arm elevation task in people with very severe COPD and chronic 
HRF (Poggi et al, 2006).  Assessment of baseline pulmonary hyperinflation, inspiratory capacity at 
peak exercise to assess dynamic hyperinflation, and the relationship between the response to NIV 
during exercise and inspiratory capacity may help to determine whether any of these measures can be 
used to assist in the selection of individuals with COPD who are likely to benefit from NIV during 
exercise. 
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In addition to the selection of an appropriate candidate for NIV during exercise, selection of an 
adequate level of ventilatory support for exercise is likely to be equally as important and failure to do 
so may contribute to the variability in the response to NIV during exercise that has been described in 
the literature.  During pressure preset ventilation, the tidal volume delivered and degree of respiratory 
muscle unloading that occurs will vary depending on factors such as respiratory system compliance, 
airways resistance and inspiratory time (Mehta & Hill, 2001).  As a result, a given level of PS can 
have a different effect between subjects and even within a subject, for example if dynamic 
hyperinflation occurs during exercise and respiratory system compliance is reduced.  Therefore, 
individualised titration of PS during exercise may be required in order to achieve optimal benefits 
from NIV during exercise.  Respiratory muscle unloading is an important mechanism associated with 
the use of NIV during exercise (Kyroussis et al, 2000).  However, measurement of respiratory muscle 
loading is impractical in the clinical setting.  While dyspnoea is a subjective measure, it has been 
shown to be inversely proportional to respiratory muscle unloading (Maltais et al, 1995).  In addition, 
a significant relationship was found between the reduction in dyspnoea with NIV during exercise and 
the response to NIV during exercise in the studies described in Chapter 3 and Chapter 5 of this thesis.  
A mean reduction in isotime dyspnoea of approximately two points on a 0-10 category-ratio scale 
(Borg, 1982) has been reported in a number of studies where NIV during exercise was found to 
improve exercise performance (Bianchi et al, 1998; Borel et al, 2008; Dreher et al, 2007; Menadue et 
al, 2009b; Menadue et al, 2010b; van 't Hul et al, 2002).  Therefore, future studies could determine 
whether individualised titration of PS to achieve a reduction in isotime dyspnoea of approximately two 
points on a 0-10 scale can permit greater improvements in exercise performance compared with using 
a pre-set level of PS in a group of subjects with similar disease severity. 
 
In severely limited individuals with chronic HRF, investigation of the effect of NIV during the 
performance of daily activities, including ambulation and tasks that involve use of the upper limbs is 
warranted.  The impact of using NIV during daily activities on the amount of physical activity 
performed should also be assessed.  Several studies have investigated the acute effects of NIV during 
ground walking in people with severe COPD and it is apparent that the portable ventilator must have 
the capacity to support ventilation during exertion if NIV is to be of benefit (Highcock et al, 1997; 
 252 
Revill et al, 2000).  One barrier to using NIV during daily activities relates to how the equipment is 
transported with the patient.  The study described in Chapter 2 used a bilevel machine without an 
internal battery.  Consequently a trolley was required to carry the external battery and associated 
equipment, which would not be practical during daily activities.  Placing a ventilator with an internal 
battery and O2 cylinder in a backpack, while potentially giving an individual greater access to their 
environment, was poorly accepted by patients due to the heavy weight (7.3 kg) and deemed to be 
impractical (Dreher et al, 2009).  Placing the ventilator and O2 cylinder on a rollator frame during 
walking has been shown to be an effective, well accepted strategy (Dreher et al, 2007) but may limit 
individuals to walking on flat, even surfaces.  Clearly, the feasibility of using NIV during daily 
activities hinges on the development of lightweight portable ventilators that have the capacity to 
support ventilation during exertion.  In addition, as the intensity, duration and type of activity will vary 
frequently, a mode of ventilatory support that delivers inspiratory assistance in proportion to demand, 
such as proportional assist ventilation, may be of value and should be assessed during daily activities 
in people with very severe COPD and chronic HRF.   
 
Patients with severe kyphoscoliosis and chronic HRF who use nocturnal NIV and daytime O2 therapy 
may also benefit from using NIV during daily activities.  In the absence of lung disease, daytime 
hypoxaemia in people with severe kyphoscoliosis is often due to hypoventilation.  While supplemental 
O2 during ground walking can improve oxygenation and reduce dyspnoea, it does not enhance exercise 
capacity (Meecham Jones et al, 1995a).  Investigation of the role of high level PS during daily 
activities in people with severe kyphoscoliosis who demonstrate an acute improvement in exercise 
performance with high level PS is warranted, and may negate the need for daytime supplemental O2.  
As technology advances, the development of lightweight portable ventilators with internal batteries 
and the capacity to support ventilation during exercise, may allow ambulatory NIV to be as feasible 
and as accessible as portable O2 therapy. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 254 
Agusti, A. G., Noguera, A., Sauleda, J., Sala, E., Pons, J., & Busquets, X. (2003). Systemic effects of chronic 
obstructive pulmonary disease. European Respiratory Journal, 21(2), 347-360. 
 
Agusti, A. G., Sauleda, J., Miralles, C., Gomez, C., Togores, B., Sala, E., Batle, S., & Busquets, X. (2002). 
Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. American Journal 
of Respiratory & Critical Care Medicine, 166(4), 485-489. 
 
Aida, A., Miyamoto, K., Nishimura, M., Aiba, M., Kira, S., & Kawakami, Y. (1998). Prognostic value of 
hypercapnia in patients with chronic respiratory failure during long-term oxygen therapy. American 
Journal of Respiratory & Critical Care Medicine, 158, 188-193. 
 
Alifano, M., Cuvelier, A., Delage, A., Roche, N., Lamia, B., Molano, L. C., Couderc, L. J., Marquette, C. H., & 
Devillier, P. (2010). Treatment of COPD: from pharmacological to instrumental therapies. European 
Respiratory Review, 19(115), 7-23. 
 
Alison, J. A., Regnis, J. A., Donnelly, P. M., Adams, R. D., Sullivan, C. E., & Bye, P. T. (1998). End-expiratory 
lung volume during arm and leg exercise in normal subjects and patients with cystic fibrosis. American 
Journal of Respiratory & Critical Care Medicine, 158(5 Pt 1), 1450-1458. 
 
Ambrosino, N., Nava, S., Bertone, P., Fracchia, C., & Rampulla, C. (1992). Physiologic evaluation of pressure 
support ventilation by nasal mask in patients with stable COPD. Chest, 101(2), 385-391. 
 
Ambrosino, N., Nava, S., Torbicki, A., Riccardi, G., Fracchia, C., Opasich, C., & Rampulla, C. (1993). 
Haemodynamic effects of pressure support and PEEP ventilation by nasal route in patients with stable 
chronic obstructive pulmonary disease. Thorax, 48(5), 523-528. 
 
Ambrosino, N., & Rossi, A. (2002). Proportional assist ventilation (PAV): a significant advance or a futile 
struggle between logic and practice? Thorax, 57(3), 272-276. 
 
American Thoracic Society. ATS statement: guidelines for the six-minute walk test. (2002). American Journal of 
Respiratory & Critical Care Medicine, 166(1), 111-117. 
 
American Thoracic Society/European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive 
pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. 
(1999). American Journal of Respiratory & Critical Care Medicine, 159(4 Pt 2), S1-40. 
 
Annane, D., Quera-Salva, M. A., Lofaso, F., Vercken, J. B., Lesieur, O., Fromageot, C., Clair, B., Gajdos, P., & 
Raphael, J. C. (1999). Mechanisms underlying effects of nocturnal ventilation on daytime blood gases 
in neuromuscular diseases. European Respiratory Journal, 13(1), 157-162. 
 
Appendini, L., Patessio, A., Zanaboni, S., Carone, M., Gukov, B., Donner, C. F., & Rossi, A. (1994). 
Physiologic effects of positive end-expiratory pressure and mask pressure support during exacerbations 
of chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 
149(5), 1069-1076. 
 
Appendini, L., Zanaboni, S., Patessio, A., Carone, M., Gukov, B., Donner, C. F., & Rossi, A. (1993). 
Respiratory mechanics and respiratory muscle performance in CO2 retainers during non-invasive 
mechanical ventilation. Monaldi Archives for Chest Disease, 48(5), 506-508. 
 
Bailey, P., Thomsen, G. E., Spuhler, V. J., Blair, R., Jewkes, J., Bezdjian, L., Veale, K., Rodriquez, L., & 
Hopkins, R. O. (2007). Early activity is feasible and safe in respiratory failure patients. Critical Care 
Medicine, 35(1), 139-145. 
 
Banfi, P., Redolfi, S., & Robert, D. (2007). Home treatment of infection-related acute respiratory failure in 
kyphoscoliotic patients on long-term mechanical ventilation. Respiratory Care, 52(6), 713-719. 
 
Barbera, J. A., Peinado, V. I., & Santos, S. (2003). Pulmonary hypertension in chronic obstructive pulmonary 
disease. European Respiratory Journal, 21(5), 892-905. 
 
Barbera, J. A., Roca, J., Ferrer, A., Felez, M. A., Diaz, O., Roger, N., & Rodriguez-Roisin, R. (1997). 
Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary 
disease. European Respiratory Journal, 10(6), 1285-1291. 
 
Barnes, P. J., & Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. European Respiratory 
 255 
Journal, 33(5), 1165-1185. 
 
Barreiro, E., de la Puente, B., Minguella, J., Corominas, J. M., Serrano, S., Hussain, S. N., & Gea, J. (2005). 
Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. 
American Journal of Respiratory & Critical Care Medicine, 171(10), 1116-1124. 
 
Barrios, C., Perez-Encinas, C., Maruenda, J. I., & Laguia, M. (2005). Significant ventilatory functional 
restriction in adolescents with mild or moderate scoliosis during maximal exercise tolerance test. Spine, 
30(14), 1610-1615. 
 
Becker, H. F., Piper, A. J., Flynn, W. E., McNamara, S. G., Grunstein, R. R., Peter, J. H., & Sullivan, C. E. 
(1999). Breathing during sleep in patients with nocturnal desaturation. American Journal of Respiratory 
& Critical Care Medicine, 159(1), 112-118. 
 
Begin, P., & Grassino, A. (1991). Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive 
pulmonary disease. American Review of Respiratory Disease, 143(5 Pt 1), 905-912. 
 
Belaise, C., Annicchiarico, N., Camerota, G., & Occhi, G. (1988). The natural progression of cardiorespiratory 
failure in scoliosis. Italian Journal of Orthopaedics and Traumatology, 14(2), 273-279. 
 
Belman, M. J. (1993). Exercise in patients with chronic obstructive pulmonary disease. Thorax, 48(9), 936-946. 
 
Berger, V. W. (2005). Quantifying the magnitude of baseline covariate imbalances resulting from selection bias 
in randomized clinical trials. Biometrical  Journal, 47(2), 119-127. 
 
Bergofsky, E. H. (1979). Respiratory failure in disorders of the thoracic cage. American Review of Respiratory 
Disease, 119(4), 643-669. 
 
Bergofsky, E. H., Turino, G. M., & Fishman, A. P. (1959). Cardiorespiratory failure in kyphoscoliosis. 
Medicine, 38, 263-317. 
 
Bianchi, L., Foglio, K., Pagani, M., Vitacca, M., Rossi, A., & Ambrosino, N. (1998). Effects of proportional 
assist ventilation on exercise tolerance in COPD patients with chronic hypercapnia. European 
Respiratory Journal, 11(2), 422-427. 
 
Bianchi, L., Foglio, K., Porta, R., Baiardi, R., Vitacca, M., & Ambrosino, N. (2002). Lack of additional effect of 
adjunct of assisted ventilation to pulmonary rehabilitation in mild COPD patients. Respiratory 
Medicine, 96(5), 359-367. 
 
Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet, 1(8476), 307-310. 
 
Borel, J. C., Verges, S., Pepin, J. L., Vivodtzev, I., Levy, P., & Wuyam, B. (2009). Home exercise training with 
non-invasive ventilation in thoracic restrictive respiratory disorders: a randomised study. Respiratory 
Physiology & Neurobiology, 167(2), 168-173. 
 
Borel, J. C., Wuyam, B., Chouri-Pontarollo, N., Deschaux, C., Levy, P., & Pepin, J. L. (2008). During exercise 
non-invasive ventilation in chronic restrictive respiratory failure. Respiratory Medicine, 102(5), 711-
719. 
 
Borg, G. A. (1982). Psychophysical bases of perceived exertion. Medicine & Science in Sports & Exercise, 
14(5), 377-381. 
 
Borghi-Silva, A., Di Thommazo, L., Pantoni, C. B. F., Mendes, R. G., De Fatima Salvini, T., & Costa, D. 
(2009). Non-invasive ventilation improves peripheral oxygen saturation and reduces fatigability of 
quadriceps in patients with COPD. Respirology, 14(4), 537-544. 
 
Borghi-Silva, A., Oliveira, C. C., Carrascosa, C., Maia, J., Berton, D., Queiroga, F., Ferreira, E., Ribeiro, D., 
Nery, L., & Neder, J. A. (2008). Respiratory Muscle Unloading Improves Leg Muscle Oxygenation 
During Exercise in Patients with COPD. Thorax, 63(10), 910-915. 
 
Bott, J., Carroll, M. P., Conway, J. H., Keilty, S. E., Ward, E. M., Brown, A. M., Paul, E. A., Elliott, M. W., 
Godfrey, R. C., Wedzicha, J. A., & et al. (1993). Randomised controlled trial of nasal ventilation in 
acute ventilatory failure due to chronic obstructive airways disease. Lancet, 341(8860), 1555-1557. 
 
 256 
British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. 
(2002). Thorax, 57(3), 192-211. 
 
Brochard, L., Harf, A., Lorino, H., & Lemaire, F. (1989). Inspiratory pressure support prevents diaphragmatic 
fatigue during weaning from mechanical ventilation. American Review of Respiratory Disease, 139(2), 
513-521. 
 
Brooks, D., De Rosie, J., Mousseau, M., Avendano, M., & Goldstein, R. S. (2002) Long term follow-up of 
ventilated patients with thoracic restrictive or neuromuscular disease. Canadian Respiratory Journal, 
9(2), 99-106. 
 
Budweiser, S., Heidtkamp, F., Jorres, R. A., Heinemann, F., Arzt, M., Schroll, S., Schmidbauer, K., Hitzl, A. P., 
& Pfeifer, M. (2008). Predictive significance of the six-minute walk distance for long-term survival in 
chronic hypercapnic respiratory failure. Respiration, 75(4), 418-426. 
 
Budweiser, S., Heinemann, F., Fischer, W., Dobroschke, J., & Pfeifer, M. (2005). Long-term reduction of 
hyperinflation in stable COPD by non-invasive nocturnal home ventilation. Respiratory Medicine, 
99(8), 976-984. 
 
Budweiser, S., Jorres, R. A., Riedl, T., Heinemann, F., Hitzl, A. P., Windisch, W., & Pfeifer, M. (2007). 
Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving 
noninvasive home ventilation. Chest, 131(6), 1650-1658. 
 
Budweiser, S., Moertl, M., Jorres, R. A., Windisch, W., Heinemann, F., & Pfeifer, M. (2006). Respiratory 
muscle training in restrictive thoracic disease: a randomized controlled trial. Archives of Physical 
Medicine & Rehabilitation, 87(12), 1559-1565. 
 
Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Menezes, A. M., 
Sullivan, S. D., Lee, T. A., Weiss, K. B., Jensen, R. L., Marks, G. B., Gulsvik, A., & Nizankowska-
Mogilnicka, E. (2007). International variation in the prevalence of COPD (the BOLD Study): a 
population-based prevalence study. Lancet, 370(9589), 741-750. 
 
Burrows, B., & Earle, R. H. (1969). Course and prognosis of chronic obstructive lung disease. A prospective 
study of 200 patients. New England Journal of Medicine, 280(8), 397-404. 
 
Burtin, C., Clerckx, B., Robbeets, C., Ferdinande, P., Langer, D., Troosters, T., Hermans, G., Decramer, M., & 
Gosselink, R. (2009). Early exercise in critically ill patients enhances short-term functional recovery. 
Critical Care Medicine, 37(9), 2499-2505. 
 
Butland, R. J., Pang, J., Gross, E. R., Woodcock, A. A., & Geddes, D. M. (1982). Two-, six-, and 12-minute 
walking tests in respiratory disease. British Medical Journal (Clinical Research Edition), 284(6329), 
1607-1608. 
 
Buyse, B., Meersseman, W., & Demedts, M. (2003). Treatment of chronic respiratory failure in kyphoscoliosis: 
oxygen or ventilation? European Respiratory Journal, 22(3), 525-528. 
 
Calverley, P. M. (2003). Respiratory failure in chronic obstructive pulmonary disease. European Respiratory 
Journal - Supplement, 47, 26s-30s. 
 
Calverley, P. M., & Koulouris, N. G. (2005). Flow limitation and dynamic hyperinflation: key concepts in 
modern respiratory physiology. European Respiratory Journal, 25(1), 186-199. 
 
Cambach, W., Wagenaar, R. C., Koelman, T. W., van Keimpema, A. R., & Kemper, H. C. (1999). The long-term 
effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a 
research synthesis. Archives of Physical Medicine of Rehabilitation, 80(1), 103-111. 
 
Caro, C. G., & Dubois, A. B. (1961). Pulmonary function in kyphoscoliosis. Thorax, 16, 282-290. 
 
Carone, M., Anchisi, F., & Donner, C. F. (1997). Quality of life and chronic respiratory failure. Monaldi 
Archives for Chest Disease, 52(6), 525-528. 
 
Carone, M., Patessio, A., Ambrosino, N., Baiardi, P., Balbi, B., Balzano, G., Cuomo, V., Donner, C. F., 
Fracchia, C., Nava, S., Neri, M., Pozzi, E., Vitacca, M., & Spanevello, A. (2007). Efficacy of 
pulmonary rehabilitation in chronic respiratory failure (CRF) due to chronic obstructive pulmonary 
 257 
disease (COPD): The Maugeri Study. Respiratory Medicine, 101(12), 2447-2453. 
 
Carr, S. J., Goldstein, R. S., & Brooks, D. (2007). Acute exacerbations of COPD in subjects completing 
pulmonary rehabilitation. Chest, 132(1), 127-134. 
 
Carrey, Z., Gottfried, S. B., & Levy, R. D. (1990). Ventilatory muscle support in respiratory failure with nasal 
positive pressure ventilation. Chest, 97(1), 150-158. 
 
Casaburi, R. (2003). Limitation to exercise tolerance in chronic obstructive pulmonary disease: look to the 
muscles of ambulation. American Journal of Respiratory & Critical Care Medicine, 168(4), 409-410. 
 
Casaburi, R. (2004). Factors determining constant work rate exercise tolerance in COPD and their role in 
dictating the minimal clinically important difference in response to interventions. Journal of Chronic 
Obstructive Pulmonary Disease, 2(1), 131-136. 
 
Casaburi, R., Kukafka, D., Cooper, C. B., Witek, T. J., Jr., & Kesten, S. (2005). Improvement in exercise 
tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. 
Chest, 127(3), 809-817. 
 
Casaburi, R., Patessio, A., Ioli, F., Zanaboni, S., Donner, C. F., & Wasserman, K. (1991). Reductions in exercise 
lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. 
American Review of Respiratory Disease, 143(1), 9-18. 
 
Casaburi, R., Porszasz, J., Burns, M. R., Carithers, E. R., Chang, R. S., & Cooper, C. B. (1997). Physiologic 
benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary 
disease. American Journal of Respiratory & Critical Care Medicine, 155(5), 1541-1551. 
 
Casaburi, R., & ZuWallack, R. (2009). Pulmonary rehabilitation for management of chronic obstructive 
pulmonary disease. New England Journal of Medicine, 360(13), 1329-1335. 
 
Cejudo, P., Lopez-Marquez, I., Lopez-Campos, J. L., Ortega, F., Bernal, C. C., Marquez, E., Tallon, R., 
Sanchez-Riera, H., & Barrot, E. (2009). Factors associated with quality of life in patients with chronic 
respiratory failure due to kyphoscoliosis. Disability & Rehabilitation, 31(11), 928-934. 
 
Celli, B., Criner, G., & Rassulo, J. (1988). Ventilatory muscle recruitment during unsupported arm exercise in 
normal subjects. Journal of Applied Physiology, 64(5), 1936-1941. 
 
Celli, B. R. (2010). Predictors of mortality in COPD. Respiratory Medicine, 104(6), 773-779. 
 
Celli, B. R., & MacNee, W. (2004). Standards for the diagnosis and treatment of patients with COPD: a 
summary of the ATS/ERS position paper. European Respiratory Journal, 23(6), 932-946. 
 
Chadha, T. S., Birch, S., & Sackner, M. A. (1987). Oronasal distribution of ventilation during exercise in normal 
subjects and patients with asthma and rhinitis. Chest, 92(6), 1037-1041. 
 
Chapman, K. R., Mannino, D. M., Soriano, J. B., Vermeire, P. A., Buist, A. S., Thun, M. J., Connell, C., Jemal, 
A., Lee, T. A., Miravitlles, M., Aldington, S., & Beasley, R. (2006). Epidemiology and costs of chronic 
obstructive pulmonary disease. European Respiratory Journal, 27(1), 188-207. 
 
Chemla, D., Castelain, V., Herve, P., Lecarpentier, Y., & Brimioulle, S. (2002). Haemodynamic evaluation of 
pulmonary hypertension. European Respiratory Journal, 20(5), 1314-1331. 
 
Chen, R. C., & Yan, S. (1999). Perceived inspiratory difficulty during inspiratory threshold and 
hyperinflationary loadings. American Journal of Respiratory & Critical Care Medicine, 159(3), 720-
727. 
 
Chiang, L. L., Wang, L. Y., Wu, C. P., Wu, H. D., & Wu, Y. T. (2006). Effects of physical training on functional 
status in patients with prolonged mechanical ventilation. Physical Therapy, 86(9), 1271-1281. 
 
Chong, K. C., Letts, R. M., & Cumming, G. R. (1981). Influence of spinal curvature on exercise capacity. 
Journal of Pediatric Orthopaedics, 1(3), 251-254. 
 
Chu, C. M., Chan, V. L., Lin, A. W., Wong, I. W., Leung, W. S., & Lai, C. K. (2004). Readmission rates and life 
threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic 
respiratory failure. Thorax, 59(12), 1020-1025. 
 258 
Clini, E., & Ambrosino, N. (2005). Early physiotherapy in the respiratory intensive care unit. Respiratory 
Medicine, 99(9), 1096-1104. 
 
Cobb, J. R. (1948). Outline for the study of scoliosis. Instructional Course Lectures, American Academy of 
Orthopedic Surgeons, 5, 261-275. 
 
Confalonieri, M., Garuti, G., Cattaruzza, M. S., Osborn, J. F., Antonelli, M., Conti, G., Kodric, M., Resta, O., 
Marchese, S., Gregoretti, C., & Rossi, A. (2005). A chart of failure risk for noninvasive ventilation in 
patients with COPD exacerbation. European Respiratory Journal, 25(2), 348-355. 
 
Confalonieri, M., Gazzaniga, P., Gandola, L., Aiolfi, S., Della Porta, R., Frisinghelli, A., & Bellone, A. (1998). 
Haemodynamic response during initiation of non-invasive positive pressure ventilation in COPD 
patients with acute ventilatory failure. Respiratory Medicine, 92(2), 331-337. 
 
Connors, A. F., Jr., Dawson, N. V., Thomas, C., Harrell, F. E., Jr., Desbiens, N., Fulkerson, W. J., Kussin, P., 
Bellamy, P., Goldman, L., & Knaus, W. A. (1996). Outcomes following acute exacerbation of severe 
chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and 
Preferences for Outcomes and Risks of Treatments). American Journal of Respiratory & Critical Care 
Medicine, 154(4 Pt 1), 959-967. 
 
Conti, G., Rocco, M., Antonelli, M., Bufi, M., Tarquini, S., Lappa, A., & Gasparetto, A. (1997). Respiratory 
system mechanics in the early phase of acute respiratory failure due to severe kyphoscoliosis. Intensive 
Care Medicine, 23(5), 539-544. 
 
Cooper, D. M., Rojas, J. V., Mellins, R. B., Keim, H. A., & Mansell, A. L. (1984). Respiratory mechanics in 
adolescents with idiopathic scoliosis. American Review of Respiratory Disease, 130(1), 16-22. 
 
Cormick, W., Olson, L. G., Hensley, M. J., & Saunders, N. A. (1986). Nocturnal hypoxaemia and quality of 
sleep in patients with chronic obstructive lung disease. Thorax, 41(11), 846-854. 
 
Corner, E., & Garrod, R. (2010). Does the addition of non-invasive ventilation during pulmonary rehabilitation 
in patients with chronic obstructive pulmonary disease augment patient outcome in exercise tolerance? 
A literature review. Physiotherapy Research International, 15(1), 5-15.. 
 
Costes, F., Agresti, A., Court-Fortune, I., Roche, F., Vergnon, J. M., & Barthelemy, J. C. (2003). Noninvasive 
ventilation during exercise training improves exercise tolerance in patients with chronic obstructive 
pulmonary disease. Journal of Cardiopulmonary Rehabilitation, 23(4), 307-313. 
 
Costi, S., Crisafulli, E., Antoni, F. D., Beneventi, C., Fabbri, L. M., & Clini, E. M. (2009). Effects of 
unsupported upper extremity exercise training in patients with COPD: a randomized clinical trial. 
Chest, 136(2), 387-395. 
 
Cote, C. G., Casanova, C., Marin, J. M., Lopez, M. V., Pinto-Plata, V., de Oca, M. M., Dordelly, L. J., Nekach, 
H., & Celli, B. R. (2008). Validation and comparison of reference equations for the 6-min walk distance 
test. European Respiratory Journal, 31(3), 571-578. 
 
Couillard, A., Maltais, F., Saey, D., Debigare, R., Michaud, A., Koechlin, C., LeBlanc, P., & Prefaut, C. (2003). 
Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic 
obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 167(12), 
1664-1669. 
 
Criner, G. J., & Celli, B. R. (1988). Effect of unsupported arm exercise on ventilatory muscle recruitment in 
patients with severe chronic airflow obstruction. American Review of Respiratory Disease, 138(4), 856-
861. 
 
Currie, G. P., & Wedzicha, J. A. (2006). ABC of chronic obstructive pulmonary disease. Acute exacerbations. 
British Medical Journal, 333(7558), 87-89. 
 
Cuttica, M. J., Kalhan, R., Shlobin, O. A., Ahmad, S., Gladwin, M., Machado, R. F., Barnett, S. D., & Nathan, S. 
D. (2010). Categorization and impact of pulmonary hypertension in patients with advanced COPD. 
Respiratory Medicine, doi: 10.1016/j.rmed.2010.1005.1009. 
 
De Troyer, A. (1997). Effect of hyperinflation on the diaphragm. European Respiratory Journal, 10(3), 708-713. 
 
De Troyer, A., Leeper, J. B., McKenzie, D. K., & Gandevia, S. C. (1997). Neural drive to the diaphragm in 
 259 
patients with severe COPD. American Journal of Respiratory & Critical Care Medicine, 155(4), 1335-
1340. 
 
Decramer, M., Gosselink, R., Troosters, T., Verschueren, M., & Evers, G. (1997). Muscle weakness is related to 
utilization of health care resources in COPD patients. European Respiratory Journal, 10(2), 417-423. 
 
Decramer, M., Lacquet, L. M., Fagard, R., & Rogiers, P. (1994). Corticosteroids contribute to muscle weakness 
in chronic airflow obstruction. American Journal of Respiratory & Critical Care Medicine, 150(1), 11-
16. 
 
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008). Chapter 9: Analysing data and undertaking meta-
analyses. In J. P. T. Higgins & S. Green (Eds.), Cochrane Handbook for Systematic Reviews of 
Interventions (Vol. Version 5.0.1 (updated September 2008)): The Cochrane Collaboration, 2008. 
Available from www.cochrane-handbook.org. 
 
Diaz, O., Begin, P., Andresen, M., Prieto, M. E., Castillo, C., Jorquera, J., & Lisboa, C. (2005). Physiological 
and clinical effects of diurnal noninvasive ventilation in hypercapnic COPD. European Respiratory 
Journal, 26(6), 1016-1023. 
 
Diaz, O., Begin, P., Torrealba, B., Jover, E., & Lisboa, C. (2002). Effects of noninvasive ventilation on lung 
hyperinflation in stable hypercapnic COPD. European Respiratory Journal, 20(6), 1490-1498. 
 
Diaz, O., Iglesia, R., Ferrer, M., Zavala, E., Santos, C., Wagner, P. D., Roca, J., & Rodriguez-Roisin, R. (1997). 
Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics during acute 
hypercapnic exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory 
& Critical Care Medicine, 156(6), 1840-1845. 
 
Dickson, J. H., Mirkovic, S., Noble, P. C., Nalty, T., & Erwin, W. D. (1995). Results of operative treatment of 
idiopathic scoliosis in adults. Journal of Bone and Joint Surgery, 77(4), 513-523. 
 
Dodd, D. S., Brancatisano, T., & Engel, L. A. (1984). Chest wall mechanics during exercise in patients with 
severe chronic air-flow obstruction. American Review of Respiratory Disease, 129(1), 33-38. 
 
Dolmage, T. E., & Goldstein, R. S. (1997). Proportional assist ventilation and exercise tolerance in subjects with 
COPD. Chest, 111(4), 948-954. 
 
Donaldson, G. C., Seemungal, T. A., Bhowmik, A., & Wedzicha, J. A. (2002). Relationship between 
exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 
57(10), 847-852. 
 
Donaldson, G. C., Seemungal, T. A., Patel, I. S., Lloyd-Owen, S. J., Wilkinson, T. M., & Wedzicha, J. A. 
(2003). Longitudinal changes in the nature, severity and frequency of COPD exacerbations. European 
Respiratory Journal, 22(6), 931-936. 
 
Donath, J., & Miller, A. (2009). Restrictive chest wall disorders. Seminars in Respiratory & Critical Care 
Medicine, 30(3), 275-292. 
 
dos Santos Alves, V. L., Stirbulov, R., & Avanzi, O. (2006). Impact of a physical rehabilitation program on the 
respiratory function of adolescents with idiopathic scoliosis. Chest, 130(2), 500-505. 
 
Douglas, N. J., White, D. P., Pickett, C. K., Weil, J. V., & Zwillich, C. W. (1982). Respiration during sleep in 
normal man. Thorax, 37(11), 840-844. 
 
Dreher, M., Doncheva, E., Schwoerer, A., Walterspacher, S., Sonntag, F., Kabitz, H. J., & Windisch, W. (2009). 
Preserving Oxygenation during Walking in Severe Chronic Obstructive Pulmonary Disease: 
Noninvasive Ventilation versus Oxygen Therapy. Respiration, 78(2), 154-160. 
 
Dreher, M., Storre, J. H., Schmoor, C., & Windisch, W. (2010). High-intensity versus low-intensity non-invasive 
ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax, 65(4), 303-
308. 
 
Dreher, M., Storre, J. H., & Windisch, W. (2007). Noninvasive ventilation during walking in patients with severe 
COPD: a randomised cross-over trial. European Respiratory Journal, 29(5), 930-936. 
 
Dubois, A. B., Botelho, S. Y., Bedell, G. N., Marshall, R., & Comroe, J. H., Jr. (1956). A rapid 
 260 
plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout 
method for measuring functional residual capacity in normal subjects. Journal of Clinical Investigation, 
35(3), 322-326. 
 
Duiverman, M. L., Wempe, J. B., Bladder, G., Jansen, D. F., Kerstjens, H. A., Zijlstra, J. G., & Wijkstra, P. J. 
(2008). Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with 
COPD. Thorax, 63(12), 1052-1057. 
 
Duron, B. (1973). Postural and ventilatory functions of intercostal muscles. Acta Neurobiologiae Experimentalis, 
33(1), 355-380. 
 
Elliott, M. W. (2009). Domiciliary non-invasive ventilation in stable COPD? Thorax, 64(7), 553-556. 
 
Elliott, M. W., Mulvey, D. A., Moxham, J., Green, M., & Branthwaite, M. A. (1991). Domiciliary nocturnal 
nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial 
blood gas tensions. European Respiratory Journal, 4(9), 1044-1052. 
 
Elliott, M. W., Steven, M. H., Phillips, G. D., & Branthwaite, M. A. (1990). Non-invasive mechanical ventilation 
for acute respiratory failure. British Medical Journal, 300(6721), 358-360. 
 
Ellis, E. R., Bye, P. T., Bruderer, J. W., & Sullivan, C. E. (1987). Treatment of respiratory failure during sleep in 
patients with neuromuscular disease. Positive-pressure ventilation through a nose mask. American 
Review of Respiratory Disease, 135(1), 148-152. 
 
Ellis, E. R., Grunstein, R. R., Chan, S., Bye, P. T., & Sullivan, C. E. (1988). Noninvasive ventilatory support 
during sleep improves respiratory failure in kyphoscoliosis. Chest, 94(4), 811-815. 
 
Emtner, M., Porszasz, J., Burns, M., Somfay, A., & Casaburi, R. (2003). Benefits of supplemental oxygen in 
exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. American Journal of 
Respiratory & Critical Care Medicine, 168(9), 1034-1042. 
 
Emtner, M. I., Arnardottir, H. R., Hallin, R., Lindberg, E., & Janson, C. (2007). Walking distance is a predictor 
of exacerbations in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 101(5), 
1037-1040. 
 
Ergun, P., Aydin, G., Turay, U. Y., Erdogan, Y., Caglar, A., & Biber, C. (2002). Short-term effect of nasal 
intermittent positive-pressure ventilation in patients with restrictive thoracic disease. Respiration, 69(4), 
303-308. 
 
Esteban, C., Quintana, J. M., Moraza, J., Aburto, M., Egurrola, M., Espana, P. P., Perez-Izquierdo, J., Aguirre, 
U., Aizpiri, S., & Capelastegui, A. (2009). Impact of hospitalisations for exacerbations of COPD on 
health-related quality of life. Respiratory Medicine, 103(8), 1201-1208. 
 
Estenne, M., Derom, E., & De Troyer, A. (1998). Neck and abdominal muscle activity in patients with severe 
thoracic scoliosis. American Journal of Respiratory & Critical Care Medicine, 158(2), 452-457. 
 
Eves, N. D., Sandmeyer, L. C., Wong, E. Y., Jones, L. W., MacDonald, G. F., Ford, G. T., Petersen, S. R., 
Bibeau, M. D., & Jones, R. L. (2009). Helium-hyperoxia: a novel intervention to improve the benefits 
of pulmonary rehabilitation for patients with COPD. Chest, 135(3), 609-618. 
 
Ferris, G., Servera-Pieras, E., Vergara, P., Tzeng, A. C. Perez, M., Marin, J., & Bach, J. R. (2000). 
Kyphoscoliosis ventilatory insufficiency: noninvasive management outcomes. American Journal of 
Physical Medicine and Rehabilitation, 79(1), 24-29. 
 
Field, G. B. (1973). Aspects of applied physiology in chronic bronchitis and emphysema. Australian Journal of 
Physiotherapy, 19(4), 125-131. 
 
Field, S., Kelly, S. M., & Macklem, P. T. (1982). The oxygen cost of breathing in patients with cardiorespiratory 
disease. American Review of Respiratory Disease, 126(1), 9-13. 
 
Finlay, G., Concannon, D., & McDonnell, T. J. (1995). Treatment of respiratory failure due to kyphoscoliosis 
with nasal intermittent positive pressure ventilation (NIPPV).  Israel Journal of Medical Science, 
164(1), 28-30. 
 
Fleetham, J., West, P., Mezon, B., Conway, W., Roth, T., & Kryger, M. (1982). Sleep, arousals, and oxygen 
 261 
desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. American Review 
of Respiratory Disease, 126(3), 429-433. 
 
Fletcher, C., & Peto, R. (1977). The natural history of chronic airflow obstruction. British Medical Journal, 
1(6077), 1645-1648. 
 
Fleury, B., Murciano, D., Talamo, C., Aubier, M., Pariente, R., & Milic-Emili, J. (1985). Work of breathing in 
patients with chronic obstructive pulmonary disease in acute respiratory failure. American Review of 
Respiratory Disease, 131(6), 822-827. 
 
Foglio, K., Carone, M., Pagani, M., Bianchi, L., Jones, P. W., & Ambrosino, N. (2000). Physiological and 
symptom determinants of exercise performance in patients with chronic airway obstruction. Respiratory 
Medicine, 94(3), 256-263. 
 
Forster, H. V., Dempsey, J. A., Thomson, J., Vidruk, E., & DoPico, G. A. (1972). Estimation of arterial PO2, 
PCO2, pH, and lactate from arterialized venous blood. Journal of Applied Physiology, 32(1), 134-137. 
 
Foster, S., Lopez, D., & Thomas, H. M., 3rd. (1988). Pulmonary rehabilitation in COPD patients with elevated 
PCO2. American Review of Respiratory Disease, 138(6), 1519-1523. 
 
Fowles, J. V., Drummond, D. S., L'Ecuyer, S., Roy, L., & Kassab, M. T. (1978). Untreated scoliosis in the adult. 
Clinical Orthopaedics and Related Research, (134), 212-217. 
 
Freedman, S. (1970). Sustained maximum voluntary ventilation. Respiratory Physiology, 8(2), 230-244. 
 
Fujimoto, K., Matsuzawa, Y., Yamaguchi, S., Koizumi, T., & Kubo, K. (2002). Benefits of oxygen on exercise 
performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. Chest, 
122(2), 457-463. 
 
Fuschillo, S., De Felice, A., Gaudiosi, C., & Balzano, G. (2003). Nocturnal mechanical ventilation improves 
exercise capacity in kyphoscoliotic patients with respiratory impairment. Monaldi Archives for Chest 
Disease, 59(4), 281-286. 
 
Gandevia, S. C., Leeper, J. B., McKenzie, D. K., & De Troyer, A. (1996). Discharge frequencies of parasternal 
intercostal and scalene motor units during breathing in normal and COPD subjects. American Journal of 
Respiratory & Critical Care Medicine, 153(2), 622-628. 
 
Garcia-Aymerich, J., Farrero, E., Felez, M. A., Izquierdo, J., Marrades, R. M., & Anto, J. M. (2003). Risk factors 
of readmission to hospital for a COPD exacerbation: a prospective study. Thorax, 58(2), 100-105. 
 
Garcia-Aymerich, J., Lange, P., Benet, M., Schnohr, P., & Anto, J. M. (2006). Regular physical activity reduces 
hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort 
study. Thorax, 61(9), 772-778. 
 
Garcia-Rio, F., Lores, V., Mediano, O., Rojo, B., Hernanz, A., Lopez-Collazo, E., & Alvarez-Sala, R. (2009). 
Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with 
dynamic hyperinflation. American Journal of Respiratory & Critical Care Medicine, 180(6), 506-512. 
 
Garrod, R., Marshall, J., Barley, E., & Jones, P. W. (2006). Predictors of success and failure in pulmonary 
rehabilitation. European Respiratory Journal, 27(4), 788-794. 
 
Garrod, R., Mikelsons, C., Paul, E. A., & Wedzicha, J. A. (2000). Randomized controlled trial of domiciliary 
noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary 
disease. American Journal of Respiratory & Critical Care Medicine, 162(4 Pt 1), 1335-1341. 
 
Gea, J. G., Pasto, M., Carmona, M. A., Orozco-Levi, M., Palomeque, J., & Broquetas, J. (2001). Metabolic 
characteristics of the deltoid muscle in patients with chronic obstructive pulmonary disease. European 
Respiratory Journal, 17(5), 939-945. 
 
Giaid, A., & Saleh, D. (1995). Reduced expression of endothelial nitric oxide synthase in the lungs of patients 
with pulmonary hypertension. New England Journal of Medicine, 333(4), 214-221. 
 
Gigliotti, F., Coli, C., Bianchi, R., Grazzini, M., Stendardi, L., Castellani, C., & Scano, G. (2005). Arm exercise 
and hyperinflation in patients with COPD: effect of arm training. Chest, 128(3), 1225-1232. 
 
 262 
Gimenez, M., Servera, E., Vergara, P., Bach, J. R., & Polu, J. M. (2000). Endurance training in patients with 
chronic obstructive pulmonary disease: a comparison of high versus moderate intensity. Archives of 
Physical Medicine & Rehabilitation, 81(1), 102-109. 
 
Girault, C., Richard, J. C., Chevron, V., Tamion, F., Pasquis, P., Leroy, J., & Bonmarchand, G. (1997). 
Comparative physiologic effects of noninvasive assist-control and pressure support ventilation in acute 
hypercapnic respiratory failure. Chest, 111(6), 1639-1648. 
 
Godfrey, S. (1970). Respiratory and cardiovascular consequences of scoliosis. Respiration, 27, Suppl:67-70. 
 
Gold, P. M. (2009). The 2007 GOLD Guidelines: a comprehensive care framework. Respiratory Care, 54(8), 
1040-1049. 
 
Goldstein, R. S., De Rosie, J. A., Avendano, M. A., & Dolmage, T. E. (1991). Influence of noninvasive positive 
pressure ventilation on inspiratory muscles. Chest, 99(2), 408-415. 
 
Gonzalez, M. M., Parreira, V. F., & Rodenstein, D. O. (2002). Non-invasive ventilation and sleep. Sleep 
Medicine Reviews, 6(1), 29-44. 
 
Gonzalez, C., Ferris, G., Diaz, J., Fontana, I., Nunez, J., & Marin, J. (2003). Kyphoscoliotic ventilatory 
insufficiency: effects of long-term intermittent positive-pressure ventilation. Chest, 124 (3), 857-862. 
 
Gosselink, R., Bott, J., Johnson, M., Dean, E., Nava, S., Norrenberg, M., Schonhofer, B., Stiller, K., van de Leur, 
H., & Vincent, J. L. (2008). Physiotherapy for adult patients with critical illness: recommendations of 
the European Respiratory Society and European Society of Intensive Care Medicine Task Force on 
Physiotherapy for Critically Ill Patients. Intensive Care Medicine, 34(7), 1188-1199. 
 
Gosselink, R., Troosters, T., & Decramer, M. (1996). Peripheral muscle weakness contributes to exercise 
limitation in COPD. American Journal of Respiratory & Critical Care Medicine, 153(3), 976-980. 
 
Grassi, V., & Tantucci, C. (1993). Respiratory prognosis in chest wall diseases. Monaldi Archives for Chest 
Disease, 48(2), 183-187. 
 
Griffiths, T. L., Phillips, C. J., Davies, S., Burr, M. L., & Campbell, I. A. (2001). Cost effectiveness of an 
outpatient multidisciplinary pulmonary rehabilitation programme. Thorax, 56(10), 779-784. 
 
Grimby, G., Soderholm, B. (1963). Spirometric studies in normal subjects. III Static lung volumes and maximum 
voluntary ventilation in adults with a note on physical fitness. Acta Medica Scandinavica, 173(2), 199-
206. 
 
Grimby, G., & Stiksa, J. (1970). Flow-volume curves and breathing patterns during exercise in patients with 
obstructive lung disease. Scandinavian Journal of Clinical and Laboratory Investigation, 25(3), 303-
313. 
 
Groenewegen, K. H., Schols, A. M., & Wouters, E. F. (2003). Mortality and mortality-related factors after 
hospitalization for acute exacerbation of COPD. Chest, 124(2), 459-467. 
 
Guilleminault, C., Kurland, G., Winkle, R., & Miles, L. E. (1981). Severe kyphoscoliosis, breathing, and sleep: 
the "Quasimodo" syndrome during sleep. Chest, 79(6), 626-630. 
 
Gustafson, T., Franklin, K. A., Midgren, B., Pehrsson, K., Ranstam, J., & Strom, K. (2006). Survival of patients 
with kyphoscoliosis receiving mechanical ventilation or oxygen at home. Chest, 130(6), 1828-1833. 
 
Guyatt, G. H., Pugsley, S. O., Sullivan, M. J., Thompson, P. J., Berman, L., Jones, N. L., Fallen, E. L., & Taylor, 
D. W. (1984). Effect of encouragement on walking test performance. Thorax, 39(11), 818-822. 
 
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. B. 
(1985). The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. 
Canadian Medical Association Journal, 132(8), 919-923. 
 
Haines, R. F. (1974). Effect of bed rest and exercise on body balance. Journal of Applied Physiology, 36(3), 323-
327. 
 
Halbert, R. J., Isonaka, S., George, D., & Iqbal, A. (2003). Interpreting COPD prevalence estimates: what is the 
true burden of disease? Chest, 123(5), 1684-1692. 
 263 
Harms, C. A., Babcock, M. A., McClaran, S. R., Pegelow, D. F., Nickele, G. A., Nelson, W. B., & Dempsey, J. 
A. (1997). Respiratory muscle work compromises leg blood flow during maximal exercise. Journal of 
Applied Physiology, 82(5), 1573-1583. 
 
Harms, C. A., Wetter, T. J., McClaran, S. R., Pegelow, D. F., Nickele, G. A., Nelson, W. B., Hanson, P., & 
Dempsey, J. A. (1998). Effects of respiratory muscle work on cardiac output and its distribution during 
maximal exercise. Journal of Applied Physiology, 85(2), 609-618. 
 
Harms, C. A., Wetter, T. J., St Croix, C. M., Pegelow, D. F., & Dempsey, J. A. (2000). Effects of respiratory 
muscle work on exercise performance. Journal of Applied Physiology, 89(1), 131-138. 
 
Hawkins, P., Johnson, L. C., Nikoletou, D., Hamnegard, C. H., Sherwood, R., Polkey, M. I., & Moxham, J. 
(2002). Proportional assist ventilation as an aid to exercise training in severe chronic obstructive 
pulmonary disease. Thorax, 57(10), 853-859. 
 
Henke, K. G., Regnis, J. A., & Bye, P. T. (1993). Benefits of continuous positive airway pressure during exercise 
in cystic fibrosis and relationship to disease severity. American Review of Respiratory Disease, 148(5), 
1272-1276. 
 
Hepper, N. G., Black, L. F., & Fowler, W. S. (1965). Relationships of Lung Volume to Height and Arm Span in 
Normal Subjects and in Patients with Spinal Deformity. American Review of Respiratory Disease, 91, 
356-362. 
 
Hernandez, P., Maltais, F., Gursahaney, A., Leblanc, P., & Gottfried, S. B. (2001). Proportional assist ventilation 
may improve exercise performance in severe chronic obstructive pulmonary disease. Journal of 
Cardiopulmonary Rehabilitation, 21(3), 135-142. 
 
Heus, R., Wertheim, A. H., & Havenith, G. (1998). Human energy expenditure when walking on a moving 
platform. European Journal of Applied Physiology & Occupational Physiology, 77(4), 388-394. 
 
Higgins, J. P. T., & Altman, D. G. (2008). Chapter 8: Assessing risk of bias in included studies. In J. P. T. 
Higgins & S. Green (Eds.), Cochrane Handbook for Systematic Reviews of Intervenions (Version 5.0.1 
(Updated September 2008) ed., Vol. Version 5.0.1 (updated September 2008)): The Cochrane 
Collaboration, 2008. Available from www.cochrane-handbook.org. 
 
Higgins, J. P. T., & Deeks, J. J. (2008). Chapter 7: Selecting studies and collecting data. In J. P. T. Higgins & S. 
Green (Eds.), Cochrane Handbook of Systematic Reviews of Interventions (Vol. Version 5.0.1 (updated 
September 2008)): The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. 
 
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-
analyses. British Medical Journal, 327(7414), 557-560. 
 
Highcock, M. P., Shneerson, J. M., & Smith, I. E. (2003). Increased ventilation with NIPPV does not necessarily 
improve exercise capacity in COPD. European Respiratory Journal, 22(1), 100-105. 
 
Highcock, M. P., Smith, I. E., & Shneerson, J. M. (1997). The hippy ventilator: effects of a portable ventilator on 
exercise tolerance in COPD. Thorax, 52(Suppl 6), A38. 
 
Highcock, M. P., Smith, I. E., & Shneerson, J. M. (2002). The effect of noninvasive intermittent positive-
pressure ventilation during exercise in severe scoliosis. Chest, 121(5), 1555-1560. 
 
Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance, Biometrika, 75, 800-802. 
 
Hogg, J. C. (2004). Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 
364(9435), 709-721. 
 
Hogg, J. C., Macklem, P. T., & Thurlbeck, W. M. (1968). Site and nature of airway obstruction in chronic 
obstructive lung disease. New England Journal of Medicine, 278(25), 1355-1360. 
 
Holland, A. E., Hill, C. J., Rasekaba, T., Lee, A., Naughton, M. T., & McDonald, C. F. (2010). Updating the 
minimal important difference for six-minute walk distance in patients with chronic obstructive 
pulmonary disease. Archives of Physical Medicine & Rehabilitation, 91(2), 221-225. 
 
Holverda, S., Rietema, H., Westerhof, N., Marcus, J. T., Gan, C. T., Postmus, P. E., & Vonk-Noordegraaf, A. 
(2009). Stroke volume increase to exercise in chronic obstructive pulmonary disease is limited by 
 264 
increased pulmonary artery pressure. Heart, 95(2), 137-141. 
 
Hurst, J. R., & Wedzicha, J. A. (2004). Chronic obstructive pulmonary disease: the clinical management of an 
acute exacerbation. Postgraduate Medical Journal, 80(947), 497-505. 
Johnson, J. E., Gavin, D. J., & Adams-Dramiga, S. (2002). Effects of training with heliox and noninvasive 
positive pressure ventilation on exercise ability in patients with severe COPD. Chest, 122(2), 464-472. 
 
Jones, P. W. (2002). Interpreting thresholds for a clinically significant change in health status in asthma and 
COPD. European Respiratory Journal, 19(3), 398-404. 
 
Jones, R. S., Kennedy, J. D., Hasham, F., Owen, R., & Taylor, J. F. (1981). Mechanical inefficiency of the 
thoracic cage in scoliosis. Thorax, 36(6), 456-461. 
 
Jonville, S., Delpech, N., & Denjean, A. (2002). Contribution of respiratory acidosis to diaphragmatic fatigue at 
exercise. European Respiratory Journal, 19(6), 1079-1086. 
 
Joppa, P., Petrasova, D., Stancak, B., & Tkacova, R. (2006). Systemic inflammation in patients with COPD and 
pulmonary hypertension. Chest, 130(2), 326-333. 
 
Juan, G., Calverley, P., Talamo, C., Schnader, J., & Roussos, C. (1984). Effect of carbon dioxide on 
diaphragmatic function in human beings. New England Journal of Medicine, 310(14), 874-879. 
 
Kearon, C., Viviani, G. R., Kirkley, A., & Killian, K. J. (1993a). Factors determining pulmonary function in 
adolescent idiopathic thoracic scoliosis. American Review of  Respiratory Disease, 148(2), 288-294. 
 
Kearon, C., Viviani, G. R., & Killian, K. J. (1993b). Factors influencing work capacity in adolescent idiopathic 
thoracic scoliosis. American Review of Respiratory Disease, 148(2), 295-303. 
 
Keenan, S. P., Gregor, J., Sibbald, W. J., Cook, D., & Gafni, A. (2000). Noninvasive positive pressure 
ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more 
effective and less expensive. Critical Care Medicine, 28(6), 2094-2102. 
 
Keilty, S. E., Ponte, J., Fleming, T. A., & Moxham, J. (1994). Effect of inspiratory pressure support on exercise 
tolerance and breathlessness in patients with severe stable chronic obstructive pulmonary disease. 
Thorax, 49(10), 990-994. 
 
Kerby, G. R., Mayer, L. S., & Pingleton, S. K. (1987). Nocturnal positive pressure ventilation via nasal mask. 
American Review of Respiratory Disease, 135(3), 738-740. 
 
Kessler, R., Faller, M., Fourgaut, G., Mennecier, B., & Weitzenblum, E. (1999). Predictive factors of 
hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary 
disease. American Journal of Respiratory & Critical Care Medicine, 159(1), 158-164. 
 
Kesten, S., Garfinkel, S. K., Wright, T., & Rebuck, A. S. (1991). Impaired exercise capacity in adults with 
moderate scoliosis. Chest, 99(3), 663-666. 
 
Killian, K. J., Leblanc, P., Martin, D. H., Summers, E., Jones, N. L., & Campbell, E. J. (1992). Exercise capacity 
and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. 
American Review of Respiratory Disease, 146(4), 935-940. 
 
Kohnlein, T., Schonheit-Kenn, U., Winterkamp, S., Welte, T., & Kenn, K. (2009). Noninvasive ventilation in 
pulmonary rehabilitation of COPD patients. Respiratory Medicine, 103(9), 1329-1336. 
 
Kolodziej, M. A., Jensen, L., Rowe, B., & Sin, D. (2007). Systematic review of noninvasive positive pressure 
ventilation in severe stable COPD. European Respiratory Journal, 30(2), 293-306. 
 
Kory, R. C., Callahan, R., Boren, H. G., & Syner, J. C. (1961). The Veterans Administration-Army cooperative 
study of pulmonary function. I. Clinical spirometry in normal men. American Journal of Medicine, 30, 
243-258. 
 
Koumbourlis, A. C. (2006). Scoliosis and the respiratory system. Paediatric Respiratory Reviews, 7(2), 152-160. 
 
Krieger, J., Turlot, J. C., Mangin, P., & Kurtz, D. (1983). Breathing during sleep in normal young and elderly 
subjects: hypopneas, apneas, and correlated factors. Sleep, 6(2), 108-120. 
 
 265 
Kwok, H., McCormack, J., Cece, R., Houtchens, J., & Hill, N. S. (2003). Controlled trial of oronasal versus 
nasal mask ventilation in the treatment of acute respiratory failure. Critical Care Medicine, 31(2), 468-
473. 
 
Kyroussis, D., Polkey, M. I., Hamnegard, C. H., Mills, G. H., Green, M., & Moxham, J. (2000). Respiratory 
muscle activity in patients with COPD walking to exhaustion with and without pressure support. 
European Respiratory Journal, 15(4), 649-655. 
 
Lacasse, Y., Goldstein, R., Lasserson, T. J., & Martin, S. (2006). Pulmonary rehabilitation for chronic 
obstructive pulmonary disease. Cochrane Database of Systematic Reviews, Issue 4., Art. No.: 
CD003793. DOI: 003710.001002/14651858.CD14003793.pub14651852. 
 
Lahaije, A., van Helvoort, H., Dekhuijzen, P., & Heijdra, Y. (2010). Physiologic limitations during daily life 
activities in COPD patients. Respiratory Medicine, 104, 1152-1159. 
 
Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 
33(1), 159-174. 
 
Laub, M., & Midgren, B. (2007). Survival of patients on home mechanical ventilation: a nationwide prospective 
study. Respiratory Medicine, 101(6), 1074-1078. 
 
Laude, E. A., Duffy, N. C., Baveystock, C., Dougill, B., Campbell, M. J., Lawson, R., Jones, P. W., & Calverley, 
P. M. (2006). The effect of helium and oxygen on exercise performance in chronic obstructive 
pulmonary disease: a randomized crossover trial. American Journal of Respiratory & Critical Care 
Medicine, 173(8), 865-870. 
 
Leger, P., Bedicam, J. M., Cornette, A., Reybet-Degat, O., Langevin, B., Polu, J. M., Jeannin, L., & Robert, D. 
(1994). Nasal intermittent positive pressure ventilation. Long-term follow-up in patients with severe 
chronic respiratory insufficiency. Chest, 105(1), 100-105. 
 
Levine, S., Nguyen, T., Kaiser, L. R., Rubinstein, N. A., Maislin, G., Gregory, C., Rome, L. C., Dudley, G. A., 
Sieck, G. C., & Shrager, J. B. (2003). Human diaphragm remodeling associated with chronic 
obstructive pulmonary disease: clinical implications. American Journal of Respiratory & Critical Care 
Medicine, 168(6), 706-713. 
 
Levison, H., & Cherniack, R. M. (1968). Ventilatory cost of exercise in chronic obstructive pulmonary disease. 
Journal of Applied Physiology, 25(1), 21-27. 
 
Libby, D. M., Briscoe, W. A., Boyce, B., & Smith, J. P. (1982). Acute respiratory failure in scoliosis or 
kyphosis: prolonged survival and treatment. American Journal of Medicine, 73(4), 532-538. 
 
Liesching, T., Kwok, H., & Hill, N. S. (2003). Acute applications of noninvasive positive pressure ventilation. 
Chest, 124(2), 699-713. 
 
Linderholm, H., & Lindgren, U. (1978). Prediction of spirometric values in patients with scoliosis. Acta 
Orthopaedica Scandinavica, 49(5), 469-474. 
 
Lisboa, C., Moreno, R., Fava, M., Ferretti, R., & Cruz, E. (1985). Inspiratory muscle function in patients with 
severe kyphoscoliosis. Amercian Review of Respiratory Disease, 132(1), 48-52. 
 
Lloyd-Owen, S. J., Donaldson, G. C., Ambrosino, N., Escarabill, J., Farre, R., Fauroux, B., Robert, D., 
Schoenhofer, B., Simonds, A. K., & Wedzicha, J. A. (2005). Patterns of home mechanical ventilation 
use in Europe: results from the Eurovent survey. European Respiratory Journal, 25(6), 1025-1031. 
 
Lofaso, F., Brochard, L., Touchard, D., Hang, T., Harf, A., & Isabey, D. (1995). Evaluation of carbon dioxide 
rebreathing during pressure support ventilation with airway management system (BiPAP) devices. 
Chest, 108(3), 772-778. 
 
Lopes, J. M., Tabachnik, E., Muller, N. L., Levison, H., & Bryan, A. C. (1983). Total airway resistance and 
respiratory muscle activity during sleep. Journal of Applied Physiology, 54(3), 773-777. 
 
Lopez-Campos, J. L., Cejudo, P., Ortega, F., Lopez-Marquez, I., Marquez-Martin, E., Capote, F., Echevarria, 
M., Montemayor, T., & Barrot, E. (2008). Shuttle walking versus maximal cycle testing: clinical 
correlates in patients with kyphoscoliosis. Respiratory Physiology & Neurobiology, 160(3), 334-340. 
 
 266 
Loring, S. H., Garcia-Jacques, M., & Malhotra, A. (2009). Pulmonary characteristics in COPD and mechanisms 
of increased work of breathing. Journal of Applied Physiology, 107(1), 309-314. 
 
Loveridge, B., West, P., Anthonisen, N. R., & Kryger, M. H. (1984). Breathing patterns in patients with chronic 
obstructive pulmonary disease. American Review of Respiratory Disease, 130(5), 730-733. 
 
MacIntyre, N. R., Cheng, K. C., & McConnell, R. (1997). Applied PEEP during pressure support reduces the 
inspiratory threshold load of intrinsic PEEP. Chest, 111(1), 188-193. 
 
Macklem, P. T. (1984). Hyperinflation. American Review of Respiratory Disease, 129(1), 1-2. 
 
Macklem, P. T. (2010). Therapeutic implications of the pathophysiology of COPD. European Respiratory 
Journal, 35(3), 676-680. 
 
Macklem, P. T., Macklem, D. M., & De Troyer, A. (1983). A model of inspiratory muscle mechanics. Journal of 
Applied Physiology, 55(2), 547-557. 
 
Maclay, J. D., Rabinovich, R. A., & MacNee, W. (2009). Update in chronic obstructive pulmonary disease 2008. 
American Journal of Respiratory & Critical Care Medicine, 179(7), 533-541. 
 
Mador, M. J., Deniz, O., Aggarwal, A., & Kufel, T. J. (2003). Quadriceps fatigability after single muscle 
exercise in patients with chronic obstructive pulmonary disease. American Journal of Respiratory & 
Critical Care Medicine, 168(1), 102-108. 
 
Make, B., Gilmartin, M., Brody, J. S., & Snider, G. L. (1984). Rehabilitation of ventilator-dependent subjects 
with lung diseases. The concept and initial experience. Chest, 86(3), 358-365. 
 
Maltais, F., Bourbeau, J., Shapiro, S., Lacasse, Y., Perrault, H., Baltzan, M., Hernandez, P., Rouleau, M., Julien, 
M., Parenteau, S., Paradis, B., Levy, R. D., Camp, P., Lecours, R., Audet, R., Hutton, B., Penrod, J. R., 
Picard, D., & Bernard, S. (2008). Effects of home-based pulmonary rehabilitation in patients with 
chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine, 149(12), 869-
878. 
 
Maltais, F., LeBlanc, P., Jobin, J., Berube, C., Bruneau, J., Carrier, L., Breton, M. J., Falardeau, G., & Belleau, 
R. (1997). Intensity of training and physiologic adaptation in patients with chronic obstructive 
pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 155(2), 555-561. 
 
Maltais, F., LeBlanc, P., Simard, C., Jobin, J., Berube, C., Bruneau, J., Carrier, L., & Belleau, R. (1996b). 
Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary 
disease. American Journal of Respiratory & Critical Care Medicine, 154(2 Pt 1), 442-447. 
 
Maltais, F., LeBlanc, P., Whittom, F., Simard, C., Marquis, K., Belanger, M., Breton, M. J., & Jobin, J. (2000). 
Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with 
COPD. Thorax, 55(10), 848-853. 
 
Maltais, F., Reissmann, H., & Gottfried, S. B. (1995). Pressure support reduces inspiratory effort and dyspnea 
during exercise in chronic airflow obstruction. American Journal of Respiratory & Critical Care 
Medicine, 151(4), 1027-1033. 
 
Maltais, F., Simard, A. A., Simard, C., Jobin, J., Desgagnes, P., & LeBlanc, P. (1996a). Oxidative capacity of the 
skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. 
American Journal of Respiratory & Critical Care Medicine, 153(1), 288-293. 
 
Man, W. D., Mustfa, N., Nikoletou, D., Kaul, S., Hart, N., Rafferty, G. F., Donaldson, N., Polkey, M. I., & 
Moxham, J. (2004). Effect of salmeterol on respiratory muscle activity during exercise in poorly 
reversible COPD. Thorax, 59(6), 471-476. 
 
Man, W. D., Soliman, M. G., Gearing, J., Radford, S. G., Rafferty, G. F., Gray, B. J., Polkey, M. I., & Moxham, 
J. (2003). Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive 
pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 168(5), 562-567. 
 
Mannino, D. M., Thorn, D., Swensen, A., & Holguin, F. (2008). Prevalence and outcomes of diabetes, 
hypertension and cardiovascular disease in COPD. European Respiratory Journal, 32(4), 962-969. 
 
Marks, D. S., & Qaimkhani, S. A. (2009). The natural history of congenital scoliosis and kyphosis. Spine, 
 267 
34(17), 1751-1755. 
 
Martin, U. J., Hincapie, L., Nimchuk, M., Gaughan, J., & Criner, G. J. (2005). Impact of whole-body 
rehabilitation in patients receiving chronic mechanical ventilation. Critical Care Medicine, 33(10), 
2259-2265. 
 
Martinez-Llorens, J., Ramirez, M., Colomina, M. J., Bago, J., Molina, A., Caceres, E., & Gea, J. (2010). Muscle 
dysfunction and exercise limitation in adolescent idiopathic scoliosis. European Respiratory Journal, 
36(2), 393-400. 
 
Martinez, F. J., Couser, J. I., & Celli, B. R. (1991). Respiratory response to arm elevation in patients with 
chronic airflow obstruction. American Review of Respiratory Disease, 143(3), 476-480. 
 
Martinez, F. J., Vogel, P. D., Dupont, D. N., Stanopoulos, I., Gray, A., & Beamis, J. F. (1993). Supported arm 
exercise vs unsupported arm exercise in the rehabilitation of patients with severe chronic airflow 
obstruction. Chest, 103(5), 1397-1402. 
 
Matthay, R. A., Berger, H. J., Davies, R. A., Loke, J., Mahler, D. A., Gottschalk, A., & Zaret, B. L. (1980). 
Right and left ventricular exercise performance in chronic obstructive pulmonary disease: radionuclide 
assessment. Annals of Internal Medicine, 93(2), 234-239. 
 
McEvoy, R. D., Pierce, R. J., Hillman, D., Esterman, A., Ellis, E. E., Catcheside, P. G., O'Donoghue, F. J., 
Barnes, D. J., & Grunstein, R. R. (2009). Nocturnal non-invasive nasal ventilation in stable hypercapnic 
COPD: a randomised controlled trial. Thorax, 64(7), 561-566. 
 
McKeough, Z. J., Alison, J. A., & Bye, P. T. (2003). Arm exercise capacity and dyspnea ratings in subjects with 
chronic obstructive pulmonary disease. Journal of Cardiopulmonary Rehabilitation, 23(3), 218-225. 
 
McMaster, M. J., & Singh, H. (2001). The surgical management of congenital kyphosis and kyphoscoliosis. 
Spine, 26(19), 2146-2154; discussion 2155. 
 
Mead, J., Turner, J. M., Macklem, P. T., & Little, J. B. (1967). Significance of the relationship between lung 
recoil and maximum expiratory flow. Journal of Applied Physiology, 22(1), 95-108. 
 
Medical Research Council. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale 
complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working 
Party. (1981). Lancet, 1(8222), 681-686. 
 
Meecham Jones, D. J., Paul, E. A., Bell, J. H., & Wedzicha, J. A. (1995a). Ambulatory oxygen therapy in stable 
kyphoscoliosis. European Respiratory Journal, 8(5), 819-823. 
 
Meecham Jones, D. J., Paul, E. A., Jones, P. W., & Wedzicha, J. A. (1995b). Nasal pressure support ventilation 
plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of 
Respiratory & Critical Care Medicine, 152(2), 538-544. 
 
Mehta, S., & Hill, N. S. (2001). Noninvasive ventilation. American Journal of Respiratory & Critical Care 
Medicine, 163(2), 540-577. 
 
Menadue, C., Alison, J. A., Piper, A. J., Flunt, D., & Ellis, E. R. (2009b). Non-invasive ventilation during arm 
exercise and ground walking in patients with chronic hypercapnic respiratory failure. Respirology, 
14(2), 251-259. 
 
Menadue, C., Alison, J. A., Piper, A. J., Flunt, D., & Ellis, E. R. (2010b). Bilevel ventilation during exercise in 
acute on chronic respiratory failure: A preliminary study. Respiratory Medicine, 104, 219-227. 
 
Menadue, C., Alison, J. A., Piper, A. J., Wong, K. K., Hollier, C., & Ellis, E. R. (2010a). High and low level 
pressure support during walking in people with severe kyphoscoliosis. European Respiratory Journal, 
36(2), 370-378. 
 
Menadue, C., Piper, A. J., van't Hul, A. J., & Wong, K. K. (2009a). Non-invasive ventilation during exercise 
training for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic 
Reviews, Issue 2., Art No.: CD007714. DOI: 007710.001002/14651858.CD14007714. 
 
Menn, P., Weber, N., & Holle, R. (2010). Health-related quality of life in patients with severe COPD 
hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health and  Quality of Life 
 268 
Outcomes, 8(39), doi:10.1186/1477-7525-1188-1139. 
 
Mezon, B. L., West, P., Israels, J., & Kryger, M. (1980). Sleep breathing abnormalities in kyphoscoliosis. 
American Review of Respiratory Disease, 122(4), 617-621. 
Miller, J. D., Beck, K. C., Joyner, M. J., Brice, A. G., & Johnson, B. D. (2002). Cardiorespiratory effects of 
inelastic chest wall restriction. Journal of Applied Physiology, 92(6), 2419-2428. 
 
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998). 
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-
analyses? Lancet, 352(9128), 609-613. 
 
Montes de Oca, M., & Celli, B. R. (2000). Respiratory muscle recruitment and exercise performance in eucapnic 
and hypercapnic severe chronic obstructive pulmonary disease. Americal Journal of Respiratory & 
Critical Care Medicine, 161(3 Pt 1), 880-885. 
 
Montes de Oca, M., Rassulo, J., & Celli, B. R. (1996). Respiratory muscle and cardiopulmonary function during 
exercise in very severe COPD. American Journal of Respiratory & Critical Care Medicine, 154(5), 
1284-1289. 
 
Moretti, M., Cilione, C., Tampieri, A., Fracchia, C., Marchioni, A., & Nava, S. (2000). Incidence and causes of 
non-invasive mechanical ventilation failure after initial success. Thorax, 55(10), 819-825. 
 
Morgan, E. J., Baidwan, B., Petty, T. L., & Zwillich, C. W. (1979). The effects of unanesthetized arterial 
puncture on PCO2 and pH. American Review of Respiratory Disease, 120(4), 795-798. 
 
Morris, P. E., Goad, A., Thompson, C., Taylor, K., Harry, B., Passmore, L., Ross, A., Anderson, L., Baker, S., 
Sanchez, M., Penley, L., Howard, A., Dixon, L., Leach, S., Small, R., Hite, R. D., & Haponik, E. 
(2008). Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Critical 
Care Medicine, 36(8), 2238-2243. 
 
Morrison, D. A., Adcock, K., Collins, C. M., Goldman, S., Caldwell, J. H., & Schwarz, M. I. (1987). Right 
ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. Journal of 
the American College of Cardiology, 9(6), 1219-1229. 
 
Naeije, R., & Barbera, J. A. (2001). Pulmonary hypertension associated with COPD. Critical Care, 5(6), 286-
289. 
 
Naeye, R. L. (1961). Kyphoscoliosis and cor pulmonale; a study of the pulmonary vascular bed. American 
Journal of Pathology, 38, 561-573. 
 
Naji, N. A., Connor, M. C., Donnelly, S. C., & McDonnell, T. J. (2006). Effectiveness of pulmonary 
rehabilitation in restrictive lung disease. Journal of Cardiopulmonary Rehabilitation, 26(4), 237-243. 
 
Nauffal, D., Domenech, R., Martinez Garcia, M. A., Compte, L., Macian, V., & Perpina, M. (2002). 
Noninvasive positive pressure home ventilation in restrictive disorders: outcome and impact on health-
related quality of life. Respiratory Medicine, 96(10), 777-783. 
 
Nava, S. (1998). Rehabilitation of patients admitted to a respiratory intensive care unit. Archives of Physical 
Medicine & Rehabilitation, 79(7), 849-854. 
 
Nava, S., Ambrosino, N., Rubini, F., Fracchia, C., Rampulla, C., Torri, G., & Calderini, E. (1993). Effect of 
nasal pressure support ventilation and external PEEP on diaphragmatic activity in patients with severe 
stable COPD. Chest, 103(1), 143-150. 
 
Nava, S., Bruschi, C., Rubini, F., Palo, A., Iotti, G., & Braschi, A. (1995). Respiratory response and inspiratory 
effort during pressure support ventilation in COPD patients. Intensive Care Medicine, 21(11), 871-879. 
 
Nava, S., & Hill, N. (2009). Non-invasive ventilation in acute respiratory failure. Lancet, 374(9685), 250-259. 
 
Nici, L. (2000). Mechanisms and measures of exercise intolerance in chronic obstructive pulmonary disease. 
Clinics in Chest Medicine, 21(4), 693-704. 
 
Nici, L., Donner, C., Wouters, E., Zuwallack, R., Ambrosino, N., Bourbeau, J., Carone, M., Celli, B., Engelen, 
M., Fahy, B., Garvey, C., Goldstein, R., Gosselink, R., Lareau, S., MacIntyre, N., Maltais, F., Morgan, 
M., O'Donnell, D., Prefault, C., Reardon, J., Rochester, C., Schols, A., Singh, S., & Troosters, T. 
 269 
(2006). American Thoracic Society/European Respiratory Society statement on pulmonary 
rehabilitation. American Journal of Respiratory & Critical Care Medicine, 173(12), 1390-1413. 
 
Nickol, A. H., Hart, N., Hopkinson, N. S., Moxham, J., Simonds, A., & Polkey, M. I. (2005). Mechanisms of 
improvement of respiratory failure in patients with restrictive thoracic disease treated with non-invasive 
ventilation. Thorax, 60(9), 754-760. 
 
Nonoyama, M. L., Brooks, D., Lacasse, Y., Guyatt, G. H., & Goldstein, R. S. (2007). Oxygen therapy during 
exercise training in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 
Issue 2., Art. No.: CD005372. DOI: 005310.001002/14651858.CD14005372.pub14651852. 
 
O'Donnell, D. E., D'Arsigny, C., Fitzpatrick, M., & Webb, K. A. (2002). Exercise hypercapnia in advanced 
chronic obstructive pulmonary disease: the role of lung hyperinflation. American Journal of Respiratory 
& Critical Care Medicine, 166(5), 663-668. 
 
O'Donnell, D. E., D'Arsigny, C., Raj, S., Abdollah, H., & Webb, K. A. (1999). Ventilatory assistance improves 
exercise endurance in stable congestive heart failure. American Journal of Respiratory & Critical Care 
Medicine, 160(6), 1804-1811. 
 
O'Donnell, D. E., D'Arsigny, C., & Webb, K. A. (2001b). Effects of hyperoxia on ventilatory limitation during 
exercise in advanced chronic obstructive pulmonary disease. American Journal of Respiratory & 
Critical Care Medicine, 163(4), 892-898. 
 
O'Donnell, D. E., & Laveneziana, P. (2006). Physiology and consequences of lung hyperinflation in COPD. 
European Respiratory Review, 15(100), 61-67. 
 
O'Donnell, D. E., McGuire, M., Samis, L., & Webb, K. A. (1995). The impact of exercise reconditioning on 
breathlessness in severe chronic airflow limitation. American Journal of Respiratory & Critical Care 
Medicine, 152(6 Pt 1), 2005-2013. 
 
O'Donnell, D. E., & Parker, C. M. (2006). COPD exacerbations. 3: Pathophysiology. Thorax, 61(4), 354-361. 
 
O'Donnell, D. E., Revill, S. M., & Webb, K. A. (2001a). Dynamic hyperinflation and exercise intolerance in 
chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 
164(5), 770-777. 
 
O'Donnell, D. E., Sanii, R., & Younes, M. (1988). Improvement in exercise endurance in patients with chronic 
airflow limitation using continuous positive airway pressure. American Review of Respiratory Disease, 
138(6), 1510-1514. 
 
O'Donnell, D. E., & Webb, K. A. (1993). Exertional breathlessness in patients with chronic airflow limitation. 
The role of lung hyperinflation. American Review of Respiratory Disease, 148(5), 1351-1357. 
 
O'Donoghue, F. J., Catcheside, P. G., Ellis, E. E., Grunstein, R. R., Pierce, R. J., Rowland, L. S., Collins, E. R., 
Rochford, S. E., & McEvoy, R. D. (2003). Sleep hypoventilation in hypercapnic chronic obstructive 
pulmonary disease: prevalence and associated factors. European Respiratory Journal, 21(6), 977-984. 
 
O'Donoghue, F. J., Catcheside, P. G., Jordan, A. S., Bersten, A. D., & McEvoy, R. D. (2002). Effect of CPAP on 
intrinsic PEEP, inspiratory effort, and lung volume in severe stable COPD. Thorax, 57(6), 533-539. 
 
Oga, T., Nishimura, K., Tsukino, M., Hajiro, T., Ikeda, A., & Izumi, T. (2000). The effects of oxitropium 
bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A 
comparison of three different exercise tests. American Journal of Respiratory & Critical Care 
Medicine, 161(6), 1897-1901. 
 
Oga, T., Nishimura, K., Tsukino, M., Sato, S., & Hajiro, T. (2003). Analysis of the factors related to mortality in 
chronic obstructive pulmonary disease: role of exercise capacity and health status. American Journal of 
Respiratory & Critical Care Medicine, 167(4), 544-549. 
 
Olgiati, R., Levine, D., Smith, J. P., Briscoe, W. A., & King, T. K. (1982). Diffusing capacity in idiopathic 
scoliosis and its interpretation regarding alveolar development. American Review of Respiratory 
Disease, 126(2), 229-234. 
 
Oliveira, C. C., Carrascosa, C. R., Borghi-Silva, A., Berton, D. C., Queiroga, F., Jr., Ferreira, E. M., Nery, L. E., 
& Alberto Neder, J. (2010). Influence of respiratory pressure support on hemodynamics and exercise 
 270 
tolerance in patients with COPD. European Journal of Applied Physiology, 194(4), 681-9.   
 
Orozco-Levi, M., Gea, J., Lloreta, J. L., Felez, M., Minguella, J., Serrano, S., & Broquetas, J. M. (1999). 
Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. European 
Respiratory Journal, 13(2), 371-378. 
 
Palange, P., Forte, S., Onorati, P., Paravati, V., Manfredi, F., Serra, P., & Carlone, S. (1998). Effect of reduced 
body weight on muscle aerobic capacity in patients with COPD. Chest, 114(1), 12-18. 
 
Papi, A., Bellettato, C. M., Braccioni, F., Romagnoli, M., Casolari, P., Caramori, G., Fabbri, L. M., & Johnston, 
S. L. (2006). Infections and airway inflammation in chronic obstructive pulmonary disease severe 
exacerbations. American Journal of Respiratory & Critical Care Medicine, 173(10), 1114-1121. 
 
Pardy, R. L., Hussain, S. N., & Macklem, P. T. (1984). The ventilatory pump in exercise. Clinics in Chest 
Medicine, 5(1), 35-49. 
 
Parot, S., Miara, B., Milic-Emili, J., & Gautier, H. (1982). Hypoxemia, hypercapnia, and breathing pattern in 
patients with chronic obstructive pulmonary disease. American Review of Respiratory Disease, 126(5), 
882-886. 
 
Pauwels, R. A., & Rabe, K. F. (2004). Burden and clinical features of chronic obstructive pulmonary disease 
(COPD). Lancet, 364(9434), 613-620. 
 
Pepe, P. E., & Marini, J. J. (1982). Occult positive end-expiratory pressure in mechanically ventilated patients 
with airflow obstruction: the auto-PEEP effect. American Review of Respiratory Disease, 126(1), 166-
170. 
 
Peruzza, S., Sergi, G., Vianello, A., Pisent, C., Tiozzo, F., Manzan, A., Coin, A., Inelmen, E. M., & Enzi, G. 
(2003). Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status 
and quality of life. Respiratory Medicine, 97(6), 612-617. 
 
Petrof, B. J., Calderini, E., & Gottfried, S. B. (1990a). Effect of CPAP on respiratory effort and dyspnea during 
exercise in severe COPD. Journal of Applied Physiology, 69(1), 179-188. 
 
Petrof, B. J., Legare, M., Goldberg, P., Milic-Emili, J., & Gottfried, S. B. (1990b). Continuous positive airway 
pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe 
chronic obstructive pulmonary disease. American Review of Respiratory Disease, 141(2), 281-289. 
 
Pildal, J., Hrobjartsson, A., Jorgensen, K. J., Hilden, J., Altman, D. G., & Gotzsche, P. C. (2007). Impact of 
allocation concealment on conclusions drawn from meta-analyses of randomized trials. International 
Journal of Epidemiology, 36(4), 847-857. 
 
Pinto-Plata, V. M., Cote, C., Cabral, H., Taylor, J., & Celli, B. R. (2004). The 6-min walk distance: change over 
time and value as a predictor of survival in severe COPD. European Respiratory Journal, 23(1), 28-33. 
 
Pinto, A. C., Alves, M., Nogueira, A., Evangelista, T., Carvalho, J., Coelho, A., de Carvalho, M., & Sales-Luis, 
M. L. (1999). Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise? 
Journal of Neurological Sciences, 169(1-2), 69-75. 
 
Pires Di Lorenzo, V. A., Borghi-Silva, A., Sampaio, L. M. M., Jamami, M., Oishi, J., & Costa, D. (2003). Effect 
of physical and respiratory muscle training in patients with chronic obstructive pulmonary disease 
(COPD) undergoing BiPAP. Revista Brazileira de Fisioterapia, 7(1), 69-76. 
 
Pitta, F., Troosters, T., Probst, V. S., Langer, D., Decramer, M., & Gosselink, R. (2008). Are patients with 
COPD more active after pulmonary rehabilitation? Chest, 134(2), 273-280. 
 
Pitta, F., Troosters, T., Probst, V. S., Spruit, M. A., Decramer, M., & Gosselink, R. (2006). Physical activity and 
hospitalization for exacerbation of COPD. Chest, 129(3), 536-544. 
 
Pitta, F., Troosters, T., Spruit, M. A., Probst, V. S., Decramer, M., & Gosselink, R. (2005). Characteristics of 
physical activities in daily life in chronic obstructive pulmonary disease. American Journal of 
Respiratory & Critical Care Medicine, 171(9), 972-977. 
 
Plankeel, J. F., McMullen, B., & MacIntyre, N. R. (2005). Exercise outcomes after pulmonary rehabilitation 
depend on the initial mechanism of exercise limitation among non-oxygen-dependent COPD patients. 
 271 
Chest, 127(1), 110-116. 
 
Plant, P. K., Owen, J. L., & Elliott, M. W. (2000). One year period prevalence study of respiratory acidosis in 
acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen 
administration. Thorax, 55(7), 550-554. 
 
Plant, P. K., Owen, J. L., Parrott, S., & Elliott, M. W. (2003). Cost effectiveness of ward based non-invasive 
ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of 
randomised controlled trial. British Medical Journal, 326(7396), 956. 
 
Poggi, R., Appendini, L., Polese, G., Colombo, R., Donner, C. F., & Rossi, A. (2006). Noninvasive proportional 
assist ventilation and pressure support ventilation during arm elevation in patients with chronic 
respiratory failure. A preliminary, physiologic study. Respiratory Medicine, 100(6), 972-979. 
 
Polkey, M. I., Hawkins, P., Kyroussis, D., Ellum, S. G., Sherwood, R., & Moxham, J. (2000). Inspiratory 
pressure support prolongs exercise induced lactataemia in severe COPD. Thorax, 55(7), 547-549. 
 
Polkey, M. I., Kyroussis, D., Hamnegard, C. H., Mills, G. H., Green, M., & Moxham, J. (1996a). Diaphragm 
strength in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care 
Medicine, 154(5), 1310-1317. 
 
Polkey, M. I., Kyroussis, D., Mills, G. H., Hamnegard, C. H., Keilty, S. E., Green, M., & Moxham, J. (1996b). 
Inspiratory pressure support reduces slowing of inspiratory muscle relaxation rate during exhaustive 
treadmill walking in severe COPD. American Journal of Respiratory & Critical Care Medicine, 154(4 
Pt 1), 1146-1150. 
 
Porszasz, J., Emtner, M., Goto, S., Somfay, A., Whipp, B. J., & Casaburi, R. (2005). Exercise training decreases 
ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with 
COPD. Chest, 128(4), 2025-2034. 
 
Porta, R., Vitacca, M., Gile, L. S., Clini, E., Bianchi, L., Zanotti, E., & Ambrosino, N. (2005). Supported arm 
training in patients recently weaned from mechanical ventilation. Chest, 128(4), 2511-2520. 
 
Porto, E. F., Castro, A. A., Nascimento, O., Oliveira, R. C., Cardoso, F., & Jardim, J. R. (2009). Modulation of 
operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs 
exercise tests. Respiratory Medicine, 103(2), 251-257. 
 
Price, L. C., Lowe, D., Hosker, H. S., Anstey, K., Pearson, M. G., & Roberts, C. M. (2006). UK National COPD 
Audit 2003: Impact of hospital resources and organisation of care on patient outcome following 
admission for acute COPD exacerbation. Thorax, 61(10), 837-842. 
 
Pride, N. B., Permutt, S., Riley, R. L., & Bromberger-Barnea, B. (1967). Determinants of maximal expiratory 
flow from the lungs. Journal of Applied Physiology, 23(5), 646-662. 
 
Prinianakis, G., Delmastro, M., Carlucci, A., Ceriana, P., & Nava, S. (2004). Effect of varying the pressurisation 
rate during noninvasive pressure support ventilation. European Respiratory Journal, 23(2), 314-320. 
 
Probst, V. S., Troosters, T., Coosemans, I., Spruit, M. A., Pitta Fde, O., Decramer, M., & Gosselink, R. (2004). 
Mechanisms of improvement in exercise capacity using a rollator in patients with COPD. Chest, 126(4), 
1102-1107. 
 
Puente-Maestu, L., Perez-Parra, J., Godoy, R., Moreno, N., Tejedor, A., Gonzalez-Aragoneses, F., Bravo, J. L., 
Alvarez, F. V., Camano, S., & Agusti, A. (2009). Abnormal mitochondrial function in locomotor and 
respiratory muscles of COPD patients. European Respiratory Journal, 33(5), 1045-1052. 
 
Puhan, M. A., Scharplatz, M., Troosters, T., & Steurer, J. (2005). Respiratory rehabilitation after acute 
exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review. 
Respiratory Research, 6(54), doi: 10.1186/1465-9921-1186-1154. 
 
Puhan, M. A., Scharplatz, M., Troosters, T., Walters, E. H., & Steurer, J. (2009). Pulmonary rehabilitation 
following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic 
Reviews, Issue 1., Art. No.: CD005305. DOI: 005310.001002/14651858.CD14005305.pub14651852. 
 
Purro, A., Appendini, L., Polillo, C., Musso, G., Taliano, C., Mecca, F., Colombo, R., & Carbone, G. (2009). 
Mechanical determinants of early acute ventilatory failure in COPD patients: a physiologic study. 
 272 
Intensive Care Medicine, 35(4), 639-647. 
 
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J. C. (1993). Lung 
volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, 
European Community for Steel and Coal. Official Statement of the European Respiratory Society. 
European Respiratory Journal Supplement, 16, 5-40. 
 
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-
Roisin, R., van Weel, C., & Zielinski, J. (2007). Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of 
Respiratory & Critical Care Medicine, 176(6), 532-555. 
 
Ram, F. S., Picot, J., Lightowler, J., & Wedzicha, J. A. (2004). Non-invasive positive pressure ventilation for 
treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. 
Cochrane Database of Systematic Reviews, Issue 3. , Art, No.: CD004104. DOI: 
004110,001002/1465185.CD1004104.pub1465183. 
 
Repine, J. E., Bast, A., & Lankhorst, I. (1997). Oxidative stress in chronic obstructive pulmonary disease. 
Oxidative Stress Study Group. American Journal of Respiratory & Critical Care Medicine, 156(2 Pt 1), 
341-357. 
 
Reuveny, R., Ben-Dov, I., Gaides, M., & Reichert, N. (2005). Ventilatory support during training improves 
training benefit in severe chronic airway obstruction. Israel Medical Association Journal, 7(3), 151-
155. 
 
Revill, S. M., Morgan, M. D., Singh, S. J., Williams, J., & Hardman, A. E. (1999). The endurance shuttle walk: a 
new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. 
Thorax, 54(3), 213-222. 
 
Revill, S. M., Singh, S. J., & Morgan, M. D. (2000). Randomized controlled trial of ambulatory oxygen and an 
ambulatory ventilator on endurance exercise in COPD. Respiratory Medicine, 94(8), 778-783. 
 
Ribera, F., N'Guessan, B., Zoll, J., Fortin, D., Serrurier, B., Mettauer, B., Bigard, X., Ventura-Clapier, R., & 
Lampert, E. (2003). Mitochondrial electron transport chain function is enhanced in inspiratory muscles 
of patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical 
Care Medicine, 167(6), 873-879. 
 
Ries, A. L. (2005). Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, 
Borg Scale, and Visual Analog Scale. Journal of Chronic Obstructive Pulmonary Disease, 2(1), 105-
110. 
 
Ries, A. L., Bauldoff, G. S., Carlin, B. W., Casaburi, R., Emery, C. F., Mahler, D. A., Make, B., Rochester, C. 
L., Zuwallack, R., & Herrerias, C. (2007). Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-
Based Clinical Practice Guidelines. Chest, 131(5 Suppl), 4S-42S. 
 
Roberts, C. M., Brown, J. L., Reinhardt, A. K., Kaul, S., Scales, K., Mikelsons, C., Reid, K., Winter, R., Young, 
K., Restrick, L., & Plant, P. K. (2008). Non-invasive ventilation in chronic obstructive pulmonary 
disease: management of acute type 2 respiratory failure. Clinical Medicine, 8(5), 517-521. 
 
Robino, C., Faisy, C., Diehl, J. L., Rezgui, N., Labrousse, J., & Guerot, E. (2003). Effectiveness of non-invasive 
positive pressure ventilation differs between decompensated chronic restrictive and obstructive 
pulmonary disease patients. Intensive Care Medicine, 29(4), 603-610. 
 
Rochester, D. F. (1991). Respiratory muscle weakness, pattern of breathing, and CO2 retention in chronic 
obstructive pulmonary disease. American Review of Respiratory Disease, 143(5 Pt 1), 901-903. 
 
Rochester, D. F., & Arora, N. S. (1983). Respiratory muscle failure. Medical Clinics of North America, 67(3), 
573-597. 
 
Rochester, D. F., & Braun, N. M. (1985). Determinants of maximal inspiratory pressure in chronic obstructive 
pulmonary disease. American Review of Respiratory Disease, 132(1), 42-47. 
 
Rodriguez-Roisin, R. (2006). COPD exacerbations.5: management. Thorax, 61(6), 535-544. 
 
Rossi, A., Gottfried, S. B., Zocchi, L., Higgs, B. D., Lennox, S., Calverley, P. M., Begin, P., Grassino, A., & 
 273 
Milic-Emili, J. (1985). Measurement of static compliance of the total respiratory system in patients with 
acute respiratory failure during mechanical ventilation. The effect of intrinsic positive end-expiratory 
pressure. American Review of Respiratory Disease, 131(5), 672-677. 
 
Roussos, C., & Koutsoukou, A. (2003). Respiratory failure. European Respiratory Journal - Supplement, 47, 3s-
14s. 
 
Saatci, E., Miller, D. M., Stell, I. M., Lee, K. C., & Moxham, J. (2004). Dynamic dead space in face masks used 
with noninvasive ventilators: a lung model study. European Respiratory Journal, 23(1), 129-135. 
 
Saey, D., Debigare, R., LeBlanc, P., Mador, M. J., Cote, C. H., Jobin, J., & Maltais, F. (2003). Contractile leg 
fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary 
disease. American Journal of Respiratory & Critical Care Medicine, 168(4), 425-430. 
 
Sawicka, E. H., & Branthwaite, M. A. (1987). Respiration during sleep in kyphoscoliosis. Thorax, 42(10), 801-
808. 
 
Scanlon, P. D., Connett, J. E., Waller, L. A., Altose, M. D., Bailey, W. C., & Buist, A. S. (2000). Smoking 
cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung 
Health Study. American Journal of Respiratory & Critical Care Medicine, 161(2 Pt 1), 381-390. 
 
Scano, G., Innocenti-Bruni, G., & Stendardi, L. (2010). Do obstructive and restrictive lung diseases share 
common underlying mechanisms of breathlessness? Respiratory Medicine, 104(7), 925-933. 
 
Schettino, G. P., Chatmongkolchart, S., Hess, D. R., & Kacmarek, R. M. (2003). Position of exhalation port and 
mask design affect CO2 rebreathing during noninvasive positive pressure ventilation. Critical Care 
Medicine, 31(8), 2178-2182. 
 
Schneider, E., Duale, C., Vaille, J. L., Ouchchane, L., Gillart, T., Guelon, D., & Schoeffler, P. (2006). 
Comparison of tolerance of facemask vs. mouthpiece for non-invasive ventilation. Anaesthesia, 61(1), 
20-23. 
 
Schols, A. M., Buurman, W. A., Staal van den Brekel, A. J., Dentener, M. A., & Wouters, E. F. (1996). Evidence 
for a relation between metabolic derangements and increased levels of inflammatory mediators in a 
subgroup of patients with chronic obstructive pulmonary disease. Thorax, 51(8), 819-824. 
 
Schonhofer, B., Ardes, P., Geibel, M., Kohler, D., & Jones, P. W. (1997). Evaluation of a movement detector to 
measure daily activity in patients with chronic lung disease. European Respiratory Journal, 10(12), 
2814-2819. 
 
Schonhofer, B., Barchfeld, T., Wenzel, M., & Kohler, D. (2001a). Long term effects of non-invasive mechanical 
ventilation on pulmonary haemodynamics in patients with chronic respiratory failure. Thorax, 56(7), 
524-528. 
 
Schonhofer, B., Dellweg, D., Suchi, S., & Kohler, D. (2008). Exercise endurance before and after long-term 
noninvasive ventilation in patients with chronic respiratory failure. Respiration, 75(3), 296-303. 
 
Schonhofer, B., & Kohler, D. (2000). Effect of non-invasive mechanical ventilation on sleep and nocturnal 
ventilation in patients with chronic respiratory failure. Thorax, 55(4), 308-313. 
 
Schonhofer, B., Wallstein, S., Wiese, C., & Kohler, D. (2001b). Noninvasive mechanical ventilation improves 
endurance performance in patients with chronic respiratory failure due to thoracic restriction. Chest, 
119(5), 1371-1378. 
 
Schonhofer, B., Zimmermann, C., Abramek, P., Suchi, S., Kohler, D., & Polkey, M. I. (2003). Non-invasive 
mechanical ventilation improves walking distance but not quadriceps strength in chronic respiratory 
failure. Respiratory Medicine, 97(7), 818-824. 
 
Schweickert, W. D., Pohlman, M. C., Pohlman, A. S., Nigos, C., Pawlik, A. J., Esbrook, C. L., Spears, L., 
Miller, M., Franczyk, M., Deprizio, D., Schmidt, G. A., Bowman, A., Barr, R., McCallister, K. E., Hall, 
J. B., & Kress, J. P. (2009). Early physical and occupational therapy in mechanically ventilated, 
critically ill patients: a randomised controlled trial. Lancet, 373(9678), 1874-1882. 
 
Sciurba, F., Criner, G. J., Lee, S. M., Mohsenifar, Z., Shade, D., Slivka, W., & Wise, R. A. (2003). Six-minute 
 274 
walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course 
layout and length. American Journal of Respiratory & Critical Care Medicine, 167(11), 1522-1527. 
 
Seemungal, T. A., Donaldson, G. C., Paul, E. A., Bestall, J. C., Jeffries, D. J., & Wedzicha, J. A. (1998). Effect 
of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American 
Journal of Respiratory & Critical Care Medicine, 157(5 Pt 1), 1418-1422. 
 
Seymour, J. M., Moore, L., Jolley, C. J., Ward, K., Creasey, J., Steier, J. S., Yung, B., Man, W. D., Hart, N., 
Polkey, M. I., & Moxham, J. (2010b). Outpatient pulmonary rehabilitation following acute 
exacerbations of COPD. Thorax, 65(5), 423-428. 
 
Seymour, J. M., Spruit, M. A., Hopkinson, N. S., Natanek, S. A., Man, W. D.-C., Jackson, A., Gosker, H. R., 
Schols, A. M. W. J., Moxham, J., Polkey, M. I., & Wouters, E. F. M. (2010a). The prevalence of 
quadriceps weakness in COPD and the relationship with disease severity. European Respiratory 
Journal, 36, 81-88. 
 
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., 
Moher, D., & Bouter, L. M. (2007). Development of AMSTAR: a measurement tool to assess the 
methodological quality of systematic reviews. BMC Medical Research Methodology, 7(10). 
 
Shneerson, J. M. (1978a). Pulmonary artery pressure in thoracic scoliosis during and after exercise while 
breathing air and pure oxygen. Thorax, 33(6), 747-754. 
 
Shneerson, J. M. (1978b). The cardiorespiratory response to exercise in thoracic scoliosis. Thorax, 33(4), 457-
463. 
 
Shneerson, J. M. (1998). Rehabilitation in neuromuscular disorders and thoracic wall deformities. Monaldi 
Archives for Chest Disease, 53(4), 415-418. 
 
Shneerson, J. M., & Simonds, A. K. (2002). Noninvasive ventilation for chest wall and neuromuscular disorders. 
European Respiratory Journal, 20(2), 480-487. 
 
Shneerson, J. M., Venco, A., & Prime, F. J. (1977). A study of pulmonary artery pressure, electrocardiography, 
and mechanocardiography in thoracic scoliosis. Thorax, 32(6), 700-705. 
 
Shrout, P. E., Fleiss, J.L. (1979). Intraclass correlations: uses in assessing rater reliability. Psychological 
Bulletin, 86(2), 420-428. 
 
Simonds, A. K. (2003). Home ventilation. European Respiratory Journal Supplement, 47, 38s-46s. 
 
Simonds, A. K., & Elliott, M. W. (1995). Outcome of domiciliary nasal intermittent positive pressure ventilation 
in restrictive and obstructive disorders. Thorax, 50(6), 604-609. 
 
Sims, M. W., Margolis, D. J., Localio, A. R., Panettieri, R. A., Kawut, S. M., & Christie, J. D. (2009). Impact of 
pulmonary artery pressure on exercise function in severe COPD. Chest, 136(2), 412-419. 
 
Sin, D. D., Wu, L., & Man, S. F. (2005). The relationship between reduced lung function and cardiovascular 
mortality: a population-based study and a systematic review of the literature. Chest, 127(6), 1952-1959. 
 
Sinderby, C., Spahija, J., Beck, J., Kaminski, D., Yan, S., Comtois, N., & Sliwinski, P. (2001). Diaphragm 
activation during exercise in chronic obstructive pulmonary disease. American Journal of Respiratory 
& Critical Care Medicine, 163(7), 1637-1641. 
 
Singh, S. J., Jones, P. W., Evans, R., & Morgan, M. D. (2008). Minimum clinically important improvement for 
the incremental shuttle walking test. Thorax, 63(9), 775-777. 
 
Singh, S. J., Morgan, M. D., Scott, S., Walters, D., & Hardman, A. E. (1992). Development of a shuttle walking 
test of disability in patients with chronic airways obstruction. Thorax, 47(12), 1019-1024. 
 
Sinha, R., & Bergofsky, E. H. (1972). Prolonged alteration of lung mechanics in kyphoscoliosis by positive 
pressure hyperinflation. American Review of Respiratory Disease, 106(1), 47-57. 
 
Sliwinski, P., Kaminski, D., Zielinski, J., & Yan, S. (1998). Partitioning of the elastic work of inspiration in 
patients with COPD during exercise. European Respiratory Journal, 11(2), 416-421. 
 
 275 
Solway, S., Brooks, D., Lacasse, Y., & Thomas, S. (2001). A qualitative systematic overview of the 
measurement properties of functional walk tests used in the cardiorespiratory domain. Chest, 119(1), 
256-270. 
 
Solway, S., Brooks, D., Lau, L., & Goldstein, R. (2002). The short-term effect of a rollator on functional 
exercise capacity among individuals with severe COPD. Chest, 122(1), 56-65. 
 
Spruit, M. A., Gosselink, R., Troosters, T., Kasran, A., Gayan-Ramirez, G., Bogaerts, P., Bouillon, R., & 
Decramer, M. (2003). Muscle force during an acute exacerbation in hospitalised patients with COPD 
and its relationship with CXCL8 and IGF-I. Thorax, 58(9), 752-756. 
 
Spruit, M. A., Watkins, M. L., Edwards, L. D., Vestbo, J., Calverley, P. M., Pinto-Plata, V., Celli, B. R., Tal-
Singer, R., & Wouters, E. F. (2010). Determinants of poor 6-min walking distance in patients with 
COPD: The ECLIPSE cohort. Respiratory Medicine, 104, 849-857. 
 
Sterne, J. A. C., Egger, M., & Moher, D. (2008). Chapter 10: Addressing reporting biases. In J. P. T. Higgins & 
S. Green (Eds.), Cochrane Handbook for Systematic Reviews of Intervention (Vol. Version 5.0.1 
(Updated September 2008)): The Cochrane Collaboration, 2008. Available from www.cochrane-
handbook.org. 
 
Stewart, R. I., & Lewis, C. M. (1986). Cardiac output during exercise in patients with COPD. Chest, 89(2), 199-
205. 
 
Stubbing, D. G., Pengelly, L. D., Morse, J. L., & Jones, N. L. (1980). Pulmonary mechanics during exercise in 
subjects with chronic airflow obstruction. Journal of Applied Physiology, 49(3), 511-515. 
 
Swallow, E. B., Barreiro, E., Gosker, H., Sathyapala, S. A., Sanchez, F., Hopkinson, N. S., Moxham, J., Schols, 
A., Gea, J., & Polkey, M. I. (2009). Quadriceps muscle strength in scoliosis. European Respiratory 
Journal, 34(6), 1429-1435. 
 
Swallow, E. B., Reyes, D., Hopkinson, N. S., Man, W. D., Porcher, R., Cetti, E. J., Moore, A. J., Moxham, J., & 
Polkey, M. I. (2007). Quadriceps strength predicts mortality in patients with moderate to severe chronic 
obstructive pulmonary disease. Thorax, 62(2), 115-120. 
 
Takahashi, T., Jenkins, S. C., Strauss, G. R., Watson, C. P., & Lake, F. R. (2003). A new unsupported upper 
limb exercise test for patients with chronic obstructive pulmonary disease. Journal of Cardiopulmonary 
Rehabilitation, 23(6), 430-437. 
 
Tang, Y., Turner, M. J., Yem, J. S., & Baker, A. B. (2003). Calibration of pneumotachographs using a calibrated 
syringe. Journal of Applied Physiology, 95(2), 571-576. 
 
Tangel, D. J., Mezzanotte, W. S., & White, D. P. (1991). Influence of sleep on tensor palatini EMG and upper 
airway resistance in normal men. Journal of Applied Physiology, 70(6), 2574-2581. 
 
Tassaux, D., Gainnier, M., Battisti, A., & Jolliet, P. (2005). Impact of expiratory trigger setting on delayed 
cycling and inspiratory muscle workload. American Journal of Respiratory & Critical Care Medicine, 
172(10), 1283-1289. 
 
Thompson, C. H., Davies, R. J., Kemp, G. J., Taylor, D. J., Radda, G. K., & Rajagopalan, B. (1993). Skeletal 
muscle metabolism during exercise and recovery in patients with respiratory failure. Thorax, 48(5), 
486-490. 
 
Ting, E. Y., & Lyons, H. A. (1964). The Relation of Pressure and Volume of the Total Respiratory System and 
Its Components in Kyphoscoliosis. American Review of Respiratory Disease, 89, 379-386. 
 
Toledo, A., Borghi-Silva, A., Sampaio, L. M., Ribeiro, K. P., Baldissera, V., & Costa, D. (2007). The impact of 
noninvasive ventilation during the physical training in patients with moderate-to-severe chronic 
obstructive pulmonary disease (COPD). Clinics, 62(2), 113-120. 
 
Troosters, T., Casaburi, R., Gosselink, R., & Decramer, M. (2005). Pulmonary rehabilitation in chronic 
obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 172(1), 19-
38. 
 
Troosters, T., Gosselink, R., & Decramer, M. (2000). Short- and long-term effects of outpatient rehabilitation in 
patients with chronic obstructive pulmonary disease: a randomized trial. American Journal of Medicine, 
 276 
109(3), 207-212. 
 
Troosters, T., Gosselink, R., & Decramer, M. (2001). Exercise training in COPD: how to distinguish responders 
from nonresponders. Journal of Cardiopulmonary Rehabilitation, 21(1), 10-17. 
Troosters, T., Gosselink, R., Janssens, W., & Decramer, M. (2010c). Exercise training and pulmonary 
rehabilitation: new insights and remaining challenges. European Respiratory Review, 19(115), 24-29. 
 
Troosters, T., Probst, V. S., Crul, T., Pitta, F., Gayan-Ramirez, G., Decramer, M., & Gosselink, R. (2010b). 
Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of 
chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine, 
181(10), 1072-1077. 
 
Troosters, T., Sciurba, F., Battaglia, S., Langer, D., Valluri, S. R., Martino, L., Benzo, R., Andre, D., Weisman, 
I., & Decramer, M. (2010a). Physical inactivity in patients with COPD, a controlled multi-center pilot-
study. Respiratory Medicine, 104(7), 1005-1011. 
 
Tsuboi, T., Ohi, M., Chin, K., Hirata, H., Otsuka, N., Kita, H., & Kuno, K. (1997). Ventilatory support during 
exercise in patients with pulmonary tuberculosis sequelae. Chest, 112(4), 1000-1007. 
 
Tuggey, J. M., & Elliott, M. W. (2006). Titration of non-invasive positive pressure ventilation in chronic 
respiratory failure. Respiratory Medicine, 100(7), 1262-1269. 
Tuggey, J. M., Plant, P. K., & Elliott, M. W. (2003). Domiciliary non-invasive ventilation for recurrent acidotic 
exacerbations of COPD: an economic analysis. Thorax, 58(10), 867-871. 
 
Turner, S. E., Eastwood, P. R., Cecins, N. M., Hillman, D. R., & Jenkins, S. C. (2004). Physiologic responses to 
incremental and self-paced exercise in COPD: a comparison of three tests. Chest, 126(3), 766-773. 
 
van 't Hul, A., Gosselink, R., Hollander, P., Postmus, P., & Kwakkel, G. (2004). Acute effects of inspiratory 
pressure support during exercise in patients with COPD. European Respiratory Journal, 23(1), 34-40. 
 
van 't Hul, A., Gosselink, R., Hollander, P., Postmus, P., & Kwakkel, G. (2006). Training with inspiratory 
pressure support in patients with severe COPD. European Respiratory Journal, 27(1), 65-72. 
 
van 't Hul, A., Kwakkel, G., & Gosselink, R. (2002). The acute effects of noninvasive ventilatory support during 
exercise on exercise endurance and dyspnea in patients with chronic obstructive pulmonary disease: a 
systematic review. Journal of Cardiopulmonary Rehabilitation, 22(4), 290-297. 
 
van Helvoort, H. A., Heijdra, Y. F., de Boer, R. C., Swinkels, A., Thijs, H. M., & Dekhuijzen, P. N. (2007). Six-
minute walking-induced systemic inflammation and oxidative stress in muscle-wasted COPD patients. 
Chest, 131(2), 439-445. 
 
van Helvoort, H. A., Heijdra, Y. F., Heunks, L. M., Meijer, P. L., Ruitenbeek, W., Thijs, H. M., & Dekhuijzen, 
P. N. (2006). Supplemental oxygen prevents exercise-induced oxidative stress in muscle-wasted 
patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care 
Medicine, 173(10), 1122-1129. 
 
Vandenbergh, E., Clement, J., & Van de Woestijne, K. P. (1973). Course and prognosis of patients with 
advanced chronic obstructive pulmonary disease. Evaluation by means of functional indices. American 
Journal of Medicine, 55(6), 736-746. 
 
Vanpee, D., El Khawand, C., Rousseau, L., Jamart, J., & Delaunois, L. (2002). Effects of nasal pressure support 
on ventilation and inspiratory work in normocapnic and hypercapnic patients with stable COPD. Chest, 
122(1), 75-83. 
 
Velloso, M., Stella, S. G., Cendon, S., Silva, A. C., & Jardim, J. R. (2003). Metabolic and ventilatory parameters 
of four activities of daily living accomplished with arms in COPD patients. Chest, 123(4), 1047-1053. 
 
Viegi, G., Pistelli, F., Sherrill, D. L., Maio, S., Baldacci, S., & Carrozzi, L. (2007). Definition, epidemiology and 
natural history of COPD. European Respiratory Journal, 30(5), 993-1013. 
 
Viitanen, A., Salmenpera, M., & Heinonen, J. (1990). Right ventricular response to hypercarbia after cardiac 
surgery. Anesthesiology, 73(3), 393-400. 
 
Vila, B., Servera, E., Marin, J., Diaz, J., Gimenez, M., Komaroff, E., & Bach, J. (2007). Noninvasive ventilatory 
assistance during exercise for patients with kyphoscoliosis: a pilot study. American Journal of Physical 
 277 
Medicine & Rehabilitation, 86(8), 672-677. 
 
Vitacca, M., Bianchi, L., Sarva, M., Paneroni, M., & Balbi, B. (2006). Physiological responses to arm exercise in 
difficult to wean patients with chronic obstructive pulmonary disease. Intensive Care Medicine, 32(8), 
1159-1166. 
 
Vitacca, M., Lanini, B., Nava, S., Barbano, L., Portal, R., Clini, E., & Ambrosino, N. (2004). Inspiratory muscle 
workload due to dynamic intrinsic PEEP in stable COPD patients: effects of two different settings of 
non-invasive pressure-support ventilation. Monaldi Archives for Chest Disease, 61(2), 81-85. 
 
Vitacca, M., Nava, S., Confalonieri, M., Bianchi, L., Porta, R., Clini, E., & Ambrosino, N. (2000). The 
appropriate setting of noninvasive pressure support ventilation in stable COPD patients. Chest, 118(5), 
1286-1293. 
 
Vogiatzis, I., Athanasopoulos, D., Habazettl, H., Aliverti, A., Louvaris, Z., Cherouveim, E., Wagner, H., 
Roussos, C., Wagner, P. D., & Zakynthinos, S. (2010). Intercostal Muscle Blood Flow Limitation 
During Exercise in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory & 
Critical Care Medicine, 182, 1105-1113. 
 
Wagner, P. D. (2006). Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? 
Respirology, 11(6), 681-686. 
 
Watz, H., Waschki, B., Meyer, T., & Magnussen, H. (2009). Physical activity in patients with COPD. European 
Respiratory Journal, 33(2), 262-272. 
 
Weatherall, M., Marsh, S., Shirtcliffe, P., Williams, M., Travers, J., & Beasley, R. (2009). Quality of life 
measured by the St George's Respiratory Questionnaire and spirometry. European Respiratory Journal, 
33(5), 1025-1030. 
 
Weinstein, S. L., Dolan, L. A., Cheng, J. C., Danielsson, A., & Morcuende, J. A. (2008). Adolescent idiopathic 
scoliosis. Lancet, 371(9623), 1527-1537. 
 
Weiss, J. P., Froelicher, V. F., Myers, J. N., & Heidenreich, P. A. (2004). Health-care costs and exercise 
capacity. Chest, 126(2), 608-613. 
 
Weitzenblum, E. (1994). The pulmonary circulation and the heart in chronic lung disease. Monaldi Archives for 
Chest Disease, 49(3), 231-234. 
 
Wheatley, J. R., Amis, T. C., & Engel, L. A. (1991). Oronasal partitioning of ventilation during exercise in 
humans. Journal of Applied Physiology, 71(2), 546-551. 
 
World Health Organisation (2008).  World health report 2008. http://www.who.int/whois/whostat/2008/en. 
Accessed 30/6/2010. 
 
Wijkstra, P. J., Lacasse, Y., Guyatt, G. H., & Goldstein, R. S. (2002). Nocturnal non-invasive positive pressure 
ventilation for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic 
Reviews, Issue 2., Art. No.: CD002878. DOI: 002810.001002/14651858.CD14002878. 
 
Wilson, L., Devine, E. B., & So, K. (2000). Direct medical costs of chronic obstructive pulmonary disease: 
chronic bronchitis and emphysema. Respiratory Medicine, 94(3), 204-213. 
 
Wilson, S. H., Cooke, N. T., Edwards, R. H., & Spiro, S. G. (1984). Predicted normal values for maximal 
respiratory pressures in caucasian adults and children. Thorax, 39(7), 535-538. 
 
Windisch, W. (2008). Impact of home mechanical ventilation on health-related quality of life. European 
Respiratory Journal, 32(5), 1328-1336. 
 
Windisch, W., Freidel, K., Schucher, B., Baumann, H., Wiebel, M., Matthys, H., & Petermann, F. (2003). 
Evaluation of health-related quality of life using the MOS 36-Item Short-Form Health Status Survey in 
patients receiving noninvasive positive pressure ventilation. Intensive Care Medicine, 29(4), 615-621. 
 
Windisch, W., Haenel, M., Storre, J. H., & Dreher, M. (2009). High-intensity non-invasive positive pressure 
ventilation for stable hypercapnic COPD. International Journal of Medical Sciences, 6(2), 72-76. 
 
Windisch, W., Storre, J. H., Sorichter, S., & Virchow, J. C., Jr. (2005). Comparison of volume- and pressure-
 278 
limited NPPV at night: a prospective randomized cross-over trial. Respiratory Medicine, 99(1), 52-59. 
 
Wrigge, H., & Putensen, C. (2000). What is the "best PEEP" in chronic obstructive pulmonary disease? Intensive 
Care Med, 26(9), 1167-1169. 
Yoder, E. A., Klann, K., & Strohl, K. P. (2004). Inspired oxygen concentrations during positive pressure therapy. 
Sleep & Breathing, 8(1), 1-5. 
 
Yohannes, A. M., & Connolly, M. J. (2003). Early mobilization with walking aids following hospital admission 
with acute exacerbation of chronic obstructive pulmonary disease. Clinical Rehabilitation, 17(5), 465-
471. 
 
Younes, M. (1994). Proportional assist ventilation. In M. J. Tobin (Ed.), Principles and Practice of Mechanical 
Ventilation (pp. 349-370). New York: McGraw-Hill Inc. 
 
Zuwallack, R. (2007). The nonpharmacologic treatment of chronic obstructive pulmonary disease: advances in 
our understanding of pulmonary rehabilitation. Proceedings of the American Thoracic Society, 4(7), 
549-553. 
 
 
  
 
 
Appendix A 
 
 
 
 
 
 
 
 
Supplementary material for Chapter 4 
  
Non-invasive ventilation during exercise training in people with 
chronic obstructive pulmonary disease: a systematic review and 
meta-analysis 
 
 
 
 
 
 
 
 
 280 
Appendix A: Part (i) 
Search terms and search strategies for individual electronic databases 
___________________________________________________________________________ 
Allied and Complimentary Medicine Database (AMED) 
Search terms for randomised controlled trial (RCT) grouped using ‘or’: 
#1. Randomized controlled trial.pt. 
#2. Controlled clinical trial.pt.  
#3. Randomized.ab.  
#4. Placebo.ab.  
#5. Randomly.ab.  
#6. Trial.ab.  
#7. Groups.ab. 
#8. #1 or #2 or #3 or #4 or #5 or #6 or #7 
#9. (animals not (humans and animals)).sh.  
#10. #8 not #9  
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
#11. Respiration, Artificial/ or Positive-Pressure Respiration/  
#12. Intermittent Positive-Pressure Ventilation/  
#13. Ventilators mechanical/ 
#14. #11 or #12 or #13  
Search terms for exercise grouped using ‘or’: 
#15. Exercise/ or Exercise Therapy/ or Exercise Test/ or Exercise Tolerance/ 
#16. "Physical Education and Training"/  
#17. Rehabilitation/  
#18. Physical Fitness/ or Physical Endurance/  
#19. Ergometry/  
#20. Walking/  
#21. Bicycling/  
#22. Upper Extremity/  
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#23. #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22  
Search terms for chronic obstructive pulmonary disease (COPD) grouped using ‘or’: 
#24. Pulmonary Disease, Chronic Obstructive/  
#25. Lung diseases obstructive/ 
#26. #24 or #25  
Combination of groups of search terms using ‘and’:  
RCT (#10) and COPD (#26) and NIV (#14) and Exercise (#23) 
RCT (#10) and COPD (#26) and NIV (#14) 
RCT (#10) and COPD (#26) and Exercise (#23) 
NIV (#14) and Exercise (#23)  
 
Cochrane Central Register of Controlled Trials (CENTRAL) 
(*This search was performed in addition to the search conducted by the Cochrane Airways Group 
Trials Search Co-ordinator. CENTRAL is a database of randomised trials and systematic reviews 
therefore randomised controlled trial filter was not required) 
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
#1. Non-invasive ventilation 
#2. NIV  
#3. Proportional assist ventilation 
#4. PAV 
#5. Inspiratory pressure support 
#6. IPS 
#7. #1 or #2 or #3 or #4 or #5 or #6 
Search term for exercise: 
#8. Exercise  
Search term for chronic obstructive pulmonary disease (COPD): 
#9. COPD  
Combination of groups of search terms using ‘and’:  
COPD (#9) and NIV (#7) and Exercise (#8) 
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COPD (#9) and NIV (#7) 
COPD (#9) and Exercise (#8) 
NIV (#7) and Exercise (#8) 
 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
Search term for randomised controlled trial (RCT): 
#1. Clinical trials or placebo 
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
#2. Positive pressure ventilation 
#3. Ventilators, mechanical 
#4. #2 or #3 
Search terms for exercise grouped using ‘or’:  
#5. Exercise  
#6. Physical endurance  
#7. Endurance  
#8. Rehabilitation  
#9. Rehabilitation exercise  
#10. Conditioning  
#11. Cardiopulmonary  
#12. Ergometry 
#13. Treadmills  
#14. Exercise test  
#15. Cardiopulmonary  
#16. Upper extremity  
#17. Upper extremity exercises 
#18. #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17  
Search term for chronic obstructive pulmonary disease (COPD): 
#19. Lung diseases, obstructive 
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Combination of groups of search terms using ‘and’:  
RCT (#1) and COPD (#19) and NIV (#4) and Exercise (#18) 
RCT (#1) and COPD (#19) and NIV (#4) 
RCT (#1) and COPD (#19) and Exercise (#18) 
NIV (#4) and Exercise (#18) 
 
Embase 
Search terms for randomised controlled trial (RCT) grouped using ‘or’: 
(Free-text terms)  
#1. Random$ 
#2. Factorial$   
#3. Crossover$   
#4. Cross over$   
#5. Cross-over$   
#6. Placebo$   
#7. Doubl$ adj blind$   
#8. Singl$ adj blind$   
#9. Assign$  
#10. Allocate$   
#11. Volunteer$  
(EMTREE terms)  
#12. Crossover-procedure   
#13. Double-blind procedure   
#14. Single-blind procedure   
#15. Randomized controlled trial 
#16. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14  
        or #15 
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
(EMTREE terms)  
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#17. Artificial ventilation  
#18. Assisted ventilation   
#19. Intermittent positive pressure ventilation   
#20. Pressure support ventilation 
#21. #17 or #18 or #19 or #20 
Search terms for exercise grouped using ‘or’:  
(EMTREE terms)  
#22. Exercise 
#23.  Arm exercise 
#24. Exercise test  
#25. Exercise tolerance 
#26. Treadmill exercise 
#27. Leg exercise  
#28. Pulmonary rehabilitation 
#29. Rehabilitation 
#30. Training 
#31. Ergometry 
#32. #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 
Search term for chronic obstructive pulmonary disease (COPD): 
(EMTREE terms)  
#33. Chronic obstructive pulmonary disease 
Combination of groups of search terms using ‘and’:  
RCT (#16) and COPD (#33) and NIV (#21) and Exercise (#32) 
RCT (#16) and COPD (#33) and NIV (#21) 
RCT (#16) and COPD (#33) and Exercise (#32) 
NIV (#21) and Exercise (#32) 
 
Latin American and Caribbean Health Science Information Database (LILACS) 
Search terms for randomised controlled trial (RCT) grouped using ‘or’: 
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#1. Random$  
#2. Placebo$  
#3. Trial$ 
#4.  #1 or #2 or #3 
Search term for non-invasive ventilation (NIV): 
#5.  Respiration, artificial 
Search terms for exercise grouped using ‘or’: 
#6. Exercise$  
#7. Physical$  
#8. Train$  
#9. Rehabilitat$  
#10. Conditioning  
#11. Ergometry  
#12. Treadmill  
#13. Endurance  
#14. #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 
Search terms for chronic obstructive pulmonary disease (COPD) grouped using ‘or’: 
#15. COPD 
#16. COAD  
#17. DPOC  
#18. Emphysema$  
#19. Bronchit  
#20. #15 or #16 or #17 or #18 or #19 
Combination of groups of search terms using ‘and’:  
RCT (#4) and COPD (#20) and NIV (#5) and Exercise (#14) 
RCT (#4) and COPD (#20) and NIV (#5) 
RCT (#4) and COPD (#20) and Exercise (#14) 
NIV (#5) and Exercise (#14) 
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Medline 
Search terms for randomised controlled trial (RCT) grouped using ‘or’: 
#1. Randomized controlled trial.pt. 
#2. Controlled clinical trial.pt. 
#3. Randomized.ab.  
#4. Placebo.ab.  
#5. Randomly.ab. 
#6. trial.ab. 
#7. groups.ab.  
#8. #1 or #2 or #3 or #4 or #5 or #6 or #7  
#9. (animals not (humans and animals)).sh. 
#10. #8 not #9  
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
#11. Respiration, Artificial/ or Positive-Pressure Respiration  
#12. Intermittent Positive-Pressure Ventilation  
#13. #11 or #12 
Search terms for exercise grouped using ‘or’: 
#14. Exercise/ or Exercise Therapy/ or Exercise Test/ or Exercise Tolerance 
#15. "Physical Education and Training" 
#16. Rehabilitation 
#17. Physical Fitness/ or Physical Endurance 
#18. Ergometry 
#19. Walking 
#20. Bicycling 
#21. Upper Extremity 
#22. #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 
Search term for chronic obstructive pulmonary disease (COPD): 
#23. Pulmonary Disease, Chronic Obstructive 
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Combination of groups of search terms using ‘and’:  
RCT (#10) and COPD (#23) and NIV (#13) and Exercise (#22) 
RCT (#10) and COPD (#23) and NIV (#13) 
RCT (#10) and COPD (#23) and Exercise (#22) 
NIV (#13) and Exercise (#22) 
 
PEDro 
(PEDro is a database of randomised trials and systematic reviews therefore a randomised controlled 
trial filter was not required) 
Search terms for non-invasive ventilation (NIV) grouped using ’or’: 
#1. Non-invasive ventilation 
#2. NIV 
#3. Proportional assist ventilation 
#4. PAV 
#5. Inspiratory pressure support 
#6. IPS 
#7. #1 or #2 or #3 or #4 or #5 or #6 
Search terms for exercise grouped using ‘or’: 
#8. Exercise 
#9. Exercise training 
#10. Rehabilitation 
#11. Pulmonary rehabilitation 
#12.  #8 or #9 or #10 or #11 
Search terms for chronic obstructive pulmonary disease (COPD) grouped using ‘or’: 
#13. Chronic obstructive pulmonary disease 
#14. COPD 
#15. #13 or #14 
Combination of groups of search terms using ‘and’:  
COPD (#15) and NIV (#7) and Exercise (#12) 
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COPD (#15) and NIV (#7) 
COPD (#15) and Exercise (#12) 
NIV (#7) and Exercise (#12) 
 
PsycINFO 
Search terms for randomised controlled trial (RCT) grouped using ‘or’: 
#1. Randomized controlled trial.pt.  
#2. Controlled clinical trial.pt.  
#3. Randomized.ab.  
#4. Placebo.ab.  
#5. Randomly.ab. 
#6. Trial.ab.  
#7. Groups.ab.  
#8. #1 or #2 or #3 or #4 or #5 or #6 or #7  
#9. (animals not (humans and animals)).sh.  
#10. #8 not #9  
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
#11. Respiration, Artificial/ or Positive-Pressure Respiration 
#12. Intermittent Positive-Pressure Ventilation 
#13. Ventilators mechanical 
#14. Exp Artificial Respiration 
#15. #11 or #12 or #13 or #14 
Search terms for exercise grouped using ‘or’: 
#16. Exercise/ or Exercise Therapy/ or Exercise Test/ or Exercise Tolerance 
#17. "Physical Education and Training" 
#18. Rehabilitation 
#19. Physical Fitness/ or Physical Endurance 
#20. Ergometry 
#21. Walking 
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#22. Bicycling 
#23. Upper Extremity 
#24. #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23  
Search terms for chronic obstructive pulmonary disease (COPD) grouped using ‘or’: 
#25. Pulmonary Disease, Chronic Obstructive 
#26. Lung diseases obstructive 
#27. Exp Lung Disorders 
#28. #25 or #26 or #27  
Combination of groups of search terms using ‘and’:  
RCT (#10) and COPD (#28) and NIV (#15) and Exercise (#24) 
RCT (#10) and COPD (#28) and NIV (#15) 
RCT (#10) and COPD (#28) and Exercise (#24) 
NIV (#15) and Exercise (#24) 
 
PubMed 
Search terms for randomised controlled trial (RCT) grouped using ‘or’: 
#1. Randomized controlled trial  
#2. Controlled clinical trial 
#3. Randomized 
#4. Placebo 
#5. Randomly 
#6. Trial 
#7. Groups 
#8. #1 or #2 or #3 or #4 or #5 or #6 or #7 
Search terms for non-invasive ventilation (NIV) grouped using ‘or’: 
#9. Respiration, artificial 
#10. Positive pressure respiration 
#11. Intermittent positive-pressure ventilation 
#12. #9 or #10 or #11 
 290 
Search terms for exercise grouped using ‘or’: 
#13. Exercise 
#14. Exercise test 
#15. Exercise therapy 
#16. Exercise tolerance 
#17. Physical education and training 
#18. Rehabilitation 
#19. Physical endurance 
#20. Physical fitness 
#21. Ergometry 
#22. Walking 
#23. Bicycling 
#24. Upper extremity 
#25. #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 
Search term for chronic obstructive pulmonary disease (COPD): 
#26. Pulmonary disease, chronic obstructive 
Combination of groups of search terms using ‘and’:  
RCT (#8) and COPD (#26) and NIV (#12) and Exercise (#25) 
RCT (#8) and COPD (#26) and NIV (#12) 
RCT (#8) and COPD (#26) and Exercise (#25) 
NIV (#12) and Exercise (#25) 
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___________________________________________________________________________ 
 
*Bianchi L, Foglio K, Porta R, Baiardi R, Vitacca M, Ambrosino N. (2002). Lack of additional effect of adjunct 
of assisted ventilation to pulmonary rehabilitation in mild COPD patients. Respiratory Medicine, 96(5), 
359-67. 
*Hawkins P, Johnson L C, Nikoletou D, Hamnegard C H, Sherwood R, Polkey M I, Moxham J. (2002). 
Proportional assist ventilation as an aid to exercise training in severe chronic obstructive pulmonary 
disease. Thorax, 57(10), 853-9. 
Hawkins P, Johnson L C, Nikoletou D, Moxham J. (1999). Physiological training in severe chronic obstructive 
pulmonary disease (COPD) is possible using proportional assist ventilation (PAV). Thorax, 54(Suppl 3), 
A61. 
Hawkins P, Johnson L C, Nikoletou D, Moxham J. (2000). Physiological training in severe chronic obstructive 
pulmonary disease (COPD) using proportional assist ventilation (PAV). American Journal of Respiratory 
& Critical Care Medicine, 161(3 Suppl), A255. 
*Johnson J E, Gavin D J, Adams-Dramiga S. 2002. Effects of training with heliox and noninvasive positive 
pressure ventilation on exercise ability in patients with severe COPD. Chest, 122(2), 464-72. 
*Reuveny R, Ben-Dov I, Gaides M, Reichert N. (2005). Ventilatory support during training improves training 
benefit in severe chronic airway obstruction. Israel Medical Association Journal, 7(3), 151-5. 
Reuveny R, Ben-Dov I, Reichert N. (2001). Positive pressure ventilation training effect in patients with COPD. 
American Journal of Respiratory & Critical Care Medicine, 163(5 Suppl), A20. 
*Toledo A, Borghi-Silva A, Sampaio L M, Ribeiro K P, Baldissera V, Costa D. (2007). The impact of 
noninvasive ventilation during the physical training in patients with moderate-to-severe chronic 
obstructive pulmonary disease (COPD). Clinics, 62(2), 113-20. 
*van 't Hul A, Gosselink R, Hollander P, Postmus P, Kwakkel G. (2006). Training with inspiratory pressure 
support in patients with severe COPD. European Respiratory Journal, 27(1), 65-72. 
 
 
 
 
 
 
 
 
 
 * denotes the report used to extract data for the meta-analysis. Other references refer to reports of the same study data. 
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Allan, P. F., Thomas, K. V., Ward, M. R., Harris, A. D., Naworol, G. A., & Ward, J. A. (2009). Feasibility study 
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321-340. 
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Chiang, L. L., Wang, L. Y., Wu, C. P., Wu, H. D., & Wu, Y. T. (2006). Effects of physical training on functional 
status in patients with prolonged mechanical ventilation. Physical Therapy, 86(9), 1271-1281. 
 
Chiang, L. L., Yu, C. T., Liu, C. Y., Lo, Y. L., Kuo, H. P., & Lin, H. C. (2006). Six-month nocturnal nasal 
positive pressure ventilation improves respiratory muscle capacity and exercise endurance in patients 
with chronic hypercapnic respiratory failure. Journal of the Formosan Medical Association, 105(6), 
459-467. 
 
Costa, D., Toledo, A., Silva, A. B., & Sampaio, L. M. (2006). Influence of noninvasive ventilation by BiPAP on 
exercise tolerance and respiratory muscle strength in chronic obstructive pulmonary disease patients 
(COPD). Revista Latino-Americano Enfermagem, 14(3), 378-382. 
 
Costes, F., Agresti, A., Court-Fortune, I., Roche, F., Vergnon, J. M., & Barthelemy, J. C. (2003). Noninvasive 
ventilation during exercise training improves exercise tolerance in patients with chronic obstructive 
pulmonary disease. Journal of Cardiopulmonary Rehabilitation, 23(4), 307-313. 
 
den Hartog, E.R., & Heus, R. (2003). Positive pressure breathing during rest and exercise. Applied Ergonomics, 
34(2), 185-94. 
 
Diaz, O., Torrealba, B., Jover, E., & Lisboa, C. (2001). Sequential effects of noninvasive ventilation in stable 
hypercapnic COPD on arterial blood gases, exercise capacity and respiratory lung function. American 
Journal of Respiratory & Critical Care Medicine, 163(5 Suppl), A248. 
 
Diaz, O., Begin, P., Jover, E., Torrealba, B., & Lisboa, C. (2002). Noninvasive ventilation in stable hypercapnic 
COPD: sequential effects on arterial blood gases, respiratory lung function and exercise capacity. 
European Respiratory Journal, 20 (Suppl 38), 234s.   
 
Dieperink, W., Goorhuis, J. F., de Weerd, W., Hazenberg, A., Zijlstra, J. G., & Nijsten, M. W. (2006). Walking 
with continuous positive airway pressure. European Respiratory Journal, 27(4), 853-855. 
 
Dolmage, T. E., & Goldstein, R. S. (1997). Proportional assist ventilation and exercise tolerance in subjects with 
COPD. Chest, 111(4), 948-954. 
 
Dreher, M., Storre, J. H., & Windisch, W. (2007). Noninvasive ventilation during walking in patients with severe 
COPD: a randomised cross-over trial. European Respiratory Journal, 29(5), 930-936. 
 
Dreher, M., Kenn, K., & Windisch, W. (2008). Non-invasive ventilation and physical exercise in patients with 
COPD. Pneumologie, 62(3), 162-168. 
 
Dreher, M., Doncheva, E., Schwoerer, A., Walterspacher, S., Sonntag, F., Kabitz, H. J., et al. (2009). Preserving 
Oxygenation during Walking in Severe Chronic Obstructive Pulmonary Disease: Noninvasive 
Ventilation versus Oxygen Therapy. Respiration, 78(2), 154-160. 
 
Duiverman, M. L., Wempe, J. B., Bladder, G., Jansen, D. F., Kerstjens, H. A., Zijlstra, J. G., et al. (2008). 
Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. 
Thorax, 63(12), 1052-1057. 
 
Foglio, K., Bianchi, L., Pagani, M., Vitacca, M., & Ambrosino, N. (1997). Exercise capacity in stable 
hypercapnic COPD: effects of nasal proportional assist ventilation (PAV). European Respiratory 
Journal, 10 Suppl 25393s. 
 
Gallagher, C. G., & Younes, M. (1989). Effect of pressure assist on ventilation and respiratory mechanics in 
heavy exercise. Journal of Applied Physiology, 66(4), 1824-1837. 
 
Garrod, R., Mikelsons, C., Paul, E. A., Wedzicha, J. A. (1999). Effects on exercise tolerance of the addition of 
domiciliary non-invasive positive pressure ventilation to physical training in severe COPD. Thorax, 54 
(Suppl 3): A61. 
 
Garrod, R., Mikelsons, C., Paul, E., Wedzicha, J. A. (2000). Randomised controlled trial of domiciliary non-
invasive positive pressure ventilation and physical training in severe COPD. American Journal of 
 296 
Respiratory & Critical Care Medicine, 61 (Suppl 3), A255. 
 
Garrod, R., Mikelsons, C., Paul, E. A., & Wedzicha, J. A. (2000). Randomized controlled trial of domiciliary 
noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary 
disease. American Journal of Respiratory & Critical Care Medicine, 162(4 Pt 1), 1335-1341. 
 
Hernandez, P., Maltais, F., Gursahaney, A., LeBlanc, P., Navalesi, P., & Gottfried, S. B. (1995). Proportional 
assist ventilation (PAV) improves exercise performance in severe COPD. European Respiratory 
Journal, 8(Suppl 19), 502s. 
 
Hernandez, P., Maltais, F., Gursahaney, A., Leblanc, P., & Gottfried, S. B. (2001). Proportional assist ventilation 
may improve exercise performance in severe chronic obstructive pulmonary disease. Journal of 
Cardiopulmonary Rehabilitation, 21(3), 135-142. 
 
Highcock, M. P., Shneerson, J. M., & Smith, I. E. (2003). Increased ventilation with NiIPPV does not 
necessarily improve exercise capacity in COPD. European Respiratory Journal, 22(1), 100-105. 
 
Jackson, N. C. (1991). Pulmonary rehabilitation for mechanically ventilated patients. Critical Care Nursing 
Clinics of North America, 3(4), 591-600. 
 
Keilty, S. E., Ponte, J., Fleming, T. A., & Moxham, J. (1994). Effect of inspiratory pressure support on exercise 
tolerance and breathlessness in patients with severe stable chronic obstructive pulmonary disease. 
Thorax, 49(10), 990-994. 
 
Kenn, K., Schoenheit-Kenn, U., Jacob, B., Sauer, F. J., & Welte, T. (2002). Effects of pulmonary rehabilitation 
including exercise training in COPD patients with indication for non-invasive ventilation therapy 
(NIV). American Journal of Respiratory & Critical Care Medicine, 165(8), A737. 
 
Kleinsasser, A., Von Goedecke, A., Hoermann, C., Maier, S., Schaefer, A., Keller, C., et al. (2004). Proportional 
assist ventilation reduces the work of breathing during exercise at moderate altitude. High Altitude 
Medicine & Biology, 5(4), 420-428. 
 
Kohnlein, T., Schonheit-Kenn, U., Winterkamp, S., Welte, T., & Kenn, K. (2009). Noninvasive ventilation in 
pulmonary rehabilitation of COPD patients. Respiratory Medicine, 103(9), 1329-1336. 
 
Kyroussis, D., Polkey, M. I., Hamnegard, C. H., Mills, G. H., Green, M., & Moxham, J. (2000). Respiratory 
muscle activity in patients with COPD walking to exhaustion with and without pressure support. 
European Respiratory Journal, 15(4), 649-655. 
 
Maltais, F., Reissmann, H., & Gottfried, S. B. (1995). Pressure support reduces inspiratory effort and dyspnea 
during exercise in chronic airflow obstruction. American Journal of Respiratory & Critical Care Med, 
151(4), 1027-1033. 
 
Martin, U. J., Hincapie, L., Nimchuk, M., Gaughan, J., & Criner, G. J. (2005). Impact of whole-body 
rehabilitation in patients receiving chronic mechanical ventilation. Critical Care Medicine, 33(10), 
2259-2265. 
 
Medvedev, D. V., Gorbaneva, E. P., Iumatova, S. N., Kuznetsova, T., Solopov, I. N., & Katuntsev, V. P. (2007). 
Evaluation of benefits of the course of positive pressure breathing training on exercise performance. 
Aviakosmicheskaia i Ekologicheskaia Meditsina, 41(3), 14-18. 
 
Menadue, C., Ellis, E. R., Piper, J. A., Flunt, D., Alison, J. A. (2007). Non-invasive ventilation during 
unsupported arm exercise and walking in patients with chronic hypercapnic respiratory failure. 
Respirology, 12 (Suppl 4), A129. 
   
Menadue, C., Alison, J. A., Piper, A. J., Flunt, D., & Ellis, E. R. (2009). Non-invasive ventilation during arm 
exercise and ground walking in patients with chronic hypercapnic respiratory failure. Respirology, 
14(2), 251-259. 
 
Napolis, L. M., Malaguti, C., Nogueira, C. R., Pazin, B. A., Almeida, D. O., Nery, L. E., & Neder, J. A. (2005). 
Exercise oxygen supplementation adds benefit to non-invasive positive pressure ventilation in COPD 
patients not eligible for long-term oxygen therapy.  Proceedings of the American Thoracic Society, 2 
 297 
(Abstracts issue), A315.  
 
O'Donnell, D. E., Sanii, R., & Younes, M. (1988). Improvement in exercise endurance in patients with chronic 
airflow limitation using continuous positive airway pressure. American Review of Respiratory Disease, 
138(6), 1510-1514. 
 
O'Donnell, D. E., Sanii, R., Giesbrecht, G., & Younes, M. (1988). Effect of continuous positive airway pressure 
on respiratory sensation in patients with chronic obstructive pulmonary disease during submaximal 
exercise. American Review of Respiratory Disease, 138(5), 1185-1191.  
 
Oliveira, I. M., Britto, R. R., Borges, R. A., Oliveira, T. A., & Parreira, V. F. (2006). Acute effects of 
noninvasive ventilation during incremental exercise test in chronic obstructive pulmonary disease 
patients. European Respiratory Journal, 28(Suppl 50), 533s. 
 
Onorati, P., Rabinovich, R., Mancini, M., Acuna, A., Uribe, E., Marrades, R., Gavela, J. E., Barbera, J. A., 
Rodriguez Roisin, R., & Roca, J. (2000). Effects of proportional assist ventilation (PAV) on limb 
exercise in COPD. American Journal of Respiratory & Critical Care Medicine, 161(3 Suppl), A228.  
 
Ornadel, D., Mann, L., & Mak, W. H. F. (2000). The effect of portable non-invasive ventilation on exercise 
tolerance in patients with severe COPD. American Journal of Respiratory & Critical Care Medicine, 
161(3 Suppl), A230.  
 
Petrof, B. J., Calderini, E., & Gottfried, S. B. (1990). Effect of CPAP on respiratory effort and dyspnea during 
exercise in severe COPD. Journal of Applied Physiology, 69(1), 179-188. 
 
Pires Di Lorenzo, V. A., Borghi-Silva, A., Sampaio, L. M. M., Jamami, M., Oishi, M., & Costa, D. (2003). 
Effects of the physical and respiratory muscular training in patients suffering from severe chronic 
obstructive pulmonary disease submitted to BiPAP. Revista Brasileira Fisioterapia, 7(1), 69-76. 
 
Poggi, R., Appendini, L., Polese, G., Colombo, R., Donner, C. F., & Rossi, A. (2006). Noninvasive proportional 
assist ventilation and pressure support ventilation during arm elevation in patients with chronic 
respiratory failure. A preliminary, physiologic study. Respiratory Medicine, 100(6), 972-979. 
 
Polkey, M. I., Kyroussis, D., Keilty, S. E. J., Hamnegard, C. H., Mills, G. H., & Moxham, J. (1995) Inspiratory 
pressure support reduces inspiratory muscle loading caused by exhaustive treadmill walking in patients 
with severe COPD. European Respiratory Journal, 8 (Suppl 19): 346s.  
 
Polkey, M. I., Kyroussis, D., Mills, G. H., Hamnegard, C. H., Keilty, S. E., Green, M., et al. (1996). Inspiratory 
pressure support reduces slowing of inspiratory muscle relaxation rate during exhaustive treadmill 
walking in severe COPD. American Journal of Respiratory & Critical Care Medicine, 154(4 Pt 1), 
1146-1150. 
 
Polkey, M.I., Kyroussis, D., Sherwood, R., Flemming, T. A., Wood, C. N., Peters, T. J., & Moxham, J. (1996). 
Inspiratory pressure support (IPS) prolongs exercise-induced lactataemia in COPD. European 
Respiratory Journal Supplement, 9 (Suppl 22), 379s.  
Polkey, M. I., Hawkins, P., Kyroussis, D., Ellum, S. G., Sherwood, R., & Moxham, J. (2000). Inspiratory 
pressure support prolongs exercise induced lactataemia in severe COPD. Thorax, 55(7), 547-549. 
 
Poon, C.-S., Ward, S. A., & Whipp, B. J. (1987). Influence of inspiratory assistance on ventilatory control during 
moderate exercise. Journal of Applied Physiology, 62(2), 551-560. 
 
Puhan, M. A., Schunemann, H. J., Frey, M., & Bachmann, L. M. (2004). Value of supplemental interventions to 
enhance the effectiveness of physical exercise during respiratory rehabilitation in COPD patients. A 
systematic review. Respiratory Research, 5(1), 25. 
Revill, S. M., Singh, S. J., & Morgan, M. D. L. (1998). Effects of ambulatory inspiratory pressure support (IPS) 
and ambulatory oxygen on walking endurance capacity in severe COPD. European Respiratory 
Journal, 12(Suppl 28), 262s. 
Revill, S. M., Singh, S. J., & Morgan, M. D. (2000). Randomized controlled trial of ambulatory oxygen and an 
ambulatory ventilator on endurance exercise in COPD. Respiratory Medicine, 94(8), 778-783. 
 298 
 
Schmidt, M. J., Laier-Groeneveld, G. & Criee, C. P. (1999). Fitness training during nasal ventilation limited by 
dyspnoea. Pneumologie, 53(Suppl 2), S109-112. 
 
Schoenheit-Kenn, U., Winterkamp, S., Boensch, M., Holle, & D., Kenn, K. (2009). Effects of pulmonary 
rehabilitation including exercise training in COPD patients with indication for non-invasive ventilation 
therapy (NIV). American Journal of Respiratory & Critical Care Medicine, 179, A1053. 
 
Schonhofer, B., Zimmermann, C., Abramek, P., Suchi, S., Kohler, D., & Polkey, M. I. (2003). Non-invasive 
mechanical ventilation improves walking distance but not quadriceps strength in chronic respiratory 
failure. Respiratory Medicine, 97(7), 818-824. 
 
Schonhofer, B., Dellweg, D., Suchi, S., & Kohler, D. (2008). Exercise endurance before and after long-term 
noninvasive ventilation in patients with chronic respiratory failure. Respiration, 75(3), 296-303. 
 
Soo Hoo, G. W. (2003). Nonpharmacologic adjuncts to training during pulmonary rehabilitation: the role of 
supplemental oxygen and noninvasive ventilation. Journal of Rehabilitation Research & Development, 
40(5 Suppl 2), 81-97. 
 
Spruit, M. A. & Wouters, E. F. (2007). New modalities of pulmonary rehabilitation in patients with chronic 
obstructive pulmonary disease. Sports Medicine, 37(6), 501-518. 
 
van’t Hul, A., van der Werve, M., Kwakkel, G., Hollander, A.P., & Boonstra, A. (2000) Physiological responses 
to non-invasive ventilatory support during exercise in patients with COPD and healthy subjects: a pilot 
study. European Respiratory Journal, 16(Suppl 31), 317s.  
 
van 't Hul, A., Kwakkel, G., & Gosselink, R. (2002). The acute effects of noninvasive ventilatory support during 
exercise on exercise endurance and dyspnea in patients with chronic obstructive pulmonary disease: a 
systematic review. Journal of Cardiopulmonary Rehabilitation, 22(4), 290-297. 
 
van 't Hul, A., Gosselink, R., Hollander, P., Postmus, P., & Kwakkel, G. (2004). Acute effects of inspiratory 
pressure support during exercise in patients with COPD. European Respiratory Journal, 23(1), 34-40. 
 
Vitacca, M., Bianchi, L., Sarva, M., Paneroni, M., & Balbi, B. (2006). Physiological responses to arm exercise in 
difficult to wean patients with chronic obstructive pulmonary disease. Intensive Care Medicine, 32(8), 
1159-1166. 
 
ZuWallack, R. L. (2008). The roles of bronchodilators, supplemental oxygen, and ventilatory assistance in the 
pulmonary rehabilitation of patients with chronic obstructive pulmonary disease. Respiratory Care, 
53(9), 1190-1195. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 299 
 
Appendix A: Part (v) 
 
Characteristics of excluded studies 
 
 
Study 
 
Reason for exclusion 
 
1. Allan 2009 
 
Not exercise training 
 
2. Ambrosino 2000 
 
Not a RCT 
 
3. Ambrosino 2004 
 
Not a RCT 
 
4. Ambrosino 2006 
 
Not a RCT 
 
5. Anonymous 2007 
 
Not a RCT 
 
6. Arad 1992 
 
Not a RCT 
 
7. Araujo 2005 
 
Not a RCT 
 
8. Bach 1992 
 
Not a RCT 
 
9. Bach 1993 
 
Not a RCT 
 
10. Baer 1989 
 
Not a RCT 
 
11. Barakat 2007 
 
Not a RCT 
 
12. Bianchi 1998 
 
Not exercise training 
 
13. Borghi-Silva 2005 
 
Not exercise training 
 
14. Borghi-Silva 2008 
 
Not exercise training 
 
15. Borghi-Silva 2009 
 
Not exercise training 
 
16. Boye 1994 
 
Not NIV during exercise 
 
17. Bullemer 1999 
 
Not a RCT 
 
18. Chiang 2006a 
 
Not COPD 
 
19. Chiang 2006b 
 
Not exercise training 
 
20. Costa 2006 
 
Not a RCT 
 
21. Costes 2003 
 
Not a RCT 
 
22. den Hartog 2003 
 
Not a RCT 
 
23. Diaz 2002 
 
Not NIV during exercise 
 
24. Dieperink 2006 
 
Not a RCT 
 
25. Dolmage 1997 
 
Not exercise training 
 
26. Dreher 2007 
 
Not exercise training 
 
27. Dreher 2008 
 
Not a RCT 
 
28. Dreher 2009 
 
Not exercise training 
 
29. Duiverman 2008 
 
Not NIV during exercise 
 
30. Foglio 2000 
 
Not exercise training 
 
31. Gallagher 1989 
 
Not COPD 
 
32. Garrod 2000 
 
Not NIV during exercise 
 
33. Hernandez 2001 
 
Not exercise training 
 
34. Highcock 2003 
 
Not exercise training 
 
35. Jackson 1991 
 
Not a RCT 
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RCT: randomised controlled trial; NIV: non-invasive ventilation; COPD: chronic obstructive pulmonary disease 
 
 
 
 
 
 
36. Keilty 1994 
 
Not exercise training 
 
37. Kenn 2002 
 
Not a RCT 
 
38. Kleinsasser 2004 
 
Not COPD 
 
39. Kohnlein 2009 
 
Not NIV during exercise 
 
40. Kyroussis 2000 
 
Not exercise training 
 
41. Maltais 1995 
 
Not exercise training 
 
42. Martin 2005 
 
Not a RCT 
 
43. Medvedev 2007 
 
Not COPD 
 
44. Menadue 2009 
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45. Napolis 2005 
 
Not exercise training 
 
46. O’Donnell 1988a 
 
Not exercise training 
 
47. O’Donnell 1988b 
 
Not exercise training 
 
48. Olivera 2006 
 
Not exercise training 
 
49. Onorati 2000 
 
Not exercise training 
 
50. Ornadel 2000 
 
Not exercise training 
 
51. Petrof 1990 
 
Not exercise training 
 
52. Pires Di Lorenzo 2003 
 
Wrong comparison 
 
53. Poggi 2006 
 
Not exercise training 
 
54. Polkey 1996 
 
Not exercise training 
 
55. Polkey 2000 
 
Not exercise training 
 
56. Poon 1987 
 
Not a RCT 
 
57. Puhan 2004 
 
Not a RCT 
 
58. Revill 2000 
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59. Schmidt 1999 
 
Not a RCT 
 
60. Schoenheit-Kenn 2009 
 
Not a RCT 
 
61. Schonhofer 2003 
 
Not a RCT 
 
62. Schonhofer 2008 
 
Not a RCT 
 
63. Soo Hoo 2003 
 
Not a RCT 
 
64. Spruit 2007 
 
Not a RCT 
 
65. van’t Hul 2000 
 
Not exercise training 
 
66. van’t Hul 2002 
 
Not a RCT 
 
67. van’t Hul 2004 
 
Not exercise training 
 
68. Vitacca 2006 
 
Not exercise training 
 
69. ZuWallack 2008 
 
Not a RCT 
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